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The first National Prison Entrants’ Bloodborne Virus & Risk Behaviour Survey (NPEBBV&RBS) was 
conducted in 2004 and we are pleased to present the third iteration of this study - the 2010 national 
report.  
 
The prevalence of hepatitis C is over thirty times higher among prisoners than the general 
community, highlighting the need to monitor blood-borne viruses in this population. The 
NPEBBV&RBS fulfils this important role and represents one of the few nationally collaborated 
prisoner health projects in Australia.  
 
The 2010 survey includes data, for the first time, from all jurisdictions across Australia. It is unique in 
the world in providing routine surveillance on the prevalence of blood-borne viruses (HIV, hepatitis 
B, hepatitis C) among this population on a national basis. The NPEBBV&RBS is an important adjunct 
to the Australian National Needle and Syringe Program Survey on which the survey was originally 
based. The prison survey screens prisoners who report injecting drug use and also those with no 
history of injecting who are nonetheless at risk of contracting blood-borne viruses from other routes 
such as tattooing and other blood-to-blood contact.  
 
The NPEBBV&RBS has several features which enhance our knowledge of blood-borne virus 
epidemiology in Australia: it provides unique access to groups known to be over-represented in 
prisons such as Indigenous Australians (25% of Australia’s prisoners are Indigenous), the survey tests 
for hepatitis B immunity in a marginalised group, and venous blood samples are used providing a 
high degree of test accuracy and permits the test results to be provided back to participants.   
 
Prisoners are known to engage in sexual risk behaviours and thus the 2010 survey was expanded to 
screen for three sexually transmissible infections - syphilis, gonorrhoea and chlamydia. It is 
reassuring that the 2010 survey findings did not indicate these infections to be at levels indicating an 
outbreak among those entering prison. No cases of HIV were detected in 2010 which is reassuring.  
 
Monitoring blood-borne viruses among prisoners is important for the overall community response to 
preventing the spread of infectious diseases and the planning of appropriate prevention strategies. 
The utility of this survey is highlighted by its use in all of the Commonwealth Government’s recently 
released national communicable diseases strategies which recognise prisoners as a key population in 
communicable disease control in Australia.  
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Prisoner populations are characterised by engagement in a range of risk behaviours, most 
notably injecting drug use. Consequently they are at an increased risk of exposure to blood-
borne viruses such as hepatitis B, hepatitis C and HIV. Previous Australian research has shown 
that hepatitis C is between thirty to forty times higher among prisoners compared with the 
general community. Therefore, surveillance of this population to detect the presence of blood-
borne pathogens and identify trends in risk behaviours is important in planning effective 
prevention strategies. This is the third prison entrants’ survey to have been conducted; the first 
was undertaken in 2004 and the second in 2007. The 2010 survey was enhanced to test for 




The study represents a consecutive survey of prison entrants conducted over two weeks in 
October 2004, 2007 and 2010. Participants in 2010 were 873a of the 1154 consecutive prison 
entrants in all jurisdictions. Twenty-nine reception centres in the Australian Capital Territory 
(ACT), New South Wales (NSW), Northern Territory (NT), South Australia (SA), Queensland 
(Qld), Tasmania (Tas), Victoria (Vic) and Western Australia (WA) participated in the survey 
(Table 1).  
 
The survey screened for the following markers: HIV antibody and antigen, hepatitis B surface 
antibody and antigen, hepatitis B core antibodies (IgM and IgG), hepatitis B e-antigen and 
antibody, hepatitis C antibody, Treponema pallidum antibody, Chlamydia trachomatis DNA 
and Neisseria gonorrhoea DNA (see Appendix 1).  
 
Test results are made available to participants and appropriate treatment pathways identified 
including education and advice, hepatitis B vaccination, treatment for sexually transmissible 
infections, and referrals for hepatitis C treatment. 
 
Risk behaviour and demographic information was collected using a short questionnaire 
covering injecting and illicit drug use, body piercing and tattooing, sexual activity, hepatitis B 
and cervical cancer immunisation, and tobacco smoking (see Appendix 2).  
 
                                               
a Nine participants consented to participate in the 2010 survey but were excluded due to missing information for the 
main classification variable (injecting drug user status) and 53 participants provided a blood and/or urine specimen 
but no questionnaire information. The 2010 results report the findings for the 811 participants for whom complete 
data were available. 
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Demographic & criminographic characteristics 
• The overall response rate to the survey was high at 76%. 
 
• In 2010, 32% of the sample was Indigenous which is higher than the national census1 
proportion of Indigenous prisoners (25%).  Similarly, women represented 9.5% of the 
sample which is slightly higher than the proportion of women prisoners in Australia (7.5%).1 
 
• Only 2% of those with a history of injecting drug use and 3% of non-injectors were 
classified as primary homeless (i.e. sleeping rough, squat, long grass, boat, or car). 
 
• Most of those taking part in the 2010 survey (79%) lived in ‘highly accessible’ and 
‘accessible’ areas prior to prison based on the Accessibility/Remoteness Index of Australia2.  
Living in ‘highly accessible’ and ‘accessible’ areas was more common among people who 
reported using injecting drugs (89%) compared with those who did not (72%). 
 
• Consistent with results from the 2004 and 2007 surveys, eight out of ten prisoners in 2010 
with a history of injecting drug use reported they had previously been incarcerated. In 
2010, six out of ten non-injectors reported a prior incarceration. 
 
 
Blood-borne viruses  
• No cases of HIV were detected among the prisoners screened in 2010.  This represents a 
small decrease from 2004 and 2007, both of which reported less than 1% nationally.  
 
• In 2010, the overall prevalence of hepatitis C antibody was 22%, a decrease from 35% in 
2007.  Among states where more than 30 prisoners were tested, hepatitis C prevalence was 
highest in Victoria (33%) and lowest in the Northern Territory (4%).   
 
• As in previous surveys, hepatitis C antibody prevalence was higher among those with a 
history of injecting drug use compared with those who had not injected (51% versus 1% in 
2010) and higher among women who injected compared with men (68% versus 49% in 
2010).   
 
• Among Indigenous injecting drug users there was a decrease in the prevalence of hepatitis 
C antibody between 2007 and 2010 from 64% to 52%. 
 
• Nationally, only 7 prisoners (5%) reported having ever received treatment for hepatitis C.  
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• Nationally, 19% of those tested were positive for hepatitis B core-antibody. This was 
highest in the Northern Territory (39%) and lowest in South Australia (9%). Some 
jurisdictions, notably Tasmania and Queensland, saw an increase in hepatitis B core-
antibody prevalence from 9% in 2007 to 17% in 2010 for both jurisdictions.   
 
• While there was an increase in the prevalence of hepatitis B core-antibody among 
Indigenous injecting drug users between 2004 and 2007 (38% to 48%), 2010 saw a 
decrease in prevalence to 18%.     
 
• Nationally, 41% of those screened in 2010 showed no evidence of immunity against 
hepatitis B and are therefore vulnerable to infection. The proportion of prisoners who are 
unimmunised against hepatitis B infection was highest in Tasmania (57%) and lowest in 
Queensland (15%).  
 
• Of the 207 tested in 2010 who reported they had been vaccinated against hepatitis B, 72% 
had hepatitis B surface-antibody levels signifying immunity. Conversely, 135 individuals 
reported that they had not been vaccinated against hepatitis B but the tests revealed that 
25% of them had hepatitis B surface-antibody levels considered as conferring immunity.   
 
Sexually transmissible infections 
• Among eligible women (those who would have been 27 years or younger in 2007), 62% 
reported they had not been vaccinated against cervical cancer with one woman unsure of 
her vaccination status.   
 
• Rates of sexually transmissible infections were no higher than in the general population - 
chlamydia (5% of men, 2% of women), and gonorrhoea (1% of men, 0 women). For 
syphilis, 6% of men and 6% of women had markers consistent with past or present 
infection, 2% had markers indicating possible current infection, and only 1 had an RPR titre 




• Less than half of those screened in 2010 reported they had ever injected drugs (44%) which 
is down from 2007 (55%). Of these, 56% had injected in the past month.  
 
• As in 2004 and 2007, amphetamine was the most common drug to be last injected - 58% 
in 2004, 59% in 2007, and 59% in 2010. Heroin was the second most common drug to be 
injected at 25%, down slightly from previous years (32% in 2004, 31% in 2007).   
National Prison Entrants’ Bloodborne Virus & Risk Behaviour Survey 2004, 2007, and 2010 
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• Victoria and the Northern Territory reported the lowest levels of injecting amphetamine as 
the last drug injected (39% and 33%) and Western Australia reported the highest level at 
75%.  
 
• As in previous years, most injecting drug users had done so for more than 3 years (87%) 
suggesting that the prisoner population is characterised by longer term drug users.  
 
• Most injecting drug users reported using clean needles over the past month for ‘all’ (69%) or 
‘most’ (21%) of their injections.     
 
• As in 2007, 85% of prisoners reported they were current tobacco smokers. The median age 
of first tobacco smoking was 14 years. For those with histories of injecting drug use, the 
median age of first tobacco smoking was 13 years.  
 
• Most prisoners had had sex in the past 3 months (83%).  
 
• A small number of prison entrants reported they had been paid for sex in the past 3 months 
(2%), of these 63% reported using a condom.   
 
• Prisoners reported inconsistent condom use, regardless of whether with male or female 
partners. Half of participants reported never using condoms with ‘casual’ partners in the 
past 3 months.  
 
 
Implications of the Findings 
• Prison provides an important public health opportunity to monitor high-risk populations for 
exposure to blood-borne infections and, if appropriate, initiate prevention and treatment 
measures.  
 
• Given the high prevalence of hepatitis C and hepatitis B in this population compared with 
the community, it is important that this survey be regularly conducted to inform policy and 
health services planning for this [at-risk] group at local, state and national level. The 
findings from the previous surveys are utilised by all of the Commonwealth Government’s 
recently released national communicable diseases strategies and highlight prisoners as a 
‘priority population. It is therefore appropriate to conduct the NPEBBVS&RBS every two 
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• Prevention initiatives need to target prison entrants, particularly those with a history of 
injecting drugs and who are in prison for the first time. This group was less likely to have 
been exposed to hepatitis C (10% versus 56% for those with 10+ incarcerations) suggesting 
an important opportunity to intervene and prevent blood-borne virus acquisition.   
 
• Nationally, around 40% of all prison entrants were unimmunised against hepatitis B and 
therefore vulnerable to infection. This group should be vaccinated as a matter of priority. 
Accelerated vaccination schedules are effective and should be considered for this 
population considering their mobility and, in many cases, their inability to complete the 
recommended six month schedule. 
  
• While the prevalence of HIV has remained low in all jurisdictions across surveys (2004, 
2007 and 2010), the NPEBBV&RBS has an important role to play in monitoring this trend. 
The prisoner population is comprised of highly marginalised individuals (e.g. those with 
histories of mental illness and Indigenous Australians) who are often excluded from 
community surveys. The NPEBBV&RBS therefore provides an important opportunity to 
monitor these population groups.  
 
• In 2004, 18% of those who reported they were negative for hepatitis C tested positive for 
HCV antibody, in 2007 16% reported they were negative but tested positive, and in 2010 
7% reported they were negative but tested positive. This reinforces the benefits of ongoing 
testing of prisoners for blood-borne pathogens such as hepatitis C to reduce the number 
who are unaware of their exposure to hepatitis C.  
 
• In previous surveys, the prevalence of hepatitis B core-antibody and hepatitis C antibody 
among Indigenous injecting drugs users has been high (48% and 64% in 2007). However, 
in 2010 there were significant drops for both hepatitis B (18%) and hepatitis C (52%) 
suggesting that programs targeting Indigenous IDU may be effective. 
 
• In 2010, 7 (5%) hepatitis C antibody positive prisoners reported receiving treatment for 
hepatitis C (cf. 1 [0.5%] in 2007 and 2 [2%] in 2004). No Indigenous prisoners reported 
receiving treatment for hepatitis C in either 2004, 2007 and only 1 NSW Indigenous 
prisoner reported receiving treatment in 2010.  This suggests that this population is 
underserved with regard to hepatitis C treatment and would benefit from the development 
of comprehensive prison-based treatment programs. Culturally appropriate treatment 
programs targeting Indigenous prisoners are recommended.  
 
• Amphetamine remains the most frequently reported drug last injected by prison entrants. 
Amphetamine substitution therapies should be investigated and service providers need to  
National Prison Entrants’ Bloodborne Virus & Risk Behaviour Survey 2004, 2007, and 2010 
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ensure that staff receive training in recognising and managing amphetamine withdrawal on 
entry to prison. 
 
• Tobacco smoking is at epidemic proportions among prisoners with almost 9 out of 10 
prisoners reporting they currently smoke. Effective and sustainable (i.e. post-release) 
smoking cessation programs need to be developed for this population. This needs to be 
addressed as a matter of national health priority. Incarceration is an important, but 
underutilised, public health opportunity to initiate quit smoking programs among this group 
to ensure sustained cessation.    
 
  





Prisoner populations are characterised by engagement in a range of health risk behaviours, 
most notably injecting drug use.3-5 Consequently they are at an increased risk of exposure to 
blood-borne viruses such as HIV and viral hepatitis.6-11 Australian and overseas studies have 
consistently shown prisoner populations to have rates of blood-borne viruses many times that of 
the community. The prison setting has been shown to be a high risk environment for blood-
borne virus transmission from sharing contaminated injecting equipment, tattooing, and other 
blood-to-blood contact.12-14  
 
Monitoring blood-borne virus infections in Australia occurs through ad hoc prevalence 
surveys7,8,15 of prisoners in the states and territories, and through screening of prison 
receptions16. However, screening strategies vary across Australia in terms of both scope and 
coverage. Nationally just under one third of Australian prison entrants (31%) were tested for 
HIV. This ranged from 15% in South Australia to 45% in Western Australia. No national data 
are available for hepatitis C and hepatitis B testing among prisoners.  
 
Since 1995, the Kirby Institute (formerly the National Centre in HIV Epidemiology and Clinical 
Research [NCHECR]) has monitored blood-borne viruses in high-risk groups in the 
community.17 Injecting drug users (IDU) at community Needle and Syringe Programs (NSP) are 
invited to self-complete a risk behaviour questionnaire and to provide a finger-prick sample of 
blood to test for HIV and hepatitis C. The survey is conducted annually over a one-week 
period.  
 
Following discussions with NCHECR in 2003, it was agreed to adapt the NSP survey and apply 
it to the prison setting in an effort to provide systematic information on blood-borne virus 
prevalence across Australia and to enable comparisons with NSP survey data.  
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The study is a consecutive cross-section of prison entrants over two weeks during October 
2010. The prison survey was designed to run at the same time as the community NSP survey to 
minimise any overlap of participants between the two surveys. Participants were 873 of the 
1154 (76%) consecutive prisoners entering Australian correctional centres. However, 53 
participants provided a blood and/or urine specimen but no questionnaire information, and 9 
participants provided a blood and/or urine sample with some questionnaire information but 
were excluded due to no information on the main classification variable - injecting drug user 
status. The 2010 results therefore report the findings for the 811 participants for whom 
complete data were available. 
 
Sample Selection 
New receptions at 29 sentinel sites were invited to participate in the assessment. However, 
complete data were only available for 27 sites (Table 1). New receptions were defined as 
individuals entering prison from the community and did not include remanded inmates 




We aimed to minimise any disruption to the prison reception process by conducting the survey 
immediately after the initial health and welfare assessments which are routinely conducted on 
all individuals received into prison. Those unable to be screened at the time of reception were 
called up within approximately twenty-four hours of entry into the prison and invited to 
participate. 
 
Potential participants were given an outline of the project by a member of the survey team. The 
explanation emphasised the following: involvement was voluntary, the structure of the 
assessment consisted of a short questionnaire followed by blood testing, there was no 
obligation to answer any questions deemed intrusive or sensitive, and information would 
remain confidential. Participants were also informed that every effort would be made to return 
the blood test results, even if they were in the community, and that post-test counselling would 
be provided and referrals made to specialist services if necessary. Written consent was obtained 
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Confidentiality was maintained on the questionnaires and serology requests through the use of 
a code comprising the first two letters of each participant’s surname and first name, their date of 
birth and a unique inmate identifier number.  
 
Survey Sites 
Twenty-nine sentinel reception sites in six states and two territories participated in the 2010 
study (Table 1). These centres receive both men and women prisoners directly from the 
community. In all jurisdictions, prisoners are received into the correctional system through a 
limited number of reception sites. Therefore, by targetting these sites we could be certain that 
we were accessing most of the eligible prison receptions across the participating jurisdictions. 
For example, in Victoria all male receptions are processed through the Melbourne Assessment 
Prison and in New South Wales, the Metropolitan Reception and Remand Centre (MRRC) in 
Sydney processes approximately two-thirds of the state’s prisoners. Overall, the 2010 survey 
screened 76% of all prisoners entering the Australian correctional system at the reception sites 
given in Table 1. 
 
Screening Procedures 
Screening was divided into several stages to provide a consistent structure to the survey. 
Broadly, this involved recruiting participants and obtaining consent, administering the 
questionnaire, providing pre-test counselling for those who consented to blood testing, and 
collecting the blood specimen. Pre-test discussion included psychological assessment of the 
person’s ability to deal with a positive result, provision of information about the possible 
consequences of infection with blood-borne viruses, transmission risks, confidentiality and 
notification requirements related to blood tests and treatment options for those who tested 
positive. Those who consented to the blood test were also informed that face-to-face post-test 
counselling would be provided as soon as results became available for both positive and 
negative test results. In some cases this involved community follow-up.  
 
Blood Testing 
Screening for blood-borne viruses included testing for the following markers:  
• HIV antibody and antigen 
• Hepatitis B surface-antibody 
• Hepatitis B surface-antigen, and if positive hepatitis B e-antigen and e-antibody 
• Hepatitis B (IgM & IgG) core-antibody 
• Hepatitis C antibody 
• Treponema pallidum (syphilis) antibody 
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Urine Testing 
Screening for sexually transmissible infections included testing for the following markers:  
• Chlamydia trachomatis (chlamydia) DNA 
• Neisseria gonorrhoea (gonorrhoea) DNA 
 
 
Details of test kits used for the blood and urine testing by the various laboratories are provided 
in Appendix 1. 
 
Questionnaire 
The NSP survey questionnaire was originally designed for the community setting to collect 
behavioural risk factor information on body piercing, tattooing, injecting drug use, sexual 
activity, and immunisation status. A small number of modifications were made to this screening 
instrument to adapt it to the correctional setting (Appendix 2). The questionnaire was piloted in 
each jurisdiction to ensure it was appropriate for a prisoner population, including Indigenous 
prisoners. In 2010, questions were added on living situation prior to prison, other drug use (not 
just injecting drug use), and cervical cancer vaccination. The sexual health questions were 
modified to cover the past 3 months and differentiate male and female sex partners.   
 
Statistical Analysis 
All data were analysed using SPSS version 19. Associations between demographic and 
behavioural variables and exposure to blood-borne viruses and sexually transmissible infections 
were assessed using the χ2 test. 
 
Interviewers 
Interviewers were recruited from nursing staff within each state’s and territory correctional 
health system. Training of site co-ordinators was undertaken via a number of teleconferences 
with the principal investigator (TB) who in turn trained the local interviewers. Aboriginal health 
workers were recruited in Western Australia to facilitate data collection among Indigenous 
prisoners (around 40% of prisoners in Western Australia are Indigenous).  
 
Ethics Approval 
Approval for the project was obtained from the human research and ethics committees in the 
ACT, NSW, SA, Tas, and WA. In addition to the health-based ethics committees, approval was 
sought separately from corrective services’ ethics committees in NSW, Qld, Vic, and WA. In 
WA, approval was granted by the Western Australia Aboriginal Health and Information Ethics 
Committee. The study was also approved by the Curtin University HREC.  
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Reporting of Results 
The following sections present the findings from the survey stratified by injecting drug user 
status. For this reason, only those for whom we have information regarding injecting drug user 
status have been included in the analysis. Percentages have been rounded to the nearest whole 
number. In this report, the prisoners, prison entrant and inmate are used interchangeably as are 






A number of inmates declined to participate in the survey (‘refusers’) while others agreed to 
answer the questionnaire but opted not to provide blood. A small number initially agreed to 
provide a blood sample but were unable to do so due to poor venous access. Some of the 
reasons given by the ‘refusers’ included a perceived lack of personal gain from participation, 
needle phobia, and feeling fatigued or stressed during the reception process.b  
 







The overall response rate to the survey was 76% with men being more likely than women to 
consent to participate (76% versus 69%). The response rate for Aboriginal & Torres Strait 
Islanders was 86% compared with 71% for non-Aboriginal & Torres Strait Islanders. Screening 
rates varied between reception sites (Table 1). Low screening rates were often attributable to 




                                               
b The reception process is often conducted at the end of the day and sometimes in the early hours of the morning. 
This is because the courts process people during the day and those receiving a custodial sentence or remanded into 
custody are taken to the reception prison at the end of the day. Once at the prison there is often a waiting period in a 
holding cell before they are seen by welfare and medical staff. The high response rate seen in this survey is a credit 
to the skill of the reception nurses in highlighting the benefits of the survey to prisoners in what is perhaps one of the 
most stressful and harrowing periods of the participant’s life. 
c The response rate includes the 9 individuals who participated in the survey but were not included in the analysis 
due to missing data for the main classification variable - injector status.  
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Table 1 Reception centre, sex of prison receptions, participants screened, and total number of receptions, 
2010 NPEBBV&RBS 
State  Reception Site 
Sex of 
prisoners 









ACT Alexander Maconochie 
Centre 
Men & women  16 15   (94) 13 (81) 
NSW Bathurst CC Men 7 1   (14) 1   (14) 
 Cessnock CC Men 1 1 (100) 1 (100) 
 Grafton CC  Men 18 11   (61) 10   (56) 
 Goulburn CC Men 8 5   (63) 5   (63) 
 
Metropolitan Remand & 
Reception Centre  Men  
234 213   (91) 212  (91) 
 Silverwater Women’s CC  Women 26 13   (50) 13  (50) 
 Tamworth CC Men 17 13   (76) 12  (71) 
 Total   311 257   (83) 254 (82)  
NT Alice Springs CC Men & women 41 34   (83) 33   (80) 
 Darwin CC Men & women 42 42 (100) 42 (100) 
 Total  83 76   (92) 75   (90) 
Qld Arthur Gorrie CC  Men 86 72   (84) 69   (80) 
 Brisbane CC  Men & women 86 78   (91) 77   (90) 
 Capricornia CC  Men 21 21 (100) 19   (90) 
 Lotus Glenn CC  Men 39 39 (100) 37   (95) 
 Townsville CC  Men & women 37 35   (95) 9   (24) 
 Total  269 245   (91) 211 (78) 
SA Adelaide Remand Centre Men 62 18   (29) 17   (27) 
 Adelaide Women’s Prison Women 21 11   (52) 11   (52) 
 Port Augusta Prison Men & women 10 9   (90) 8   (80) 
 Port Lincoln Men 1 0     (0) 0     (0) 
 Yatala Labour Prison Men 53 21   (40) 20   (38) 
 Total  147 59   (40) 56   (38) 
Tas Hobart Reception Prison Men & women 23 20   (87) 18  (78) 
 
Launceston Reception 
Prison Men & women 
13 8   (62) 3  (23) 
 
Mary Hutchinson’s 
Women’s Prison Women 
1 1 (100) 1 (100) 
 Risdon Prison Complex Men 10 10 (100) 10 (100) 
 Total  47 39   (83) 32  (68) 




126 43   (34) 42 (33) 
 Total  138 49   (36) 48 (35) 
WA Bandyup Women’s Prison Women 9 8   (89) 8   (89) 
 Hakea Prison Men 123 114   (93) 114   (93) 
 Roebourne Regional Prison Men & women 11 11 (100) 0     (0) 
 Total  143 133   (93) 122 (85) 
Total   1154 873   (76) 811 (70) 
* Taken from the running sheets provided by jurisdictions for the period: 11th October - 22nd November 2010. 
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Under half (44%) of all respondents reported current or previous injecting drug use (Table 2). 
 
Table 2 Structure of the study sample by sex and injector status, 2010 NPEBBV&RBS 
 Ever Inject Drugs  
Sex No Yes Total 
Men 424 (58%) 310 (42%) 734 (100%) 
Women 34 (44%) 43 (56%) 77 (100%) 
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2010 
Table 3 Demographic characteristics of prison entrants by jurisdiction (2010) 
    State      
 ACT NSW NT Qld SA Tas Vic WA Total 
Nº of sites 1 7 2 5 4 4 2 2 27 
Nº surveyed 13 254 75 211 56 32 48 122 811 
Nº (%) Male 11 (85) 241 (95) 72 (96) 180 (85) 43 (77) 31 (97) 42 (88) 114 (93) 734 (91) 
Median age (years) 28 31 31 30 32 26 31 29 30 
Age range  18 – 53 17 – 79 18 – 56 17 – 66 19 – 80 19 – 59 20 – 75 13 – 74 13 – 80 
Nº (%) Indigenous  2 (15) 49 (19) 66 (88) 72 (34) 20 (36) 5 (16) 5 (10) 41 (34) 260 (32) 
Nº (%) Aust. Born 10 (77) 195 (77) 71 (95) 182 (86) 53 (95) 32 (100) 40 (83) 103 (84) 686 (85) 
 
Table 4 Injecting drug use, smoking status, other drug use by jurisdiction (2010) 
    State      
 ACT NSW NT Qld SA Tas Vic WA Total 
Nº (%) with IDU history 5 (39) 100 (39) 9 (12) 85 (40) 27 (48) 19 (59) 31 (65) 77 (63) 353 (44) 
Last drug injected           
Amphetamine 5 (100) 49 (49) 3 (33) 49 (58) 19 (70) 12 (63) 12 (39) 58 (75) 207 (59) 
Anabolic steroids -- 1   (1) -- -- 1   (4) -- -- -- 2   (1) 
Cocaine -- 2   (2) -- 1   (1) -- -- -- -- 3   (1) 
Heroin -- 37 (37) -- 21 (25) 6 (22) -- 14 (45) 10 (13) 88 (25) 
Heroin + amphetamine -- -- -- -- -- -- -- -- -- 
Heroin + cocaine -- 2   (2) -- -- -- -- 2   (6) -- 4   (1) 
Methadone -- 4   (4) -- -- 1   (4) -- -- -- 5   (1) 
Morphine -- 2   (2) 2 (22) 5   (6) -- 5 (26) 2   (6) 4   (5) 20   (6) 
Others -- 2   (2) 3 (33) 7   (8) -- 2 (11) 1   (3) 4   (5) 19   (5) 
Not reported -- 1   (1) 1 (11) 2   (2) -- -- -- 1   (1) 5   (1) 
Nº (%) injected last month         
No, did not inject  2 (40) 46 (46) 4 (44) 38 (45) 16 (59) 10 (53) 8 (26) 26 (34) 150 (43) 
Yes, injected 3 (60) 53 (53) 4 (44) 46 (54) 11 (41) 9 (47) 23 (74) 50 (65) 199 (56) 
Not reported -- 1   (1) 1 (11) 1   (1) -- -- -- 1   (1) 4   (1) 
Places injected last month (%)**         
Prison -- -- -- 2   (4) -- -- 1   (4) 1   (2) 4   (1) 
Own home 2 (40) 34 (64) 3 (75) 28 (61) 7 (64) 4 (44) 15 (65) 27 (55) 120 (34) 
Friend’s home 3 (60) 15 (28) 2 (50) 20 (43) 3 (27) 4 (44) 8 (35) 23 (47) 78 (22) 
Dealer’s home 1 (20) 8 (15) -- 8 (17) 1   (9) 1 (11) 3 (13) 5 (10) 27   (8) 
Street, park, beach 2 (40) 6 (11) 1 (25) 8 (17) 1   (9) 2 (22) 7 (30) 3   (6) 31   (9) 
Car 2 (40) 9 (17) -- 12 (26) 3 (27) 5 (56) 9 (39) 5 (10) 45 (13) 
Public toilet 1 (20) 7 (13) -- 11 (24) 1   (9) 2 (22) 6 (26) 3   (6) 31   (9) 
Commercial shooting room           -- -- -- 1   (2) -- -- -- -- 1 (<1) 
MSIC* -- 2   (4) -- 1   (2) -- -- -- -- 3   (1) 
Squat -- -- -- 1   (2) -- -- 2   (9) 1   (2) 4   (1) 
Other -- -- -- -- -- -- -- -- -- 
Use of sterile needles & syringes last month (%)       
All injections 1 (33) 36 (68) 4 (100) 38 (83) 10 (91) 7 (78) 11 (48) 30 (60) 137 (69) 
Most of the time 1 (33) 10 (19) -- 4   (9) 1   (9) 2 (22) 9 (39) 15 (30) 42 (21) 
Half of the time 1 (33) -- -- 2   (4) -- -- 2   (9) 2   (4) 7   (4) 
Some of the time -- 1   (2) -- -- -- -- 1   (4) 1   (2) 3   (2) 
None of the time -- 1   (2) -- 1   (2) -- -- -- 1   (2) 3   (2) 
Not reported -- 5   (9) -- 1   (2) -- -- -- 1   (2) 7   (4) 
Ever smoked a full cigarette (%)         
No -- 18   (7) 6   (8) 13   (6) 2   (4) 1   (3) 2   (4) 9   (7) 51   (6) 
Yes 13 (100) 236 (93) 69 (92) 198 (94) 54 (96) 31 (97) 45 (94) 113 (85) 759 (94) 
Not reported -- -- -- -- -- -- 1   (2) -- 1 (<1) 
Current smoker (%)          
No -- 43 (17) 7   (9) 38 (18) 5   (9) 5 (16) 5 (10) 16 (13) 119 (15) 
Yes 13 (100) 211 (83) 68 (91) 173 (82) 50 (89) 27 (84) 42 (88) 106 (87) 690 (85) 
Not reported -- -- -- -- 1   (2) -- 1   (2) -- 2 (<1) 
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Table 4 Injecting drug use, smoking status, other drug use by jurisdiction (2010) (cont.) 
    State      
 ACT NSW NT Qld SA Tas Vic WA Total 
Other drugs used last month**(%)         
No drugs in past 4 weeks 1   (8) 114 (45) 46 (61) 70 (33) 12 (21) 9 (28) 8 (17) 25 (21) 285 (37) 
Cannabis 7 (70) 98 (70) 25 (89) 93 (75) 32 (80) 18 (78) 20 (77) 79 (83) 372 (77) 
Heroin 2 (20) 31 (22) 1   (4) 24 (19) 5 (13) 1   (4) 10 (39) 15 (16) 89 (18) 
Cocaine -- 17 (12) 1   (4) 2   (2) 3   (8) 2   (9) 2   (8) 2   (2) 29   (6) 
Amphetamine 4 (40) 67 (48) 2   (7) 40 (32) 19 (48) 7 (30) 14 (54) 55 (58) 208 (43) 
Other's methadone -- 12   (9) 3 (11) 4   (3) -- -- 3 (12) 1   (1) 23   (5) 
Other opiates -- 9   (6) 3 (11) 7   (6) 2   (5) 2   (9) 7 (27) 15 (16) 45   (9) 
Other's buprenorphine 1 (10) 6   (4) -- 11   (9) 4 (10) 3 (13) 5 (19) 6   (6) 36   (7) 
Steroids -- 4   (3) 1   (4) 1 (<1) 1   (3) -- 2   (8) -- 9   (2) 
Hallucinogens 1 (10) 2   (1) -- 1 (<1) 3   (8) -- 3 (12) 2   (2) 12   (2) 
Benzodiazepines 1 (10) 21 (15) 2   (7) 19 (15) 7 (18) 6 (26) 10 (39) 11 (12) 77 (16) 
Ecstasy/MDA -- 8   (6) 1   (4) 4   (3) 5 (13) 1   (4) 2   (8) 12 (13) 33   (7) 
Inhalants (e.g. petrol) -- 1 (<1)  -- -- 1   (3) -- -- -- 2 (<1) 
Other drug -- -- 1   (4) 1 (<1) -- -- -- 1   (1) 3 (<1) 
Not reported 2 (15) -- 1   (1) 17   (8) 5   (9) -- 14 (29) 2   (2) 41   (5) 
*Medically Supervised Injecting Centre, Sydney. 
** More than one option could be selected.  
 
 
Table 5 HIV antibody prevalence by jurisdiction and sex (2010)† 









No tested No (%) 
with HIV 
ACT 5 0 (0) 1 0 (0) 6 0 (0) 
NSW 195 0 (0) 7 0 (0) 202 0 (0) 
NT 64 0 (0) 3 0 (0) 67 0 (0) 
Qld 162 0 (0) 29 0 (0) 191 0 (0) 
SA 29 0 (0) 7 0 (0) 36 0 (0) 
Tas 30 0 (0) 1 0 (0) 31 0 (0) 
Vic 26 0 (0) 5 0 (0) 31 0 (0) 
WA 93 0 (0) 4 0 (0) 97 0 (0) 
Total 604 0 (0) 57 0 (0) 661 0 (0) 
† Excludes equivocal test results and missing values. 
 
 
Table 6 HIV antibody prevalence by jurisdiction, sex and injector status (2010)† 
 Male Female Total 





















ACT 2 0 (0) 3 0 (0) 0 0 (0) 1 0 (0) 6 0 (0) 
NSW 72 0 (0) 123 0 (0) 3 0 (0) 4 0 (0) 202 0 (0) 
NT 7 0 (0) 57 0 (0) 1 0 (0) 2 0 (0) 67 0 (0) 
Qld 59 0 (0) 103 0 (0) 14 0 (0) 15 0 (0) 191 0 (0) 
SA 11 0 (0) 18 0 (0) 4 0 (0) 3 0 (0) 36 0 (0) 
Tas 18 0 (0) 12 0 (0) 1 0 (0) 0 0 (0) 31 0 (0) 
Vic 17 0 (0) 9 0 (0) 3 0 (0) 2 0 (0) 31 0 (0) 
WA 60 0 (0) 33 0 (0) 2 0 (0) 2 0 (0) 97 0 (0) 
Total 246 0 (0) 358 0 (0) 28 0 (0) 29 0 (0) 661 0 (0) 
† Excludes equivocal test results and missing values. 
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Table 7 Hepatitis C antibody prevalence by jurisdiction and sex (2010)† 
 Male Female Total 
 No 
tested 








No (%) with 
HCV 
ACT 4 2 (50) 1 0   (0) 5 2  (40) 
NSW 195 46 (24) 7 2 (29) 202 48  (24) 
NT 64 3   (5) 3 0   (0) 67 3    (4) 
Qld 160 29 (18) 28 12 (43) 188 41  (22) 
SA 26 5 (19) 7 2 (29) 33 7  (21) 
Tas 29 8 (28) 1 0   (0) 30 8  (27) 
Vic 25 7 (28) 5 3 (60) 30 10  (33) 
WA 92 22 (24) 4 0   (0) 96 22  (23) 
Total 595 122 (21) 56 19 (34) 651 141  (22) 
† Excludes equivocal test results and missing values. 
 
 
Table 8 Hepatitis C antibody prevalence by jurisdiction, sex and injector status (2010)† 
 Male Female Total 





















ACT 2 2 (100) 2 0   (0) 0 0     (0) 1 0 (0) 5 2 (40) 
NSW 71 44   (62) 124 2   (2) 3 2   (67) 4 0 (0) 202 48 (24) 
NT 7 3   (43) 57 0   (0) 1 0     (0) 2 0 (0) 67 3   (4) 
Qld 58 29   (50) 102 0   (0) 14 12   (86) 14 0 (0) 188 41 (22) 
SA 10 4   (40) 16 1   (6) 4 2   (50) 3 0 (0) 33 7 (21) 
Tas 17 8   (47) 12 0   (0) 1 0     (0) 0 0 (0) 30 8 (27) 
Vic 15 6   (40) 10 1 (10) 3 3 (100) 2 0 (0) 30 10 (33) 
WA 59 22   (37) 33 0   (0) 2 0     (0) 2 0 (0) 96 22 (23) 
Total 239 118   (49) 356 4   (1) 28 19   (68) 28 0 (0) 651 141 (22) 
† Excludes equivocal test results and missing values. 
 
 
Table 9 Hepatitis B surface-antigen prevalence by jurisdiction and sex (2010)† 
 Male Female Total 
 No 
tested 





No (%) with 
Hepatitis B 
surface-antigen 
No tested No (%) with 
Hepatitis B 
surface-antigen 
ACT 3 0   (0) 1 0   (0) 4 0   (0) 
NSW 197 6   (3) 7 0   (0) 204 6   (3) 
NT 51 2   (4) 3 1 (33) 54 3   (6) 
Qld 151 2   (1) 28 0   (0) 179 2   (1) 
SA 5 1 (20) 4 0   (0) 9 1 (11) 
Tas 29 0   (0) 1 0   (0) 30 0   (0) 
Vic 27 0   (0) 5 1 (20) 32 1   (3) 
WA 93 0   (0) 4 0   (0) 97 0   (0) 
Total 556 11   (2) 53 2   (4) 609 13   (2) 
† Excludes equivocal test results and missing values. 
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Table 10 Hepatitis B core-antibody prevalence by jurisdiction and sex (2010)† 
 Male Female Total 
 No 
tested 




No (%) with 
HBV 
No tested No (%) 
with HBV 
ACT -- -- -- -- -- -- 
NSW 198 38 (19) 4 0     (0) 202 38  (19) 
NT 51 18 (35) 3 3 (100) 54 21  (39) 
Qld 80 14 (18) 2 0     (0) 82 14  (17) 
SA 27 3 (11) 7 0     (0) 34 3    (9) 
Tas 29 5 (17) 1 0     (0) 30 5  (17) 
Vic 27 3 (11) 1 1 (100) 28 4  (14) 
WA 93 16 (17) 4 0     (0) 97 16  (16) 
Total 505 97 (19) 22 4   (18) 527 101 (19) 
† Excludes equivocal test results and missing values. 
 
 
Table 11 Hepatitis B core-antibody prevalence by jurisdiction, sex and injector status (2010)† 
 Male Female Total 





















ACT -- -- -- -- -- -- -- -- -- -- 
NSW 72 17 (24) 126 21 (17) 0 0     (0) 4 0     (0) 202 38 (19) 
NT 7 2 (29) 44 16 (36) 1 1 (100) 2 2 (100) 54 21 (39) 
Qld 32 6 (19) 48 8 (17) 1 0     (0) 1 0     (0) 82 14 (17) 
SA 11 2 (18) 16 1   (6) 4 0     (0) 3 0     (0) 34 3   (9) 
Tas 17 2 (12) 12 3 (25) 1 0     (0) -- 
1 
-- 30 5 (17) 
Vic 15 2 (13) 12 1   (8) 0 0     (0) 1 1 (100) 28 4 (14) 
WA 60 9 (15) 33 7 (21) 2 0     (0) 2 0     (0) 97 16 (16) 
Total 214 40 (19) 291 57 (20) 9 2   (14) 13 3   (23) 527 101 (19) 
† Excludes equivocal test results and missing values. 
 
 
Table 12 Hepatitis B virus immune status by jurisdiction (2010)† 
  Hepatitis B Virus Immune Status 
 No 
tested 














ACT 1 0   (0) 0   (0) 0 (0) 0   (0) 
NSW 202 101 (50) 32 (16) 6 (3) 63 (31) 
NT 54 18 (33) 18 (33) 3 (6) 15 (28) 
Qld 107 16 (15) 14 (13) 2 (2) 75 (70) 
SA 33 8 (24) 2   (6) 1 (3) 22 (67) 
Tas 28 16 (57) 5 (18) 0 (0) 7 (25) 
Vic 33 15 (45) 3   (9) 1 (3) 14 (42) 
WA 97 50 (52) 16 (16) 0 (0) 31 (32) 
Total 555 225 (41) 90 (16) 13 (2) 227 (41) 
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Table 13 Hepatitis B virus immune status - Males (2010)† 
  Hepatitis B Virus Immune Status 
 No 
tested 
No (%) with no 
evidence of 
HBV immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity 
ACT 1 1 (100) 0   (0) 0 (0) 0   (0) 
NSW 198 98   (49) 32 (16) 6 (3) 62 (31) 
NT 51 18   (35) 16 (31) 2 (4) 15 (29) 
Qld 95 10   (11) 14 (15) 2 (2) 69 (73) 
SA 27 7   (26) 2   (7) 1 (4) 17 (63) 
Tas 27 16   (59) 5 (19) 0 (0) 6 (22) 
Vic 30 15   (50) 3 (10) 0 (0) 12 (40) 
WA 93 47   (51) 16 (17) 0 (0) 30 (32) 
Total 522 212   (41) 88 (17) 11 (2) 211 (40) 




Table 14 Hepatitis B virus immune status - Females (2010)† 
  Hepatitis B Virus Immune Status 
 No 
tested 
No (%) with no 
evidence of 
HBV immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity 
ACT -- -- -- -- -- 
NSW 4 3 (75) 0   (0) 0   (0) 1   (25) 
NT 3 0   (0) 2 (67) 1 (33) 0     (0) 
Qld 12 6 (50) 0   (0) 0   (0) 6   (50) 
SA 6 1 (17) 0   (0) 0   (0) 5   (83) 
Tas 1 0   (0) 0   (0) 0   (0) 1 (100) 
Vic 3 0   (0) 0   (0) 1 (33) 2   (67) 
WA 4 3 (75) 0   (0) 0   (0) 1   (25) 
Total 33 13 (39) 2   (6) 2   (6) 16   (48) 
† Excludes equivocal test results and missing values. 
 
 
Table 15 Genital chlamydia prevalence by jurisdiction and sex (2010)† 











No tested No (%) 
with 
chlamydia 
ACT 2 0 (0) 1 0   (0) 3 0  (0) 
NSW 185 10 (5) 5 0   (0) 190 10  (5) 
NT 63 1 (2) 3 0   (0) 66 1  (2) 
Qld 158 10 (6) 31 0   (0) 189 10  (5) 
SA 29 0 (0) 8 0   (0) 37 0  (0) 
Tas 10 0 (0) -- -- 10 0  (0) 
Vic 19 1 (5) 6 0   (0) 25 1  (4) 
WA 93 5 (5) 5 1 (20) 98 6  (6) 
Total 559 27 (5) 59 1   (2) 618 28  (5) 
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Table 16 Genital gonorrhoea prevalence by jurisdiction and sex (2010)† 
 Male Female Total 
 No 
tested 




No (%) with 
gonorrhoea 
No tested No (%) with 
gonorrhoea 
ACT 2 0 (0) 1 0 (0) 3 0 (0) 
NSW 184 0 (0) 5 0 (0) 189 0 (0) 
NT 63 2 (3) 3 0 (0) 66 2 (3) 
Qld 158 2 (1) 31 0 (0) 189 2 (1) 
SA 29 0 (0) 8 0 (0) 37 0 (0) 
Tas -- -- -- -- -- -- 
Vic 19 0 (0) 6 0 (0) 25 0 (0) 
WA 93 1 (1) 5 0 (0) 98 1 (1) 
Total 548 5 (1) 59 0 (0) 607 5 (1) 
† Excludes missing values. 
 
 
Table 17 Syphilis markers by jurisdiction and sex (2010)† 
 Male Female Total 
 No 
tested 
No (%) with 
syphilis 
antibodies  
No (%) with 
reactive RPR  
No 
tested 
No (%) with 
syphilis 
antibodies  
No (%) with 
reactive RPR  
No (%) with 
any marker 
for syphilis 
ACT 3 0   (0) 0 (0) 1 0   (0) 0   (0) 0   (0) 
NSW 195 4   (2) 0 (0) 7 0   (0) 0   (0) 4   (2) 
NT 64 13 (20) 5 (8) 3 1 (33) 0   (0) 14 (21) 
Qld 161 15   (9) 7 (4) 29 2   (7) 1   (3) 17 (11) 
SA 25 2   (8) 0 (0) -- -- -- 2   (8) 
Tas 5 0   (0) 0 (0) -- -- -- 0   (0) 
Vic 27 1   (4) 0 (0) 6 0   (0) 0   (0) 1   (4) 
WA 93 2   (2) 2 (2) 4 0   (0) 0   (0) 2   (2) 
Total 573 45   (8) 14 (2) 50 3   (6) 3 (<1) 40   (7) 
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2004, 2007, 2010 
 
Table 18 Number (%) of respondents by demographic characteristics, injector status and survey year  
     2004     2007     2010 
Demographic characteristics IDU Non-IDU IDU Non-IDU IDU Non-IDU 
Number of sites surveyed N = 8 N = 17 N = 27 
No surveyed N = 357 N = 247 N = 406 N = 334 N = 353 N = 458 
Sex (%)       
Male 118 (93) 228 (92) 354 (87) 315 (94) 310 (88) 424 (93) 
Female 9   (7) 19   (8) 52 (13) 19   (6) 43 (12) 34   (7) 
Transgender -- -- -- -- -- -- 
Sexual identity (%)       
Heterosexual 341 (96) 240 (97) 385 (95) 328 (98) 336 (95) 441 (96) 
Bisexual 11   (3) 3   (1) 6   (2) 2 (<1) 8   (2) 7   (2) 
Homosexual 5   (1) 3   (1) 9   (2) 1 (<1) 6   (2) 3   (1) 
Unsure -- -- 2 (<1) -- 1 (<1) 2   (0) 
Not reported -- 1 (<1) 4 (<1) 3 (<1) 2   (1) 5   (1) 
Age and duration of injection (years)      
Median age (years) 30 34 32 29 31 28 
    Age range 17 – 58 17 – 75 18 – 54 17 – 77 13 – 78 16 – 80 
Age group (%)       
    <25 years 95 (27) 69 (28) 70 (17) 120 (36) 71 (20) 160 (35) 
    25+ years 260 (72) 178 (72) 335 (83) 214 (64) 281 (80) 298 (65) 
    Not reported 2 (<1) -- 1 (<1) -- 1(<1) -- 
Median age 1stIDU (years) 18 -- 18 -- 18 -- 
    Age range 9 – 41 -- 8 – 44 -- 7 – 42 -- 
    Not reported 8 -- 9 -- 13 -- 
Median years IDU 10 -- 12 -- 13 -- 
    Range <1 – 37 -- <1 – 36 -- <1 – 40 -- 
Duration of drug injection (%)      
    <3 years 36 (10) -- 24   (6) -- 33   (9) -- 
    3+ years 311 (87) -- 372 (92) -- 306 (87) -- 
    Not reported 10   (3) -- 10   (2) -- 14   (4) -- 
Aboriginal and Torres Strait Islander origin (%)      
No 285 (80) 209 (85) 320 (79) 283 (85) 260 (74) 291 (64) 
Yes 64 (18) 36 (15) 78 (19) 50 (15) 93 (26) 167 (36) 
Not reported 8   (2) 2 (<1) 8   (2) 1 (<1) -- -- 
Living situation prior to prison (%)*      
Not homeless n/a n/a n/a n/a 223 (63) 260 (57) 
Primary homelessness n/a n/a n/a n/a 12   (3) 10   (2) 
Secondary homelessness n/a n/a n/a n/a 56 (16) 113 (25) 
Tertiary homelessness n/a n/a n/a n/a 23   (7) 11   (2) 
Not reported n/a n/a n/a n/a 39 (11) 64 (14) 
Residential remoteness in 12 months before prison (%)     
 Highly accessible/accessible 325 (91) 215 (87) 362 (89) 286 (86) 313 (89) 329 (72) 
Moderately accessible 9   (3) 6   (2) 11   (3) 14   (4) 15   (4) 22   (5) 
Remote/very remote 13   (4) 14   (6) 11   (3) 11   (3) 14   (4) 84 (18) 
Not reported 10   (3) 12   (5) 22   (5) 23   (7) 11   (3) 23   (5) 
Region/Country of birth (%)       
Australia 310 (87) 182 (74) 354 (87) 263 (79) 314 (89) 372 (81) 
Other Oceania 12   (3) 17   (7) 9   (2) 13   (4) 15   (4) 29   (6) 
Asia 13   (4) 14   (6) 19   (5) 20   (6) 9   (3) 22   (5) 
UK & Ireland 8   (2) 9   (4) 7   (2) 7   (2) 7   (2) 6   (1) 
Other 13   (4) 23   (9) 15   (4) 27   (8) 7   (2) 29   (6) 
Not reported 1 (<1) 2 (<1) 2 (<1) 4   (1) 1 (<1) -- 
Main language spoke at home by parents (%)     
English  328 (92) 208 (84) 365 (90) 268 (80) 332 (94) 367 (80) 
Non-English  28   (8) 37 (15) 40 (10) 64 (19) 17   (5) 65 (14) 
Not reported -- 2 (<1) 1 (<1) 2 (<1) 4   (1) 26   (6) 
* Not homeless (private rental, home owner/purchaser, public/community housing, drug and alcohol treatment facility, workers’ 
accommodation, prison, nursing home, foster home); Primary homelessness (Sleeping rough, squat, long grass, boat, car); 
Secondary homelessness (Living with parent, siblings, or relatives, crisis accommodation); Tertiary homelessness (Boarding house, 
hostel, caravan park, backpackers, hotel, motel). Living situation question introduced in 2010. 
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Table 18 Number (%) of respondents by demographic characteristics, injector status and survey year 
(cont.) 
     2004     2007     2010 
Demographic characteristics IDU Non-IDU IDU Non-IDU IDU Non-IDU 
First time in prison (%)       
No 302 (85) 149 (60) 336 (83) 161 (48) 290 (82) 262 (57) 
Yes 55 (15) 98 (40) 69 (17) 171 (51) 61 (17) 190 (41) 
Not reported -- -- 1 (<1) 2 (<1) 2   (1) 6   (1) 
Lifetime imprisonments (%)       
One 55 (15) 98 (40) 69 (17) 171 (51) 118 (33) 285 (62) 
Two to four  178 (50) 117 (47) 163 (40) 119 (36) 115 (33) 109 (24) 
Five to nine   87 (24) 17   (7) 95 (23) 23   (7) 72 (20) 43   (9) 
Ten or more  32   (9) 3   (1) 60 (15) 10   (3) 46 (13) 15   (3) 
Not reported 5   (1) 12   (5) 19   (5) 11   (3) 2   (1) 6   (1) 
Imprisonment in last year (%)       
No 129 (36) 137 (55) 113 (34) 47 (29) 160 (45) 277 (60) 
Yes 220 (62) 98 (40) 214 (64) 111 (68) 180 (51) 153 (33) 
Not reported 8   (2) 12   (5) 10   (3) 5   (3) 13   (4) 28   (6) 
Frequency of injection last month (%)      
Not last month 125 (35) -- 152 (37) -- 150 (42) -- 
Less than weekly 47 (13) -- 54 (13) -- 68 (19) -- 
Weekly not daily 28   (8) -- 52 (13) -- 23   (7) -- 
Daily or more 154 (43) -- 142 (35) -- 108 (31) -- 
Not reported 3 (<1) -- 6   (2) -- 4   (1) -- 
Ever smoked a full cigarette (%)*      
No n/a n/a 14   (3) 45 (14) 7   (2) 44 (10) 
Yes n/a n/a 392 (97) 289 (87) 346 (98) 413 (90) 
Not reported n/a n/a -- -- -- 1 (<1) 
Median age first smoked (years) n/a n/a 14 14 13 15 
    Age range n/a n/a 5 – 36 4 – 31 3 – 37 6 – 50 
Current smoker (%)*       
No n/a n/a 26   (6) 85 (25) 20   (6) 99 (22) 
Yes n/a n/a 379 (93) 249 (75) 333 (94) 357 (86) 
Not reported n/a n/a 1 (<1) -- -- 2 (<1) 
Smoking frequency (%)*       
Occasional – weekly or less n/a n/a 13   (3) 22   (9) 11   (3) 12   (3) 
5 to 10 cigarettes a day n/a n/a 98 (26) 60 (24) 106 (32) 152 (42) 
11 to 20 cigarettes a day n/a n/a 154 (41) 85 (34) 144 (43) 104 (29) 
Over 20 cigarettes a day n/a n/a 113 (30) 81 (33) 70 (21) 88 (25) 
Not reported n/a n/a 2 (<1) 1 (<1) 2   (1) 1(<1) 
Other drugs used last month (%)**      
No drugs in past 4 weeks n/a n/a n/a n/a 63 (19) 222 (52) 
Cannabis n/a n/a n/a n/a 205 (74) 167 (80) 
Heroin n/a n/a n/a n/a 78 (28) 11   (5) 
Cocaine n/a n/a n/a n/a 18   (6) 11   (5) 
Amphetamine n/a n/a n/a n/a 159 (57) 49 (23) 
Other's methadone n/a n/a n/a n/a 23   (8) -- 
Other opiates n/a n/a n/a n/a 43 (16) 2   (1) 
Other's buprenorphine n/a n/a n/a n/a 33 (12)  3   (1) 
Steroids n/a n/a n/a n/a 7   (3) 2   (1) 
Hallucinogens n/a n/a n/a n/a 7   (3) 5   (2) 
Benzodiazepines n/a n/a n/a n/a 62 (22) 15   (7) 
Ecstasy/MDA n/a n/a n/a n/a 17   (6) 16   (8) 
Inhalants (e.g. petrol) n/a n/a n/a n/a 1 (<1) 1 (<1) 
Other drug n/a n/a n/a n/a 2   (1) 1 (<1) 
Not reported n/a n/a n/a n/a 13   (4) 28   (6) 
* Smoking questions not asked in 2004. 
** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected.  
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Table 19 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to 
survey and survey year 
Injecting behaviour 2004 2007 2010 
Last drug injected (%) N = 357 N = 406 N = 353 
Amphetamine (Speed, Ice) 206 (58) 238 (59) 
 
207 (59) 
Anabolic steroids 1 (<1) -- 2   (1) 
Cocaine 7   (2) 7   (2) 
 
3   (1) 
Heroin 115 (32) 126 (31)
 
88 (25) 
Heroin + amphetamine -- 
 
10   (2)
 
-- 
Heroin + cocaine 2 (<1) 1 (<1)
 
4   (1) 
Methadone 7   (2) 6   (1)
  
5   (1) 
Morphine 9   (3) 12   (3)
 
20   (6) 
Other 8   (2) 5   (1)
 
19   (5) 
Not reported -- 1 (<1) 
 
5   (1) 
No Injected last month N = 232 N = 248 N = 199 
Places injected last month (%)* 
Prison 8   (3) 7   (3) 4   (2) 
Own home 181 (78) 199 (80) 120 (61) 
Friend’s home 117 (50) 137 (55) 78 (40) 
Dealer’s home 51 (22) 74 (30) 27 (14) 
Street, park, beach 73 (31) 95 (38) 30 (15) 
Car 82 (35) 112 (45) 45 (23) 
Public toilet 56 (24) 69 (28) 31 (16) 
Commercial injecting room 8   (3) 7   (3) 1 (<1) 
Medically Supervised Injecting Centre, Sydney 9   (4) 10   (4) 3   (2) 
Squat 19   (8) 14   (6) 4   (2) 
Other place 5   (2) 12   (5) 1 (<1) 
Use of sterile needles & syringes last month (%) 
All injections 160 (69) 162 (65) 137 (69) 
Most of the time 38 (16) 52 (21) 42 (21) 
Half of the time 14   (6) 11   (4) 7   (4) 
Some of the time 17   (7) 18   (7) 3   (2) 
Not last month 2 (<1) -- 3   (2) 
Not reported 1 (<1) 5   (2) 7   (4) 
Re-used someone else’s used needle & syringe last month (%) 
None 196 (84) 198 (80) 157 (79) 
Once 6   (3) 10   (4) 11   (6) 
Twice 14   (6) 10   (4) 9   (5) 
3-5 times 7   (3) 7   (3) 7   (4) 
>5 times 7   (3) 19   (8) 9   (5) 
Not reported 2 (<1) 4   (2) 6   (3) 
Number of people needle & syringe was re-used after last month (%) 
None 197 (85) 198 (78) 156 (78) 
One 20   (9) 31 (12) 16   (8) 
Two 7   (3) 3   (1) 6   (3) 
Three to five 4   (2) 4   (2) 2   (1) 
More than five 2 (<1) -- 4   (2) 
Don’t know how many -- 5   (2) 7   (4) 
Not reported 2 (<1) 13   (5)  8   (4) 
Relationship to people needle & syringe was re-used after last month (%)* 
Regular sex partner 18   (8) 25 (10) 20 (10) 
Casual sex partner 2 (<1) 2 (<1) 3   (2) 
Close friend 7   (3) 13   (5) 7   (4) 
Acquaintance 5   (2) 5   (2) 6   (3) 
Other 5   (2) 5   (2) 4   (2) 
Equipment used after someone else last month (%)*  
Spoon 49 (21) 76 (30) 50 (25) 
Water 39 (17) 63 (25) 39 (20) 
Filter 34 (15) 57 (23) 40 (20) 
Tourniquet 18   (8) 31 (13) 26 (13) 
Drug mix 33 (14) 49 (20) 36 (18) 
* More than one option could be selected.  
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Table 20 Number (%) of respondents by treatment for drug use, injector status and survey year 
Treatment for drug use 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 357 N = 247 N = 406 N = 334 N = 353 N = 458 
Any treatment/therapy for drug use (%)   
No 195 (55) 228 (92) 125 (31) 182 (54) 157 (44) 397  (87) 
Yes 161 (45) 17   (7) 250 (62) 42 (13) 194 (55) 56 (12) 
Not reported 1 (<1) 2 (<1) 31   (8) 110 (33) 2   (1) 4   (1) 
History of methadone maintenance treatment (%)   
Currently 53 (15) 3   (1) 50 (12) -- 48 (14) 1 (<1) 
Previously 76 (21) 2 (<1) 92 (23) -- 51 (14) 4   (1) 
Never 226 (63) 240 (97) 225 (55) -- 250 (71) 449 (98) 
Not reported 2 (<1) 2 (<1) 39 (10) -- 4   (1) 4   (1) 
History of other pharmacotherapy treatment (%)   
Currently 19   (5) 3   (1) 28   (7) -- 32   (9) 4   (1) 
Previously 49 (14) 1 (<1) 95 (23) -- 44 (12) 4   (1) 
Never 284 (80) 241 (98) 268 (66) -- 276 (78) 447 (98) 
Not reported 5   (1) 2 (<1) 15   (4) -- 1 (<1) 3   (1) 
 
 
Table 21 Number (%) of respondents by site of needle and syringe acquisition last month and survey 
year 
Needle & Syringe acquisition* 2004 2007 2010 
No surveyed N = 233 N = 248 N = 353 
From an NSP last month (%)   
Daily or almost daily 31 (13) 30 (12) 26   (7) 
A couple of times each week 38 (16) 57 (22) 37 (10) 
Less than weekly 33 (14) 38 (15) 40 (11) 
Weekly n/a n/a 19   (5) 
Once last month 39 (17) 29 (12) 12   (3) 
Not in the last month 57 (24) 45 (18) 154 (44) 
Not reported 35 (15) 52 (21) 65 (18) 
From a chemist last month (%)   
Daily or almost daily 17   (7) 14   (6) 17   (5) 
A couple of times each week 36 (16) 32 (13) 29   (8) 
Less than weekly 51 (22) 35 (14) 38 (11) 
Weekly n/a n/a 36 (10) 
Once last month 38 (17) 32 (13) -- 
Not in the last month 86 (37) 84 (34) 173 (49) 
Not reported 2 (<1) 51 (21) 60 (17) 
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Table 22 Number (%) of respondents by body piercing and tattoos 
Body piercing and tattoos 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 357 N = 247 N = 406 N = 334 N = 353 N = 458 
Body or ear piercings (%)       
No 184 (52) 161 (65) 179 (44) 198 (59) 205 (58) 297 (65) 
Yes 172 (48) 85 (34) 224 (55) 133 (40) 147 (42) 161 (35) 
Not reported 1 (<1) 1 (<1) 3   (1) 3   (1) 1 (<1) -- 
Pierced in past 12 mths (%)       
No 121 (70) 49 (58) 170 (76) 95 (72) 103 (69) 108 (66) 
Yes 22 (13) 9 (10) 25 (11) 15 (11) 18 (12) 22 (13) 
Not reported 29 (17) 27 (32) 29 (13) 23 (17) 28 (19) 33 (20) 
Who did piercing (%)*      
Chemist/hairdresser/beauty 
salon  
5 (23) 3 (33) 3 (12) 5 (31) 2 (11) 5 (23) 
Professional piercer / studio 9 (41) 4 (44) 10 (40) 2 (13) 5 (28) 10 (45) 
Tattooist / parlour 1   (5) 2 (22) 4 (16) 3 (19) 3 (17) 2   (9) 
Friend 2   (9)   -- 1   (4) 1   (6) 3 (17) 2   (9) 
Prison inmate 1   (5) -- 1   (6) 1   (4) 1   (6) -- 
Self 5 (23) -- 3 (12) 4 (25) 5 (28) -- 
Family member -- -- 2   (8) -- 1   (6) -- 
Other -- -- -- -- -- -- 
Needle used by other (%)       
No  21 (95) 9 (100) 3 (12) 1   (7) 9 (50) 11 (50) 
Yes 1   (5) -- -- 2 (13) -- -- 
Unsure -- -- -- -- -- -- 
Not reported -- -- 22 (88) 12 (80) 9 (50) 11 (50) 
Tattoos (%)       
No 96 (27) 137 (55) 111 (27) 170 (51) 72 (20) 238 (52) 
Yes 261 (73) 109 (44) 294 (72) 164 (49) 275 (78) 209 (46) 
Not reported -- 1 (<1) 1 (<1) -- 6   (2) 11   (2) 
Tattoos in past 12 mths (%)       
No  205 (79) 91 (83) 220 (75) 100 (61) 197 (72) 132 (63) 
Yes 53 (20) 17 (15) 74 (25) 62 (38) 75 (27) 73 (35) 
Not reported 3   (1) 1   (2) 1 (<1) 2   (1) 3   (1) 4   (2) 
Who did tattooing (%)*       
Professional tattooist 32 (60) 10 (59) 41 (55) 47 (76) 40 (53) 47 (64) 
Friend 11 (21) 2 (12) 21 (28) 10 (16) 24 (32) 21 (29) 
Prison inmate 11 (21) 2 (12) 16 (22) 2   (3) 7   (9) 2   (3) 
Self 7 (13) 2 (12) 4   (5) 4   (7) 4   (5) 4   (5) 
Family member 1   (2) 1   (6) -- 1   (2) 7   (9) -- 
Other -- -- -- -- -- -- 
* More than one option could be selected.  
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Table 23 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by 
injector status and survey year 
Sexual behaviour 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 357 N = 247 N = 406 N = 334 N = 353 N = 458 
Sex last month / last 3 months (%)**      
No 93 (26) 75 (30) 107 (26) 84 (25) 41 (12) 80 (17) 
Yes 263 (74) 168 (68) 298 (73) 248 (74) 307 (87) 368 (80) 
Not reported 1 (<1) 4   (2) 1 (<1) 2 (<1) 5   (1) 10   (2) 
Male sex partners in last 3 months**    
    Median n/a n/a n/a n/a 1 1 
    Range n/a n/a n/a n/a 0 – 300 0 – 10 
Female sex partners in last 3 months**    
    Median n/a n/a n/a n/a 1 1 
    Range n/a n/a n/a n/a 0 – 90 0 – 26 
Condom use at last sex (%)     
No 270 (76) 175 (71) 327 (81) 239 (72) n/a  n/a  
Yes 87 (24) 69 (28) 75 (18) 94 (28) n/a  n/a  
Not reported -- 3   (1) 4 (<1) 1 (<1) n/a  n/a  
Condom use with regular sex partner(s) last month (%)*    
No 160 (86) 112 (81) 189 (84) 149 (74) n/a  n/a  
Sometimes 14   (7) 12   (9) 24 (11) 31 (15) n/a  n/a  
Always 13   (7) 14 (10) 12   (5) 22 (11) n/a  n/a  
Condom use with new sex partner(s) last month (%)*    
No 27 (55) 9 (47) 44 (59) 11 (28) n/a  n/a  
Sometimes 8 (16) 3 (16) 14 (19) 15 (38) n/a  n/a  
Always 14 (29) 7 (37) 16 (22) 14 (35) n/a  n/a  
Condom use with casual sex partner(s) last month (%)*    
No 41 (49) 18 (47) 66 (69) 19 (35) n/a  n/a  
Sometimes 14 (17) 6 (16) 15 (16) 18 (33) n/a  n/a  
Always 28 (34) 14 (37) 15 (16) 17 (31) n/a  n/a  
Condom use last sex - regular male partners - last 3 months (%)**   
Never n/a n/a n/a n/a 30 (79) 18 (64) 
Sometimes n/a n/a n/a n/a 5 (13) 4 (14) 
Always n/a n/a n/a n/a 3   (8) 6 (21) 
Condom use last sex - casual male partners - last 3 months (%)**    
Never n/a n/a n/a n/a 8 (57) 4 (57) 
Sometimes n/a n/a n/a n/a 2 (14) 2 (29) 
Always n/a n/a n/a n/a 4 (29) 1 (14) 
Condom use last sex - regular female partners - last 3 months (%)**   
Never n/a n/a n/a n/a 157 (79) 168 (62) 
Sometimes n/a n/a n/a n/a 26 (13) 47 (17) 
Always n/a n/a n/a n/a 16   (8) 57 (21) 
Condom use last sex - casual female partners - last 3 months (%)**   
Never n/a n/a n/a n/a 55 (53) 41 (37) 
Sometimes n/a n/a n/a n/a 28 (27) 25 (22) 
Always n/a n/a n/a n/a 20 (19) 46 (41) 
Sex work last month (%)      
No 349 (98) 240 (97) 392 (97) 323 (97) 340 (96) 442 (97) 
Yes 6   (2) 2 (<1) 10   (2) 5   (1) 10   (3) 3   (1) 
Not reported 2 (<1) 5   (2) 4 (<1) 6   (2) 3   (1) 13   (3) 
Condom used at last sex work last month (%)    
No 3 (43) 1 (50) 4 (40) 1 (20) 2 (20) 1 (33) 
Yes 4 (57) 1 (50) 5 (50) 2 (40) 5 (50) 2 (67) 
Not reported -- -- 1 (10) 2 (40) 3 (30)  -- 
Ever had cervical cancer vaccine (women only)*** (%)    
No  n/a n/a n/a n/a 11 (65) 7 (58) 
Yes n/a n/a n/a n/a 6 (35) 4 (33) 
Unsure n/a n/a n/a n/a -- 1   (8) 
* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month. 
** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded 
areas indicate previous survey items that were changed in 2010. 
*** Proportion of eligible women i.e. those under 27 years of age in 2007. 
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Table 24 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, 
HBV vaccination and HCV treatment by injector status and survey year 
Testing & treatment 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 357 N = 247 N = 406 N = 334 N = 353 N = 458 
Previous HIV test (%)       
Yes, last year 168 (47) 46 (19) 182 (45) 80 (24) 160 (45) 125 (27) 
>1 year ago 117 (33) 72 (29) 159 (39) 99 (30) 109 (31) 105 (23) 
Never tested 71 (20) 126 (51) 61 (15) 155 (46) 82 (23) 225 (49) 
Not reported 1 (<1) 3   (1) 4   (1)  -- 2   (1) 3   (1) 
HBV infection (%)      
No 278 (78) 226 (91) 329 (81) 311 (93) 306 (87) 411 (90) 
Yes 51 (14) 5   (2) 47 (12) 6   (2) 25   (7) 8   (2) 
Don’t know 28   (8) 16   (6) 29   (7) 12   (4) 21   (6) 36   (8) 
Not reported -- -- 1 (<1) 5   (1) 1 (<1) 3   (1) 
HBV vaccination (%)*       
No 82 (27) 116 (48) 125 (31) 162 (49) 96 (27) 186 (41) 
Yes 188 (61) 78 (32) 239 (59) 124 (37) 203 (58) 164 (36) 
Don’t know 36 (12) 44 (18) 35   (9) 45 (13) 53 (15) 103 (22) 
Not reported -- 4   (2) 7   (2) 3   (1) 1 (<1) 5   (1) 
Previous HCV test (%)       
Yes, last year 155 (43) 42 (17) 178 (44) 75 (22) 164 (46) 111 (24) 
>1 year ago 138 (39) 48 (20) 180 (44) 83 (25) 123 (35) 104 (23) 
Never tested 61 (17) 154 (63) 48 (12) 174 (52) 61 (17) 241 (53) 
Unsure  2   (1) 1 (<1) -- 1 (<1) 1 (<1) -- 
Not reported 1 (<1) 2 (<1) -- 1 (<1) 4   (1) 2 (<1) 
Any HCV treatment (%)** N = 149 N = 7 N = 197 N = 11 N = 137 N = 4 
Interferon -- -- 1 (<1) -- 4   (3) -- 
Interferon & Ribavirin 1 (<1) 1 (14) 1 (<1) -- 3   (2) -- 
Other -- -- -- -- -- -- 
No treatment 148 (99) 6 (86) 195 (99) 11 (100) 130 (99) 4 (100) 
Not reported -- -- -- -- -- -- 
Current HCV treatment        
Interferon -- -- -- -- 1 (<1) -- 
Interferon & Ribavirin 1 (<1) 1 (14) 1 (<1) -- 1 (<1) -- 
Other -- -- -- -- -- -- 
* Number (%) among participants with no history of HBV infection. 
** Number (%) of those testing positive for hepatitis C antibodies. 
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HIV antibody prevalence 
Table 25 HIV antibody prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HIV (%) 






2004       
IDU 240 2 (<1) 23 0   (0) 263 2 (<1) 
Non-IDU 172 1 (<1) 12 0   (0) 184 1 (<1) 
p value  0.8  --  0.8 
2007       
IDU 287 2 (<1) 37 1   (3) 324 3 (<1) 
Non-IDU 246 1 (<1) 16 0   (0) 262 1 (<1) 
p value  0.7  0.5  0.4 
2010       
IDU 246 0   (0) 28 0   (0) 274 0   (0) 
Non-IDU 358 0   (0) 29 0   (0) 387 0   (0) 
p value  --  --  -- 
† Excludes equivocal test results and missing values. 
 
 
Table 26 HIV antibody prevalence by sexual identity, sex and survey year† 
 Male Female Total 
Sexual identity No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
2004       
Heterosexual 407 1 (<1) 30 0   (0) 437 1 (<1) 
Bisexual 2 1 (50) 5 0   (0) 7 1 (14) 
Homosexual 3 1 (33) -- -- 3 1 (33) 
Unsure -- -- -- -- -- -- 
p value  <0.001  --  <0.001 
2007       
Heterosexual 522 2 (<1) 44 1   (2) 566 3 (<1) 
Bisexual 1 0   (0) 4 0   (0) 5 0   (0) 
Homosexual 6 1 (17) 1 0   (0) 7 1 (14) 
Unsure 1 0   (0) 1 0   (0) 2 0   (0) 
p value  <0.001  1.0  <0.001 
2010       
Heterosexual 588 0   (0) 45 0   (0) 633 0   (0) 
Bisexual 4 0   (0) 9 0   (0) 13 0   (0) 
Homosexual 4 0   (0) 3 0   (0) 7 0   (0) 
Unsure -- -- -- -- -- -- 
p value  --  --  -- 
† Excludes equivocal test results and missing values. 
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Table 27 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
2004       
Non-Indigenous 340 1 (<1) 25 0 (0) 365 1 (<1) 
Indigenous 68 2   (3) 10 0 (0) 78 2   (3) 
p value  0.06  --  0.08 
2007       
Non-Indigenous 433 3 (<1) 35 1 (3) 468 4 (<1) 
Indigenous 93 0   (0) 17 0 (0) 110 0   (0) 
p value  0.4  0.5  0.3 
2010       
Non-Indigenous 398 0   (0) 39 0 (0) 437 0   (0) 
Indigenous 206 0   (0) 18 0 (0) 224 0   (0) 
p value  --  --  -- 
† Excludes equivocal test results and missing values. 
 
 
Table 28 HIV antibody prevalence by sex, residential remoteness in the 12 months before prison and 
survey year† 
  Male Female Total  
Residential remoteness No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
2004       
Highly accessible/accessible 372 3 (100) 30 0 (0) 402 3 (100) 
Moderately accessible 9 0     (0) 1 0 (0) 10 0     (0) 
Remote/very remote 18 0     (0) 2 0 (0) 20 0     (0) 
p value  0.9  --  0.9 
2007       
Highly accessible/accessible 470 3     (1) 45 1 (2) 515 4     (1) 
Moderately accessible 16 0     (0) 1 0 (0) 17 0     (0) 
Remote/very remote 20 0     (0) 1 0 (0) 21 0     (0) 
p value  0.9  1.0  0.9 
2010       
Highly accessible/accessible 471 0     (0) 46 0 (0) 517 0     (0) 
Moderately accessible 27 0     (0) 4 0 (0) 31 0     (0) 
Remote/very remote 80 0     (0) 5 0 (0) 85 0     (0) 
p value  --  --  -- 
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Table 29 Self-reported HIV status versus HIV serology by sex† 
 HIV Serology 
 Male Female Total  
Self-report HIV No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
2004       
Positive 1 1(100) -- -- 1 1(100) 
Negative 240 2  (<1) 23 0    (0) 263 2  (<1) 
Not sure 19 0    (0) 4 0    (0) 23 0    (0) 
p value  <0.001  --  <0.001 
2007       
Positive 6 0    (0) -- -- 6 0    (0) 
Negative 334 2  (<1) 36 1    (3) 370 3  (<1) 
Not sure 25 0    (0) 5 0    (0) 30 0    (0) 
p value  0.9  0.7  0.9 
2010       
Positive 0 0    (0) 0 0    (0) 0 0    (0) 
Negative 324 0    (0) 36 0    (0) 360 0    (0) 
Not sure 30 0    (0) 2 0    (0) 32 0    (0) 
p value  --  --  -- 




HCV antibody prevalence 
Table 30 HCV antibody prevalence by sex, injector status and survey year† 
 Male Female Total 
Injector status No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
IDU 242 130 (54) 23 19 (83) 265 149 (56) 
Non-IDU 174 7   (4) 12 0   (0) 186 7   (4) 
p value  <0.001  <0.001  <0.001 
2007       
IDU 287 166 (58) 40 31 (78) 327 197 (60) 
Non-IDU 247 9   (4) 15 2 (13)  262 11   (4) 
p value  <0.001  <0.001  <0.001 
2010       
IDU 239 118 (49) 28 19 (68) 267 137 (51) 
Non-IDU 356 4   (1) 28 0   (0) 384 4   (1) 
p value  <0.001  <0.001  <0.001 
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Table 31 HCV antibody prevalence by sexual identity, sex and survey year† 
  Male Female Total  
Sexual identity No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Heterosexual 411 136 (33) 31 16   (52) 442 152 (34) 
Bisexual 2 0   (0) 4 3   (75) 6 3 (50) 
Homosexual 3 1 (33) -- -- 3 1 (33) 
Unsure -- -- -- -- -- -- 
p value  0.6  0.4  0.7 
2007       
Heterosexual 523 172 (33) 45 24   (53) 568 196 (35) 
Bisexual 1 0   (0) 4 3   (75) 5 3 (60) 
Homosexual 6 2 (33) 2 2 (100) 8 4 (50) 
Unsure 1 0   (0) 1 1 (100) 2 1 (50) 
p value  0.8  0.4  0.3 
2010       
Heterosexual 579 120 (21) 44 12   (27) 623 132 (21) 
Bisexual 4 0   (0) 9 5   (56) 13 5 (38) 
Homosexual 4 2 (50) 3 2   (67) 7 4 (57) 
Unsure -- -- -- -- -- -- 
p value  0.2  0.1  0.03 
† Excludes equivocal test results and missing values. 
 
 
Table 32 HCV antibody prevalence by age group, sex and survey year† 
 Male Female Total  
Age group N
o tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
< 20 years 36 1   (3) 1 0   (0) 37 1   (3) 
20 – 24 91 25 (27) 4 2 (50) 95 27 (28) 
25 – 29 89 28 (31) 9 6 (67) 98 34 (35) 
30 + years 205 84 (41) 20 9 (45) 225 93 (41) 
p value  <0.001  0.5  <0.001 
2007       
< 20 years 35 2   (6) 1 0   (0) 36 2   (6) 
20 – 24 117 22 (19) 6 4 (67) 123 26 (21) 
25 – 29 114 44 (39) 16 11 (69) 130 55 (42) 
30 + years 267 107 (40) 32 18 (56) 299 125 (42) 
p value  <0.001  0.5  <0.001 
2010       
< 20 years 65 1  (2) 4 1 (25) 69 2   (3) 
20 – 24 127 19 (15) 7 1 (14) 134 20 (15) 
25 – 29 126 24 (19) 11 5 (45) 137 29 (21) 
30 + years 277 78 (28) 34 12 (35) 311 90 (29) 
p value  <0.001  0.6  <0.001 
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Table 33 HCV antibody prevalence by duration of drug injection, sex and survey year† 
 Male Female Total  
Duration of drug injection No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
<3 years 28 1   (4) 1 0     (0) 29 1   (3) 
3 to 5 years 25 11 (44) 2 1   (50) 27 12 (44) 
6 to 10 years 75 34 (45) 7 6   (86) 82 40 (49) 
10 + years 111 84 (76) 12 11   (92) 123 95 (77) 
p value  <0.001  0.1  <0.001 
2007       
<3 years 19 4 (21) 1 1 (100) 20 5 (25) 
3 to 5 years 29 12 (41) 3 2   (67) 32 14 (44) 
6 to 10 years 69 28 (41) 17 12   (71) 86 40 (47) 
10 + years 161 116 (72) 19 16   (84) 180 132 (73) 
p value  <0.001  0.7  <0.001 
2010       
<3 years 28 3 (11) 2 0     (0) 30 3 (10) 
3 to 5 years 22 6 (27) 4  1   (25) 26 7 (27) 
6 to 10 years 47 24 (51) 7 4   (57) 54 28 (52) 
10 + years 133 81 (61) 14 13   (93) 147 94 (64) 
p value  <0.001  <0.01  <0.001 
† Excludes equivocal test results and missing values. 
 
 
Table 34 HCV antibody prevalence by last drug injected, duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Last drug injected No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Amphetamine (Speed, Ice) 22 1   (5) 129 65  (50) 151 66 (44) 
Heroin 1 0   (0) 75 63  (84) 76 63 (83) 
More than one 5 0   (0) 23 15  (65) 28 15 (54) 
Other/not reported 1 0   (0) 5 5(100) 6 5 (83) 
     p value  1.0  <0.001  <0.001 
2007       
Amphetamine (Speed, Ice) 17 3 (18) 178 83  (47) 195 86 (44) 
Heroin 3 2 (67) 90 76  (84) 93 78 (84) 
More than one -- -- 11 10  (91) 11 10 (91) 
Other/not reported -- -- 19 17  (89) 19 17 (89) 
     p value  0.07  <0.001  <0.001 
2010       
Amphetamine (Speed, Ice) 19 1   (5) 136 67  (49) 155 68 (44) 
Heroin 5 1 (20) 52 39  (75) 57 40 (70) 
More than one -- -- 8 1  (13) 8 1 (13) 
Other/not reported 6 1 (17) 31 22  (71) 37 23 (62) 
     p value  0.5  <0.001  <0.001 
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Table 35 HCV antibody prevalence by frequency of injection last month, duration of drug injection 
and survey year† 
 <3 years IDU 3+ years IDU Total  
Frequency of drug injection 
last month 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Less than daily 11 0   (0) 40 30 (75) 51 30 (59) 
Daily or more 9 1 (11) 101 70 (69) 110 71 (65) 
p value  0.3  0.2  0.1 
2007       
Less than daily 3 1 (33) 77 45 (58) 80 46 (58) 
Daily or more 5 2 (40) 110 86 (78) 115 88 (77) 
p value  0.9  <0.01  <0.001 
2010       
Less than daily 12 1   (8) 56 34 (61) 68 35 (51) 
Daily or more 9 2 (22) 68 46 (68) 77 48 (62) 
p value  0.4  0.4  0.2 
† Excludes equivocal test results and missing values. 
 
 
Table 36 HCV antibody prevalence by re-use of someone else’s used needle and syringe last month, 
duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Re-used someone else’s used 
needle & syringe last month 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
No 19 1   (5) 103 76 (74) 122 77 (63) 
Yes 2 0   (0) 38 25 (66) 40 25 (63) 
p value  0.1  0.7  0.8 
2007       
No 8 3 (38) 143 97 (68) 151 100 (66) 
Yes -- -- 36 28 (78) 36 28 (78) 
p value  --  0.3  0.2 
2010       
No 16 1   (6) 95 59 (62) 111 60 (54) 
Yes 4 2 (50) 18 12 (67) 22 14 (64) 
p value  0.03  0.7  0.4 
† Excludes equivocal test results and missing values. 
 
 
Table 37 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey 
year† 
 <3 years IDU 3+ years IDU Total  
Imprisonment last year No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
No 12 0   (0) 80 51 (64) 92 51 (55) 
Yes 17 1   (6) 148 94 (64) 165 95 (58) 
p value  0.4  1.0  0.7 
2007       
No 5 1 (20) 86 53 (62) 91 54 (59) 
Yes 6 3 (50) 156 114 (73) 162 117 (72) 
p value  0.3  0.07  0.04 
2010       
No 16 1   (6) 96 49 (51) 112 50 (45) 
Yes 13 2 (15) 123 75 (61) 136 77 (57) 
p value  0.4  0.1  0.06 
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Table 38 HCV antibody by number of previous imprisonments, sex and survey year† 
 Male Female Total  
Number of previous 
imprisonments 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
1 104 14 (13) 11 1     (9) 115 15 (13) 
2 to 4 211 68 (32) 17 11   (65) 228 79 (35) 
5 to 9 68 38 (56) 4 4 (100) 72 42 (58) 
10 + 23 16 (70) 3 3 (100) 26 19 (73) 
p value  <0.001  0.001  <0.001 
2007       
1 170 9   (5) 21 9   (43) 191 18   (9) 
2 to 4 210 66 (31) 20 13   (65) 230 79 (34) 
5 to 9 82 54 (66) 8 7   (88) 90 61 (68) 
10 + 52 39 (75) 4 3   (75) 56 42 (75) 
p value  <0.001  0.1  <0.001 
2010       
1 301 26   (9) 33 8   (24) 334 34 (10) 
2 to 4 169 41 (24) 14 8   (57) 183 49 (27) 
5 to 9 78 31 (40) 6 1   (17) 84 32 (38) 
10 + 42 23 (55) 3 2   (67) 45 25 (56) 
p value  <0.001  0.07  <0.001 
† Excludes equivocal test results and missing values. 
 
 
Table 39 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Non-Indigenous 345 112 (32) 24 13 (54) 369 125 (34) 
Indigenous 68 24 (35) 10 5 (50) 78 29 (37) 
p value  0.7  0.8  0.5 
2007       
Non-Indigenous 435 136 (31) 36 19 (53) 471 155 (33) 
Indigenous 92 34 (37) 18 13 (72) 110 47 (43) 
p value  0.3  0.2  0.05 
2010       
Non-Indigenous 392 88 (22) 39 13 (33) 431 101 (23) 
Indigenous 203 34 (17) 17 6 (35) 220 40 (18) 
p value  0.1  0.9  0.1 
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Table 40 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector 
status and survey year† 
 Non-IDU IDU Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Non-Indigenous 156 5 (3) 210 119 (57) 366 124 (34) 
Indigenous 28 1 (4) 49 28 (57) 77 29 (38) 
p value  0.9  0.9  0.6 
2007       
Non-Indigenous 221 9 (4) 250 146 (58) 471 155 (33) 
Indigenous 40 2 (5) 70 45 (64) 110 47 (43) 
p value  0.8  0.4  0.05 
2010       
Non-Indigenous 237 2 (1) 194 99 (51) 431 101 (23) 
Indigenous 147 2 (1) 73 38 (52) 220 40 (18) 
p value  0.6  0.9  0.1 
† Excludes equivocal test results and missing values. 
 
 
Table 41 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and 
survey year† 
  Male Female Total  
Residential remoteness No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Highly accessible/accessible 375 128 (34) 31 18 (58) 406 146 (36) 
Moderately accessible 10 2 (20) 1 0   (0) 11 2 (18) 
Remote/very remote 18 2 (11) 2 0   (0) 20 2 (10) 
p value  0.09  0.2  0.03 
2007       
Highly accessible/accessible 471 161 (34) 47 28 (60) 518 189 (36) 
Moderately accessible 16 2 (13) 1 0   (0) 17 2 (12) 
Remote/very remote 20 3 (15) 1 0   (0) 21 3 (14) 
p value  0.04  0.2  0.01 
2010       
Highly accessible/accessible 466 107 (23) 46 18 (39) 512 125 (24) 
Moderately accessible 25 6 (24) 4 1 (25) 29 7 (24) 
Remote/very remote 78 5   (6) 4 0   (0) 82 5   (6) 
p value  0.04  0.3  0.01 
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Table 42 HCV antibody prevalence by region/country of birth, sex and survey year† 
 Male Female Total  
Region/Country of birth No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Australia 338 118 (35) 33 19   (58) 371 137 (37) 
Other Oceania 23 2   (9) -- -- 23 2   (9) 
Asia 18 10 (56) 2 0     (0) 20 10 (50) 
UK & Ireland 9 2 (22) -- -- 9 2 (22) 
Other 27 5 (19) -- -- 27 5 (19) 
p value  <0.01  0.1  <0.01 
2007       
Australia 450 149 (33) 47 28   (60) 497 177 (36) 
Other Oceania 17 3 (18) 2 1   (50) 19 4 (21) 
Asia 29 14 (48) 3 1   (33) 32 15 (47) 
UK & Ireland 9 3 (33) 1 1 (100) 10 4 (40) 
Other 27 5 (19) 2 2 (100) 29 7 (24) 
p value  0.2  0.6  0.3 
2010       
Australia 512 109 (21) 46 17   (37) 558 126 (23) 
Other Oceania 33 8 (24) 2 0     (0) 35 8 (23) 
Asia 20 2 (10) 4 0     (0) 24 2   (8) 
UK & Ireland 6 0   (0) 1 1 (100) 7 1 (14) 
Other 24 3 (13) 3 1   (33) 27 4 (15) 
p value  0.4  0.3  0.4 
† Excludes equivocal test results and missing values. 
 
 
Table 43 HCV antibody prevalence by main language spoken at home by parents, sex and survey 
year† 
 Male Female Total  
Main language spoken at 
home by parents 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
English  368 120 (33) 31 17 (55) 399 137 (34) 
Non-English  47 17 (36) 4 2 (50) 51 19 (37) 
p value  0.6  0.9  0.7 
2007       
English  464 150 (32) 50 30 (60) 514 180 (35) 
Non-English  69 24 (35) 5 3 (60) 74 27 (36) 
p value  0.3  1.0  0.4 
2010       
English  517 116 (22) 50 18 (36) 567 134 (24) 
Non-English  55 6 (11) 4 1 (25) 59 7 (12) 
p value  <0.01  0.5  0.04 
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Table 44 Self-reported HCV status versus HCV serology by sex and survey year† 
 Male Female Total  
Self-report HCV No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Positive 88 87 (99) 16 16 (100) 104 103 (99) 
Negative 138 25 (18) 7 1   (14) 145 26 (18) 
Not sure 22 13 (59) 2 1   (50) 24 14 (58) 
p value  <0.001  <0.001  <0.001 
2007       
Positive 125 120 (96) 29  28   (97) 154 148 (96) 
Negative 211 33 (16) 13 2   (15) 224 35 (16) 
Not sure 25 10 (40) 4 2   (50) 29 12 (41) 
p value  <0.001  <0.001  <0.001 
2010       
Positive 79 78 (99) 19 19 (100) 98 97 (99) 
Negative 231 17   (7) 21 0     (0) 252 17   (7) 
Not sure 35 11 (31) 1 0     (0) 36 11 (31) 
p value  <0.001  <0.001  <0.001 





Table 45 HBV surface-antigen prevalence by sex, injector status and survey year† 
 Male Female Total  












2004       
IDU 244 12 (5) 24 1 (4) 268 13 (5) 
Non-IDU 172 0 (0) 12 0 (0) 184 0 (0) 
p value  <0.01  0.5  <0.01 
2007       
IDU 288 9 (3) 38 2 (5) 326 11 (3) 
Non-IDU 247 3 (1) 14 0 (0) 261 3 (1) 
p value  0.1  0.4  0.08 
2010       
IDU 232 3 (1) 25 0 (0) 257 3 (1) 
Non-IDU 324 8 (2) 28 2 (7) 352 10 (3) 
p value  0.3  0.2  0.2 
† Excludes equivocal test results and missing values. 
 
 
Table 46 HBV core-antibody prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
IDU 239 64 (27) 23 7 (30) 264 71 (27) 
Non-IDU 172 14   (8) 10 3 (30) 182 17   (9) 
p value  <0.001  1.0  <0.001 
2007       
IDU 272 83 (31) 39 13 (33) 311 96 (31) 
Non-IDU 239 22   (9)  16 2 (13) 255 24   (9) 
p value  <0.001  0.1  <0.001 
2010       
IDU 214 40 (19) 9 1 (11) 223 41 (18) 
Non-IDU 291 57 (20) 13 3 (23) 304 60 (20) 
p value  0.8  0.5  0.7 
† Excludes equivocal test results and missing values. 
 
  
National Prison Entrants’ Bloodborne Virus & Risk Behaviour Survey 2004, 2007, and 2010 
National 
 42 
Table 47 HBV core-antibody prevalence by sexual identity, sex and survey year† 
  Male Female Total  
Sexual identity No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Heterosexual 406 78 (19) 29 9   (31) 435 87 (20) 
Bisexual 2 0   (0) 4 1   (25) 6 1 (17) 
Homosexual 3 0   (0) --   -- 3 0   (0) 
Unsure -- -- -- -- -- -- 
p value  0.6  0.8  0.7 
2007       
Heterosexual 501 104 (21) 45 12   (27) 546 116 (21) 
Bisexual 1 0   (0) 4 0     (0) 5 0   (0) 
Homosexual 5 1 (20) 2 1   (50) 7 2 (29) 
Unsure 1 0   (0) 1 1 (100) 2 1 (50) 
p value  0.9  0.2  0.5 
2010       
Heterosexual 494 93 (19) 16 4   (25) 510 97 (19) 
Bisexual 4 1 (25) 4 0     (0) 8 1 (13) 
Homosexual 2 1 (50) 2 0     (0) 4 1 (25) 
Unsure -- -- -- -- -- -- 
p value  0.5  0.4  0.9 
† Excludes equivocal test results and missing values. 
 
 
Table 48 HBV core-antibody prevalence by age group, sex and survey year† 
 Male Female Total  
Age group No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
< 20 years 37 1   (3) 1 0   (0) 38 1   (3) 
20 – 24 89 11 (12) 5 2 (40) 94 13 (14) 
25 – 29 89 17 (19) 8 2 (25) 97 19 (20) 
30 + years 201 49 (24) 19 6 (32) 220 55 (25) 
p value  <0.01  0.9  <0.01 
2007       
< 20 years 32  2   (6) 1 0   (0) 33 2   (6) 
20 – 24 115 11 (10) 6 0   (0) 121 11   (9) 
25 – 29 110 24 (22) 15 2 (13) 125 26 (21) 
30 + years 253 68 (27) 33 13 (39) 286 81 (28) 
p value  <0.001  0.09  <0.001 
2010       
< 20 years 54 3   (6) 1 0   (0) 55 3   (6) 
20 – 24 107 6   (6) 4 0   (0) 111 6   (5) 
25 – 29 106 19 (18) 3 1 (33) 109 20 (18) 
30 + years 238 69 (29) 14 3 (21) 252 72 (29) 
p value  <0.001  0.6  <0.001 
† Excludes equivocal test results and missing values. 
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Table 49 HBV core-antibody prevalence by duration of drug injection, sex and survey year† 
 Male Female Total  
Duration of drug injection No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
<3 years 29 2   (7) 1 0   (0) 30 2   (7) 
3 to 5 years 23 2   (9) 3 1 (33) 26 3 (12) 
6 to 10 years 76 18 (24) 7 3 (43) 83 21 (25) 
10 + years 108 41 (38) 12 3 (25) 120 44 (37) 
p value  <0.01  0.8  <0.01 
2007       
<3 years 19 2 (11) 1 0   (0) 20 2 (10) 
3 to 5 years 29 5 (17) 3 0   (0) 32 5 (16) 
6 to 10 years 66 17 (26) 17 4 (24) 83 21 (25) 
10 + years 149 55 (37) 18 9 (50) 167 64 (38) 
p value  0.02  0.2  <0.01 
2010       
<3 years 25 1   (4) 1 0   (0) 26 1   (4) 
3 to 5 years 19 3 (16) 2 1 (50) 21 4 (19) 
6 to 10 years 41 5 (12) 3 0   (0) 44 5 (11) 
10 + years 123 29 (24) 3 0   (0) 126 29 (23) 
p value  0.08  0.3  0.07 
† Excludes equivocal test results and missing values. 
 
 
Table 50 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey 
year† 
 <3 years IDU 3+ years IDU Total  
Last drug injected No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Amphetamine (Speed, Ice) 23 2   (9) 130 38 (22) 153 40 (26) 
Heroin 1 0   (0) 70 22 (31) 71 22 (31) 
More than one 5 0   (0) 23 7 (30) 28 7 (25) 
Other/not reported 1 0   (0) 5 1 (20) 6 1 (17) 
     p value  0.9  0.9  0.8 
2007       
Amphetamine (Speed, Ice) 17 2 (12) 165 41 (25) 182 43 (24) 
Heroin 3 0   (0) 87 35 (40) 90 35 (39) 
More than one -- -- 11 5 (45) 11 5 (45) 
Other/not reported -- -- 19 9 (47) 19 9 (47) 
     p value  0.5  0.02  0.01 
2010       
Amphetamine (Speed, Ice) 16 0   (0) 119 22 (18) 135 22 (16) 
Heroin 4 0   (0) 39 13 (33) 43 13 (30) 
More than one -- -- 6 1 (17) 6 1 (17) 
Other/not reported 6 1 (17) 27 2   (7) 33 3   (9) 
     p value  0.2  0.06  0.09 
† Excludes equivocal test results and missing values. 
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Table 51 HBV core-antibody prevalence by frequency of injection last month, duration of drug 
injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Frequency of drug injection 
last month 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Less than daily 11 1 (19) 41 20 (49) 52 21 (40) 
Daily or more 10 0   (0) 99 26 (26) 109 26 (24) 
p value  0.3  0.01  0.02 
2007       
Less than daily 3 0   (0) 73 24 (33) 76 24 (32) 
Daily or more 6 0   (0) 102 39 (38) 108 39 (36) 
p value  --  0.5  0.5 
2010       
Less than daily 10 0   (0) 52 11 (21) 62 11 (18) 
Daily or more 8 0   (0) 54 8 (15) 62 8 (13) 
p value  --  0.4  0.5 
† Excludes equivocal test results and missing values. 
 
 
Table 52 HBV core antibody prevalence by re-use of someone else’s used needle and syringe last 
month, duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Re-used someone else’s used 
needle & syringe last month 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
No 20 1 (5) 101 33 (33) 121 34 (28) 
Yes 2 0 (0) 39 13 (33) 41 13 (32) 
p value  0.7  0.9  0.8 
2007       
No 9 0 (0) 135 47 (35) 144 47 (33) 
Yes -- -- 32 13 (41)  32 13 (41) 
p value  --  0.5  0.4 
2010       
No 15 0 (0) 81 15 (19) 96 15 (16) 
Yes 2 0 (0) 15 1   (7) 17 1   (6) 
p value  --  0.3  0.3 
† Excludes equivocal test results and missing values. 
 
 
Table 53 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and 
survey year† 
 <3 years IDU 3+ years IDU Total  
Imprisonment last year No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
No 12 0   (0) 79 29 (37) 91 29 (32) 
Yes 18 2 (11) 145 37 (26) 163 39 (24) 
p value  0.2  0.2  0.6 
2007       
No 5 2 (40) 81 25 (31) 86 27 (31) 
Yes 6  0   (0) 148 49 (33) 154 49 (32) 
p value  0.9  0.7  0.9 
2010       
No 14 0   (0) 84 17 (20) 98 17 (17) 
Yes 11 1   (9) 100 19 (19) 111 20 (18) 
p value  0.3  0.8  0.9 
† Excludes equivocal test results and missing values. 
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Table 54 HBV core-antibody by number of previous imprisonments, sex and survey year† 
 Male Female Total  
Number of previous 
imprisonments 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
1 103 9   (9) 9 3 (33) 112 12 (11) 
2 to 4 211 40 (19) 17 4 (24) 228 44 (19) 
5 to 9 67 22 (33) 4 1 (25) 71 23 (32) 
10 + 22 6 (27) 3 2 (67) 25 8 (32) 
p value  <0.01  0.5  <0.01 
2007       
1 163 15   (9) 21 6 (29) 184 21 (11) 
2 to 4 204 44 (22) 21 2 (10) 225 46 (20) 
5 to 9 76 24 (32) 7 4 (57) 83 28 (34) 
10 + 48 16 (33) 4 1 (25) 52 17 (33)  
p value  <0.01  0.08  <0.01 
2010       
1 250 31 (12) 12 3 (25) 262 34 (13) 
2 to 4 145 33 (23) 7 0   (0) 152 33 (22) 
5 to 9 67 21 (31) 3 1 (33) 70 22 (31) 
10 + 38 12 (32) -- -- 38 12 (32) 
p value  <0.001  0.3  <0.01 
† Excludes equivocal test results and missing values. 
 
 
Table 55 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Non-Indigenous 340 57 (17) 23 7 (30) 363 64 (18) 
Indigenous 68 20 (29) 9 2 (22) 77 22 (29) 
p value  0.02  0.6  0.03 
2007        
Non-Indigenous 416 67 (16) 36 8 (22) 452 75 (17) 
Indigenous 88 37 (42) 18 7 (39) 106 44 (42) 
p value  <0.001  0.2  <0.001 
2010       
Non-Indigenous 342 53 (15) 14 2 (14) 356 55 (15) 
Indigenous 163 44 (27) 8 2 (25) 171 46 (27) 
p value  <0.01  0.5  <0.01 
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Table 56 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector 
status and survey year† 
 Non-IDU IDU Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Non-Indigenous 154 14   (9) 206 50 (24) 360 64 (18) 
Indigenous 26 3 (12) 50 19 (38) 76 22 (29) 
p value  0.7  0.05  0.03 
2007       
Non-Indigenous 215 12   (6) 237 63 (27) 452 75 (17) 
Indigenous 39 12 (31) 67 32 (48) 106 44 (42) 
p value  <0.001  0.01  <0.001 
2010       
Non-Indigenous 194 25 (13) 162 30 (19) 356 55 (15) 
Indigenous 110 35 (32) 61 11 (18) 171 46 (27) 
p value  <0.001  0.9  <0.01 
† Excludes equivocal test results and missing values. 
 
 
Table 57 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before 
prison and survey year† 
  Male Female Total  
Residential remoteness No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Highly accessible/accessible 370 66 (18) 28 8   (29) 398 74 (19) 
Moderately accessible 10 1 (10) 1 0     (0) 11 1   (9) 
Remote/very remote 18 7 (39) 2 0     (0) 20 7 (35) 
p value  0.06  0.6  0.1 
2007       
Highly accessible/accessible 454 89 (20) 47 13   (28) 501 102 (20) 
Moderately accessible 15 1   (7) 1 0     (0) 16 1   (6) 
Remote/very remote 17 7 (41) 1 1 (100) 18 8 (44) 
p value  0.04  0.2  0.02 
2010       
Highly accessible/accessible 411 68 (17) 16 2   (13) 427 70 (16) 
Moderately accessible 19 5 (26) 1 0     (0) 20 5 (25) 
Remote/very remote 56 20 (36) 3 2   (67) 59 22 (37) 
p value  <0.01  0.09  <0.01 
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Table 58 HBV core-antibody prevalence by region/country of birth, sex and survey year† 
 Male Female Total  
Region/Country of birth No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Australia 337 63 (19) 31 8   (26) 368 71 (19) 
Other Oceania 23 6 (26) -- -- 23 6 (26) 
Asia 15 6 (40) 2 2 (100) 17 8 (47) 
UK & Ireland 9 1 (11) -- -- 9 1 (11) 
Other 26 2   (8) -- -- 26  2   (8) 
p value  0.1  0.07  0.02 
2007       
Australia 431 86 (20) 47 11   (23) 478 97 (20) 
Other Oceania 17 5 (29) 2 1   (50) 19 6 (32) 
Asia 29 7 (24) 3 1   (33) 32 8 (25) 
UK & Ireland 8 3 (38) 1 0     (0) 9 3 (33) 
Other 24 4 (17) 2 2 (100) 26 6 (23) 
p value  0.6  0.2  0.7 
2010       
Australia 431 74 (17) 18 2   (11) 449 76 (17) 
Other Oceania 26 7 (27) -- -- 26 7 (27) 
Asia 20 8 (40) 3 2   (67) 23 10 (43) 
UK & Ireland 5 0   (0) -- -- 5 0   (0) 
Other 23 8 (35) 1 0     (0) 24 8 (33) 
p value  0.01  0.06  <0.01 
† Excludes equivocal test results and missing values. 
 
 
Table 59 HBV core-antibody prevalence by main language spoken at home by parents, sex and 
survey year† 
 Male Female Total  
Main language spoken at 
home by parents 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
English  367 66 (18) 29 7   (24) 396 73 (18) 
Non-English  43   12 (28) 4 3   (75) 47 15 (32) 
p value  0.1  0.04  0.03 
2007       
English  444 86 (19) 49 12   (24) 493 98 (20) 
Non-English  66 18 (27) 6 3   (50) 72 21 (29) 
p value  0.1  0.2  0.07 
2010       
English  442 76 (17) 18 0     (0) 460 76 (17) 
Non-English  53 17 (32) 2 2 (100) 55 19 (35) 
p value  <0.01  <0.001  <0.01 
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Table 60 Hepatitis B virus immune status by injector status and survey year† 
  Hepatitis B Virus Immune Status 
Injector status No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
IDU 270 117 (43) 60 (22) 13 (5) 80 (30) 
Non-IDU 185 134 (72) 17   (9) 0 (0) 34 (18) 
p value     <0.001 
2007      
IDU 308 111 (36) 90 (29) 10  (3) 97 (31) 
Non-IDU 246 166 (67) 21   (9) 3  (1) 56 (23) 
p value     <0.001 
2010      
IDU 236 80 (34) 38 (16) 3 (1) 115 (49) 
Non-IDU 319 145 (45) 52 (16) 10 (3) 112 (35) 
p value     <0.01 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 61 Hepatitis B virus immune status by sexual identity and survey year† 
  Hepatitis B Virus Immune Status 
Sexual identity No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
Heterosexual  445 245 (55) 76 (17) 13  (3) 111 (25) 
Bisexual 7 4 (57) 1 (14) 0  (0) 2 (29) 
Homosexual 3 2 (67) 0   (0) 0  (0) 1 (33) 
Unsure -- -- -- -- -- 
p value     -- 
2007      
Heterosexual  534 269 (50) 108 (20) 11  (2) 146 (27) 
Homosexual 5 2 (40) -- -- 3 (60) 
Bisexual 7 3 (43) 1 (14) 1 (14) 2 (29) 
Unsure 2 1 (50) 1 (50) -- 146 (27) 
p value     0.4 
2010      
Heterosexual  534 218 (41) 86 (16) 13  (2) 217 (41) 
Homosexual 4 2 (50) 1 (25) 0  (0) 1 (25) 
Bisexual 11 2 (18) 1   (9) 0  (0) 8 (73) 
Unsure -- -- -- -- -- 
p value     0.5 
† Excludes equivocal test results and missing values.   
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Table 62 Hepatitis B virus immune status by age group and survey year† 
  Hepatitis B Virus Immune Status 
Age group No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
< 20 years 38 23 (61) 0   (0) 1 (3) 14 (37) 
20 – 24 96 53 (55) 10 (10) 4 (4) 29 (30) 
25 – 29 100 57 (57) 16 (16) 3 (3) 24 (24) 
30 + years 226 123 (54) 51 (23) 5 (2) 47 (21) 
p value     0.02 
2007      
< 20 years 34 21 (62) 3   (9) 0 (0) 10 (29) 
20 – 24 117 59 (50) 9   (8) 2 (2)  47 (40) 
25 – 29 121 54 (45) 24 (20) 3 (2) 40 (33) 
30 + years 281 142 (51) 75 (27) 8 (3) 56 (20) 
p value     <0.001 
2010      
< 20 years 59 23 (39) 3   (5) 0 (0) 33 (56) 
20 – 24 110 49 (45) 6   (5) 0 (0) 55 (50) 
25 – 29 120 53 (44) 16 (13) 5 (4) 46 (38) 
30 + years 266 100 (38) 65 (24) 8 (3) 93 (35) 
p value     <0.001 
† Excludes equivocal test results and missing values.  
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 63 Hepatitis B virus immune status by number of previous imprisonments and survey year† 






No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
1 115 85 (74) 10   (9) 2 (2) 18 (16) 
2 to 4 232 124 (53) 39 (17) 8 (3) 61 (26) 
5 to 9 74 25 (34) 21 (28) 1 (1) 27 (36) 
10 + 25 11 (44) 6 (24) 2 (8) 6 (24) 
p value     <0.001 
2007      
1 182 130 (71) 19 (10) 3 (2) 30 (16) 
2 to 4 215 109 (51) 42 (20) 5 (2) 59 (27) 
5 to 9 83 16 (19) 27 (33) 3 (4) 37 (45) 
10 + 52 13 (25) 15 (29) 2 (4) 22 (42) 
p value     <0.001 
2010      
1 277 143 (52) 28 (10) 6 (2) 100 (36) 
2 to 4 154 51 (33) 31 (20) 3 (2) 69 (45) 
5 to 9 75 22 (29) 20 (27) 2 (3) 31 (41) 
10 + 44 6 (14) 11 (25) 2 (5) 25 (57) 
p value     <0.001 
† Excludes equivocal test results and missing values.   
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Table 64 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey 
year† 






No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
Non-Indigenous 372 223 (60) 57 (15) 9 (2) 83 (22) 
Indigenous 78 26 (33) 18 (23) 4 (5) 30 (38) 
p value     <0.001 
2007      
Non-Indigenous 442 242 (55) 70 (16) 8 (2) 122  (28) 
Indigenous 104 32 (31) 40 (38) 5 (5) 27  (26) 
p value     <0.001 
2010      
Non-Indigenous 370 174 (47) 48 (13) 7 (2) 141 (38) 
Indigenous 185 51 (28) 42 (23) 6 (3) 86 (46) 
p value     <0.001 
† Excludes equivocal test results and missing values.  
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 65 Hepatitis B virus immune status by residential remoteness and survey year† 
  Hepatitis B Virus Immune Status 
Residential remoteness No 
tested 
No (%) with no 
evidence of 
HBV immunity 






No (%) vaccine 
conferred 
immunity* 
2004      
Highly 
 
409 231 (56) 64 (16) 12 (3) 102 (25) 
Moderately accessible 11 6 (55) 1   (9) 0 (0) 4 (36) 
Remote/very remote 20 7 (35) 7 (35) 0 (0) 6 (30) 
p value     0.2 
2007      
Highly 
 
494 248 (50) 92 (19) 13 (3) 141 (29) 
Moderately accessible 14 13 (93) 1   (7) 0 (0) 0   (0) 
Remote/very remote 15 3 (20) 9 (60) 0 (0) 3 (20) 
p value     <0.001 
2010      
Highly 
 
447 191 (43) 64 (14) 6 (1) 186 (42) 
Moderately accessible 25 9 (36) 4 (16) 2 (8) 10 (40) 
Remote/very remote 64 17 (27) 18 (28) 5 (8) 24 (38) 
p value     <0.001 
† Excludes equivocal test results and missing values.  
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Table 66 Hepatitis B virus immune status by main language spoken at home by parents and survey 
year† 
  Hepatitis B Virus Immune Status 
Main language 




No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
English 403 222 (55) 65 (16) 9   (2) 107 (27) 
Non-English 51 28 (55) 12 (24) 4   (8) 7 (14) 
p value     0.02 
2007      
English 482 248 (51) 94 (20) 8   (2) 132 (27) 
Non-English 71 29 (41) 16 (23) 5   (7) 21 (30) 
p value     0.02 
2010      
English 485 205 (42) 72 (15) 6   (1) 202 (42) 
Non-English 57 18 (32) 13 (23) 6 (11) 20 (35) 
p value     <0.001 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 67 Self-reported hepatitis B immunisation versus serological testing and survey year*  
 Male Female Total  
Self-report HBV 
immunisation** 
No tested No immune 
(%) 
No tested No immune 
(%) 
No tested No immune 
(%) 
2004       
No 128 14 (11) 8 3 (38) 136 17 (13) 
Yes 163 81 (50) 12 5 (42) 175 86 (49) 
Not sure 46 9 (20) 6 2 (33) 52 11 (21) 
p value  <0.001  0.9  <0.001 
2007       
No 144 17 (12) 21 4 (19) 165 21 (13) 
Yes 196 111 (57) 18 11 (61) 214 122 (57) 
Not sure 47 9 (19) 1 0   (0) 48 9 (19) 
p value  <0.001  0.02  <0.001 
2010        
No 135 34 (25)  7 1 (14) 142 35 (25) 
Yes 207 149 (72) 21 15 (71) 228 164 (72) 
Not sure 78 27 (35) 1 0   (0) 79 27 (34) 
p value  <0.001  0.4  <0.001 
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  









Table 68 Genital chlamydia prevalence by sex and survey year† 
Sex  No tested No with 
chlamydia (%) 
2010   
Male  559 27 (5) 
Female 59 1 (2) 
p value  0.3 




Table 69 Genital gonorrhoea prevalence by sex and survey year† 
Sex  No tested No with 
gonorrhoea (%) 
2010   
Male  548 5 (1) 
Female 59 0 (0) 
p value  0.5 




Table 70 Syphilis markers by sex and survey year† 








No with any 
marker for 
syphilis (%) 
2010     
Male  573 37 (6) 14 (2) 37 (6) 
Female 50 3 (6) 1 (2) 3 (6) 
p value  0.9 0.9 0.9 
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New South Wales 
2004, 2007, 2010 
Table 71 Number (%) of respondents by demographic characteristics, injector status and survey year 
     2004     2007 2010 
Demographic characteristics IDU Non-IDU IDU Non-IDU IDU Non-IDU 
Number of sites surveyed N = 2 N = 3 N = 7 
No surveyed N = 183 N = 127 N = 132 N =113  N = 100 N = 154 
Sex (%)       
Male 152 (83) 118 (93) 101 (77) 103 (91) 92 (92) 149 (97) 
Female 30 (16) 9   (7) 31 (23) 10   (9) 8   (8) 5   (3) 
Transgender 1 (<1) -- -- -- -- -- 
Sexual identity (%)       
Heterosexual 171 (93) 123 (97) 120 (91) 110 (97) 99 (99) 152 (99) 
Bisexual 7   (4) 1 (<1) 4   (3) -- -- 1 (<1) 
Homosexual 5   (3) 2   (2) 5   (4) -- 1   (1) -- 
Unsure -- -- -- -- -- -- 
Not reported -- 1 (<1) 3   (2) 3   (3) -- 1 (<1) 
Age and duration of injection (years)      
Median age (years) 30 32 31 31 34 27 
    Age range 18 – 58 18 – 75 19 – 53 18 – 71 18 – 79 17 – 72 
Age group (%)       
    <25 years 47 (26) 39 (31) 22 (17) 37 (33) 9   (9) 55 (36) 
    25+ years 136 (74) 88 (69) 109 (83) 76 (67) 91 (91) 99 (64) 
    Not reported -- -- 1 (<1) 0   (0) -- -- 
Median age 1stIDU (years) 18 -- 18 -- 19 -- 
    Age range 9 – 41 -- 8 – 35 -- 7 – 40 -- 
    Not reported 4 -- 3 -- 4 -- 
Median years IDU 10 -- 13 -- 14 -- 
    Range <1 – 31 -- <1 – 36 -- <1 – 38 -- 
Duration of drug injection (%)      
    <3 years 16   (9) -- 6   (5) -- 9   (9) -- 
    3+ years 163 (89) -- 122 (92) -- 87 (87) -- 
    Not reported 4   (2) -- 4   (3) -- 4   (4) -- 
Aboriginal and Torres Strait Islander origin (%)     
No 155 (85) 118 (93) 93 (70) 97 (86) 80 (80) 126 (81) 
Yes 28 (15) 9   (7) 33 (25) 15 (13) 20 (20) 29 (19) 
Not reported -- -- 6   (5) 1 (<1) -- -- 
Living situation prior to prison (%)*      
Not homeless n/a n/a n/a n/a 67 (67) 104 (68) 
Primary homelessness n/a n/a n/a n/a 2   (2) 2   (1) 
Secondary homelessness n/a n/a n/a n/a 22 (22) 46 (30) 
Tertiary homelessness n/a n/a n/a n/a 9 (9) 2   (1) 
Not reported n/a n/a n/a n/a -- -- 
Residential remoteness in 12 months before prison (%)     
Highly accessible/accessible 174 (95) 117 (92) 121 (92) 104 (92) 139 (90) 92 (92) 
Moderately accessible 3   (2) 2   (2) 1   (1) 1   (1) 5   (3) 6   (6) 
Remote/very remote 3   (2) -- -- -- 4   (3) 1   (1) 
Not reported 3   (2) 8   (6) 10   (8) 8   (7) 6   (4) 1   (1) 
Region/Country of birth (%)      
Australia 156 (85) 87 (69) 118 (89) 73 (65) 85 (85) 110 (71) 
Other Oceania 3   (2) 8   (6) 2   (2) 9   (8) 8   (8) 13   (8) 
Asia 11   (6) 11   (9) 7   (5) 13 (12) 4   (4) 16 (10) 
UK & Ireland 3   (2) 5   (4) 1 (<1) 2   (2) 1   (1) 1   (1) 
Other 10   (5) 16 (13) 3   (2) 13 (12) 2   (2) 14   (9) 
Not reported -- -- 1 (<1) 3   (3) -- -- 
Main language spoke at home by parents (%)     
English  159 (87) 99 (78) 115 (87) 74 (65) 91 (91) 122 (79) 
Non-English  24 (13) 28 (22) 17 (13) 39 (35) 9   (9) 31 (20) 
Not reported -- -- -- -- -- 1   (1) 
* Not homeless (private rental, home owner/purchaser, public/community housing, drug and alcohol treatment facility, workers’ 
accommodation, prison, nursing home, foster home); Primary homelessness (Sleeping rough, squat, long grass, boat, car); 
Secondary homelessness (Living with parent, siblings, or relatives, crisis accommodation); Tertiary homelessness (Boarding house, 
hostel, caravan park, backpackers, hotel, motel). Living situation question introduced in 2010.
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Table 71 Number (%) of respondents by demographic characteristics, injector status and survey year 
(cont.) 
     2004     2007     2010 
Demographic characteristics IDU Non-IDU IDU Non-IDU IDU Non-IDU 
First time in prison (%)       
No 157 (86) 59 (46) 112 (85) 63 (56) 84 (84) 86 (56) 
Yes 26 (14) 68 (54) 19 (14) 50 (44) 14 (14) 64 (42) 
Not reported -- -- 1 (<1) -- 2   (2) 4   (3) 
Lifetime imprisonments (%)       
One 26 (14) 68 (54) 19 (14) 50 (44) 30 (30) 96 (62) 
Two to four  84 (46) 44 (35) 50 (38) 49 (43) 30 (30) 39 (25) 
Five to nine   50 (27) 9   (7) 32 (24) 7   (6) 22 (22) 13   (8) 
Ten or more  20 (11) 2   (2) 27 (20) 3   (3) 16 (16) 2   (1) 
Not reported 3   (2) 4   (3) 4   (3) 4   (4) 2   (2) 4   (3) 
Imprisonment in last year (%)       
No 84 (46) 97 (76) 35 (31) 14 (22) 50 (50) 94 (61) 
Yes 99 (54) 27 (21) 76 (67) 48 (76) 48 (48) 56 (36) 
Not reported -- 3   (2) 2   (2) 1   (2) 2   (2) 4   (3) 
Frequency of injection last month (%)      
Not last month 55 (30) -- 44 (33) -- 46 (46) -- 
Less than weekly 29 (16) -- 22 (17) -- 18 (18) -- 
Weekly not daily 14   (8) -- 14 (11) -- 7   (7) -- 
Daily or more 83 (45) -- 49 (37) -- 28 (28) -- 
Not reported 2   (1) -- 3   (2) -- 1   (1) -- 
Ever smoked a full cigarette (%)*      
No n/a n/a 4   (3) 10   (9) 3   (3) 15 (10) 
Yes n/a n/a 128 (97) 103 (91) 97 (97) 139 (90) 
Not reported n/a n/a -- -- -- -- 
Median age first smoked (years) n/a n/a 13 14 14 15 
    Age range n/a n/a 6 – 30  4 – 31 7 – 28 6 – 34 
Current smoker (%)*       
No n/a n/a 8   (6) 27 (24) 6   (6) 37 (24) 
Yes n/a n/a 124 (94) 86 (76) 94 (94) 117 (76) 
Not reported n/a n/a -- -- -- -- 
Smoking frequency (%)*       
Occasional – weekly or less n/a n/a 4   (3) 10 (12) 2   (2) -- 
5 to 10 cigarettes a day n/a n/a 26 (21) 16 (19) 26 (28) 45 (38) 
11 to 20 cigarettes a day n/a n/a 61 (49) 31 (36) 48 (51) 45 (38) 
Over 20 cigarettes a day n/a n/a 32 (26) 29 (34) 18 (19) 27 (23) 
Not reported n/a n/a 1 (<1) -- -- -- 
Other drugs used last month (%)**      
No drugs in past 4 weeks n/a n/a n/a n/a 24 (24) 90 (58) 
Cannabis n/a n/a n/a n/a 52 (68) 46 (72) 
Heroin n/a n/a n/a n/a 25 (33) 6   (9) 
Cocaine n/a n/a n/a n/a 9 (12) 8 (13) 
Amphetamine n/a n/a n/a n/a 42 (55) 25 (39) 
Other's methadone n/a n/a n/a n/a 12 (16) -- 
Other opiates n/a n/a n/a n/a 9 (12) -- 
Other's buprenorphine n/a n/a n/a n/a 5   (7) 1   (2) 
Steroids n/a n/a n/a n/a 3   (4) 1   (2) 
Hallucinogens n/a n/a n/a n/a 1   (1) 1   (2) 
Benzodiazepines n/a n/a n/a n/a 15 (20) 6   (9) 
Ecstasy/MDA n/a n/a n/a n/a -- 8 (13) 
Inhalants (e.g. petrol) n/a n/a n/a n/a -- 1   (2) 
Other drug n/a n/a n/a n/a -- -- 
Not reported n/a n/a n/a n/a -- -- 
* Smoking questions not asked in 2004. 
** Other drugs used in the last month not asked in 2004 and 2007. More than one option could be selected.   
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Table 72 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to 
survey and survey year 
Injecting behaviour 2004 2007 2010 
Last drug injected (%) N = 183 N = 132 N = 100 
Amphetamine (Speed, Ice) 73 (40) 64 (48) 49 (49) 
Anabolic steroids 1   (1) -- 1   (1) 
Cocaine 7   (4) 5   (4) 2   (2) 
Heroin 86 (47) 53 (40) 37 (37) 
Heroin + amphetamine -- 3   (2) -- 
Heroin + cocaine 2   (1) 1   (1) 2   (2) 
Methadone 6   (3) 4   (3) 4   (4) 
Morphine 1   (1) 2   (2) 2   (2) 
Other 7   (4) -- 2   (2) 
Not reported -- -- 1   (1) 
No Injected last month N = 128 N = 88 N = 53 
Places injected last month (%)* 
Prison 3   (2) 3   (3) -- 
Own home 99 (77) 65 (76) 34 (64) 
Friend’s home 54 (42) 46 (54) 15 (28) 
Dealer’s home 21 (16) 23 (27) 8 (15) 
Street, park, beach 40 (31) 38 (45) 6 (11) 
Car 37 (29) 36 (42) 9 (17) 
Public toilet 29 (23) 25 (29) 7 (13) 
Commercial injecting room 6   (5) 7   (8) -- 
Medically Supervised Injecting Centre, Sydney 5   (4) 10 (12) 2  (4) 
Squat 10   (8) 8   (9) -- 
Other place 5   (4) -- -- 
Use of sterile needles & syringes last month (%) 
All injections 86 (67) 49 (58) 36 (68) 
Most of the time 20 (16) 16 (19) 10 (19) 
Half of the time 8   (6) 7   (8) -- 
Some of the time 12   (9) 10 (12) 1   (2) 
Not last month 2   (2) -- 1   (2) 
Not reported -- 3   (4) 5   (9)    
Re-used someone else’s used needle & syringe last month (%) 
None 116 (91) 68 (80) 38 (72) 
Once 4   (3) 7   (8) 2   (4) 
Twice 3   (2) 2   (2) 3   (6) 
3-5 times 4   (3) 3   (4) 4   (8) 
>5 times 1 (<1) 4   (5) 2   (4) 
Not reported -- 1   (1) 4   (8) 
Number of people needle & syringe was re-used after last month (%) 
None 117 (91) 68 (77) 37 (70) 
One 8   (6) 12 (14) 9 (17) 
Two 2   (2) -- 1   (2) 
Three to five 1 (<1) -- -- 
More than five -- -- -- 
Don’t know how many -- -- 1   (2) 
Not reported -- 8   (9) 5   (9) 
Relationship to people needle & syringe was re-used after last month (%)*  
Regular sex partner 4   (3) 7   (8)  6 (11) 
Casual sex partner 1 (<1) -- 1   (2) 
Close friend 3   (2) 2   (2) 1   (2) 
Acquaintance 3   (2) 2   (2) 1   (2) 
Other 1 (<1) 1   (1) 1   (2) 
Equipment used after someone else last month (%)*  
Spoon 28 (22) 26 (31) 11 (21) 
Water 19 (15) 23 (27) 9 (17) 
Filter 17 (13) 20 (24) 8 (15) 
Tourniquet 10   (8) 11 (13) 10 (19) 
Drug mix 18 (14) 17 (20) 8 (15) 
* More than one option could be selected.    
  
National Prison Entrants’ Bloodborne Virus & Risk Behaviour Survey 2004, 2007, and 2010 
New South Wales 
 56 
Table 73 Number (%) of respondents by treatment for drug use, injector status and survey year 
Treatment for drug use 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 183 N = 127 N = 132 N =113  N = 100 N = 154  
Any treatment/therapy for drug use (%)   
No 89 (49) 118 (93) 24 (18) 76 (67) 29 (29) 128 (83) 
Yes 93 (51) 9   (7) 100 (76) 15 (13) 70 (70) 26 (17) 
Not reported 1 (<1) -- 8   (6) 22 (19) 1   (1) -- 
History of methadone maintenance treatment (%)   
Currently 44 (24) -- 25 (19) -- 25 (25) 1   (1) 
Previously 50 (27) 2   (2) 39 (30) -- 17 (17) 3   (2) 
Never 88 (48) 125 (98) 57 (43) -- 55 (55) 150 (97) 
Not reported 1 <(1) -- 11   (8) -- 3   (3) -- 
History of other pharmacotherapy treatment (%)   
Currently 9   (5) -- 4   (3) -- 18 (18) 2   (1) 
Previously 31 (17) 1 (<1) 35 (27) -- 13 (13) 3   (2) 
Never 139 (77) 126 (98) 89 (67) -- 69 (69) 149 (97) 
Not reported 1 (<1) -- 4   (3) -- -- -- 
 
 
Table 74 Number (%) of respondents by site of needle and syringe acquisition last month and survey 
year 
Needle & Syringe acquisition*   2004       2007 2010 
No surveyed N = 129 N = 85  N = 53 
From an NSP last month (%)   
Daily or almost daily 17   (6) 11 (13) 8 (15) 
A couple of times each week 21   (7) 18 (21) 11 (21) 
Less than weekly 14   (5) 13 (15) 11 (21) 
Weekly n/a n/a -- 
Once last month 24   (8) 15 (18) 13 (25) 
Not in the last month 28   (9) 12 (14) 10 (19) 
Not reported 25   (8) 16 (19) -- 
From a chemist last month (%)   
Daily or almost daily 5   (2) 5   (6) 3   (6) 
A couple of times each week 17   (6) 8   (9) 5   (9) 
Less than weekly 30 (10) 9 (11) 7 (13) 
Weekly n/a n/a 8 (15) 
Once last month 19   (6) 11 (13) -- 
Not in the last month 54 (17) 37 (44) 30 (57) 
Not reported 4   (3) 15 (18) -- 
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Table 75 Number (%) of respondents by body piercing and tattoos 
Body piercing and tattoos 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 183 N = 127 N = 132 N =113  N = 100 N = 154  
Body or ear piercings (%)       
No 93 (51) 84 (66) 43 (33) 59 (52) 59 (59) 94 (61) 
Yes 90 (49) 42 (33) 88 (67) 52 (46) 41 (41) 60 (39) 
Not reported -- 1   (1) 1   (1) 2   (2) -- -- 
Pierced in past 12 mths (%)       
No 74 (82) 30 (71) 73 (82) 43 (82) 41 (100) 47 (78) 
Yes 11 (12) 5 (12) 13 (15) 6 (12) -- 12 (20) 
Not reported 5   (6) 7 (17) 2   (3) 3   (6) -- 1   (2) 
Who did piercing (%)*      
Chemist/hairdresser/beauty 
salon  
2 (18) 3 (60) 1   (8) 1 (17) -- 1   (8) 
Professional piercer / studio 7 (64) 1 (20) 4 (31) 1 (17) -- 6 (50) 
Tattooist / parlour -- -- 4 (31) 1 (17) -- 1   (8) 
Friend -- -- -- 1 (17) -- 2 (17) 
Prison inmate -- -- 1   (8) -- -- -- 
Self 1   (9) -- -- 2 (33) -- -- 
Family member -- -- 2 (15) -- -- -- 
Other -- -- -- -- -- -- 
Needle used by other (%)       
No  2 (18) -- -- -- -- 10 (83) 
Yes -- -- -- 2 (33) -- -- 
Unsure -- -- -- -- -- -- 
Not reported 9 (82) 5 (100) 13 (100) 4 (67) -- 2 (17) 
Tattoos (%)       
No 48 (26) 67 (53) 25 (19) 44 (39) 20 (20) 64 (42) 
Yes 135 (74) 59 (46) 107 (81) 69 (61) 80 (80) 90 (58) 
Not reported -- 1   (1) -- -- -- -- 
Tattoos in past 12 mths (%)       
No  114 (84) 48 (80) 81 (76) 44 (64) 64 (80) 55 (61) 
Yes 21 (16) 10 (17) 26 (24) 24 (35) 16 (20) 35 (39) 
Not reported -- 1   (3) -- 1   (1) -- -- 
Who did tattooing (%)*       
Professional tattooist 12 (57) 4 (40) 14 (54) 18 (75) 9 (56) 23 (80) 
Friend 5 (24) 1 (10) 7 (27) 4 (17) 6 (38) 6 (17) 
Prison inmate 5 (24) 2 (20) 6 (23) -- 1   (6) -- 
Self 3 (14) 1 (10) 1   (4) 2   (8) -- 1   (3) 
Family member 1   (5) -- -- 1   (4) -- -- 
Other -- -- -- -- -- -- 
* More than one option could be selected.  
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Table 76 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by 
injector status and survey year 
Sexual behaviour 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 183  N = 127 N = 132  N = 113 N = 100  N = 154  
Sex last month / last 3 months (%)**      
No 47 (26) 38 (30) 39 (30) 28 (25) 17 (17) 28 (18) 
Yes 136 (74) 86 (68) 93 (70) 84 (74) 83 (83) 123 (80) 
Not reported -- -- -- 1 (<1) -- -- 
Male sex partners in last 3 months**    
    Median n/a n/a n/a n/a 1 1 
    Range n/a n/a n/a n/a 0 – 23 0 – 20 
Female sex partners in last 3 months**     
    Median n/a n/a n/a n/a 1 1 
    Range n/a n/a n/a n/a 0 – 1 0 – 10 
Condom use at last sex (%)        
No 136 (74) 85 (67) 114 (86) 90 (80) n/a  n/a  
Yes 47 (26) 39 (31) 15 (11) 22 (19) n/a  n/a  
Not reported   3   (2) 1 (<1) n/a  n/a  
Condom use with regular sex partner(s) last month (%)*      
No 83 (84) 57 (81) 69 (88) 57 (77) n/a  n/a  
Sometimes 8   (8) 7 (10) 8 (10) 9 (12) n/a  n/a  
Always 8   (8) 6   (9) 1 (<1) 8 (11) n/a  n/a  
Condom use with new sex partner(s) last month (%)*     
No 6 (27) 2 (22) 17 (63) 5 (36) n/a  n/a  
Sometimes 6 (27) 1 (11) 5 (19) 5 (36) n/a  n/a  
Always 10 (45) 6 (67) 5 (19) 4 (29) n/a  n/a  
Condom use with casual sex partner(s) last month (%)*      
No 17 (40) 8 (40) 17 (74) 6 (43) n/a  n/a  
Sometimes 9 (21) 4 (20) 4 (17) 5 (36) n/a  n/a  
Always 17 (40) 8 (40) 2   (9) 3 (21) n/a  n/a  
Condom use last sex - regular male partners - last 3 months (%)**   
Never n/a n/a n/a n/a 6 (86) 3 (60) 
Sometimes n/a n/a n/a n/a 1 (14) 1 (20) 
Always n/a n/a n/a n/a -- 1 (20) 
Condom use last sex - regular male partners - last 3 months (%)**   
Never n/a n/a n/a n/a 6 (86) 3 (60) 
Sometimes n/a n/a n/a n/a 1 (14) 1 (20) 
Always n/a n/a n/a n/a -- 1 (20) 
Condom use last sex - regular female partners - last 3 months (%)**   
Never n/a n/a n/a n/a 47 (78) 57 (62) 
Sometimes n/a n/a n/a n/a 7 (12) 12 (13) 
Always n/a n/a n/a n/a 6 (10) 23 (25) 
Condom use last sex - casual female partners - last 3 months (%)**   
Never n/a n/a n/a n/a 7 (28) 15 (36) 
Sometimes n/a n/a n/a n/a 11 (44) 10 (24) 
Always n/a n/a n/a n/a 7 (28) 17 (40) 
Sex work last month (%)      
No 178 (97) 122 (96) 126 (95) 103 (91) 97 (97) 151 (98) 
Yes 5   (3) -- 3   (2) 5   (4)  2   (2) -- 
Not reported -- 5   (4) 3   (2) 5   (4) 1   (1) 3   (2) 
Condom used at last sex work last month (%)    
No 2 (50) -- -- 1 (20) -- -- 
Yes 3 (60) -- 2 (67) 2 (40) -- -- 
Not reported -- -- 1 (33) 2 (40) 2 (100) -- 
Ever had cervical cancer vaccine (women only)*** (%)    
No  n/a n/a n/a n/a -- -- 
Yes n/a n/a n/a n/a -- -- 
Unsure n/a n/a n/a n/a -- -- 
* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month. 
** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded 
areas indicate previous survey items that were changed in 2010. 
*** Proportion of eligible women i.e. those under 27 years of age in 2007.  
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Table 77 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, 
HBV vaccination and HCV treatment by injector status and survey year 
Testing & treatment        2004          2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 183  N = 127 N = 132  N = 113 N = 100  N = 154 
Previous HIV test (%)       
Yes, last year 96 (52) 23 (18) 52 (39) 25 (22) 41 (41) 31 (20) 
>1 year ago 59 (32) 31 (25) 62 (47) 34 (30) 40 (40) 35 (23) 
Never tested 27 (15) 72 (57) 17 (13) 54 (48) 19 (19) 88 (57) 
Not reported 1 (<1) -- 1 (<1) -- -- -- 
HBV infection (%)      
No 131 (72) 115 (91) 97 (73) 106 (94) 82 (82) 140 (91) 
Yes 34 (19) 3   (2) 26 (20) 4   (4) 11 (11) 1   (1) 
Don’t know 18 (10) 9   (7) 8   (6) 3   (3) 7    (7) 13   (8) 
Not reported -- -- 1 (<1) -- -- -- 
HBV vaccination (%)*       
No 65 (36) 58 (46) 43 (33) 60 (53) 27 (27) 50 (32) 
Yes 87 (48) 33 (26) 70 (53) 36 (32) 52 (52) 50 (32) 
Don’t know 30 (16) 33 (26) 13 (10) 15 (13) 21 (21) 51 (33) 
Not reported -- 3   (2) 6   (5) 2   (2) -- 3   (2) 
Previous HCV test (%)       
Yes, last year 23 (13) 84 (67) 43 (33) 22 (19) 14 (14) 100 (65) 
>1 year ago 85 (46) 23 (18) 77 (58) 30 (27) 41 (41) 24 (16) 
Never tested 72 (39) 17 (13) 12   (9) 59 (52) 44 (44) 30 (19) 
Unsure -- -- -- 1 (<1) -- -- 
Not reported 2   (1) 1 (<1) -- 1 (<1) 1   (1) -- 
Any HCV treatment (%)** N = 85 N = 2 N = 80  N = 3 N = 46  N = 2 
Interferon -- -- -- -- 3 (7) -- 
Interferon & Ribavirin 1   (1) -- -- -- 2 (4) -- 
Pegasys & Ribavirin -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
No treatment 84 (99) 2 (100) 80 (100) 3 (100) 46 (100) 2 (100) 
Not reported -- -- -- -- -- -- 
Current HCV treatment        
Interferon -- -- -- -- -- -- 
Interferon & Ribavirin -- -- -- -- -- -- 
Pegasys & Ribavirin -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
* Number (%) among participants with no history of HBV infection. 
** Number (%) of those testing positive for hepatitis C antibodies. 
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HIV antibody prevalence 
Table 78 HIV antibody prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
2004       
IDU 104 2 (2) 16 0 (0) 120 2 (2) 
Non-IDU 75 0 (0) 5 0 (0) 80 0 (0) 
p value  0.2  --  0.2 
2007       
IDU 84 1 (1) 27 1 (4) 111 2 (2) 
Non-IDU 75 1 (1) 10 0 (0) 85 1 (1) 
p value  0.9  0.5  0.7 
2010       
IDU 72 0 (0) 3 0 (0) 75 0 (0) 
Non-IDU 123 0 (0) 4 0 (0) 127 0 (0) 
p value  --  --  -- 




HCV antibody prevalence 
Table 79 HCV antibody prevalence by sex, injector status and survey year† 
 Male Female Total 
Injector status No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
IDU 108 72 (67) 16 13 (81) 124 85 (69) 
Non-IDU 75 2   (3) 5 0  (0) 80 2   (3) 
p value  <0.001  <0.01  <0.001 
2007       
IDU 84 57 (68) 28 23 (82) 112 80 (71) 
Non-IDU 76 2   (3) 9 1 (11) 85 3   (3) 
p value  <0.001  <0.001  <0.001 
2010       
IDU 71 44 (62) 3 2 (67) 74 46 (62) 
Non-IDU 124 2   (2) 4 0   (0) 128 2   (2) 
p value  <0.001  0.05  <0.001 
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Table 80 HCV antibody prevalence by sexual identity, sex and survey year† 
  Male Female Total  
Sexual identity No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Heterosexual 180 73 (41) 18 11   (61) 198 84 (42) 
Bisexual -- -- 3 2   (67) 3 2 (67) 
Homosexual 3 1 (33) -- -- 3 1 (33) 
Unsure -- -- -- -- -- -- 
p value  0.8  0.9  0.7 
2007       
Heterosexual 155 59 (38) 29 16   (55) 184 75 (41) 
Bisexual 1 0   (0) 3 3 (100) 4 3 (75) 
Homosexual 2 0   (0) 2 2 (100) 4 2 (50) 
Unsure -- -- -- -- -- -- 
p value  0.4  0.2  0.4 
2010       
Heterosexual 194 46 (24) 7 2   (29) 201 48 (24) 
Bisexual 1 0   (0) -- -- 1 0   (0) 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value 0.3   --  0.6 
† Excludes equivocal test results and missing values. 
 
 
Table 81 HCV antibody prevalence by age group, sex and survey year† 
 Male Female Total  









2004       
< 20 years 13 0   (0) 1 0   (0) 14 0   (0) 
20 – 24 44 16 (36) 3 2 (67) 47 18 (38) 
25 – 29 40 14 (35) 4 3 (75) 44 17 (39) 
30 + years 86 44 (51) 13 8 (62) 99 52 (53) 
p value  0.003  0.6  0.002 
2007       
< 20 years 8  1 (13) 1 0   (0) 9 1 (11) 
20 – 24 32 5 (16) 6 4 (67) 38 9 (24) 
25 – 29 31 11 (35) 11 9 (82) 42 20 (48) 
30 + years 88 42 (48) 19 11 (58) 107 53 (50) 
p value  0.005  0.3  0.03 
2010       
< 20 years 22 0   (0) -- -- 22 0   (0) 
20 – 24 34 2   (6) -- -- 34 2   (6) 
25 – 29 42 9 (21) -- -- 42 9 (21) 
30 + years 97 35 (36) 7 2 (29) 104 37 (36) 
p value  <0.001  --  <0.001 
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Table 82 HCV antibody prevalence by duration of drug injection, sex and survey year† 
 Male Female Total  
Duration of drug injection No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
<3 years 11 1   (9) 1 0     (0) 12 1   (8) 
3 to 5 years 11 7 (64) 2 1   (50) 13 8 (62) 
6 to 10 years 35 20 (57) 5 4   (80) 40 24 (60) 
10 + years 50 44 (88) 8 8 (100) 58 52 (90) 
p value  <0.001  0.06  <0.001 
2007       
<3 years 4  3 (75) 1 1 (100) 5 4 (80) 
3 to 5 years 5 3 (60) 2 1   (50) 7 4 (57) 
6 to 10 years 17 7 (41) 14 11   (79) 31 18 (58) 
10 + years 55 43 (78) 11 10   (91) 66 53 (80) 
p value  0.04  0.5  0.1 
2010       
<3 years 6 1 (17) 1 0     (0) 7 1 (14) 
3 to 5 years 5 0   (0) -- -- 5 0   (0) 
6 to 10 years 11 7 (64) -- -- 11 7 (64) 
10 + years 47 35 (74) 2 2 (100) 49 37 (76) 
p value  <0.01  0.08  <0.001 
† Excludes equivocal test results and missing values. 
 
 
Table 83 HCV antibody prevalence by last drug injected, duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Last drug injected No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Amphetamine (Speed, Ice) 6 1   (17) 42 26   (62) 48 27   (56) 
Heroin 1 0     (0) 55 47   (85) 56 47   (84) 
More than one -- -- 9 6   (67) 6 5   (83) 
Other/not reported 1 0     (0) 5 5 (100) 15 8   (53) 
     p value  0.6  0.03  0.008 
2007       
Amphetamine (Speed, Ice) 3 3 (100) 49 28   (57) 52 31   (60) 
Heroin 2 1   (50) 43 36   (84) 45 37   (82) 
More than one -- -- 4 4 (100) 4 4 (100) 
Other/not reported -- -- 8 7   (88) 8 7   (88) 
     p value  0.2  0.01  0.003 
2010       
Amphetamine (Speed, Ice) 2 0     (0) 37 22   (59) 39 22  (56) 
Heroin 4 1   (25) 17 13   (76) 21 14  (67) 
More than one -- -- 2 1   (50) 2 1  (50) 
Other/not reported 1 0     (0) 9 8   (89) 10 8  (80) 
     p value  0.7  0.3  0.5 
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Table 84 HCV antibody prevalence by frequency of injection last month, duration of drug injection 
and survey year† 
 <3 years IDU 3+ years IDU Total  
Frequency of drug injection 
last month 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Less than daily 6 0     (0) 21 17 (81) 27 17 (63) 
Daily or more 2 1   (50) 52 39 (75) 54 40 (74) 
p value  0.08  0.8  0.2 
2007       
Less than daily 2 1   (50) 24 17 (71) 26 18 (69) 
Daily or more 1 1 (100) 42 33 (79) 43 34 (79) 
p value  0.4  0.5  0.5 
2010       
Less than daily 2 0     (0) 17 16 (94) 19 16 (84) 
Daily or more 3 1   (33) 14 10 (71) 17 11 (65) 
p value  0.4  0.09  0.2 
† Excludes equivocal test results and missing values. 
 
 
Table 85 HCV antibody prevalence by re-use of someone else’s used needle and syringe last month, 
duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Re-used someone else’s used 










2004       
No 8 1 (13) 53 44   (83) 61 45 (74) 
Yes 1 0   (0) 20 12   (60) 21 12 (57) 
p value  0.7  0.01  0.02 
2007       
No 3 2 (67) 50 39   (78) 53 41 (77) 
Yes -- -- 12 8   (67) 12 8 (67) 
p value  --  0.4  0.4 
2010       
No 3 0   (0) 21 17  (81) 24 17 (71) 
Yes 2 1 (50) 6 6 (100) 8 7 (88) 
p value  0.2  0.3  0.4 
† Excludes equivocal test results and missing values. 
 
 
Table 86 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey 
year† 
 <3 years IDU 3+ years IDU Total  
Imprisonment last year No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
No 6 0     (0) 53 39 (74) 59 39 (66) 
Yes 6 1   (17) 58 45 (78) 64 46 (72) 
p value  0.3  0.6  0.5 
2007       
No 1 1 (100) 30 22 (73) 31 23 (74) 
Yes 2 2 (100) 58 45 (78) 60 47 (78) 
p value  --  0.7  0.7 
2010       
No 5 0     (0) 29 17 (59) 34 17 (50) 
Yes 2 1   (50) 34 26 (76) 36 27 (75) 
p value  0.1  0.1  0.03 
† Excludes equivocal test results and missing values. 
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Table 87 HCV antibody by number of previous imprisonments, sex and survey year† 
 Male Female Total  
Number of previous 
imprisonments 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
1 61 9 (15) 6 1   (17) 67 10 (15) 
2 to 4 72 33 (46) 10 7   (70) 82 40 (49) 
5 to 9 32 19 (59) 3 3 (100) 35 22 (63) 
10 + 15 12 (80) 2 2 (100) 17 14 (82) 
p value  <0.001  0.04  <0.001 
2007       
1 40 5 (13) 13 5   (38) 53 10 (19) 
2 to 4 67 19 (28) 14 10   (71) 81 29 (36) 
5 to 9 25 18 (72) 5 5 (100) 30 23 (77) 
10 + 22 16 (73) 4 3   (75) 26 19 (73) 
p value  <0.001  0.07  <0.001 
2010       
1 103 8   (8) 6 2   (33) 109 10   (9) 
2 to 4 52 14 (27) 1 0     (0) 53 14 (26) 
5 to 9 23 12 (52) -- -- 23 12 (52) 
10 + 13 11 (85) -- -- 13 11 (85) 
p value  <0.001  0.5  <0.001 
† Excludes equivocal test results and missing values. 
 
 
Table 88 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Non-Indigenous 163 63 (39) 17 10 (59) 180 73 (41) 
Indigenous 20 11 (55) 4 3 (75) 24 14 (58) 
p value  0.2  0.6  0.1 
2007       
Non-Indigenous 124 38 (31) 24 12 (50) 148 50 (34) 
Indigenous 30 16 (53) 12 11 (92) 42 27 (64) 
p value  0.02  0.01  <0.001 
2010       
Non-Indigenous 159 38 (24) 3 0   (0) 162 38 (23) 
Indigenous 36 8 (22) 4 2 (50) 40 10 (25) 
p value  0.8  0.2  0.8 
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Table 89 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector 
status and survey year† 
 Non-IDU IDU Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Non-Indigenous 77 2   (3) 103 71 (69) 180 73 (41) 
Indigenous 3 0   (0) 21 14 (67) 24 14 (58) 
p value  0.8  0.8  0.1 
2007       
Non-Indigenous 74 2   (3) 74 48 (65) 148 50 (34) 
Indigenous 10 1 (10) 32 26 (81) 42 27 (64) 
p value  0.2  0.09  <0.001 
2010       
Non-Indigenous 103 1   (1) 59 37 (63) 162 38 (23) 
Indigenous 25 1   (4) 15 9 (60) 40 10 (25) 
p value  0.3  0.9  0.8 
† Excludes equivocal test results and missing values. 
 
 
Table 90 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison, 
and survey year† 
  Male Female Total  
Residential remoteness No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Highly accessible/accessible 171 70 (41) 21 13 (62) 192 83 (43) 
Moderately accessible 3 1 (33) -- -- 3 1 (33) 
Remote/very remote 1 0   (0) -- -- 1 0   (0) 
p value  0.7  --  0.6 
2007       
Highly accessible/accessible 151 55 (36) 30 19 (63) 181 74 (41) 
Moderately accessible 1 0   (0) 1 0   (0) 2 0   (0) 
Remote/very remote -- -- -- -- -- -- 
p value  0.5  0.2  0.2 
2010       
Highly accessible/accessible 181 41 (23) 5 2 (40) 186 43 (23) 
Moderately accessible 8 4 (50) 1 0   (0) 9 4 (44) 
Remote/very remote 3 1 (33) -- -- 3 1 (33) 
p value  0.2  0.4  0.3 
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Table 91 HCV antibody prevalence by region/country of birth, sex and survey year† 
 Male Female Total  
Region/Country of birth No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Australia 138 60  (43) 19 13   (68) 157 73 (46) 
Other Oceania 7 0    (0) -- -- 7 0   (0) 
Asia 14 8  (57) 2 0     (0) 16 8 (50) 
UK & Ireland 5 2  (40) -- -- 5 2 (40) 
Other 19 4  (21) -- -- 19 4 (21) 
p value  0.04  0.06  0.04 
2007       
Australia 127 52 (41) 32 21   (66) 159 73 (46) 
Other Oceania 8 1 (13) 1 1 (100) 9 2 (22) 
Asia 14 5 (36) 2 0     (0) 16 5 (31) 
UK & Ireland -- -- -- -- -- -- 
Other 9 0   (0) 2 2 (100) 11 2 (18) 
p value  0.08  0.1  0.1 
2010       
Australia 151 38 (25) 5 2   (40) 156 40 (26) 
Other Oceania 16 5 (31) -- -- 16 5 (31) 
Asia 15 1   (7) 1 0     (0) 16 1   (6) 
UK & Ireland 2 0   (0) -- -- 2 0   (0) 
Other 11 2 (18) 1 0     (0) 12 2 (17) 
p value  0.4  0.6  0.4 
† Excludes equivocal test results and missing values. 
 
 
Table 92 HCV antibody prevalence by main language spoken at home by parents, sex and survey 
year† 
 Male Female Total  
Main language spoken at 
home by parents 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
English  146 59 (40) 18 12 (67) 164 71 (43) 
Non-English  37 15 (41) 3 1 (33) 40 16 (40) 
p value  1.0  0.3  0.7 
2007       
English  121 48 (40) 33 22 (67) 154 70 (45) 
Non-English  39 11 (28) 4 2 (50) 43 13 (30) 
p value  0.2  0.5  0.07 
2010       
English  162 41 (25) 7 2 (29) 169 43 (25) 
Non-English  32 5 (16) -- -- 32 5 (16) 
p value  0.4  --  0.2 
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Table 93 Self-reported HCV status versus HCV serology by sex and survey year† 
 Male Female Total  
Self-report HCV No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Positive 45 44   (98) 12 12 (100) 57 56   (98) 
Negative 45 12   (27) 4 1   (25) 49 13   (27) 
Not sure 14 9   (64) 1 0     (0) 15 9   (60) 
p value  <0.001  0.002  <0.001 
2007       
Positive 44 42   (95) 20 19   (95) 64 61   (95) 
Negative 55 8   (15) 9 2   (22) 64 10   (16) 
Not sure 5 4   (80) 4 2   (50) 9 6   (67) 
p value  <0.001  <0.001  <0.001 
2010       
Positive 36 36 (100) 2 2 (100) 38 38 (100) 
Negative 55 6   (11) 4 0     (0) 59 6   (10) 
Not sure 5 1   (20) -- -- 5 1   (20) 
p value  <0.001  0.014  <0.001 





Table 94 HBV surface-antigen prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
IDU 108 6 (6) 16 0 (0) 124 6 (5) 
Non-IDU 75 0 (0) 5 0 (0) 80 0 (0) 
p value  0.04  --  0.05 
2007       
IDU 85 1 (1) 27 2 (7) 112 3 (3) 
Non-IDU 76 3 (4) 10 0 (0) 86 3 (3) 
p value  0.3  0.4  0.7 
2010       
IDU 72 2 (3) 3 0 (0) 75 2 (3) 
Non-IDU 125 4 (3) 4 0 (0) 129 4 (3) 
p value  0.9  --  0.9 
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Table 95 HBV core-antibody prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
IDU 105 35 (33) 16 3 (19) 121 38 (31) 
Non-IDU 74 6   (8) 5 3 (60) 79 9 (11) 
p value  <0.001  0.08  0.001 
2007       
IDU 85 33 (39) 28 9 (32) 113 42 (37) 
Non-IDU 76 11 (14) 10 1 (10) 86 12 (14) 
p value  0.001  0.2  0.0 
2010       
IDU 72 17 (24) -- -- 72 17 (24) 
Non-IDU 126 21 (17) 4 0 (0) 130 21 (16) 
p value  0.2  --  0.2 
† Excludes equivocal test results and missing values. 
 
 
Table 96 HBV core-antibody prevalence by sexual identity, sex and survey year† 
  Male Female Total  
Sexual identity No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Heterosexual 176 41 (23) 18 5 (28) 194 46 (24) 
Bisexual -- -- 3 1 (33) 3 1 (33) 
Homosexual 3 0   (0) -- -- 3 0   (0) 
Unsure -- -- -- --  -- 
p value  0.3  0.8  0.6 
2007       
Heterosexual 156 44 (28) 30 8 (27) 186 52 (28) 
Bisexual 1 0   (0) 3 0   (0) 4 0   (0) 
Homosexual 2 0   (0) 2 1 (50) 4 1 (25) 
Unsure -- -- -- --  -- 
p value  0.6  0.4  0.5 
2010       
Heterosexual 197 38 (19) 4 0   (0) 201 38 (19) 
Bisexual 1 0   (0) -- -- 1 0   (0) 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value  0.6  --  0.6 
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Table 97 HBV core-antibody prevalence by age group, sex and survey year† 
 Male Female Total  
Age group No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
< 20 years 13 0   (0) 1 0   (0) 14 0   (0) 
20 – 24 43 9 (21) 3 1 (33) 46 10 (22) 
25 – 29 40 8 (20) 4 0   (0) 44 8 (18) 
30 + years 83 24 (29) 13 5 (38) 96 29 (30) 
p value  0.1  0.5  0.06 
2007       
< 20 years 8 0   (0) 1 0   (0) 9 0   (0) 
20 – 24 32 5 (16) 6 0   (0) 38 5 (13) 
25 – 29 31 7 (23) 11 2 (18) 42 9 (21) 
30 + years 89 32 (36) 20 8 (40) 109 40 (37) 
p value  0.03  0.2  0.01 
2010       
< 20 years 22 2   (9) -- -- 22 2   (9) 
20 – 24 34 6   (6) -- -- 34 2   (6) 
25 – 29 43 9 (21) -- -- 43 9 (21) 
30 + years 99 25 (25) 4 0   (0) 103 25 (24) 
p value  0.05  --  0.07 
† Excludes equivocal test results and missing values. 
 
 
Table 98 HBV core-antibody prevalence by duration of drug injection, sex and survey year† 
 Male Female Total  
Duration of drug injection No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
<3 years 11 0   (0) 1 0   (0) 12 0   (0) 
3 to 5 years 9 2 (22) 2 0   (0) 11 2 (18) 
6 to 10 years 35 12 (34) 5 1 (20) 40 13 (33) 
10 + years 49 21 (43) 8 2 (25) 57 23 (40) 
p value  0.05  0.8  0.04 
2007       
<3 years 4 0   (0) 1 0   (0) 5 0   (0) 
3 to 5 years 5 1 (20) 2 0   (0) 7 1 (14) 
6 to 10 years 17 6 (35) 14 3 (21) 31 9 (29) 
10 + years 56 25 (45) 11 6 (55) 67 31 (46) 
p value  0.2  0.2  0.05 
2010       
<3 years 6 0   (0) -- -- 6 0   (0) 
3 to 5 years 5 2 (40) -- -- 5 2 (40) 
6 to 10 years 11 2 (18) -- -- 11 2 (18) 
10 + years 48 12 (25) -- -- 48 12 (25) 
p value  0.4  --  0.4 
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Table 99 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey 
year† 
 <3 years IDU 3+ years IDU Total  
Last drug injected No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Amphetamine (Speed, Ice) 6 0 (0) 42 16 (38) 48 16 (33) 
Heroin 1 0 (0) 52 18 (35) 53 18 (34) 
More than one 4 0 (0) 9 3 (33) 13 3 (23) 
Other/not reported 1 0 (0) 5 1 (20) 6 1 (17) 
     p value  --  0.9  0.7 
2007       
Amphetamine (Speed, Ice) 3 0 (0) 50 16 (32) 53 16 (30) 
Heroin 2 0 (0) 43 18 (42) 45 18 (40) 
More than one -- -- 4 2 (50) 4 2 (50) 
Other/not reported -- -- 8 5 (63) 8 5 (63) 
     p value  --  0.4  0.3 
2010       
Amphetamine (Speed, Ice) 2 0 (0) 38 8 (21) 40 8 (20) 
Heroin 3 0 (0) 16 7 (44) 19 7 (37) 
More than one -- -- 1 0   (0) 1 0   (0) 
Other/not reported 1 0 (0) 9 1 (11) 10 1 (10) 
     p value  --  0.2  0.3 
† Excludes equivocal test results and missing values. 
 
 
Table 100 HBV core-antibody prevalence by frequency of injection last month, duration of drug 
injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Frequency of drug injection 
last month 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Less than daily 6 0 (0) 21 10 (48) 27 10 (37) 
Daily or more 2 0 (0) 50 14 (28) 52 14 (27) 
p value  --  0.1  0.4 
2007       
Less than daily 2 0 (0) 25 6 (24) 27 6 (22) 
Daily or more 1 0 (0) 42 18 (43) 43 18 (42) 
p value  --  0.2  0.1 
2010       
Less than daily 2 0 (0) 17 4 (24) 19 4 (21) 
Daily or more 2 0 (0) 14 2 (14) 16 2 (13) 
p value  --  0.5  0.5 
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Table 101 HBV core antibody prevalence by re-use of someone else’s used needle and syringe last 
month, duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Re-used someone else’s used 
needle & syringe last month 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
No 8 0 (0) 51 16 (31) 59  16 (27) 
Yes 1 0 (0) 20 8 (40) 21 8 (38) 
p value  --  0.5  0.3 
2007       
No 3 0 (0) 51 18 (35) 54 18 (33) 
Yes -- -- 12 5 (42) 12 5 (42) 
p value  --  0.7  0.6 
2010       
No 3 0 (0) 21 4 (19) 24 4 (17) 
Yes 1 0 (0) 6 1 (17) 7 1 (14) 
p value  --  0.9  0.9 
† Excludes equivocal test results and missing values. 
 
 
Table 102 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and 
survey year† 
 <3 years IDU 3+ years IDU Total  
Imprisonment last year No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
No 6 0 (0) 52 20 (38) 58 20 (34) 
Yes 6 0 (0) 56 18 (32) 62 18 (29) 
p value  --  0.5  0.6 
2007       
No 1 0 (0) 30 11 (37) 31 11 (35) 
Yes 2 0 (0) 59 26 (44) 61 26 (43) 
p value  --  0.5  0.5 
2010       
No 4 0 (0) 27 8 (30) 31 8 (26) 
Yes 2 0 (0) 35 8 (23) 37 8 (22) 
p value  --  0.6  0.7 
† Excludes equivocal test results and missing values. 
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Table 103 HBV core-antibody by number of previous imprisonments, sex and survey year† 
 Male Female Total  
Number of previous 
imprisonments 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
1 60 4   (7) 6 3 (50) 66 7 (11) 
2 to 4 72 19 (26) 10 1 (10) 82 20 (24) 
5 to 9 31 13 (42) 3 1 (33) 34 14 (41) 
10 + 14 5 (36) 2 1 (50) 16 6 (38) 
p value  0.001  0.3  0.003 
2007       
1 40 3   (8) 13  4 (31) 53 7 (13) 
2 to 4 67 20 (30) 15 1   (7) 82 21 (26) 
5 to 9 26 10 (38) 5 3 (60) 31 13 (42) 
10 + 22 10 (45) 4 1 (25) 26 11 (42) 
p value  0.004  0.01  0.008 
2010       
1 103 13 (13) 3 0   (0) 106 13 (12) 
2 to 4 55 14 (25) 1 0   (0) 56 14 (25) 
5 to 9 23 5 (22) -- -- 23 5 (22) 
10 + 13 6 (46) -- -- 13 6 (46) 
p value  0.02  --  0.01 
† Excludes equivocal test results and missing values. 
 
 
Table 104 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Non-Indigenous 158 33 (21) 17 5 (29) 175 38 (22) 
Indigenous 21 8 (38) 4 1 (25) 25 9 (36) 
p value  0.08  0.9  0.1 
2007       
Non-Indigenous 125 29 (23) 25 6 (24) 150 35 (23) 
Indigenous 30 15 (50) 12 4 (33) 42 19 (45) 
p value  0.003  0.5  0.005 
2010       
Non-Indigenous 162 30 (19) 2 0   (0) 164 30 (18) 
Indigenous 36 8 (22) 2 0   (0) 38 8 (21) 
p value  0.6  --  0.7 
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Table 105 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector 
status and survey year† 
 Non-IDU IDU Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Non-Indigenous 76 9 (12) 99 29 (29) 175 38 (22) 
Indigenous 3 0   (0) 22 9 (41) 25 9 (36) 
p value  0.5  0.3  0.1 
2007       
Non-Indigenous 75 8 (11) 75 27 (36) 150 35 (23) 
Indigenous 10 4 (40) 32 15 (47) 42 19 (45) 
p value  0.01  0.3  0.005 
2010       
Non-Indigenous 105 16 (15) 59 14 (24) 164 30 (18) 
Indigenous 25 5 (20) 13 3 (23) 38 8 (21) 
p value  0.6  1.0  0.7 
† Excludes equivocal test results and missing values. 
 
 
Table 106 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before 
prison and survey year† 
  Male Female Total  
Residential remoteness No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Highly accessible/accessible 167 39 (23) 21 6 (29) 188 45 (24) 
Moderately accessible 3 0   (0) -- -- 3 0   (0) 
Remote/very remote 1 0   (0) -- -- 1 0   (0) 
p value  0.5  --  0.5 
2007       
Highly accessible/accessible 152 40 (26) 31 9 (29) 183 49 (27) 
Moderately accessible 1 0   (0) 1 0   (0) 2 0   (0) 
Remote/very remote -- -- -- --  -- 
p value  0.6  0.5  0.4 
2010       
Highly accessible/accessible 183 33 (18) 2 0   (0) 185 33 (18) 
Moderately accessible 8 3 (38) 1 0   (0) 9 3 (33) 
Remote/very remote 4 1 (25) -- -- 4 1 (25) 
p value  0.4  --  0.5 
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Table 107 HBV core-antibody prevalence by region/country of birth, sex and survey year† 
 Male Female Total  
Region/Country of birth No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Australia 138 32 (23) 19 4   (21) 157 36 (23) 
Other Oceania 7 3 (43) -- -- 7 3 (43) 
Asia 11 4 (36) 2 2 (100) 13 6 (46) 
UK & Ireland 5 1 (20) -- -- 5 1 (20) 
Other 18 1   (6) -- -- 18 1   (6) 
p value  0.2  0.02  0.08 
2007       
Australia 128 35 (27) 33 6   (18) 161 41 (25) 
Other Oceania 8 3 (38) 1 1 (100) 9 4 (44) 
Asia 14 3 (21) 2 1   (50) 16 4 (25) 
UK & Ireland -- --  -- --  -- --  
Other 9 3 (33) 2 2 (100) 11 5 (45) 
p value  0.8  0.02  0.4 
2010       
Australia 153 23 (15) 2 0     (0) 155 23 (15) 
Other Oceania 16 4 (25) -- -- 16 4 (25) 
Asia 15 7 (47) 1 0     (0) 16 7 (44) 
UK & Ireland 2 0   (0) -- -- 2 0   (0) 
Other 12 4 (33) 1 0     (0) 13 4 (31) 
p value  0.02  --  0.04 
† Excludes equivocal test results and missing values. 
 
 
Table 108 HBV core-antibody prevalence by main language spoken at home by parents, sex and 
survey year† 
 Male Female Total  
Main language spoken at 
home by parents 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
English  146 32 (22) 18 4 (22) 164 36 (22) 
Non-English  33 9 (27) 3 2 (67) 36 11 (31) 
p value  0.5  0.1  0.3 
2007       
English  122 34 (28) 33  7 (21) 155 41 (26) 
Non-English  39 10 (26) 5 3 (60) 44 13 (30) 
p value  0.8  0.07  0.7 
2010       
English  164 12 (36) 4 0 (0) 168 26 (15) 
Non-English  33 26 (16) -- -- 33 12 (36) 
p value  0.006  --  0.005 
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Table 109 Hepatitis B virus immune status by injector status and survey year† 
  Hepatitis B Virus Immune Status 
Injector status No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
IDU 124 60 (40) 33 (27) 6 (5) 25 (20) 
Non-IDU 80 62 (78) 9 (11) 0 (0) 9 (11) 
p value     <0.001 
2007      
IDU 112 36 (32) 39 (35) 3 (3) 34 (30) 
Non-IDU 86 53 (62) 9 (10) 3 (3) 21 (24) 
p value     <0.001 
2010      
IDU 72 27 (38) 15 (21) 2 (3) 28 (39) 
Non-IDU 130 74 (57) 17 (13) 4 (3) 35 (27) 
p value     0.06 
† Excludes equivocal test results and missing values.  
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 110 Hepatitis B virus immune status by sexual identity and survey year† 
  Hepatitis B Virus Immune Status 
Sexual identity No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
Heterosexual  198 119 (60) 41 (21) 6   (3) 32   (16) 
Bisexual 3 1 (33) 1 (33) 0   (0) 1   (33) 
Homosexual 3 2 (37) 0   (0) 0   (0) 1   (33) 
Unsure -- -- -- --       -- 
p value     0.9 
2007      
Heterosexual  185 85 (46) 47 (25) 5   (3) 48   (26) 
Homosexual 4 1 (25) 0   (0) 1 (25) 2   (50) 
Bisexual 4 1 (25) 0   (0) 0   (0) 3   (75) 
Unsure -- -- -- -- -- 
p value     0.4 
2010      
Heterosexual  201 101 (50) 32 (16) 6   (3) 62   (31) 
Homosexual -- -- -- -- -- 
Bisexual 1 0   (0) 0   (0) 0   (0) 1 (100) 
Unsure -- -- -- -- -- 
p value     0.5 
† Excludes equivocal test results and missing values.  
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Table 111 Hepatitis B virus immune status by age group and survey year† 
  Hepatitis B Virus Immune Status 
Age group No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
< 20 years 14 11 (79) 0   (0) 0 (0) 3 (21) 
20 – 24 46 27 (59) 8 (17) 2 (4) 9 (20) 
25 – 29 44 29 (66) 7 (16) 1 (2) 7 (16) 
30 + years 100 55 (55) 27 (27) 3 (3) 15 (15) 
p value     0.5 
2007      
< 20 years 9 7 (78) 0   (0) 0 (0) 2 (22) 
20 – 24 38 21 (55) 4 (11) 1 (3) 12 (32) 
25 – 29 41 14 (34) 8 (20) 1 (2) 18 (44) 
30 + years 109 46 (42) 36 (33) 4 (4) 23 (21) 
p value     0.02 
2010      
< 20 years 22 7 (32) 2   (9) 0 (0) 13 (59) 
20 – 24 34 23 (68) 2   (6) 0 (0) 9 (26) 
25 – 29 43 20 (47) 8 (19) 1 (2) 14 (33) 
30 + years 103 51 (50) 20 (19) 5 (5) 27 (26) 
p value     0.05 
† Excludes equivocal test results and missing values.  
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 112 Hepatitis B virus immune status by number of previous imprisonments and survey year† 






No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
1 67 52 (78) 6   (9) 1 (1) 8 (12) 
2 to 4 83 46 (55) 17 (20) 4 (4) 16 (19) 
5 to 9 35 14 (40) 14 (40) 0 (0) 7 (20) 
10 + 16 8 (50) 5 (31) 1 (6) 2 (13) 
p value     <0.01 
2007      
1 53 37 (70) 6 (11) 1 (2) 9 (17) 
2 to 4 81 41 (51) 18 (22) 3 (4) 19 (23) 
5 to 9 31 2   (6) 11 (35) 2 (6) 16 (52) 
10 + 26 6 (23) 11 (42) 0 (0) 9 (35) 
p value     <0.001 
2010      
1 106 69 (65) 10   (9) 3 (3) 24 (23) 
2 to 4 56 20 (36) 12 (21) 2 (4) 22 (39) 
5 to 9 23 8 (35) 5 (22) 0 (0) 10 (43) 
10 + 13 1   (8) 5 (38) 1 (8) 6 (46) 
p value     0.001 
† Excludes equivocal test results and missing values.   
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Table 113 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey 
year† 






No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
Non-Indigenous 179 112 (63) 35 (20) 4 (2) 28 (16) 
Indigenous 25 10 (40) 7 (28) 2 (8) 6 (24) 
p value     0.1 
2007      
Non-Indigenous 149 76 (51) 32 (21) 3 (2) 38 (26) 
Indigenous 42 10 (24) 16 (38) 3 (7) 13 (31) 
p value     <0.01 
2010      
Non-Indigenous 164 86 (52) 25 (15) 5 (3) 48 (29) 
Indigenous 38 15 (39) 7 (18) 1 (3) 15 (39) 
p value     0.5 
† Excludes equivocal test results and missing values. 
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded. 
 
 
Table 114 Hepatitis B virus immune status by residential remoteness and survey year† 
  Hepatitis B Virus Immune Status 
Residential remoteness No 
tested 
No (%) with no 
evidence of 
HBV immunity 






No (%) vaccine 
conferred 
immunity* 
2004      
Highly accessible/accessible 192 115   (60) 40 (21) 6   (3) 31   (16) 
Moderately accessible 3 2   (67) 0   (0) 0   (0) 1   (33) 
Remote/very remote 1 0     (0) 0   (0) 0   (0) 1 (100) 
p value     0.4 
2007      
Highly accessible/accessible 182 84   (46) 43 (24) 6   (3) 49   (27) 
Moderately accessible 2 2 (100) 0   (0) 0   (0) 0     (0) 
Remote/very remote -- -- -- -- -- 
p value     0.5 
2010      
Highly accessible/accessible 185 95   (51) 28 (15) 5   (3) 57   (31) 
Moderately accessible 9 3   (33) 2 (22) 1 (11) 3   (33) 
Remote/very remote 4 1   (25) 1 (25) 0   (0) 2   (50) 
p value     0.6 
† Excludes equivocal test results and missing values.  
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Table 115 Hepatitis B virus immune status by main language spoken at home by parents and survey 
year† 
  Hepatitis B Virus Immune Status 
Main language 




No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
English 164 98 (60) 33 (20) 3   (2) 30 (18) 
Non-English  40 24 (60) 9 (23) 3   (8) 4 (10) 
p value     0.2 
2007      
English  154 74 (48) 38 (25) 3   (2) 39 (25) 
Non-English  44 15 (34) 10 (23) 3   (7) 16 (36) 
p value     0.1 
2010      
English 168 89 (53) 24 (14) 2   (1) 53 (32) 
Non-English 33 12 (36) 8 (24) 4 (12) 9 (27) 
p value     0.002 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 116 Self-reported hepatitis B immunisation versus serological testing and survey year*  
 Male Female Total  
Self-report HBV 
immunisation** 
No tested No immune 
(%) 
No tested No immune 
(%) 
No tested No immune 
(%) 
2004       
No 56 5   (9) 3 1   (33) 59 6 (10) 
Yes 50 19 (38) 10 4   (40) 60 23 (38) 
Not sure 34 4 (12) 2 1   (50) 36 5 (14) 
p value  <0.001  0.9  <0.001 
2007       
No 49 8 (16) 13 3   (23) 62 11 (18) 
Yes 54 30 (56) 13 9   (69) 67 39 (58) 
Not sure 12 4 (33) -- -- 12 4 (33) 
p value  <0.001  0.02  <0.001 
2010       
No 47 6 (13) 2 0     (0) 49 6 (12) 
Yes 65 41 (63) 1 1 (100) 66 42 (64) 
Not sure 47 15 (32) 1 0     (0) 48 15 (31) 
p value  <0.001  0.1  <0.001 
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
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Chlamydia 
 
Table 117 Genital chlamydia prevalence by sex and survey year† 
Sex  No tested No with 
chlamydia (%) 
2010   
Male  185 10 (5) 
Female 5 0 (0) 
p value  0.6 




Table 118 Genital gonorrhoea prevalence by sex and survey year† 
Sex  No tested No with 
gonorrhoea (%) 
2010   
Male  184 0 (0) 
Female 5 0 (0) 
p value  -- 




Table 119 Syphilis markers by sex and survey year† 








No with any 
marker for 
syphilis (%) 
2010     
Male  195 4 (2) 0 (0) 4 (2) 
Female 7 0 (0) 0 (0) 0 (0) 
p value  0.7 -- 0.7 











Table 120 Number (%) of respondents by demographic characteristics, injector status and survey year  
 2010 
Demographic characteristics IDU Non-IDU 
Number of sites surveyed N = 2 
No surveyed N = 9 N = 66 
Sex (%)   
Male 8 (89) 64 (97) 
Female 1 (11) 2   (3) 
Transgender -- -- 
Sexual identity (%)   
Heterosexual 9 (100) 62 (94) 
Bisexual -- 2   (3) 
Homosexual -- 1   (2) 
Unsure -- 1   (2) 
Not reported -- -- 
Age and duration of injection (years)  
Median age (years) 34 30 
    Age range 25 – 21 18 – 56 
Age group (%)   
    <25 years -- 19 (29) 
    25+ years 9 (100) 47 (71) 
    Not reported -- -- 
Median age 1stIDU (years) 25 -- 
    Age range 14 – 42 -- 
    Not reported 1 -- 
Median years IDU 11 -- 
    Range 1 – 32 -- 
Duration of drug injection (%)  
    <3 years 1 (11) -- 
    3+ years 7 (78) -- 
    Not reported 1 (11) -- 
Aboriginal and Torres Strait Islander origin (%) 
No 4 (44) 5   (8) 
Yes 5 (56) 61 (92) 
Not reported -- -- 
Living situation prior to prison (%)*  
Not homeless 5 (56) 11 (17) 
Primary homelessness -- 1   (2) 
Secondary homelessness 1 (11) 22 (33) 
Tertiary homelessness -- 1   (2) 
Not reported 3 (33) 31 (47) 
Residential remoteness in 12 months before prison (%) 
 Highly accessible/accessible 5 (56) 11 (17) 
Moderately accessible -- 1   (2) 
Remote/very remote 4 (44) 47 (71) 
Not reported -- 7 (11) 
Region/Country of birth (%)  
Australia 7 (78) 64 (97) 
Other Oceania 1 (11) -- 
Asia 1 (11) 2   (3) 
UK & Ireland -- -- 
Other -- -- 
Not reported -- -- 
Main language spoke at home by parents (%) 
English  6 (67) 34 (52) 
Non-English  1 (11) 10 (15) 
Not reported 2 (22) 22 (33) 
* Not homeless (private rental, home owner/purchaser, public/community housing, drug and alcohol treatment facility, workers’ 
accommodation, prison, nursing home, foster home); Primary homelessness (Sleeping rough, squat, long grass, boat, car); 
Secondary homelessness (Living with parent, siblings, or relatives, crisis accommodation); Tertiary homelessness (Boarding house, 
hostel, caravan park, backpackers, hotel, motel). Living situation question introduced in 2010. 
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Table 120 Number (%) of respondents by demographic characteristics, injector status and survey year 
(cont.) 
 2010 
Demographic characteristics IDU Non-IDU 
 
* Smoking questions not asked in 2004. 
** Other drugs used in the past month not asked in 2004 and 2007. More 
     than one option could be selected. 
  
First time in prison (%)   
No 7 (78) 52 (79) 
Yes 2 (22) 14 (21) 
Not reported -- -- 
Lifetime imprisonments (%)   
One 3 (33) 29 (44) 
Two to four  3 (33) 20 (30) 
Five to nine   3 (33) 14 (21) 
Ten or more  -- 3   (5) 
Not reported -- -- 
Imprisonment in last year (%)   
No 4 (44) 27 (41) 
Yes 5 (56) 29 (44) 
Not reported -- 10 (15) 
Frequency of injection last month (%)  
Not last month 4 (44) -- 
Less than weekly 1 (11) -- 
Weekly not daily -- -- 
Daily or more 3 (33) -- 
Not reported 1 (11) -- 
Ever smoked a full cigarette (%)*  
No -- 6   (9) 
Yes 9 (100) 60 (91) 
Not reported -- --- 
Median age first smoked (years) 15 17 
    Age range 5 – 17 10 – 27 
Current smoker (%)*   
No -- 7 (11) 
Yes 9 (100) 59 (89) 
Not reported -- -- 
Smoking frequency (%)*   
Occasional – weekly or less -- 3   (5) 
5 to 10 cigarettes a day 4 (44) 19 (32) 
11 to 20 cigarettes a day 1 (11) 7 (12) 
Over 20 cigarettes a day 4 (44) 30 (51) 
Not reported -- -- 
Other drugs used last month (%)**  
No drugs in past 4 weeks -- 46   (71) 
Cannabis 6 (67) 19 (100) 
Heroin 1 (11) -- 
Cocaine 1 (11) -- 
Amphetamine 2 (22) -- 
Other's methadone 3 (33) -- 
Other opiates 3 (33) -- 
Other's buprenorphine -- -- 
Steroids 1 (11) -- 
Hallucinogens -- -- 
Benzodiazepines 1 (11) 1 (5) 
Ecstasy/MDA 1 (11) -- 
Inhalants (e.g. petrol) -- -- 
Other drug 1 (11) -- 
Not reported -- 1 (2) 
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Table 121 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to 
survey and survey year 
Injecting behaviour 2010 
Last drug injected (%) N = 9 
Amphetamine (Speed, Ice) 3 (33) 
Anabolic steroids -- 
Cocaine -- 
Heroin -- 
Heroin + amphetamine -- 
Heroin + cocaine -- 
Methadone -- 
Morphine 2 (22) 
Other 3 (33) 
Not reported 1 (11) 
No Injected last month N = 4 
Places injected last month (%)* 
Prison -- 
Own home 3 (75) 
Friend’s home 2 (50) 
Dealer’s home -- 
Street, park, beach 1 (25) 
Car -- 
Public toilet -- 
Commercial injecting room -- 
Medically Supervised Injecting Centre, Sydney -- 
Squat -- 
Other place -- 
Use of sterile needles & syringes last month (%) 
All injections 4 (100) 
Most of the time -- 
Half of the time -- 
Some of the time -- 
Not last month -- 
Not reported -- 
Re-used someone else’s used needle & syringe last month (%) 
None 4 (100) 
Once -- 
Twice -- 
3-5 times -- 
>5 times -- 
Not reported -- 
Number of people needle & syringe was re-used after last month (%) 
None 4 (100) 
One -- 
Two -- 
Three to five -- 
More than five -- 
Don’t know how many -- 
Not reported -- 
Relationship to people needle & syringe was re-used after last month (%)*  
Regular sex partner -- 
Casual sex partner -- 
Close friend -- 
Acquaintance -- 
Other -- 





Drug mix -- 
* More than one option could be selected.    
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Table 122 Number (%) of respondents by treatment for drug use, injector status and survey year 
Treatment for drug use 2010 
 IDU Non-IDU 
No surveyed N = 9 N = 66 
Any treatment/therapy for drug use (%) 
No 3 (33) 64  (97) 
Yes 6 (67) 2    (3) 
Not reported -- -- 
History of methadone maintenance treatment (%) 
Currently 1 (11) -- 
Previously 3 (33) -- 
Never 5 (56) 66 (100) 
Not reported -- -- 
History of other pharmacotherapy treatment (%) 
Currently -- -- 
Previously 2 (22) -- 
Never 7 (78) 66 (100) 




Table 123 Number (%) of respondents by site of needle and syringe acquisition last month and survey 
year 
Needle & Syringe acquisition* 2010 
No surveyed N = 8 
From an NSP last month (%) 
Daily or almost daily -- 
A couple of times each week 1 (13) 
Less than weekly 1 (13) 
Weekly -- 
Once last month 1 (13) 
Not in the last month 4 (50) 
Not reported 1 (13) 
From a chemist last month (%) 
Daily or almost daily -- 
A couple of times each week 1 (11) 
Less than weekly -- 
Weekly -- 
Once last month -- 
Not in the last month 6 (67) 
Not reported 1 (11) 
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Table 124 Number (%) of respondents by body piercing and tattoos 
Body piercing and tattoos 2010 
 IDU Non-IDU 
No surveyed N = 9 N = 66 
Body or ear piercings (%)   
No 6 (67) 56 (85) 
Yes 3 (33) 10 (15) 
Not reported -- -- 
Pierced in past 12 mths (%)   
No 1 (33) 7 (70) 
Yes -- 2 (20) 




-- 1 (50) 
Professional piercer / studio -- -- 
Tattooist / parlour -- -- 
Friend -- -- 
Prison inmate -- -- 
Self -- -- 
Family member -- -- 
Other -- -- 
Needle used by other (%)   
No  -- -- 
Yes -- -- 
Unsure -- -- 
Not reported -- 2 (100) 
Tattoos (%)   
No 2 (22) 55 (83) 
Yes 7 (78) 10 (15) 
Not reported -- 1   (2) 
Tattoos in past 12 mths (%)   
No  6 (86) 5 (50) 
Yes 1 (14) 4 (40) 
Not reported -- 1 (10) 
Who did tattooing (%)*   
Professional tattooist 1 (100) 3 (75) 
Friend -- -- 
Prison inmate -- 1 (25) 
Self -- -- 
Family member -- -- 
Other -- -- 
* More than one option could be selected.  
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Table 125 Number (%) of respondents by sexual behaviour, injector status and survey year 
 
*** Proportion of eligible women i.e. those under 27 years of age in 2007.  
Sexual behaviour 2010 
 IDU Non-IDU 
No surveyed N = 9 N = 66 
Sex last 3 months (%)    
No 1 (11) 8 (12) 
Yes 8 (89) 57 (86) 
Not reported -- 1   (2) 
Male sex partners in last 3 months 
    Median -- 0 
    Range -- 0 – 1 
Female sex partners in last 3 months 
    Median 1 1 
    Range 0 – 90 0 – 7 
Condom use last sex - regular male partners - last 3 
months (%) 
Never 1 (100) 2 (100) 
Sometimes -- -- 
Always -- -- 
Condom use last sex - casual male partners - last 3 
months (%) 
Never -- 1 (33) 
Sometimes -- 1 (33) 
Always -- 1 (33) 
Condom use last sex - regular female partners - 
last 3 months (%) 
Never 4 (80) 25 (61) 
Sometimes -- 4 (10) 
Always 1 (20) 12 (29) 
Condom use last sex - casual female partners - 
last 3 months (%) 
Never 2 (100) 7 (37) 
Sometimes -- 3 (16) 
Always -- 9 (47) 
Sex work last month (%)  
No 8 (89) 63 (95) 
Yes 1 (11) 2   (3) 
Not reported -- 1   (2) 
Condom used at last sex work last month (%) 
No 1 (100) 1 (50) 
Yes -- 1 (50) 
Not reported -- -- 
Ever had cervical cancer vaccine (women only)*** 
(%) 
No  -- -- 
Yes -- -- 
Unsure -- -- 
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Table 126 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, 
HBV vaccination and HCV treatment by injector status and survey year 
Testing & treatment 2010 
 IDU Non-IDU 
No surveyed N = 9 N = 66 
Previous HIV test (%)   
Yes, last year 4 (44) 10 (15) 
>1 year ago 1 (11) 14 (21) 
Never tested 4 (44) 42 (64) 
Not reported -- -- 
HBV infection (%)  
No 8 (89) 61 (92) 
Yes -- -- 
Don’t know 1 (11) 4   (6) 
Not reported -- 1   (2) 
HBV vaccination (%)*   
No 4 (44) 48 (73) 
Yes 5 (56) 12 (18) 
Don’t know -- 5   (8) 
Not reported -- 1   (2) 
Previous HCV test (%)   
Yes, last year 4 (44) 6   (9) 
>1 year ago 1 (11) 18 (27) 
Never tested 3 (33) 42 (64) 
Unsure -- -- 
Not reported 1 (11) -- 
Any HCV treatment (%)** N = 3 N = 0 
Interferon -- -- 
Interferon & Ribavirin -- -- 
Pegasys & Ribavirin -- -- 
Other -- -- 
No treatment 3 (100) -- 
Not reported -- -- 
Current HCV treatment    
Interferon -- -- 
Interferon & Ribavirin -- -- 
Pegasys & Ribavirin -- -- 
Other -- -- 
* Number (%) among participants with no history of HBV infection. 
** Number (%) of those testing positive for hepatitis C antibodies. 
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HIV antibody prevalence 
Table 127 HIV antibody prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
2010       
IDU 7 0 (0) 1 0 (0) 59 0 (0) 
Non-IDU 57 0 (0) 2 0 (0) 8 0 (0) 
p value  --  --  -- 




HCV antibody prevalence 
Table 128 HCV antibody prevalence by sex, injector status and survey year† 
 Male Female Total 
Injector status No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
IDU 7 3 (43) 1 0   (0) 8 3 (38) 
Non-IDU 57 0   (0) 2 0   (0) 59 0   (0) 
p value  <0.001  --  <0.001 
† Excludes equivocal test results and missing values. 
 
 
Table 129 HCV antibody prevalence by sexual identity, sex and survey year† 
  Male Female Total  
Sexual identity No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
Heterosexual 61 3 (5) 3 0 (0) 64 3 (5) 
Bisexual 1 0 (0) -- -- 1 0 (0) 
Homosexual 1 0 (0) -- -- 1 0 (0) 
Unsure -- -- -- -- -- -- 
p value  0.1  --  0.9 
† Excludes equivocal test results and missing values. 
 
 
Table 130 HCV antibody prevalence by age group, sex and survey year† 
 Male Female Total  
Age group 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
< 20 years 6 0 (0) -- -- 6 0 (0) 
20 – 24 12 0 (0) -- -- 12 0 (0) 
25 – 29 13 0 (0) -- -- 13 0 (0) 
30 + years 33 3 (9) -- -- 36 3 (8) 
p value  0.4  --  0.4 
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Table 131 HCV antibody prevalence by duration of drug injection, sex and survey year† 
 Male Female Total  
Duration of drug injection No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
<3 years 1 0   (0) -- -- 1 0   (0) 
3 to 5 years -- -- 1 0 (0) 1 0   (0) 
6 to 10 years -- -- -- -- -- -- 
10 + years 5 3 (60) -- -- 5 3 (60) 
p value  0.3  --  0.4 
† Excludes equivocal test results and missing values. 
 
 
Table 132 HCV antibody prevalence by last drug injected, duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Last drug injected No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
Amphetamine (Speed, Ice) -- -- 3 2   (67) 3 2 (67) 
Heroin -- -- -- -- -- -- 
More than one -- -- 2 0     (0) 2 0   (0) 
Other/not reported 1 0 (0) 1 1 (100) 2 1 (50) 
     p value  --  0.2  0.3 
† Excludes equivocal test results and missing values. 
 
 
Table 133 HCV antibody prevalence by frequency of injection last month, duration of drug injection 
and survey year† 
 <3 years IDU 3+ years IDU Total  
Frequency of drug injection 
last month 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
Less than daily -- -- 1 1 (100) 1 1 (100) 
Daily or more -- -- 3 1   (33) 3 1   (33) 
p value  --  0.3  0.3 
† Excludes equivocal test results and missing values. 
 
 
Table 134 HCV antibody prevalence by re-use of someone else’s used needle and syringe last month, 
duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Re-used someone else’s used 
needle & syringe last month 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
No -- -- 4 2 (50) 4 2 (50) 
Yes -- -- -- -- -- -- 
p value  --  --  -- 
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Table 135 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey 
year† 
 <3 years IDU 3+ years IDU Total  
Imprisonment last year No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
No -- -- 3 2 (67) 3 2 (67) 
Yes 1 0 (0) 3 1 (33) 4 1 (25) 
p value  --  0.4  0.3 
† Excludes equivocal test results and missing values. 
 
 
Table 136 HCV antibody by number of previous imprisonments, sex and survey year† 
 Male Female Total  
Number of previous 
imprisonments 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
1 26 1 (4) 2 0     (0) 28 1 (4) 
2 to 4 21 1 (5) -- -- 21 1 (5) 
5 to 9 14 1 (7) 1 1 (100) 15 1 (7) 
10 + 3 0 (0) -- -- 3 0 (0) 
p value  1.0  --  1.0 
† Excludes equivocal test results and missing values. 
 
 
Table 137 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
Non-Indigenous 7 2 (29) 1 0 (0) 8 2 (25) 
Indigenous 57 1   (2) 2 0 (0) 59 1   (2) 
p value  0.002  --  0.003 
† Excludes equivocal test results and missing values. 
 
 
Table 138 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector 
status and survey year† 
 Non-IDU IDU Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
Non-Indigenous 4 0 (0) 4 2 (50) 8 2 (25) 
Indigenous 55 0 (0) 4 1 (25) 59 1   (2) 
p value  --  0.5  0.003 
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Table 139 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and 
survey year† 
  Male Female Total  
Residential remoteness No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
Highly accessible/accessible 14 1 (7) 1 0 (0) 15 1 (7) 
Moderately accessible -- -- -- -- -- -- 
Remote/very remote 43 2 (5) 2 0 (0) 45 2 (4) 
p value  0.7  --  0.7 
† Excludes equivocal test results and missing values. 
 
 
Table 140 HCV antibody prevalence by region/country of birth, sex and survey year† 
 Male Female Total  
Region/Country of birth No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
Australia 61 2     (3) 2 0 (0) 63 2     (3) 
Other Oceania 1 1 (100) -- -- 1 1 (100) 
Asia 2 0     (0) 1 0 (0) 3 0     (0) 
UK & Ireland -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
p value  <0.001  --  <0.001 
† Excludes equivocal test results and missing values. 
 
 
Table 141 HCV antibody prevalence by main language spoken at home by parents, sex and survey 
year† 
 Male Female Total  
Main language spoken at 
home by parents 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
English  37 3 (8) -- -- 37 3 (8) 
Non-English  8 0 (0) 1 0 (0) 9 0 (0) 
p value  0.3  --  0.4 
† Excludes equivocal test results and missing values. 
 
 
Table 142 Self-reported HCV status versus HCV serology by sex and survey year† 
 Male Female Total  
Self-report HCV No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
Positive 2 2 (100) -- -- 2 2 (100) 
Negative 24 0     (0) -- -- 24 0     (0) 
Not sure -- -- 1 0 (0) 1 0     (0) 
p value  <0.001    <0.001 
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HBV prevalence 
Table 143 HBV surface-antigen prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
IDU 7 0 (0) 1 0   (0) 8 0 (0) 
Non-IDU 44 2 (5) 2 1 (50) 46 3 (7) 
p value  0.6  0.4  0.5 
† Excludes equivocal test results and missing values. 
 
 
Table 144 HBV core-antibody prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
IDU 7 2 (29) 1 1 (100) 8 3 (38) 
Non-IDU 44 16 (36) 2 2 (100) 46 18 (39) 
p value  0.7  --  0.9 
† Excludes equivocal test results and missing values. 
 
 
Table 145 HBV core-antibody prevalence by sexual identity, sex and survey year† 
 Male Female Total  
Sexual identity No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
Heterosexual 49 17 (35) 3 0 (0) 52 20 (38) 
Bisexual 1 0   (0) -- -- 1 0   (0) 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value  0.5  --  0.4 
† Excludes equivocal test results and missing values. 
 
 
Table 146 HBV core-antibody prevalence by age group, sex and survey year† 
 Male Female Total  
Age group No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
< 20 years 6 1 (17) -- -- 6 1 (17) 
20 – 24 10 1 (10) -- -- 10 1 (10) 
25 – 29 9 3 (33) -- -- 9 3 (33) 
30 + years 26 13 (50) 3 3 (100) 29 16 (55) 
p value  0.1  --  0.04 







National Prison Entrants’ Bloodborne Virus & Risk Behaviour Survey 2004, 2007, and 2010 
Northern Territory 
 92 
Table 147 HBV core-antibody prevalence by duration of drug injection, sex and survey year† 
 Male Female Total  
Duration of drug injection No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
<3 years 1 1 (100) -- -- 1 1 (100) 
3 to 5 years -- -- 1 1 (100) 1 1 (100) 
6 to 10 years 1 0     (0) -- -- 1 0     (0) 
10 + years 5 1   (20) -- -- 5 1   (20) 
p value  0.2  --  0.2 
† Excludes equivocal test results and missing values. 
 
 
Table 148 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey 
year† 
 <3 years IDU 3+ years IDU Total  
Last drug injected No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
Amphetamine (Speed, Ice) -- -- 3 1 (33) 3 1 (33) 
Heroin -- -- -- -- -- -- 
More than one -- -- 2 1 (50) 2 1 (50) 
Other/not reported 1 1 (100) 2 0   (0) 3 1 (33) 
     p value  --  0.5  0.9 
† Excludes equivocal test results and missing values. 
 
 
Table 149 HBV core-antibody prevalence by frequency of injection last month, duration of drug 
injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Frequency of drug injection 
last month 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
Less than daily -- -- 1 1 (100) 1 1 (100) 
Daily or more -- -- 3 1   (33) 3 1   (33) 
p value  --  0.3  0.3 
† Excludes equivocal test results and missing values. 
 
 
Table 150 HBV core antibody prevalence by re-use of someone else’s used needle and syringe last 
month, duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Re-used someone else’s used 
needle & syringe last month 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
No -- -- 4 2 (50) 4 2 (50) 
Yes -- -- -- -- -- -- 
p value  --  --  -- 
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Table 151 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and 
survey year† 
 <3 years IDU 3+ years IDU Total  
Imprisonment last year No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
No -- -- 3 0   (0) 3 0   (0) 
Yes 1 1 (100) 4 2 (50) 5 3 (60) 
p value  --  0.2  0.1 
† Excludes equivocal test results and missing values. 
 
 
Table 152 HBV core-antibody by number of previous imprisonments, sex and survey year† 
 Male Female Total  
Number of previous 
imprisonments 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
1 21 5 (24) 2 2 (100) 23 7 (30) 
2 to 4 15 5 (33) -- -- 15 5 (33) 
5 to 9 12 6 (50) 1 1 (100) 13 7 (54) 
10 + 3 2 (67) -- -- 3 2 (67) 
p value  0.3  --  0.4 
† Excludes equivocal test results and missing values. 
 
 
Table 153 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
Non-Indigenous 7 1 (14) 1 1 (100) 8 2 (25) 
Indigenous 44 17 (39) 2 2 (100) 46 19 (41) 
p value  0.2  --  0.4 
† Excludes equivocal test results and missing values. 
 
 
Table 154 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector 
status and survey year† 
 Non-IDU IDU Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
Non-Indigenous 4 0   (0) 4 2 (50) 8 2 (25) 
Indigenous 42 18 (43) 4 1 (25) 46 19 (41) 
p value  0.09  0.5  0.4 




National Prison Entrants’ Bloodborne Virus & Risk Behaviour Survey 2004, 2007, and 2010 
Northern Territory 
 94 
Table 155 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before 
prison and survey year† 
  Male Female Total  
Residential remoteness No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
Highly accessible/accessible 15 6 (40) 1 1 (100) 16 7 (44) 
Moderately accessible -- -- -- -- -- -- 
Remote/very remote 32 12 (38) 2 2 (100) 34 14 (41) 
p value  0.9  --  0.9 
† Excludes equivocal test results and missing values. 
 
 
Table 156 HBV core-antibody prevalence by region/country of birth, sex and survey year† 
 Male Female Total  
Region/Country of birth No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
Australia 48 17   (35) 2 2 (100) 50 19   (38) 
Other Oceania 1 1 (100) -- -- 1 1 (100) 
Asia 2 0     (0) 1 1 (100) 3 1   (33) 
UK & Ireland -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
p value  0.2  --  0.4 
† Excludes equivocal test results and missing values. 
 
 
Table 157 HBV core-antibody prevalence by main language spoken at home by parents, sex and 
survey year† 
 Male Female Total  
Main language spoken at 
home by parents 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
English  36 11 (31) -- -- 36 11 (31) 
Non-English  7 3 (43) 1 1 (100) 8 4 (50) 
p value  0.5          --  0.3 
† Excludes equivocal test results and missing values. 
 
 
Table 158 Hepatitis B virus immune status by injector status and survey year† 
  Hepatitis B Virus Immune Status 
Injector status No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2010      
IDU 8 1 (13) 3 (38) 0 (0) 4 (50) 
Non-IDU 46 17 (37) 15 (33) 3 (7) 11 (24) 
p value     0.3 
† Excludes equivocal test results and missing values.   
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Table 159 Hepatitis B virus immune status by sexual identity and survey year† 
  Hepatitis B Virus Immune Status 
Sexual identity No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2010      
Heterosexual  52 18 (35) 17 (33) 3 (6) 14   (27) 
Homosexual -- -- -- -- -- 
Bisexual 1 0   (0) 0   (0) 0 (0) 1 (100) 
Unsure -- -- -- -- -- 
p value     0.5 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.   
 
 
Table 160 Hepatitis B virus immune status by age group and survey year† 
  Hepatitis B Virus Immune Status 
Age group No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2010      
< 20 years 6 4 (67) 1 (17) 0   (0) 1 (17) 
20 – 24 10 3 (30) 1 (10) 0   (0) 6 (60) 
25 – 29 9 3 (33) 1 (11) 2 (22) 3 (33) 
30 + years 29 8 (28) 15 (52) 1   (3) 5 (17) 
p value     0.02 
† Excludes equivocal test results and missing values.  
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.   
 
 
Table 161 Hepatitis B virus immune status by number of previous imprisonments and survey year† 






No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2010      
1 23 10 (43) 5 (22) 2 (9) 6 (26) 
2 to 4 15 6 (40) 5 (33) 0 (0) 4 (27) 
5 to 9 13 2 (15) 6 (46) 1 (8) 4 (31) 
10 + 3 0   (0) 2 (67) 0 (0) 1 (33) 
p value     0.6 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 162 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey 
year† 






No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2010      
Non-Indigenous 8 4 (50) 2 (25) 0 (0) 2 (25) 
Indigenous 46 14 (33) 16 (35) 3 (7) 13 (28) 
p value     0.7 
† Excludes equivocal test results and missing values.  
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
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Table 163 Hepatitis B virus immune status by residential remoteness and survey year† 
  Hepatitis B Virus Immune Status 
Residential remoteness No 
tested 
No (%) with no 
evidence of 
HBV immunity 






No (%) vaccine 
conferred 
immunity* 
2010      
Highly accessible/accessible 16 3 (19) 7 (44) 0 (0) 6 (38) 
Moderately accessible -- -- -- -- -- 
Remote/very remote 34 11 (32) 11 (32) 3 (9)   9 (26) 
p value     0.4 
† Excludes equivocal test results and missing values.  
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 164 Hepatitis B virus immune status by main language spoken at home by parents and survey 
year† 
  Hepatitis B Virus Immune Status 
Main language 




No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2010      
English  36 15 (42) 10 (28) 1   (3) 10 (28) 
Non-English 
 
8 1 (13) 3 (38) 1 (13) 3 (38) 
p value     0.3 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 165 Self-reported hepatitis B immunisation versus serological testing and survey year*  
 Male Female Total  
Self-report HBV 
immunisation** 
No tested No immune 
(%) 
No tested No immune 
(%) 
No tested No immune 
(%) 
2010       
No 23 9 (39) -- -- 23 9 (39) 
Yes 8 5 (63) -- -- 8 5 (63) 
Not sure 1 0   (0) -- -- 1 0   (0) 
p value  1.0  --  0.3 
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
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Chlamydia 
 
Table 166 Genital chlamydia prevalence by sex and survey year† 
Sex  No tested No with 
chlamydia (%) 
2010   
Male  63 1 (2) 
Female 3 0 (0) 
p value  0.8 




Table 167 Genital gonorrhoea prevalence by sex and survey year† 
Sex  No tested No with 
gonorrhoea (%) 
2010   
Male  63 2 (3) 
Female 3 0 (0) 
p value  0.8 




Table 168 Syphilis markers by sex and survey year† 








No with any 
marker for 
syphilis (%) 
2010     
Male  64 13 (20) 5 (8) 13 (20) 
Female 3 1 (33) 0 (0) 1 (33) 
p value  0.6 0.4 0.6 



















2004, 2007, 2010 
Table 169 Number (%) of respondents by demographic characteristics, injector status and survey year  
 2004 2007 2010 
Demographic characteristics IDU Non-IDU IDU Non-IDU IDU Non-IDU 
Number of sites surveyed N = 1 N = 1 N = 5 
No surveyed N = 82 N = 58  N = 91 N = 66 N = 85 N = 126 
Sex (%)       
Male 80 (100) 58 (100) 91 (100) 66 (100) 70 (82) 110 (87) 
Female -- -- -- -- 15 (18) 16 (13) 
Transgender -- -- -- -- -- -- 
Sexual identity (%)       
Heterosexual 81   (99) 56 (97) 90 (99) 66 (100) 76 (89) 123 (98) 
Bisexual 1     (1) 2   (3) -- -- 5   (6) 1   (1) 
Homosexual -- -- -- -- 2   (2) -- 
Unsure -- -- -- -- -- 1   (1) 
Not reported -- -- 1  (1) -- 2   (2) 1   (1) 
Age and duration of injection (years)      
Median age (years) 29 36 29 27 30 30 
    Age range 17 – 53 17 – 67 18 – 47 17 – 63 18 – 52 17 – 66 
Age group (%)       
    <25 years 28 (34) 12 (21) 21 (23) 29 (44) 26 (31) 43 (34) 
    25+ years 54 (64) 46 (79) 70 (77) 37 (56) 59 (69) 83 (66) 
    Not reported     -- -- 
Median age 1stIDU (years) 17 -- 17 -- 17 -- 
    Age range 11 – 38 -- 11 – 34 -- 8 – 35 -- 
    Not reported -- -- 5 -- 4 -- 
Median years IDU 9 -- 10 -- 13 -- 
    Range <1 – 28 -- <1 – 33 -- <1 – 34 -- 
Duration of drug injection (%)      
    <3 years 9 (11) -- 6   (7) -- 5   (6) -- 
    3+ years 73 (89) -- 80 (88) -- 76 (89) -- 
    Not reported   5   (5) -- 4   (5) -- 
Aboriginal and Torres Strait Islander origin (%)     
No 74 (90) 52 (90) 77 (85) 57 (86) 63 (74) 76 (60) 
Yes 8 (10) 6 (10) 14 (15) 9 (14) 22 (26) 50 (40) 
Not reported -- -- -- -- -- -- 
Living situation prior to prison (%)*      
Not homeless n/a n/a n/a n/a 50 (59) 72 (57) 
Primary homelessness n/a n/a n/a n/a 5   (6) 4   (3) 
Secondary homelessness n/a n/a n/a n/a 18 (21) 31 (25) 
Tertiary homelessness n/a n/a n/a n/a 7   (8) 3   (2) 
Not reported n/a n/a n/a n/a 5   (6) 16 (13) 
Residential remoteness in 12 months before prison (%)     
 Highly accessible/accessible 80 (98) 52 (90) 82 (90) 60 (91) 72 (85) 89 (71) 
Moderately accessible -- 1 (2) 1   (1) 2   (3) 4   (5) 9   (7) 
Remote/very remote 2   (2) 2 (3) 2   (2) 1   (2) 3   (4) 22 (17) 
Not reported -- 3 (5) 6   (7) 3   (5) 6   (7) 6   (5) 
Region/Country of birth (%)      
Australia 71 (87) 40 (69) 83 (91) 61 (92) 76 (89) 106 (84) 
Other Oceania 8 (10) 8 (14) 1   (1) 1   (2) 4   (5) 11   (9) 
Asia 2   (2) 2   (3) 6   (7) 1   (2) 1   (1) -- 
UK & Ireland 1   (1) 3   (5) -- -- 3   (4) 2   (2) 
Other -- 5   (9) -- 3   (5) 1   (1) 7   (6) 
Not reported -- -- 1   (1) -- -- -- 
Main language spoke at home by parents (%)     
English  79 (96) 52 (90) 86 (95) 63 (95) 82 (96) 118 (94) 
Non-English  3   (4) 6 (10) 5   (5) 3   (5) 2   (2) 7   (6) 
Not reported -- -- -- -- 1   (1) 1   (1) 
* Not homeless (private rental, home owner/purchaser, public/community housing, drug and alcohol treatment facility, workers’ 
accommodation, prison, nursing home, foster home); Primary homelessness (Sleeping rough, squat, long grass, boat, car); 
Secondary homelessness (Living with parent, siblings, or relatives, crisis accommodation); Tertiary homelessness (Boarding house, 
hostel, caravan park, backpackers, hotel, motel). Living situation question introduced in 2010. 
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Table 169 Number (%) of respondents by demographic characteristics, injector status and survey year 
(cont.) 
 2004 2007 2010 
Demographic characteristics IDU Non-IDU IDU Non-IDU IDU Non-IDU 
First time in prison (%)       
No 81  (99) 53 (91) 80 (88) 33 (50) 73 (86) 68 (54) 
Yes 1    (1) 5   (9) 11 (12) 32 (48) 12 (14) 56 (44) 
Not reported -- -- -- 1   (2) -- 2   (2) 
Lifetime imprisonments (%)       
One 1   (1) 5   (9) 11 (12) 32 (48) 25 (29) 78 (62) 
Two to four  57 (70) 47 (81) 48 (53) 25 (38) 28 (33) 30 (24) 
Five to nine   19 (23) 4   (7) 20 (22) 3   (5) 21 (25) 8   (6) 
Ten or more  5   (6) 1   (2) 10 (11) 4   (6) 11 (13) 8   (6) 
Not reported -- 1   (2) 2   (2) 2   (3) -- 2   (2) 
Imprisonment in last year (%)       
No 2    (2) 5   (9) 32 (40) 11 (32) 27 (32) 80 (63) 
Yes 80  (98) 53 (91) 46 (58) 22 (65) 55 (65) 41 (33) 
Not reported -- -- 2   (3) 1   (3) 3   (4) 5   (4) 
Frequency of injection last month (%)      
Not last month 32  (39) -- 44 (48) -- 38 (45) -- 
Less than weekly 6    (7) -- 10 (11) -- 8   (9) -- 
Weekly not daily 7    (9) -- 6   (7) -- 5   (6) -- 
Daily or more 37  (45) -- 28 (31) -- 33 (39) -- 
Not reported   3   (3) -- 1   (1) -- 
Ever smoked a full cigarette (%)*      
No n/a n/a 5   (5) 14 (21) 2   (2) 11   (9) 
Yes n/a n/a 86 (95) 52 (79) 83 (98) 115 (91) 
Not reported n/a n/a -- -- -- -- 
Median age first smoked (years) n/a n/a 14 14 14 14 
    Age range n/a n/a 6 – 25 6 – 22 7 – 37 6 – 50 
Current smoker (%)*       
No n/a n/a 5   (6) 14 (21) 8   (9) 30 (24) 
Yes n/a n/a 86 (95) 52 (79) 77 (91) 96 (76) 
Not reported   -- -- -- -- 
Smoking frequency (%)*       
Occasional – weekly or less n/a n/a 5   (6) 4   (8) 1   (1) 6   (6) 
5 to 10 cigarettes a day n/a n/a 19 (22) 11 (21) 18 (23) 46 (48) 
11 to 20 cigarettes a day n/a n/a 28 (33) 15 (29) 40 (52) 24 (25) 
Over 20 cigarettes a day n/a n/a 34 (40) 21 (40) 17 (22) 19 (20) 
Not reported n/a n/a --  1   (2) 1   (1) 1   (1) 
Other drugs used last month (%)**      
No drugs in past 4 weeks n/a n/a n/a n/a 17 (21) 53 (47) 
Cannabis n/a n/a n/a n/a 45 (69) 48 (81) 
Heroin n/a n/a n/a n/a 23 (35) 1   (2) 
Cocaine n/a n/a n/a n/a 1   (2) 1   (2) 
Amphetamine n/a n/a n/a n/a 33 (51) 7 (12) 
Other's methadone n/a n/a n/a n/a 4   (6) -- 
Other opiates n/a n/a n/a n/a 6   (9) 1   (2) 
Other's buprenorphine n/a n/a n/a n/a 10 (15) 1   (2) 
Steroids n/a n/a n/a n/a -- 1   (2) 
Hallucinogens n/a n/a n/a n/a 1   (2) -- 
Benzodiazepines n/a n/a n/a n/a 15 (23) 4   (7) 
Ecstasy/MDA n/a n/a n/a n/a 2   (3) 2   (3) 
Inhalants (e.g. petrol) n/a n/a n/a n/a -- -- 
Other drug n/a n/a n/a n/a -- 1   (2) 
Not reported n/a n/a n/a n/a 3   (4) 14 (11) 
* Smoking questions not asked in 2004. 
** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected. 
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Table 170 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to 
survey and survey year 
Injecting behaviour 2004 2007 2010 
Last drug injected (%) N = 82  N = 91 N = 85 
Amphetamine (Speed, Ice) 59 (72) 57 (63) 
 
49 (58) 
Anabolic steroids -- -- -- 
Cocaine -- 1   (1) 
 
1   (1) 
Heroin 20 (24) 20 (22)
 
21 (25) 
Heroin + amphetamine -- 2   (2)
 
-- 
Heroin + cocaine -- -- -- 
Methadone 1   (1) 2   (2) 
 
-- 
Morphine 2   (2) 4   (4)
 
5   (6) 
Other -- 4   (4)
 
7   (8) 
Not reported -- 1   (1)
 
2   (2) 
No Injected last month N = 50 N = 44 N = 46 
Places injected last month (%)* 
Prison 3   (6) 1   (2) 2   (4) 
Own home 45 (90) 39 (89) 28 (61) 
Friend’s home 37 (74) 27 (61) 20 (43) 
Dealer’s home 23 (46) 19 (43) 8 (17) 
Street, park, beach 25 (50) 20 (45) 8 (17) 
Car 31 (62) 21 (48) 12 (26) 
Public toilet 21 (42) 16 (36) 11 (24) 
Commercial injecting room 2   (4) -- 1   (2) 
Medically Supervised Injecting Centre, Sydney 4   (8) -- 1   (2) 
Squat 9 (18) 1   (2) 1   (2) 
Other place -- 1   (2) 1   (2) 
Use of sterile needles & syringes last month (%) 
All injections 37 (74) 28 (64) 38 (83) 
Most of the time 8 (16) 9 (20) 4   (9) 
Half of the time 4   (8) 4   (9) 2   (4) 
Some of the time 1   (2) 3   (7) -- 
Not last month -- -- 1   (2) 
Not reported -- -- 1   (2) 
Re-used someone else’s used needle & syringe last month (%) 
None 39 (78) 33 (75) 36 (78) 
Once 1   (2) 2   (5) 2   (4) 
Twice 4   (8) 3   (7) 3   (7) 
3-5 times 2   (4) 3   (7) 2   (4) 
>5 times 4   (8) 3   (7) 2   (4) 
Not reported  -- 1   (2) 
Number of people needle & syringe was re-used after last month (%) 
None 39 (78) 33 (75) 37 (80) 
One 8 (16) 5 (11) 2   (4) 
Two 2   (4) 1   (2) 2   (4) 
Three to five 1   (2) 2   (5) 1   (2) 
More than five -- -- 2   (4) 
Don’t know how many -- 3   (7) 1   (2) 
Not reported -- -- 1   (2) 
Relationship to people needle & syringe was re-used after last month (%)*  
Regular sex partner 8 (16) 6 (14) 3   (7) 
Casual sex partner 1   (2) 1   (2) 2   (4) 
Close friend 2   (4) 5 (11) 2   (4) 
Acquaintance 1   (2) 1   (2) 3   (7) 
Other 1   (2) -- 1   (2) 
Equipment used after someone else last month (%)*  
Spoon 11 (22) 20 (46)  15 (33) 
Water 42 (84) 18 (41) 12 (26) 
Filter 42 (84) 19 (43) 12 (26) 
Tourniquet 2   (4) 10 (23) 9 (20) 
Drug mix 7 (14) 18 (41) 10 (22) 
* More than one option could be selected.    
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Table 171 Number (%) of respondents by treatment for drug use, injector status and survey year 
Treatment for drug use 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 82 N = 58 N = 91 N = 66 N = 85 N = 126 
Any treatment/therapy for drug use (%)   
No 50 (61) 55 (95) 48 (53) 9 (14) 48 (56) 115 (91) 
Yes 32 (38) 2   (3) 24 (26) -- 37 (44) 8   (6) 
Not reported -- 1   (2) 19 (21) 57 (86) -- 3   (2) 
History of methadone maintenance treatment (%)   
Currently 3   (4) 2   (3) 2   (2) -- 4   (5) -- 
Previously 17 (21) -- 9 (10) -- 12 (14) -- 
Never 62 (76) 56 (97) 62 (68) -- 69 (81) 123 (98) 
Not reported -- -- 18 (20) -- -- 3  (2) 
History of other pharmacotherapy treatment (%)   
Currently 66 (80) 56 (97) 7   (8) -- 5   (6) 1   (1) 
Previously 4   (5) 2   (3) 9 (10) -- 11 (13) -- 
Never 12 (15) -- 64 (70) -- 69 (81) 123 (98) 
Not reported -- -- 11 (12) -- -- 2   (2) 
 
 
Table 172 Number (%) of respondents by site of needle and syringe acquisition last month and survey 
year 
Needle & Syringe acquisition* 2004        2007 2010 
No surveyed N = 50  N = 44  N = 85 
Daily or almost daily 11 (22) 4   (9) 6   (7) 
A couple of times each week 10 (20) 7 (16) 17 (20) 
Weekly n/a n/a 6   (7) 
Less than weekly 8 (16) 8 (18) 12 (14) 
Once last month 10 (20) 3   (7) -- 
Not in the last month 11 (22) 6 (14) 37 (44) 
Not reported -- 16 (36) 6   (7) 
From a chemist last month (%)   
Daily or almost daily 4   (8) 5 (11) 1   (1) 
A couple of times each week 12 (24) 2   (5) 10 (12) 
Less than weekly 12 (24) 12 (27) 7   (8) 
Weekly n/a n/a 7   (8) 
Once last month 7 (14) 5 (11) -- 
Not in the last month 15 (30) 4   (9) 54 (64) 
Not reported -- 16 (36) 4   (5) 
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Table 173 Number (%) of respondents by body piercing and tattoos  
Body piercing and tattoos 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 82 N = 58 N = 91 N = 66 N = 85 N = 126 
Body or ear piercings (%)       
No 50 (61) 40 (69) 55 (60) 44  (67) 46 (54) 76 (60) 
Yes 31 (38) 18 (31) 35 (38) 22  (33) 39 (46) 50 (40) 
Not reported 1   (1) -- 1   (1) -- -- -- 
Pierced in past 12 mths (%)       
No 10 (32) 5 (28) 14 (40) 9  (40) 26 (65) 26 (50) 
Yes 5 (16) -- 4 (11) 1    (5) 4 (10) 3   (6) 
Not reported  16 (52) 13 (72) 17 (49) 12  (55) 10 (25) 23 (44) 
Who did piercing (%)*      
Chemist/hairdresser/beauty 
salon  
-- -- -- -- -- -- 
Professional piercer / studio 1 (20) -- 3 (75) 1 (100) -- 2 (67) 
Tattooist / parlour -- -- -- -- 1 (25) 1 (33) 
Friend 1 (20) -- -- -- 1 (25) -- 
Prison inmate 1 (20) -- -- -- -- -- 
Self 3 (60) -- 1 (25) -- 2 (50) -- 
Family member -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
Needle used by other (%)       
No  5 (100) -- 1 (25) -- 3 (75) -- 
Yes -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
Not reported -- -- 3 (75) 1 (100) 1 (25) 3 (100) 
Tattoos (%)       
No 23 (28) 30 (52) 25 (27) 36 (55) 9 (11) 53 (42) 
Yes 59 (72) 28 (48) 66 (73) 30 (45) 71 (84) 64 (51) 
Not reported -- -- -- -- 5   (6) 9   (7) 
Tattoos in past 12 mths (%)       
No  42 (71) 24 (86) 51 (77) 13 (43) 49 (69) 44 (69) 
Yes 15 (25) 4 (14) 15 (23) 17 (57) 21 (30) 17 (27) 
Not reported 2   (3) -- -- -- 1   (1) 3   (5) 
Who did tattooing (%)*       
Professional tattooist 9 (60) 2 (50) 3 (20) 12 (71) 10 (48) 6 (35) 
Friend 2 (13) -- 7 (47) 4 (24) 7 (33) 9 (53) 
Prison inmate 3 (20) -- 3 (20) 1   (6) 3 (14) 1   (6) 
Self 2 (13) 1 (25) 1   (7) -- 1   (5)    2 (12) 
Family member -- 1 (25) -- -- 3 (14) -- 
Other -- -- -- -- -- -- 
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Table 174 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by 
injector status and survey year 
Sexual behaviour 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 82  N = 58  N = 91 N = 66 N =85 N = 126 
Sex last month / last 3 months (%)**      
No 13   (16) 15   (26) 26   (29) 20   (30) 9 (11) 26 (21) 
Yes 69   (84) 43   (74) 64   (70) 46   (70) 73 (86) 97 (77) 
Not reported -- -- 1     (1) -- 3   (4) 3   (2) 
Male sex partners in last 3 months**    
    Median n/a n/a n/a n/a 1 1 
    Range n/a n/a n/a n/a 0 – 300 0 – 2 
Female sex partners in last 3 months**    
    Median n/a n/a n/a n/a 1 1 
    Range n/a n/a n/a n/a 0 – 12 0 – 26 
Condom use at last sex (%)        
No 66   (80) 44   (76) 69   (76) 45   (68) n/a  n/a  
Yes 16   (20) 14   (24) 21   (23) 21   (32) n/a  n/a  
Not reported -- -- 1     (1) -- n/a  n/a  
Condom use with regular sex partner(s) last month (%)*     
No 47   (94) 29   (81) 33   (75) 29   (85) n/a  n/a  
Sometimes 3     (6) 2     (6) 4     (9) 4   (12) n/a  n/a  
Always -- 5   (14) 7   (16) 1     (3) n/a  n/a  
Condom use with new sex partner(s) last month (%)*     
No 8 (100) 2 (100) 1 (100) -- n/a  n/a  
Sometimes -- -- -- 1   (50) n/a  n/a  
Always -- -- -- 1   (50) n/a  n/a  
Condom use with casual sex partner(s) last month (%)*     
No 10   (50) 3   (33) 17   (85) 5   (42) n/a  n/a  
Sometimes 2   (10) -- 1     (5) 4   (33) n/a  n/a  
Always 8   (40) 6   (67) 2   (10) 3   (25) n/a  n/a  
Condom use last sex - regular male partners - last 3 months (%)**   
Never n/a n/a n/a n/a 8 (73) 9 (64) 
Sometimes n/a n/a n/a n/a 1   (9) 2 (14) 
Always n/a n/a n/a n/a 2 (18) 3 (21) 
Condom use last sex - casual male partners - last 3 months (%)**   
Never n/a n/a n/a n/a 3 (60) 1 (100) 
Sometimes n/a n/a n/a n/a -- -- 
Always n/a n/a n/a n/a 2 (40) -- 
Condom use last sex - regular female partners - last 3 months (%)**   
Never n/a n/a n/a n/a 37 (84) 40 (62) 
Sometimes n/a n/a n/a n/a 4   (9) 12 (18) 
Always n/a n/a n/a n/a 3   (7) 13 (20) 
Condom use last sex - casual female partners - last 3 months (%)**   
Never n/a n/a n/a n/a 16 (70) 8 (24) 
Sometimes n/a n/a n/a n/a 4 (17) 9 (27) 
Always n/a n/a n/a n/a 3 (13) 16 (48) 
Sex work last month (%)       
No 81 (99) 57 (98) 90 (99) 66 (100) 82 (96) 122 (97) 
Yes -- 1   (2)  -- -- 3   (4) -- 
Not reported 1   (1) -- 1   (1) -- -- 4   (3) 
Condom used at last sex work last month (%)    
No -- -- -- -- -- -- 
Yes -- 1 (100) -- -- 2 (67) -- 
Not reported -- -- -- -- 1 (33) -- 
Ever had cervical cancer vaccine (women only)*** (%)    
No  n/a n/a n/a n/a 6 (75) 2 (50) 
Yes n/a n/a n/a n/a 2 (25) 1 (25) 
Unsure n/a n/a n/a n/a -- 1 (25) 
* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month. 
** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded 
areas indicate previous survey items that were changed in 2010. 
*** Proportion of eligible women i.e. those under 27 years of age in 2007.    
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Table 175 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, 
HBV vaccination and HCV treatment by injector status and survey year 
Testing & treatment 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 82 N = 58 N = 91 N = 66 N = 85 N = 126 
Previous HIV test (%)       
Yes, last year 33 (40) 10 (17) 59 (65) 26 (39) 52 (61) 53 (42) 
>1 year ago 33 (40) 26 (45) 24 (26) 25 (38) 23 (27) 33 (26) 
Never tested 16 (20) 22 (38) 7   (8) 15 (23) 9 (11) 40 (32) 
Not reported -- -- 1   (1) -- 1   (1) -- 
HBV infection (%)      
No 76 (93) 56 (97) 88 (97) 61 (92) 75 (88) 113 (90) 
Yes 6   (7) 1   (2) 2  (2) -- 1   (1) 3   (2) 
Don’t know -- 1   (2) 1  (1) 1   (2) 9 (11) 10   (8) 
Not reported -- -- -- 4   (6) -- -- 
HBV vaccination (%)*       
No 13 (16) 27 (47) 14 (15) 17 (26) 11 (13) 34 (27) 
Yes 69 (84) 31 (53) 72 (79) 42 (64) 68 (80) 68 (54) 
Don’t know -- -- 5  (5) 7 (11) 6   (7) 24 (19) 
Not reported -- -- -- -- -- -- 
Previous HCV test (%)       
Yes, last year 30 (37) 9 (16) 6   (7) 15 (23) 54 (64) 51 (40) 
>1 year ago 43 (52) 21 (36) 60 (66) 28 (42) 24 (28) 34 (27) 
Never tested 9 (11) 28 (48) 25 (27) 23 (35) 6   (7) 41 (33) 
Unsure -- -- -- -- 1   (1) -- 
Not reported -- -- -- -- -- -- 
Any HCV treatment (%)** N = 36 N = 2 N = 41  N = 2 N = 41  N = 0 
Interferon -- -- 1   (2) -- 1 (2) -- 
Interferon & Ribavirin -- -- -- -- -- -- 
Pegasys & Ribavirin -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
No treatment 36 (100) 2 (100) 40 (98) 2 (100) 40 (98) -- 
Not reported -- -- -- -- -- -- 
Current HCV treatment        
Interferon -- -- -- -- 1 (2) -- 
Interferon & Ribavirin -- -- -- -- -- -- 
Pegasys & Ribavirin -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
* Number (%) among participants with no history of HBV infection. 
** Number (%) of those testing positive for hepatitis C antibodies. 
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HIV antibody prevalence 
Table 176 HIV antibody prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
2004       
IDU 77 0 (0) -- -- 77 0 (0) 
Non-IDU 53 1 (2) -- -- 53 1 (2) 
p value  0.2  --  0.2 
2007       
IDU 77 1 (1) -- -- 77 1 (1) 
Non-IDU 59 0 (0) -- -- 59 0 (0) 
p value  0.4  --  0.4 
2010       
IDU 59 0 (0) 14 0 (0) 73 0 (0) 
Non-IDU 103 0 (0) 15 0 (0) 118 0 (0) 
p value  --  --  -- 




HCV antibody prevalence 
Table 177 HCV antibody prevalence by sex, injector status and survey year† 
 Male Female Total 
Injector status No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
IDU 75 36 (48) -- -- 75 36 (48) 
Non-IDU 54 2   (4) -- -- 54 2   (4) 
p value  <0.001  --  <0.001 
2007       
IDU 77 41 (53) -- -- 77 41 (53) 
Non-IDU 58 2   (3) -- -- 58 2   (3) 
p value  <0.001  --  <0.001 
2010       
IDU 58 29 (50) 14 12 (86) 72 41 (57) 
Non-IDU 102 0   (0) 14 0   (0) 116 0    (0) 
p value  <0.001  <0.001  <0.001 
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Table 178 HCV antibody prevalence by sexual identity, sex and survey year† 
  Male Female Total  
Sexual identity No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Heterosexual 127 38   (30) -- -- 127 38 (30) 
Bisexual 2 0     (0) -- -- 2 0   (0) 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value  0.4    0.4 
2007       
Heterosexual 134 42   (31) -- -- 134 42 (31) 
Bisexual -- -- -- -- -- -- 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value  --  --  -- 
2010       
Heterosexual 154 28   (18) 23 8   (35) 177 36   (20) 
Bisexual 1 0     (0) 4 3   (75) 5 3   (60) 
Homosexual 1 1 (100) 1 1 (100) 2 2 (100) 
Unsure -- -- -- -- -- -- 
p value  0.1  0.2  <0.01 
† Excludes equivocal test results and missing values. 
 
 
Table 179 HCV antibody prevalence by age group, sex and survey year† 
 Male Female Total  
Age group N
o tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
< 20 years 11 0   (0) -- -- 11 0   (0) 
20 – 24 27 6 (22) -- -- 27 6 (22) 
25 – 29 24 11 (46) -- -- 24 11 (46) 
30 + years 67 21 (31) -- -- 67 21 (31) 
p value  0.04  --  0.04 
2007       
< 20 years 13 1   (8) -- -- 13 1   (8) 
20 – 24 32 10 (31) -- -- 32 10 (31) 
25 – 29 36 13 (36) -- -- 36 13 (36) 
30 + years 54 19 (35) -- -- 54 19 (35) 
p value  0.3  --  0.3 
2010       
< 20 years 23 0   (0) 3 1 (33) 26 1   (4) 
20 – 24 36 8 (22) 3 1 (33) 39 9 (23) 
25 – 29 28 5 (18) 6 4 (67) 34 9 (27) 
30 + years 73 16 (22) 16 6 (38) 89 22 (25) 
p value  0.1  0.6  0.1 
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Table 180 HCV antibody prevalence by duration of drug injection, sex and survey year† 
 Male Female Total  
Duration of drug injection No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
<3 years 8 0   (0) -- -- 8 0   (0) 
3 to 5 years 9 1 (11) -- -- 9 1 (11) 
6 to 10 years 22 10 (45) -- -- 22 10 (45) 
10 + years 36 25 (69) -- -- 36 25 (69) 
p value  <0.001  --  <0.001 
2007       
<3 years 5 1 (20) -- -- 5 1 (20) 
3 to 5 years 10 5 (50) -- -- 10 5 (50) 
6 to 10 years 23 9 (39) -- -- 23 9 (39) 
10 + years 34 22 (65) -- -- 34 22 (65) 
p value  0.1  --  0.1 
2010       
<3 years 4 1 (25) -- -- 4 1 (25) 
3 to 5 years 5 1 (20) 2 1   (50) 7 2 (29) 
6 to 10 years 13 6 (46) 3 3 (100) 16 9 (56) 
10 + years 33 20 (61) 8 7   (88) 41 27 (66) 
p value  0.2  0.3  0.2 
† Excludes equivocal test results and missing values. 
 
 
Table 181 HCV antibody prevalence by last drug injected, duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Last drug injected No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Amphetamine (Speed, Ice) 8 0     (0) 46 20   (43) 54 20   (37) 
Heroin -- -- 19 15   (79) 19 15   (79) 
More than one -- -- 2 1   (50) 2 1   (50) 
Other/not reported -- -- -- -- -- -- 
     p value  --  0.03  0.007 
2007       
Amphetamine (Speed, Ice) 4 0     (0) 46 19   (41) 50 19   (38) 
Heroin 1 1 (100) 13 10   (77) 14 1   (79) 
More than one -- -- 2 2 (100) 2 2 (100) 
Other/not reported -- -- 6 5   (83) 6 5   (83) 
     p value  0.03  0.02  0.002 
2010       
Amphetamine (Speed, Ice) 4 1   (25) 36 17   (47) 40 18   (45) 
Heroin -- -- 18 15   (83) 18 15   (83) 
More than one -- -- 1 0     (0) 1 0     (0) 
Other/not reported -- -- 9 6   (67) 9 6   (67) 
     p value  --  0.04  0.03 
† Excludes equivocal test results and missing values. 
  
National Prison Entrants’ Bloodborne Virus & Risk Behaviour Survey 2004, 2007, and 2010 
Queensland 
 108 
Table 182 HCV antibody prevalence by frequency of injection last month, duration of drug injection 
and survey year† 
 <3 years IDU 3+ years IDU Total  
Frequency of drug injection 
last month 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Less than daily 2 0     (0) 9 7 (78) 11 7 (64) 
Daily or more 3 0     (0) 30 18 (60) 33 18 (55) 
p value  --  0.09  0.6 
2007       
Less than daily 1 0     (0) 13 6 (46) 14 6 (43) 
Daily or more 1 1 (100) 21 15 (71) 22 16 (73) 
p value  0.2  0.1  0.07 
2010       
Less than daily 2 1 (50) 9 4 (44) 11 5 (45) 
Daily or more -- -- 24 19 (79) 24 19 (79) 
p value  --  0.05  0.05 
† Excludes equivocal test results and missing values. 
 
 
Table 183 HCV antibody prevalence by re-use of someone else’s used needle and syringe last month, 
duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Re-used someone else’s used 
needle & syringe last month 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
No 5 0     (0) 28 16   (57) 33 16   (48) 
Yes 0 0     (0) 11 9   (82) 11 9   (82) 
p value  --  0.1  0.05 
2007       
No 2 1   (50) 25 12   (48) 27 13   (48) 
Yes -- -- 7 7 (100) 7 7 (100) 
p value  --  0.01  0.005 
2010       
No 1 0     (0) 27 19   (70) 28 19   (68) 
Yes 1 1 (100) 5 3   (60) 6 4   (67) 
p value  0.2  0.7  1.0 
† Excludes equivocal test results and missing values. 
 
 
Table 184 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey 
year† 
 <3 years IDU 3+ years IDU Total  
Imprisonment last year No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
No -- -- 1 1(100) 1 1(100) 
Yes 8 0   (0) 66 35  (53) 74 35  (47) 
p value  --  0.4  0.3 
2007       
No 2 0   (0) 24 9  (38) 26 9  (35) 
Yes 2 1 (50) 33 26  (79) 35 27  (77) 
p value  0.2  0.002  0.001 
2010       
No 1 0   (0) 20 9  (45) 21 9  (43) 
Yes 3 1 (33) 42 27  (64) 45 28  (62) 
p value  0.5  0.2  0.1 
† Excludes equivocal test results and missing values. 
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Table 185 HCV antibody by number of previous imprisonments, sex and survey year† 
 Male Female Total  
Number of previous 
imprisonments 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
1 5 1 (20) -- -- 5 1 (20) 
2 to 4 97 24 (25) -- -- 97 24 (25) 
5 to 9 20 10 (50) -- -- 20 10 (50) 
10 + 6 3 (50) -- -- 6 3 (50) 
p value  0.09  --  0.09 
2007       
1 40 0   (0) -- -- 40 0   (0) 
2 to 4 64 22 (34) -- -- 64 22 (34) 
5 to 9 17 11 (65) -- -- 17 11 (65) 
10 + 12 9 (75) -- -- 12 9 (75) 
p value  <0.001  --  <0.001 
2010       
1 78 4   (5) 17 5 (29) 95 9 (10) 
2 to 4 50 11 (22) 6 5 (83) 56 16 (29) 
5 to 9 17 9 (53) 3 1 (33) 20 10 (50) 
10 + 14 5 (36) 2 1 (50) 16 6 (38) 
p value  <0.001  0.1  <0.001 
† Excludes equivocal test results and missing values. 
 
 
Table 186 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Non-Indigenous 115 34 (30) -- -- 115 34 (30) 
Indigenous 14 4 (29) -- -- 14 4 (29) 
p value  0.9  --  0.9 
2007       
Non-Indigenous 116 36 (31) -- -- 116 36 (31) 
Indigenous 19 7 (37) -- -- 19 7 (37) 
p value  0.6  --  0.6 
2010       
Non-Indigenous 99 19 (19) 21 8 (38) 120 27 (23) 
Indigenous 61 10 (16) 7 4 (57) 68 14 (21) 
p value  0.7  0.4  0.8 
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Table 187 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector 
status and survey year† 
 Non-IDU IDU Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Non-Indigenous 48 2   (4) 67 32 (48) 115 34 (30) 
Indigenous 6 0   (0) 8 4 (50) 14 4 (29) 
p value  0.6  0.9  0.9 
2007       
Non-Indigenous 50 1   (2) 66 35 (53) 116 36 (31) 
Indigenous 8 1 (13) 11 6 (55) 19 7 (37) 
p value  0.1  0.9  0.6 
2010       
Non-Indigenous 68 0   (0) 52 27 (52) 120 27 (23) 
Indigenous 48 0   (0) 20 14 (70) 68 14 (21) 
p value  --  0.2  0.8 
† Excludes equivocal test results and missing values. 
 
 
Table 188 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and 
survey year† 
  Male Female Total  
Residential remoteness No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Highly accessible/accessible 123 37 (30)  -- -- 123 37 (30) 
Moderately accessible 1 0   (0)  -- -- 1 0   (0) 
Remote/very remote 3 1 (33)  -- -- 3 1 (33) 
p value    0.8   --  0.8 
2007       
Highly accessible/accessible 123 40 (33)  -- -- 123 40 (33) 
Moderately accessible 2 0   (0)  -- -- 2 0   (0) 
Remote/very remote 3 0   (0)  -- -- 3 0   (0) 
p value  0.6   --  0.6 
2010       
Highly accessible/accessible 118 26 (22) 24 11 (46) 142 37 (26) 
Moderately accessible 8 0   (0) 3 1 (33) 11 1   (9) 
Remote/very remote 23 0   (0) 1 0   (0) 24 0   (0) 
p value  0.02  0.6  0.01 
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Table 189 HCV antibody prevalence by region/country of birth, sex and survey year† 
 Male Female Total  
Region/Country of birth No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Australia 104 34   (33) -- -- 104 34   (33) 
Other Oceania 15 2   (13) -- -- 15 2   (13) 
Asia 3 2   (67) -- -- 3 2   (67) 
UK & Ireland 3 0     (0) -- -- 3 0     (0) 
Other 4 0     (0) -- -- 4 0     (0) 
p value  0.1  --  0.1 
2007       
Australia 124 38   (31) -- -- 124 38   (31) 
Other Oceania 2 1   (50) -- -- 2 1   (50) 
Asia 6 4   (67) -- -- 6 4   (67) 
UK & Ireland -- -- -- -- -- -- 
Other 3 0     (0) -- -- 3 0     (0) 
p value  0.2  --  0.2 
2010       
Australia 143 26   (18) 23 10   (43) 166 36   (22) 
Other Oceania 11 2   (18) 2 0     (0) 13 2   (15) 
Asia 1 1 (100) -- -- 1 1 (100) 
UK & Ireland 1 0     (0) 1 1 (100) 2 1   (50) 
Other 4 0     (0) 2 1   (50) 6 1   (17) 
p value  0.2  0.4  0.3 
† Excludes equivocal test results and missing values. 
 
 
Table 190 HCV antibody prevalence by main language spoken at home by parents, sex and survey 
year† 
 Male Female Total  
Main language spoken at 
home by parents 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
English  121 36 (30) -- -- 121 36 (30) 
Non-English  8 2 (25) -- -- 8 2 (25) 
p value  0.8  --  0.8 
2007       
English  128 40 (31) -- -- 128 40 (31) 
Non-English  7 3 (43) -- -- 7 3 (43) 
p value  0.5  --  0.5 
2010       
English  153 28 (18) 26 11 (42) 179 39 (22) 
Non-English  5 1 (20) 2 1 (50) 7 2 (29) 
p value  0.8  0.8  0.7 
† Excludes equivocal test results and missing values. 
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Table 191 Self-reported HCV status versus HCV serology by sex and survey year† 
 Male Female Total  
Self-report HCV No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Positive 29 29 (100) -- -- 29 29 (100) 
Negative 61 5     (8) -- -- 61 5     (8) 
Not sure 4 2   (50) -- -- 4 2   (50) 
p value  <0.001  --  <0.001 
2007       
Positive 30 27  (90) -- -- 30 27   (90) 
Negative 80 11  (14) -- -- 80 11   (14) 
Not sure 7 4  (57) -- -- 7 4   (57) 
p value  <0.001  --  <0.001 
2010       
Positive 16 16 (100) 12 12 (100) 28 28 (100) 
Negative 87 6     (7) 9 0     (0) 96 6     (6) 
Not sure 18 6   (33) -- -- 18 6   (33) 
p value  <0.001  <0.001  <0.001 





Table 192 HBV surface-antigen prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
IDU 77 3 (4) -- -- 77 3 (4) 
Non-IDU 54 0 (0) -- -- 54 0 (0) 
p value  0.1  --  0.1 
2007       
IDU 78 1 (1) -- -- 78 1 (1) 
Non-IDU 59 0 (0) -- -- 59 0 (0) 
p value  0.4  --  0.4 
2010       
IDU 58 0 (0) 14 0 (0) 72 0 (0) 
Non-IDU 93 2 (2) 14 0 (0) 107 2 (2) 
p value  0.3  --  0.2 
† Excludes equivocal test results and missing values. 
 
 
Table 193 HBV core-antibody prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
IDU 74 12 (16) -- -- 74 12 (16) 
Non-IDU 54 5   (9) -- -- 54 5   (9) 
p value  0.3  --  0.3 
2007       
IDU 78 8 (10) -- -- 78 8 (10) 
Non-IDU 59 4   (7) -- -- 59 4   (7) 
p value  0.5  --  0.5 
2010       
IDU 32 6 (19) 1 0 (0) 33 6 (18) 
Non-IDU 48 8 (17) 1 0 (0) 49 8 (16) 
p value  0.8  --  0.8 
† Excludes equivocal test results and missing values. 
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Table 194 HBV core-antibody prevalence by sexual identity, sex and survey year† 
 Male Female Total  
Sexual identity No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Heterosexual 126 17 (13) -- -- 126 17 (13) 
Bisexual 2 0   (0) -- -- 2 0   (0) 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value  0.6  --  0.6 
2007       
Heterosexual 136 12   (9) -- -- 136 12   (9) 
Bisexual -- -- -- -- -- -- 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value  --  --  -- 
2010       
Heterosexual 78 14 (18) 2 0 (0) 80 14 (18) 
Bisexual 1 0   (0) -- -- 1 0   (0) 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value  0.6  --  0.7 
† Excludes equivocal test results and missing values. 
 
 
Table 195 HBV core-antibody prevalence by age group, sex and survey year† 
 Male Female Total  
Age group No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
< 20 years 12 1   (8) -- -- 12 1   (8) 
20 – 24 26 1   (4) -- -- 26 1   (4) 
25 – 29 24 3 (13) -- -- 24 3 (13) 
30 + years 66 12 (18) -- -- 66 12 (18) 
p value  0.3  --  0.3 
2007       
< 20 years 13 2 (15) -- -- 13 2 (15) 
20 – 24 33 1   (3) -- -- 33 1   (3) 
25 – 29 36 4 (11) -- -- 36 4 (11) 
30 + years 55 5   (9) -- -- 55 5   (9) 
p value  0.5  --  0.5 
2010       
< 20 years 13 0   (0) -- -- 13 0   (0) 
20 – 24 19 1   (5) -- -- 19 1   (5) 
25 – 29 12 2 (17) -- -- 12 2 (17) 
30 + years 36 11 (31) 2 0 (0) 38 11 (29) 
p value  0.03  --  0.04 
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Table 196 HBV core-antibody prevalence by duration of drug injection, sex and survey year† 
 Male Female Total  
Duration of drug injection No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
<3 years 9 1 (11) -- -- 9 1 (11) 
3 to 5 years 9 0   (0) -- -- 9 0   (0) 
6 to 10 years 22 2   (9) -- -- 22 2   (9) 
10 + years 34 9 (26) -- -- 34 9 (26) 
p value  0.1  --  0.1 
2007       
<3 years 5 1 (20) -- -- 5 1 (20) 
3 to 5 years 10 0   (0) -- -- 10 0   (0) 
6 to 10 years 23 2   (9) -- -- 23 2   (9) 
10 + years 35 3   (9) -- -- 35 3   (9) 
p value  0.6  --  0.6 
2010       
<3 years 1 0   (0) -- -- 1 0   (0) 
3 to 5 years 4 0   (0) -- -- 4 0   (0) 
6 to 10 years 7 1 (14) -- -- 7 1 (14) 
10 + years 19 5 (26) 1 0 (0) 20 5 (25) 
p value  0.6  --  0.6 
† Excludes equivocal test results and missing values. 
 
 
Table 197 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey 
year† 
 <3 years IDU 3+ years IDU Total  
Last drug injected No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Amphetamine (Speed, Ice) 9 1 (11) 46 7 (15) 55 8 (15) 
Heroin -- -- 17 4 (24) 17 4 (24) 
More than one -- -- 2 0   (0) 2 0   (0) 
Other/not reported -- -- -- -- -- -- 
     p value  --  0.6  0.6 
2007       
Amphetamine (Speed, Ice) 4 1 (25) 47 4   (9) 51 5 (10) 
Heroin 1 0   (0) 13 0   (0) 14 0   (0) 
More than one -- -- 2 0   (0) 2 0   (0) 
Other/not reported -- -- 6 1 (17) 6 1 (17) 
     p value  0.6  0.6  0.5 
2010       
Amphetamine (Speed, Ice) 1 0   (0) 19 2 (11) 20 2 (10) 
Heroin -- -- 8 4 (50) 8 4 (50) 
More than one -- -- -- -- -- -- 
Other/not reported -- -- 4 0   (0) 4 0   (0) 
     p value  --  0.04  0.03 
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Table 198 HBV core-antibody prevalence by frequency of injection last month, duration of drug 
injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Frequency of drug injection 
last month 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Less than daily 2 0   (0) 9 5 (56) 11 5 (45) 
Daily or more 4 0   (0) 29 4 (14) 33 4 (12) 
p value  --  0.01  0.01 
2007       
Less than daily 1 0   (0) 13 2 (15) 14 2 (14) 
Daily or more 1 0   (0) 21 1   (5) 22 1   (5) 
p value  --  0.3  0.3 
2010       
Less than daily -- -- 6 0   (0) 6 0   (0) 
Daily or more -- -- 12 4 (33) 12 4 (33) 
p value  --  0.1  0.1 
† Excludes equivocal test results and missing values. 
 
 
Table 199 HBV core antibody prevalence by re-use of someone else’s used needle and syringe last 
month, duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Re-used someone else’s used 
needle & syringe last month 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
No 6 0 (0) 27 6 (22) 33 6 (18) 
Yes 0 0 (0) 11 3 (27) 11 3 (27) 
p value  --  0.7  0.5 
2007       
No 2 0 (0) 25 3 (12) 27 3 (11) 
Yes -- -- 7 0   (0) 7 0   (0) 
p value  --  0.3  0.4 
2010       
No -- -- 15 3 (20) 15 3 (20) 
Yes -- -- 2 0   (0) 2 0   (0) 
p value  --  0.5  0.5 
† Excludes equivocal test results and missing values. 
 
 
Table 200 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and 
survey year† 
 <3 years IDU 3+ years IDU Total  
Imprisonment last year No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
No -- -- 1 1(100) 1 1(100) 
Yes 9 1 (11) 64 11  (17) 73 12  (16) 
p value  --  0.7  0.4 
2007       
No 2 1 (50) 25 3  (12) 27 4  (15) 
Yes 2 0   (0) 33 2    (6) 35 2    (6) 
p value  0.3  0.4  0.2 
2010       
No -- -- 11 4  (36) 11 4  (36) 
Yes 1 0 (0) 19 2  (11) 20 2  (10) 
p value  --  0.1  0.1 
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Table 201 HBV core-antibody by number of previous imprisonments, sex and survey year† 
 Male Female Total  
Number of previous 
imprisonments 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
1 5 0   (0) -- -- 5 0   (0) 
2 to 4 96 12 (13) -- -- 96 12 (13) 
5 to 9 20 4 (20) -- -- 20 4 (20) 
10 + 6 1 (17) -- -- 6 1 (17) 
p value  0.7  --  0.7 
2007       
1 40 2   (5) -- -- 40 2   (5) 
2 to 4 66 10 (15) -- -- 66 10 (15) 
5 to 9 17 0   (0) -- -- 17 0   (0) 
10 + 12 0   (0) -- -- 12 0   (0) 
p value  0.08  --  0.08 
2010       
1 32 2   (6) 1 0 (0) 33 2   (6) 
2 to 4 31 6 (19) 1 0 (0) 32 6 (19) 
5 to 9 8 4 (50) -- -- 8 4 (50) 
10 + 8 2 (25) -- -- 8 2 (25) 
p value  0.03  --  0.03 
† Excludes equivocal test results and missing values. 
 
 
Table 202 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Non-Indigenous 114 15 (13) -- -- 114 15 (13) 
Indigenous 14 2 (14) -- -- 14 2 (14) 
p value  0.9  --  0.9 
2007       
Non-Indigenous 117 7   (6) -- -- 117 7   (6) 
Indigenous 20 5 (25) -- -- 20 5 (25) 
p value  0.005  --  0.005 
2010       
Non-Indigenous 47 4   (9) 1 0 (0) 48 4   (8) 
Indigenous 33 10 (30) 1 0 (0) 34 10 (29) 
p value  0.01  --  0.01 
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Table 203 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector 
status and survey year† 
 Non-IDU IDU Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Non-Indigenous 48 5 (10) 66 10 (15) 114 15 (13) 
Indigenous 6 0   (0) 8 2 (25) 14 2 (14) 
p value  0.7  0.5  0.9 
2007       
Non-Indigenous 50 1   (2) 67 6   (9) 117 7   (6) 
Indigenous 9 3 (33) 11 2 (18) 20 5 (25) 
p value  0.001  0.4  0.005 
2010       
Non-Indigenous 24 0   (0) 24 4 (17) 48 4   (8) 
Indigenous 25 8 (32) 9 2 (22) 34 10 (29) 
p value  0.002  0.7  0.01 
† Excludes equivocal test results and missing values. 
 
 
Table 204 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before 
prison and survey year† 
  Male Female Total  
Residential remoteness No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Highly accessible/accessible 122 15 (12) -- -- 122 15 (12) 
Moderately accessible 1 0   (0) -- -- 1 0   (0) 
Remote/very remote 3 2 (67) -- -- 3 2 (67) 
p value  0.02  --  0.02 
2007       
Highly accessible/accessible 125 9   (7) -- -- 125 9   (7) 
Moderately accessible 2 0   (0) -- -- 2 0   (0) 
Remote/very remote 3 1 (33) -- -- 3 1 (33) 
p value  0.2  --  0.2 
2010       
Highly accessible/accessible 60 7 (12) 2 0 (0) 62 7 (11) 
Moderately accessible 2 0   (0) -- -- 2 0   (0) 
Remote/very remote 11 5 (45) -- -- 11 5 (46) 
p value  0.02  --  0.01 
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Table 205 HBV core-antibody prevalence by region/country of birth, sex and survey year† 
 Male Female Total  
Region/Country of birth No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Australia 103 12  (12) -- -- 103 12  (12) 
Other Oceania 15 2  (13) -- -- 15 2  (13) 
Asia 3 2  (67) -- -- 3 2  (67) 
UK & Ireland 3 0    (0) -- -- 3 0    (0) 
Other 4 1  (25) -- -- 4 1  (25) 
p value  0.07  --  0.07 
2007       
Australia 126 11    (9) -- -- 126 11    (9) 
Other Oceania 2 1  (50) -- -- 2 1  (50) 
Asia 6 0    (0) -- -- 6 0    (0) 
UK & Ireland -- -- -- -- -- -- 
Other 3 0    (0) -- -- 3 0    (0) 
p value  0.2  --    0.2 
2010       
Australia 72 13  (18) 2 0 (0) 74 13  (18) 
Other Oceania 4 0    (0) -- -- 4 0    (0) 
Asia 1 1(100) -- -- 1 1(100) 
UK & Ireland -- -- -- -- -- -- 
Other 3 0    (0) -- -- 3 0    (0) 
p value  0.1  --  0.1 
† Excludes equivocal test results and missing values. 
 
 
Table 206 HBV core-antibody prevalence by main language spoken at home by parents, sex and 
survey year† 
 Male Female Total  
Main language spoken at 
home by parents 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
English  120 14 (12) -- -- 120 14 (12) 
Non-English  8 3 (38) -- -- 8 3 (38) 
p value  0.04  --  0.04 
2007       
English  130 11   (8) -- -- 130 11   (8) 
Non-English  7 1 (14) -- -- 7 1 (14) 
p value  0.6  --  0.6 
2010       
English  77 14 (18) 2 0 (0) 79 14 (18) 
Non-English  3 0   (0) -- -- 3 0   (0) 
p value  0.4  --  0.4 
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Table 207 Hepatitis B virus immune status by injector status and survey year† 
  Hepatitis B Virus Immune Status 
Injector status No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
IDU 77 29 (38) 10 (13) 3 (4) 35 (45) 
Non-IDU 54 35 (65) 5   (9) 0 (0) 14 (26) 
p value     0.02 
2007      
IDU 78 30 (38) 8 (10) 1 (1) 39 (50) 
Non-IDU 59 38 (64) 4   (7) 0 (0) 17 (29) 
p value     0.02 
2010      
IDU 43 6 (14) 6 (14) 0 (0) 31 (72) 
Non-IDU 64 10 (16) 8 (13) 2 (3) 44 (69) 
p value     0.7 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 208 Hepatitis B virus immune status by sexual identity and survey year† 
  Hepatitis B Virus Immune Status 
Sexual identity No tested No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
Heterosexual  129 62   (48) 15 (12) 3 (2) 49 (38) 
Bisexual 2 2 (100) 0   (0) 0 (0) 0   (0) 
Homosexual -- -- -- -- -- 
Unsure -- -- -- -- -- 
p value     -- 
2007      
Heterosexual  136 68   (50) 12   (9) 0 (0) 56 (41) 
Homosexual --  -- -- -- -- 
Bisexual -- -- -- -- -- 
Unsure -- -- -- -- -- 
p value     -- 
2010      
Heterosexual  102 13  (13) 14 (14) 2 (2) 73 (72) 
Homosexual -- -- -- -- -- 
Bisexual 3 1  (33) 0 (0) 0 (0) 2 (67) 
Unsure -- -- -- -- -- 
p value     0.7 
† Excludes equivocal test results and missing values.   
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Table 209 Hepatitis B virus immune status by age group and survey year† 
  Hepatitis B Virus Immune Status 
Age group No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
< 20 years 12 5 (42) 0   (0) 1 (8) 6 (50) 
20 – 24 28 12 (43) 2   (7) 0 (0) 14 (50) 
25 – 29 24 9 (38) 2   (8) 1 (4) 12 (50) 
30 + years 67 38 (57) 11 (16) 1 (1) 17 (25) 
p value     0.1 
2007      
< 20 years 13 8 (62) 2 (15) 0 (0) 3 (23) 
20 – 24 33 11 (33) 1   (3) 0 (0) 21 (64)  
25 – 29 36 18 (50) 4 (11) 0 (0) 14 (39) 
30 + years 55 31 (53) 5   (9) 1 (2) 18 (33) 
p value     0.2 
2010      
< 20 years 17 5 (29) 0   (0) 0 (0) 12 (71) 
20 – 24 19 2 (11) 1   (5) 0 (0) 16 (84) 
25 – 29 21 3 (14) 2 (10) 1 (5) 15 (71) 
30 + years 50 6 (12) 11 (22) 1 (2) 32 (64) 
p value     0.2 
† Excludes equivocal test results and missing values.  
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.   
 
 
Table 210 Hepatitis B virus immune status by number of previous imprisonments and survey year† 




No tested No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
1 5 4 (80) 0   (0) 0   (0) 1 (20) 
2 to 4 98 50 (51) 12 (12) 2   (2) 34 (35) 
5 to 9 21 6 (29) 3 (14) 0   (0) 12 (57) 
10 + 6 3 (50) 0   (0) 1 (17) 2 (33) 
p value     0.2 
2007      
1 40 31 (78) 2   (5) 0   (0) 7 (18) 
2 to 4 66 26 (39) 10 (15) 1   (2) 29 (44) 
5 to 9 17 7 (41) 0   (0) 0   (0) 10 (59) 
10 + 12 3 (25) 0   (0) 0   (0) 9 (75) 
p value     <0.01 
2010      
1 46 10 (22) 2   (4) 0  (0) 34 (74) 
2 to 4 35 4 (11) 6 (17) 1  (3) 24 (69) 
5 to 9 12 2 (17) 4 (33) 0  (0) 6 (50) 
10 + 13 0   (0) 2 (15) 1  (8) 10 (77) 
p value     0.1 
† Excludes equivocal test results and missing values.   
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Table 211 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey 
year† 






No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
Non-Indigenous 117 60 (51) 13 (11) 3 (3) 41 (35) 
Indigenous 14 4 (29) 2 (14) 0 (0) 8 (57) 
p value     0.3 
2007      
Non-Indigenous 117 61 (52) 7   (6) 0 (0) 49 (42) 
Indigenous 20 7 (35) 5 (25) 1 (5) 7 (35) 
p value     <0.01 
2010      
Non-Indigenous 59 11 (19) 4   (7) 0 (0) 44 (75) 
Indigenous 48 5 (10) 10 (21) 2 (4) 31 (65) 
p value     <0.01 
† Excludes equivocal test results and missing values.  
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 212 Hepatitis B virus immune status by residential remoteness and survey year† 
  Hepatitis B Virus Immune Status 
Residential remoteness No 
tested 
No (%) with no 
evidence of 
HBV immunity 






No (%) vaccine 
conferred 
immunity* 
2004      
Highly accessible/accessible 125 62  (50) 13 (10) 3  (2) 47 (38) 
Moderately accessible 1 1(100) 0   (0) 0  (0) 0   (0) 
Remote/very remote 3 0    (0) 2 (67) 0  (0) 1 (33) 
p value     0.1 
2007      
Highly accessible/accessible 125 61  (49) 9   (7) 1  (1) 54 (43) 
Moderately accessible 2 2(100) 0   (0) 0  (0) 0   (0) 
Remote/very remote 3 1  (33) 1 (33) 0  (0) 1 (33) 
p value     0.6 
2010      
Highly accessible/accessible 78 12  (15) 7   (9) 0  (0) 59 (76) 
Moderately accessible 7 2  (29) 0   (0) 1(14) 4 (57) 
Remote/very remote 22 8  (36) 1   (5) 1  (5) 12 (55) 
p value     <0.01 
† Excludes equivocal test results and missing values.  
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Table 213 Hepatitis B virus immune status by main language spoken at home by parents and survey 
year† 
  Hepatitis B Virus Immune Status 
Main language 




No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
English  123 62 (50) 13 (11) 2   (2) 46  (37) 
Non-English  8 2 (25) 2 (25) 1 (13) 3  (38) 
p value     0.1 
2007      
English  130 65 (50) 11   (8) 1   (1) 53  (42) 
Non-English 7 3 (43) 1 (14) 0   (0) 3  (43) 
p value     0.4 
2010      
English  102 16 (16) 14 (14) 2   (2) 70  (69) 
Non-English 4 0   (0) 0   (0) 0   (0) 4(100) 
p value     0.6 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 214 Self-reported hepatitis B immunisation versus serological testing and survey year*  
 Male Female Total  
Self-report HBV 
immunisation** 
No tested No immune 
(%) 
No tested No immune 
(%) 
No tested No immune 
(%) 
2004       
No 32 4 (13) -- -- 32 4 (13) 
Yes 81 45 (56) -- -- 81 45 (56) 
Not sure -- -- -- -- -- -- 
p value  <0.001  --  <0.001 
2007       
No 26 3 (12) -- -- 26 3 (12) 
Yes 88 52 (59) -- -- 88 52 (59) 
Not sure 10 1 (10) -- -- 10 1 (10) 
p value  <0.001  --  <0.001 
2010       
No 6 1 (17) 1 0   (0) 7 1 (14) 
Yes 69 65 (94) 11 6 (55) 80 71 (89) 
Not sure 4 3 (75) -- -- 4 3 (75) 
p value  <0.001  0.3  <0.001 
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  




National Prison Entrants’ Bloodborne Virus & Risk Behaviour Survey 2004, 2007, and 2010 
Queensland 
123        
Chlamydia 
 
Table 215 Genital chlamydia prevalence by sex and survey year† 
Sex  No tested No with 
chlamydia (%) 
2010   
Male  158 10 (6) 
Female 31 0 (0) 
p value  0.2 




Table 216 Genital gonorrhoea prevalence by sex and survey year† 
Sex  No tested No with 
gonorrhoea (%) 
2010   
Male  158 2 (1) 
Female 31 0 (0) 
p value  0.5 




Table 217 Syphilis markers by sex and survey year† 








No with any 
marker for 
syphilis (%) 
2010     
Male  161 15 (9) 7 (4) 15 (9) 
Female 29 2 (7) 1 (3) 2 (7) 
p value  0.7 0.9 0.7 
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South Australia  
2010 
Table 218 Number (%) of respondents by demographic characteristics, injector status and survey year  
 2010 
Demographic characteristics IDU Non-IDU 
Number of sites surveyed N = 4 
No surveyed N = 27 N = 29 
Sex (%)   
Male 19 (70) 24 (83) 
Female 8 (30) 5 (17) 
Transgender -- -- 
Sexual identity (%)   
Heterosexual 24 (89) 27 (93) 
Bisexual 2   (7) 1   (3) 
Homosexual 1   (4) -- 
Unsure -- -- 
Not reported -- 1   (3) 
Age and duration of injection (years)  
Median age (years) 32 37 
    Age range 20 – 45 19 – 80 
Age group (%)   
    <25 years 5 (19) 10 (34) 
    25+ years 22 (81) 19 (66) 
    Not reported -- -- 
Median age 1stIDU (years) 16 -- 
    Age range 10 – 35 -- 
    Not reported 2 -- 
Median years IDU 13 -- 
    Range <1 – 30 -- 
Duration of drug injection (%)  
    <3 years 1   (4) -- 
    3+ years 24 (89) -- 
    Not reported 2   (7) -- 
Aboriginal and Torres Strait Islander origin (%) 
No 19 (70) 17 (59) 
Yes 8 (30) 12 (41) 
Not reported -- -- 
Living situation prior to prison (%)*  
Not homeless 21 (78) 20 (69) 
Primary homelessness -- 2   (7) 
Secondary homelessness 2   (7) 5 (17) 
Tertiary homelessness 4 (15) 2   (7) 
Not reported -- -- 
Residential remoteness in 12 months before prison (%) 
 Highly accessible/accessible 24 (89) 22 (76) 
Moderately accessible -- 2   (7) 
Remote/very remote 1   (4) 4 (14) 
Not reported 2   (7) 1   (3) 
Region/Country of birth (%)  
Australia 25 (93) 28 (97) 
Other Oceania -- 1   (3) 
Asia 2   (7) -- 
UK & Ireland -- -- 
Other -- -- 
Not reported -- -- 
Main language spoke at home by parents (%) 
English  26 (96) 25 (86) 
Non-English  1   (4) 2   (7) 
Not reported -- 2   (7) 
* Not homeless (private rental, home owner/purchaser, public/community housing, drug and alcohol treatment facility, workers’ 
accommodation, prison, nursing home, foster home); Primary homelessness (Sleeping rough, squat, long grass, boat, car); 
Secondary homelessness (Living with parent, siblings, or relatives, crisis accommodation); Tertiary homelessness (Boarding house, 
hostel, caravan park, backpackers, hotel, motel). Living situation question introduced in 2010. 
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Table 218 Number (%) of respondents by demographic characteristics, injector status and survey year 
(cont.) 
 2010 
Demographic characteristics IDU Non-IDU 
 
* Smoking questions not asked in 2004. 
** Other drugs used in the past month not asked in 2004 and 2007. More  
    than one option could be selected. 
  
First time in prison (%)   
No 24 (89) 21 (72) 
Yes 3 (11) 8 (28) 
Not reported -- -- 
Lifetime imprisonments (%)   
One 7 (26) 19 (66) 
Two to four  11 (41) 5 (17) 
Five to nine   5 (19) 4 (14) 
Ten or more  4 (15) 1   (3) 
Not reported -- -- 
Imprisonment in last year (%)   
No 13 (48) 12 (41) 
Yes 12 (44) 11 (38) 
Not reported 2   (7) 6 (21) 
Frequency of injection last month (%)  
Not last month 16 (59) -- 
Less than weekly 4 (15) -- 
Weekly not daily 2   (7) -- 
Daily or more 5 (19) -- 
Not reported -- -- 
Ever smoked a full cigarette (%)*  
No 1   (4) 1   (3) 
Yes 26 (96) 28 (97) 
Not reported -- -- 
Median age first smoked (years) 13 14 
    Age range 8 – 20 6 – 20 
Current smoker (%)*   
No 1 (4) 4 (14) 
Yes 26 (96) 24 (83) 
Not reported -- 1   (3) 
Smoking frequency (%)*   
Occasional – weekly or less 1   (4) 2   (8) 
5 to 10 cigarettes a day 7 (27) 8 (33) 
11 to 20 cigarettes a day 10 (38) 11 (46) 
Over 20 cigarettes a day 8 (31) 3 (13) 
Not reported -- -- 
Other drugs used last month (%)**  
No drugs in past 4 weeks 5 (19) 7 (29) 
Cannabis 18 (82) 14 (78) 
Heroin 4 (18) 1   (6) 
Cocaine 3 (14) -- 
Amphetamine 14 (64) 5 (28) 
Other's methadone -- -- 
Other opiates 2   (9) -- 
Other's buprenorphine 4 (18) -- 
Steroids 1   (5) -- 
Hallucinogens 1   (5) 2 (11) 
Benzodiazepines 4 (18) 3 (17) 
Ecstasy/MDA 3 (14) 2 (11) 
Inhalants (e.g. petrol) 1   (5) -- 
Other drug -- -- 
Not reported -- 5 (17) 
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Table 219 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to 
survey and survey year 
Injecting behaviour 2010 
Last drug injected (%) N = 27 
Amphetamine (Speed, Ice) 19 (70) 
Anabolic steroids 1   (4) 
Cocaine -- 
Heroin 6 (22) 
Heroin + amphetamine -- 
Heroin + cocaine -- 
Methadone 1   (4) 
Morphine -- 
Other -- 
Not reported -- 
No Injected last month N = 11 
Places injected last month (%)* 
Prison -- 
Own home 7 (64) 
Friend’s home 3 (27) 
Dealer’s home 1   (9) 
Street, park, beach 1   (9) 
Car 3 (27) 
Public toilet 1   (9) 
Commercial injecting room -- 
Medically Supervised Injecting Centre, Sydney -- 
Squat -- 
Other place -- 
Use of sterile needles & syringes last month (%) 
All injections 10 (91) 
Most of the time 1   (9) 
Half of the time -- 
Some of the time -- 
Not last month -- 
Not reported -- 
Re-used someone else’s used needle & syringe last month (%) 
None 10 (91) 
Once 1   (9) 
Twice -- 
3-5 times -- 
>5 times -- 
Not reported -- 
Number of people needle & syringe was re-used after last month (%) 
None 10 (91) 
One -- 
Two 1   (9) 
Three to five -- 
More than five -- 
Don’t know how many -- 
Not reported -- 
Relationship to people needle & syringe was re-used after last month (%)*  
Regular sex partner -- 
Casual sex partner -- 
Close friend 1   (9) 
Acquaintance -- 
Other -- 
Equipment used after someone else last month (%)*  
Spoon 1   (9) 
Water -- 
Filter -- 
Tourniquet 1   (9) 
Drug mix -- 
* More than one option could be selected.    
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Table 220 Number (%) of respondents by treatment for drug use, injector status and survey year 
Treatment for drug use 2010 
 IDU Non-IDU 
No surveyed N = 27 N = 29 
Any treatment/therapy for drug use (%) 
No 14 (52) 24 (83) 
Yes 13 (48) 4 (14) 
Not reported -- 1   (3) 
History of methadone maintenance treatment (%) 
Currently 4 (15) -- 
Previously 7 (26) 1   (3) 
Never 16 (59) 27 (93) 
Not reported -- 1   (3) 
History of other pharmacotherapy treatment (%) 
Currently 2   (7) -- 
Previously 5 (19) -- 
Never 20 (74) 28 (97) 
Not reported -- 1   (3) 
 
 
Table 221 Number (%) of respondents by site of needle and syringe acquisition last month and survey 
year 
Needle & Syringe acquisition* 2010 
No surveyed N = 27 
From an NSP last month (%) 
Daily or almost daily 2   (7) 
A couple of times each week 1   (4) 
Less than weekly 2   (7) 
Weekly 3 (11) 
Once last month -- 
Not in the last month 18 (67) 
Not reported 1   (4) 
From a chemist last month (%) 
Daily or almost daily 1   (4) 
A couple of times each week 1   (4) 
Less than weekly 3 (11) 
Weekly 1   (4) 
Once last month -- 
Not in the last month 20 (74) 
Not reported 1   (4) 
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Table 222 Number (%) of respondents by body piercing and tattoos 
Body piercing and tattoos 2010 
 IDU Non-IDU 
No surveyed N = 27 N = 29 
Body or ear piercings (%)   
No 13 (48) 18 (62) 
Yes 13 (48) 11 (38) 
Not reported 1   (4) -- 
Pierced in past 12 mths (%)   
No 8 (57) 10 (91) 
Yes 2 (14) -- 
Not reported 4 (29) 1   (9) 
Who did piercing (%)* 
Chemist/hairdresser/beauty 
salon  
1 (50) -- 
Professional piercer / studio 1 (50) -- 
Tattooist / parlour -- -- 
Friend -- -- 
Prison inmate -- -- 
Self -- -- 
Family member -- -- 
Other -- -- 
Needle used by other (%)   
No  -- -- 
Yes -- -- 
Unsure -- -- 
Not reported -- 2 (100) 
Tattoos (%)   
No 8 (30) 17 (59) 
Yes 18 (67) 12 (41) 
Not reported 1   (4) -- 
Tattoos in past 12 mths (%)   
No  14 (78) 10 (83) 
Yes 3 (17) 2 (17) 
Not reported 1   (5) -- 
Who did tattooing (%)*   
Professional tattooist 3 (100) 2 (100) 
Friend -- -- 
Prison inmate -- -- 
Self -- -- 
Family member -- -- 
Other -- -- 
* More than one option could be selected.  
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Table 223 Number (%) of respondents by sexual behaviour, injector status and survey year 
Sexual behaviour 2010 
 IDU Non-IDU 
No surveyed N = 27 N = 29 
Sex last 3 months (%)    
No 3 (11) 3 (10) 
Yes 24 (89) 24 (83) 
Not reported -- 2   (7) 
Male sex partners in last 3 months 
    Median 1 1 
    Range 0 – 2 0 – 1 
Female sex partners in last 3 months 
    Median 1 1 
    Range 0 – 11 0 – 6 
Condom use last sex - regular male partners - last 
3 months (%) 
No 5 (83) 2 (67) 
Yes -- -- 
Not reported 1 (17) 1 (33) 
Condom use last sex - casual male partners - last 3 
months (%) 
No 2 (100) -- 
Sometimes -- -- 
Always -- -- 
Condom use last sex - regular female partners - 
last 3 months (%) 
No 12 (75) 16 (84) 
Sometimes 4 (25) 3 (16) 
Always -- -- 
Condom use last sex - casual female partners - 
last 3 months (%) 
No 2 (67) 6 (100) 
Sometimes -- -- 
Always 1 (33) -- 
Sex work last month (%)  
No 26 (96) 26 (90) 
Yes 1   (4) -- 
Not reported -- 3 (10) 
Condom used at last sex work last month (%) 
No -- -- 
Yes 1 (100) -- 
Not reported -- -- 
Ever had cervical cancer vaccine (women only)*** 
(%) 
No  2 (40) 1 (33) 
Yes 3 (60) 2 (67) 
Unsure -- -- 
***Proportion of eligible women i.e. those under 27 years of age in 2007.   
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Table 224 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, 
HBV vaccination and HCV treatment by injector status and survey year 
Testing & treatment 2010 
 IDU Non-IDU 
No surveyed N = 27 N = 29 
Previous HIV test (%)   
Yes, last year 14 (52) 6 (21) 
>1 year ago 5 (19) 7 (24) 
Never tested 8 (30) 14 (48) 
Not reported -- -- 
HBV infection (%)  
No 25 (93) 23 (79) 
Yes 2   (7) -- 
Don’t know -- 5 (17) 
Not reported -- 1   (3) 
HBV vaccination (%)*   
No 8 (30) 11 (38) 
Yes 17 (63) 11 (38) 
Don’t know 2   (7) 6 (21) 
Not reported -- 1   (3) 
Previous HCV test (%)   
Yes, last year 13 (48) 7 (24) 
>1 year ago 7 (26) 4 (14) 
Never tested 6 (22) 16 (55) 
Unsure -- -- 
Not reported 1   (4) 2   (7) 
Any HCV treatment (%)** N = 6  N = 1 
Interferon -- -- 
Interferon & Ribavirin -- -- 
Pegasys & Ribavirin -- -- 
Other -- -- 
No treatment 6 (100) 1 (100) 
Not reported -- -- 
Current HCV treatment    
Interferon -- -- 
Interferon & Ribavirin -- -- 
Pegasys & Ribavirin -- -- 
Other -- -- 
* Number (%) among participants with no history of HBV infection. 
** Number (%) of those testing positive for hepatitis C antibodies. 
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HIV antibody prevalence 
Table 225 HIV antibody prevalence by sex, injector status and survey year† 
 Male Female Total 
Injector status No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
2010       
IDU 11 0 (0) 4 0 (0) 15 0 (0) 
Non-IDU 18 0 (0) 3 0 (0) 21 0 (0) 
p value  --  --  -- 




HCV antibody prevalence 
Table 226 HCV antibody prevalence by sex, injector status and survey year† 
 Male Female Total 
Injector status No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
IDU 10 4 (40) 4 2 (50) 14 6 (43) 
Non-IDU 16 1   (6) 3 0   (0) 19 1   (5) 
p value  0.03  0.2  <0.01 
† Excludes equivocal test results and missing values. 
 
 
Table 227 HCV antibody prevalence by sexual identity, sex and survey year† 
  Male Female Total  
Sexual identity No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
Heterosexual 25 5 (20) 3 0     (0) 28 5   (18) 
Bisexual -- -- 3 1   (33) 3 1   (33) 
Homosexual -- -- 1 1 (100) 1 1 (100) 
Unsure -- -- -- -- -- -- 
p value  --  0.2  0.1 
† Excludes equivocal test results and missing values. 
 
 
Table 228 HCV antibody prevalence by age group, sex and survey year† 
 Male Female Total  
Age group N
o tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
< 20 years 1 0   (0) -- -- 1 0   (0) 
20 – 24 6 0   (0) 1 0   (0) 7 0   (0) 
25 – 29 5 1 (20) 2 0   (0) 7 1 (14) 
30 + years 14 4 (29) 4 2 (50) 18 6 (33) 
p value  0.5  0.4  0.3 
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Table 229 HCV antibody prevalence by duration of drug injection, sex and survey year† 
 Male Female Total  
Duration of drug injection No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
<3 years 1 0   (0) -- -- 1 0   (0) 
3 to 5 years 1 0   (0) 1 0     (0) 2 0   (0) 
6 to 10 years 1 0   (0) 1 0     (0) 2 0   (0) 
10 + years 6 3 (50) 2 2 (100) 8 5 (63) 
p value  0.5  0.1  0.2 
† Excludes equivocal test results and missing values. 
 
 
Table 230 HCV antibody prevalence by last drug injected, duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Last drug injected No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
Amphetamine (Speed, Ice) -- -- 8 4   (50) 8 4 (50) 
Heroin -- -- 3 0     (0) 3 0   (0) 
More than one -- -- -- -- -- -- 
Other/not reported 1 0 (0) 1 1 (100) 2 1 (50) 
     p value  --  0.2  0.3 
† Excludes equivocal test results and missing values. 
 
 
Table 231 HCV antibody prevalence by frequency of injection last month, duration of drug injection 
and survey year† 
 <3 years IDU 3+ years IDU Total  
Frequency of drug injection 
last month 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
Less than daily -- -- 3 1 (33) 3 1 (33) 
Daily or more -- -- 2 0   (0)  2 0   (0) 
p value  --  0.4  0.4 
† Excludes equivocal test results and missing values. 
 
 
Table 232 HCV antibody prevalence by re-use of someone else’s used needle and syringe last month, 
duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Re-used someone else’s used 
needle & syringe last month 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
No -- -- 4 1 (25) 4 1 (25) 
Yes -- -- 1 0   (0) 1 0   (0) 
p value  --  0.6  0.6 
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Table 233 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey 
year† 
 <3 years IDU 3+ years IDU Total  
Imprisonment last year No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
No -- -- 5 2 (40) 5 2 (40) 
Yes 1 0 (0) 5 2 (40) 6 2 (33) 
p value  --  1.0  0.8 
† Excludes equivocal test results and missing values. 
 
 
Table 234 HCV antibody by number of previous imprisonments, sex and survey year† 
 Male Female Total  
Number of previous 
imprisonments 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
1 16 2 (13) 3 1 (33) 19 3 (16) 
2 to 4 4 1 (25) 2 1 (50) 6 2 (33) 
5 to 9 4 1 (25) 2 0   (0) 6 1 (17) 
10 + 2 1 (50) -- -- 2 1 (50) 
p value  0.6  0.5  0.6 
† Excludes equivocal test results and missing values. 
 
 
Table 235 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
Non-Indigenous 18 3 (17) 7 2 (29) 25 5 (20) 
Indigenous 8 2 (25) -- -- 8 2 (25) 
p value  0.6  --  0.8 
† Excludes equivocal test results and missing values. 
 
 
Table 236 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector 
status and survey year† 
 Non-IDU IDU Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
Non-Indigenous 14 0   (0) 11 5 (45) 25 5 (20) 
Indigenous 5 1 (20) 3 1 (33) 8 2 (25) 
p value  0.1  0.7  0.8 










National Prison Entrants’ Bloodborne Virus & Risk Behaviour Survey 2004, 2007, and 2010 
South Australia 
 134 
Table 237 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and 
survey year† 
  Male Female Total  
Residential remoteness No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
Highly accessible/accessible 23 4   (17) 6 2 (33) 29 6   (21) 
Moderately accessible 1 0     (0) --  1 0     (0) 
Remote/very remote 1 1 (100) --  1 1 (100) 
p value  0.1  --  0.2 
† Excludes equivocal test results and missing values. 
 
 
Table 238 HCV antibody prevalence by region/country of birth, sex and survey year† 
 Male Female Total  
Region/Country of birth No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
Australia 25 5 (20) 7 2 (29) 32 7 (22) 
Other Oceania 1 0   (0) -- -- 1 0   (0) 
Asia -- -- -- -- -- -- 
UK & Ireland -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
p value  0.6  --  0.6 
† Excludes equivocal test results and missing values. 
 
 
Table 239 HCV antibody prevalence by main language spoken at home by parents, sex and survey 
year† 
 Male Female Total  
Main language spoken at 
home by parents 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
English  25 5 (20) 7 2 (29) 32 7 (22) 
Non-English  -- -- -- -- -- -- 
p value  --  --  -- 
† Excludes equivocal test results and missing values. 
 
 
Table 240 Self-reported HCV status versus HCV serology by sex and survey year† 
 Male Female Total  
Self-report HCV No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2010       
Positive 3 3 (100) 2 2 (100) 5 5 (100) 
Negative 7 1   (14) 3 0     (0) 10 1   (10) 
Not sure 1 0     (0) -- -- 1 0     (0) 
p value  0.03  0.03  0.002 
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HBV prevalence 
Table 241 HBV surface-antigen prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
IDU 2 1 (50) 1 0 (0) 3 1 (33) 
Non-IDU 3 0   (0) 3 0 (0) 6 0   (0) 
p value  0.2    0.1 
† Excludes equivocal test results and missing values. 
 
 
Table 242 HBV core-antibody prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
IDU 11 2 (18) 4 0 (0) 15 2 (13) 
Non-IDU 16 1   (6) 3 0 (0) 19 1   (5) 
p value  0.3  --  0.4 
† Excludes equivocal test results and missing values. 
 
 
Table 243 HBV core-antibody prevalence by sexual identity, sex and survey year† 
 Male Female Total  
Sexual identity No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
Heterosexual 26 3 (12) 3 0 (0) 29 3 (10) 
Bisexual -- -- 3 0 (0) 3 0   (0) 
Homosexual -- -- 1 0 (0) 1 0   (0) 
Unsure -- -- -- -- -- -- 
p value  --  --  0.8 
† Excludes equivocal test results and missing values. 
 
 
Table 244 HBV core-antibody prevalence by age group, sex and survey year† 
 Male Female Total  
Age group No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
< 20 years 1 0   (0) -- -- 1  0   (0) 
20 – 24 6 0   (0) 1 0 (0) 7 0   (0) 
25 – 29 5 0   (0) 2 0 (0) 7 0   (0) 
30 + years 15 3 (20) 4 0 (0) 19 3 (16) 
p value  0.4  --  0.5 
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Table 245 HBV core-antibody prevalence by duration of drug injection, sex and survey year† 
 Male Female Total  
Duration of drug injection No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
<3 years 1 0   (0) -- -- 1 0   (0) 
3 to 5 years 1 0   (0) 1 0 (0) 2 0   (0) 
6 to 10 years 1 0   (0) 1 0 (0) 2 0   (0) 
10 + years 7 2 (29) 2 0 (0) 9 2 (22) 
p value  0.8  --  0.7 
† Excludes equivocal test results and missing values. 
 
 
Table 246 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey 
year† 
 <3 years IDU 3+ years IDU Total  
Last drug injected No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
Amphetamine (Speed, Ice) -- -- 9 2 (22) 9 2 (22) 
Heroin -- -- 3 0   (0) 3 0   (0) 
More than one -- -- -- -- -- -- 
Other/not reported 1 0 (0) 1 0   (0) 2 0   (0) 
     p value  --  0.6  0.5 
† Excludes equivocal test results and missing values. 
 
 
Table 247 HBV core-antibody prevalence by frequency of injection last month, duration of drug 
injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Frequency of drug injection 
last month 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
Less than daily -- -- 3 1 (33) 3 1 (33) 
Daily or more -- -- 2 0   (0) 2 0   (0) 
p value  --  0.4  0.4 
† Excludes equivocal test results and missing values. 
 
 
Table 248 HBV core antibody prevalence by re-use of someone else’s used needle and syringe last 
month, duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Re-used someone else’s used 
needle & syringe last month 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
No -- -- 4 1 (25) 4 1 (25) 
Yes -- -- 1 0   (0) 1 0   (0) 
p value  --  0.6  0.6 
† Excludes equivocal test results and missing values. 
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Table 249 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and 
survey year† 
 <3 years IDU 3+ years IDU Total  
Imprisonment last year No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
No -- -- 6 0   (0) 6 0   (0) 
Yes 1 0 (0) 5 1 (20) 6 1 (17) 
p value  --  0.3  0.3 
† Excludes equivocal test results and missing values. 
 
 
Table 250 HBV core-antibody by number of previous imprisonments, sex and survey year† 
 Male Female Total  
Number of previous 
imprisonments 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
1 16 1   (6) 3 0 (0) 19 1   (5) 
2 to 4 5 0   (0) 2 0 (0) 7 0   (0) 
5 to 9 4 1 (25) 2 0 (0) 6 1 (17) 
10 + 2 1 (50) -- -- 2 1 (50) 
p value  0.2  --  0.1 
† Excludes equivocal test results and missing values. 
 
 
Table 251 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
Non-Indigenous 19 1   (5) 7 0 (0) 26 1   (4) 
Indigenous 8 2 (25) -- -- 8 2 (25) 
p value  0.1  --  0.07 
† Excludes equivocal test results and missing values. 
 
 
Table 252 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector 
status and survey year† 
 Non-IDU IDU Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
Non-Indigenous 14 0   (0) 12 1   (8) 26 1   (4) 
Indigenous 5 1 (20) 3 1 (33) 8 2 (25) 
p value  0.09  0.3  0.07 
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Table 253 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before 
prison and survey year† 
  Male Female Total  
Residential remoteness No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
Highly accessible/accessible 24 2     (8) 6 0 (0) 30 2     (7) 
Moderately accessible 1 0     (0) -- -- 1 0     (0) 
Remote/very remote 1 1 (100) -- -- 1 1 (100) 
p value  0.02  --  0.01 
† Excludes equivocal test results and missing values. 
 
 
Table 254 HBV core-antibody prevalence by region/country of birth, sex and survey year† 
 Male Female Total  
Region/Country of birth No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
Australia 26 3 (12) 7 0 (0) 33 3 (9) 
Other Oceania 1 0   (0) -- -- 1 0 (0) 
Asia -- -- -- --  -- 
UK & Ireland -- -- -- --  -- 
Other -- -- -- --  -- 
p value  0.7  --  0.8 
† Excludes equivocal test results and missing values. 
 
 
Table 255 HBV core-antibody prevalence by main language spoken at home by parents, sex and 
survey year† 
 Male Female Total  
Main language spoken at 
home by parents 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2010       
English  26 3 (12) 7 0 (0) 33 3 (9) 
Non-English  -- -- -- -- -- -- 
p value  --  --  -- 
† Excludes equivocal test results and missing values. 
 
 
Table 256 Hepatitis B virus immune status by injector status and survey year† 
  Hepatitis B Virus Immune Status 
Injector status No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2010      
IDU 15 1   (7) 1 (7) 1 (7) 12 (80) 
Non-IDU 18 7 (39) 1 (6) 0 (0) 10 (56) 
p value     0.1 
† Excludes equivocal test results and missing values.   
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Table 257 Hepatitis B virus immune status by sexual identity and survey year† 
  Hepatitis B Virus Immune Status 
Sexual identity No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2010      
Heterosexual  28 7 (25) 2 (7) 1 (4) 18   (64) 
Homosexual 1 0   (0) 0 (0) 0 (0) 1 (100) 
Bisexual 3 0   (0) 0 (0) 0 (0) 3 (100) 
Unsure -- -- -- -- -- 
p value     0.9 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.   
 
 
Table 258 Hepatitis B virus immune status by age group and survey year† 
  Hepatitis B Virus Immune Status 
Age group No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2010      
< 20 years 1 1 (100) 0   (0) 0 (0) 0     (0) 
20 – 24 7 0     (0) 0   (0) 0 (0) 7 (100) 
25 – 29 7 1   (14) 0   (0) 0 (0) 6   (86) 
30 + years 18 6   (33) 2 (11) 1 (6) 9   (50) 
p value     0.3 
† Excludes equivocal test results and missing values.  
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.   
 
 
Table 259 Hepatitis B virus immune status by number of previous imprisonments and survey year† 






No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2010      
1 18 6 (33) 1   (6) 0   (0) 11 (61) 
2 to 4 7 1 (14) 0   (0) 0   (0) 6 (86) 
5 to 9 6 1 (17) 0   (0) 1 (17) 4 (67) 
10 + 2 0   (0) 1 (50) 0   (0) 1 (50) 
p value     0.1 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 260 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey 
year† 






No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2010      
Non-Indigenous 25 5 (20) 0   (0) 1 (4) 19 (76) 
Indigenous 8 3 (38) 2 (25) 0 (0) 3 (38) 
p value     0.03 
† Excludes equivocal test results and missing values.  
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
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Table 261 Hepatitis B virus immune status by residential remoteness and survey year† 
  Hepatitis B Virus Immune Status 
Residential remoteness No 
tested 
No (%) with no 
evidence of 
HBV immunity 






No (%) vaccine 
conferred 
immunity* 
2010      
Highly accessible/accessible 29 7 (24) 2 (7) 0     (0) 20   (69) 
Moderately accessible 1 0   (0) 0 (0) 0     (0) 1 (100) 
Remote/very remote 1 0   (0) 0 (0) 1 (100) 0     (0) 
p value     <0.001 
† Excludes equivocal test results and missing values.  
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 262 Hepatitis B virus immune status by main language spoken at home by parents and survey 
year† 
  Hepatitis B Virus Immune Status 
Main language spoken at 




No (%) with no 
evidence of 
HBV immunity 










2010      
English  32 8 (25) 2 (6) 1 (3) 21 (66) 
Non-English  -- -- -- -- -- 
p value     -- 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 263 Self-reported hepatitis B immunisation versus serological testing and survey year*  
 Male Female Total  
Self-report HBV 
immunisation** 
No tested No immune 
(%) 
No tested No immune 
(%) 
No tested No immune 
(%) 
2010       
No 8 4 (50) 1 0     (0) 9 4 (44) 
Yes 11 10 (91) 5 5 (100) 16 15 (94) 
Not sure 4 3 (75) -- -- 4 3 (75) 
p value  0.1  0.01  0.02 
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
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Chlamydia 
 
Table 264 Genital chlamydia prevalence by sex and survey year† 
Sex  No tested No with 
chlamydia (%) 
2010   
Male  29 0 (0) 
Female 8 0 (0) 
p value  -- 




Table 265 Genital gonorrhoea prevalence by sex and survey year† 
Sex  No tested No with 
gonorrhoea (%) 
2010   
Male  29 0 (0) 
Female 8 0 (0) 
p value  -- 




Table 266 Syphilis markers by sex and survey year† 








No with any 
marker for 
syphilis (%) 
2010     
Male  25 2 (8) 0 (0) 2 (8) 
Female -- -- -- -- 
p value  -- -- -- 
















2004, 2007, 2010 
Table 267 Number (%) of respondents by demographic characteristics, injector status and survey year  
     2004    2007 2010 
Demographic characteristics IDU Non-IDU IDU Non-IDU IDU Non-IDU 
Number of sites surveyed N = 2 N = 3 N = 4 
No surveyed N = 26 N = 15  N = 22 N = 24 N = 19 N = 13 
Sex (%)       
Male 22 (85) 14   (93) 19 (86) 21 (88) 18 (95) 13 (100) 
Female 4 (15) 1     (7) 3 (14) 3 (13) 1   (5) -- 
Transgender -- -- -- -- -- -- 
Sexual identity (%)       
Heterosexual 25 (96) 15 (100) 21 (95) 23 (96) 19 (100) 12 (92) 
Bisexual 1   (4) -- -- 1   (4) -- 1   (8) 
Homosexual -- -- 1   (5) -- -- -- 
Unsure -- -- -- -- -- -- 
Not reported -- -- -- -- -- -- 
Age and duration of injection (years)      
Median age (years) 25 42 32 26 27 26 
    Age range 21 – 48 17 – 64 21 – 45 19 – 58 19 – 50 19 – 59 
Age group (%)       
    <25 years 2   (8) 3 (20) 1   (5) 11 (46) 6 (32) 5 (38) 
    25+ years 24 (92) 12 (80) 21 (95) 13 (54) 13 (68) 8 (62) 
    Not reported     -- -- 
Median age 1stIDU (years) 20  -- 19 -- 18 -- 
    Age range 14 – 30 -- 12 – 40 -- 12 – 35 -- 
    Not reported -- -- -- -- -- -- 
Median years IDU 10  -- 10 -- 9 -- 
    Range 1 – 32 -- <1 – 27 -- <1 – 25 -- 
Duration of drug injection (%)      
    <3 years 1   (4) -- 1   (5) -- 4 (21) -- 
    3+ years 23 (88) -- 21 (95) -- 15 (79) -- 
    Not reported 2   (8) -- -- -- -- -- 
Aboriginal and Torres Strait Islander origin (%)     
No 16 (62) 9 (60) 18 (82) 20 (83) 17 (89) 10 (77) 
Yes 2   (8) 4 (27) 4 (18) 4 (17) 2 (11) 3 (23) 
Not reported 8 (31) 2 (13) -- -- -- -- 
Living situation prior to prison (%)*      
Not homeless n/a n/a n/a n/a 10 (53) 7 (54) 
Primary homelessness n/a n/a n/a n/a 2 (11) 1   (8) 
Secondary homelessness n/a n/a n/a n/a 6 (32) 5 (38) 
Tertiary homelessness n/a n/a n/a n/a 1   (5) -- 
Not reported n/a n/a n/a n/a -- -- 
Residential remoteness in 12 months before prison (%)     
 Highly accessible/accessible 20   (77) 11 (73) 13 (59) 18 (75) 16 (84) 8 (62) 
Moderately accessible 2     (8) 1   (7) 6 (27) 4 (17) 1   (5) 4 (31) 
Remote/very remote -- 2 (13) 3 (14) 2   (8) 1   (5) -- 
Not reported 4   (15) 1   (7) -- -- 1   (5) 1   (8) 
Region/Country of birth (%)      
Australia 26 (100) 13 (87) 22 (100) 23 (96) 19 (100) 13 (100) 
Other Oceania -- -- -- -- -- -- 
Asia -- -- -- -- -- -- 
UK & Ireland -- -- -- -- -- -- 
Other -- -- -- 1   (4) -- -- 
Not reported -- 2 (13) -- -- -- -- 
Main language spoke at home by parents (%)     
English  26 (100) 13 (87) 22 (100) 23 (96) 19 (100) 12 (92) 
Non-English  -- -- -- 1   (4) -- 1   (8) 
Not reported -- 2 (13) -- -- -- -- 
* Not homeless (private rental, home owner/purchaser, public/community housing, drug and alcohol treatment facility, workers’ 
accommodation, prison, nursing home, foster home); Primary homelessness (Sleeping rough, squat, long grass, boat, car); 
Secondary homelessness (Living with parent, siblings, or relatives, crisis accommodation); Tertiary homelessness (Boarding house, 
hostel, caravan park, backpackers, hotel, motel). Living situation question introduced in 2010. 
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Table 267 Number (%) of respondents by demographic characteristics, injector status and survey year 
(cont.) 
     2004    2007 2010 
Demographic characteristics IDU Non-IDU IDU Non-IDU IDU Non-IDU 
First time in prison (%)       
No 17   (65)    10 (67) 19 (86) 12 (50) 15 (79) 10 (77) 
Yes 9   (35) 5 (33) 3 (14) 12 (50) 4 (21) 3 (23) 
Not reported -- -- -- -- -- -- 
Lifetime imprisonments (%)       
One 9   (35) 5 (33) 3 (14) 12 (50) 5 (26) 6 (46) 
Two to four  8   (31) 5 (33) 10 (45) 9 (38) 8 (42) 6 (46) 
Five to nine   6   (23) 1   (7) 6 (27) 3 (13) 4 (21) -- 
Ten or more  2     (8) -- 2   (9) -- 2 (11) 1 (8) 
Not reported 1     (4) 4 (27) 1   (5) -- -- -- 
Imprisonment in last year (%)       
No 12   (46) 7 (47) 5 (26) 5 (42) 11 (58) 8 (62) 
Yes 11   (42) 4 (27) 13 (68) 7 (58) 8 (42) 5 (38) 
Not reported 3   (12) 4 (27) 1   (5) -- -- -- 
Frequency of injection last month (%)      
Not last month 12   (46) -- 6 (27) -- 10 (53) -- 
Less than weekly 2     (8) -- 4 (18) -- 5 (26) -- 
Weekly not daily 6   (23) -- 4 (18) -- 2 (11) -- 
Daily or more 5   (19) -- 8 (36) -- 2 (11) -- 
Not reported 1     (4) -- -- -- -- -- 
Ever smoked a full cigarette (%)*      
No n/a n/a -- 1   (4) -- 1   (8) 
Yes n/a n/a 22 (100) 23 (96) 19 (100) 12 (92) 
Not reported n/a n/a -- -- -- -- 
Median age first smoked (years) n/a n/a 14 14 13 13 
    Age range n/a n/a 7 – 36 6 – 17 8 – 15 10 – 20 
Current smoker (%)*       
No n/a n/a 1   (5) 4 (17) 1   (5) 4 (31) 
Yes n/a n/a 21 (95) 20 (83) 18 (85) 9 (69) 
Not reported n/a n/a -- -- -- -- 
Smoking frequency (%)*       
Occasional – weekly or less n/a n/a -- 1   (5) -- -- 
5 to 10 cigarettes a day n/a n/a 4 (19) 3 (15) 12 (67) 6 (67) 
11 to 20 cigarettes a day n/a n/a 8 (38) 9 (45) 3 (17) 3 (33) 
Over 20 cigarettes a day n/a n/a 9 (43) 7 (35) 3 (17) -- 
Not reported n/a n/a -- -- -- -- 
Other drugs used last month (%)**      
No drugs in past 4 weeks n/a n/a n/a n/a 5 (26) 4 (31) 
Cannabis n/a n/a n/a n/a 10 (71) 8 (89) 
Heroin n/a n/a n/a n/a 1   (7) -- 
Cocaine n/a n/a n/a n/a 2 (14) -- 
Amphetamine n/a n/a n/a n/a 7 (50) -- 
Other's methadone n/a n/a n/a n/a -- -- 
Other opiates n/a n/a n/a n/a 2 (14) -- 
Other's buprenorphine n/a n/a n/a n/a 2 (14) 1 (11) 
Steroids n/a n/a n/a n/a -- -- 
Hallucinogens n/a n/a n/a n/a -- -- 
Benzodiazepines n/a n/a n/a n/a 6 (43) -- 
Ecstasy/MDA n/a n/a n/a n/a 1   (7) -- 
Inhalants (e.g. petrol) n/a n/a n/a n/a -- -- 
Other drug n/a n/a n/a n/a -- -- 
Not reported n/a n/a n/a n/a   --  -- 
* Smoking questions not asked in 2004. 
** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected. 
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Table 268 Number (%) of respondents by last drug injected, injecting behaviour in the 
month prior to survey and survey year 
Injecting behaviour 2004 2007 2010 
Last drug injected (%) N = 26 N = 22 N = 19 
Amphetamine (Speed, Ice) 20 (77) 16 (73) 12 (63) 
Anabolic steroids -- -- -- 
Cocaine -- -- -- 
Heroin 2   (8) 1   (5) -- 
Heroin + amphetamine -- -- -- 
Heroin + cocaine -- -- -- 
Methadone -- -- -- 
Morphine 3 (12) 4 (18) 5 (26) 
Other 1   (4) 1   (5) 2 (11) 
Not reported -- -- -- 
No Injected last month N = 14 N =16 N = 9 
Places injected last month (%)* 
Prison 1   (8) 1   (6) -- 
Own home 11 (79) 15 (94) 4 (44) 
Friend’s home 7 (50) 13 (81) 4 (44) 
Dealer’s home 2 (14) 4 (25) 1 (11) 
Street, park, beach 2 (14) 3 (19) 2 (22) 
Car 7 (50) 10 (63) 5 (56) 
Public toilet 4 (29) 4 (25) 2 (22) 
Commercial injecting room -- -- -- 
Medically Supervised Injecting Centre, Sydney -- -- -- 
Squat -- -- -- 
Other place -- -- -- 
Use of sterile needles & syringes last month (%) 
All injections 12 (86) 13 (81) 7 (28) 
Most of the time 1   (7) 2 (13) 2 (22) 
Half of the time 1   (7) -- -- 
Some of the time -- -- -- 
Not last month -- -- -- 
Not reported -- 1   (6) -- 
Re-used someone else’s used needle & syringe last month (%) 
None 12 (86) 14 (88) 8 (89) 
Once 1   (7) 1   (6) -- 
Twice 1   (7) -- -- 
3-5 times -- 1   (6) 1 (11) 
>5 times -- -- -- 
Not reported -- -- -- 
Number of people needle & syringe was re-used after last month (%) 
None 12 (86) 14 (88) 8 (89) 
One 1   (7) 1   (6) -- 
Two -- -- -- 
Three to five -- -- -- 
More than five -- -- -- 
Don’t know how many -- 1   (6) 1 (11) 
Not reported 1   (7) -- -- 
Relationship to people needle & syringe was re-used after last month (%)*  
Regular sex partner 1   (7) 2 (13) 1 (11) 
Casual sex partner -- -- -- 
Close friend -- -- 1 (11) 
Acquaintance 1   (7) -- -- 
Other -- -- -- 
Equipment used after someone else last month (%)*  
Spoon   1   (7) 3 (19) 1 (11) 
Water 4 (29) 2 (13) 1 (11) 
Filter 2 (14) 1   (6) 1 (11) 
Tourniquet 1   (7) -- 1 (11) 
Drug mix 1   (7) 2 (13) 1 (11) 
* More than one option could be selected.    
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Table 269 Number (%) of respondents by treatment for drug use, injector status and survey 
year 
Treatment for drug use 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 26 N = 15 N = 22 N = 24 N = 19 N = 13 
Any treatment/therapy for drug use (%)   
No 10 (38) 14 (93) 9 (41) 16 (67) 7 (37) 12 (92) 
Yes 16 (62) -- 13 (59) 4 (17) 12 (63) 1   (8) 
Not reported -- 1   (7) -- 4 (17) -- -- 
History of methadone maintenance treatment (%)   
Currently 3 (12) -- 3 (14) -- 1   (5) -- 
Previously 6 (23) -- 2   (9) -- 2 (11) -- 
Never 16 (62) 14 (93) 17 (77) -- 16 (84) 13 (100) 
Not reported 1   (4) 1   (7) -- -- -- -- 
History of other pharmacotherapy treatment (%)   
Currently 2   (8) -- -- -- 2 (11) 1   (8) 
Previously 2   (8) -- 5 (23) -- 3 (16) -- 
Never 21 (81) 14 (93) 17 (77) -- 14 (74) 12 (92) 
Not reported 1   (4) 1   (7) -- -- -- -- 
 
 
Table 270 Number (%) of respondents by site of needle and syringe acquisition last month and survey 
year 
Needle & Syringe acquisition*        2004          2007 2010 
No surveyed N = 14 N = 16 N = 19 
From an NSP last month (%)   
Daily or almost daily -- 1   (6) -- 
A couple of times each week 2 (14) 5 (31) 3 (16) 
Less than weekly 4 (29) 1   (6) 1   (5) 
Weekly n/a n/a 4 (21) 
Once last month -- 1   (6) -- 
Not in the last month -- 1   (6) 11 (58) 
Not reported 8 (57) 7 (44) -- 
From a chemist last month (%)   
Daily or almost daily 2 (14) -- -- 
A couple of times each week 1   (7) 3 (19) -- 
Less than weekly 1   (7) 3 (19) 1   (5) 
Weekly n/a n/a 3 (16) 
Once last month 6 (43) -- -- 
Not in the last month 4 (29) 2 (13) 15 (79) 
Not reported -- 8 (50) -- 
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Table 271 Number (%) of respondents by body piercing and tattoos  
Body piercing and tattoos 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 26 N = 15 N = 22 N = 24 N = 19 N = 13 
Body or ear piercings (%)       
No 11 (42) 8 (53) 8 (36) 15 (63) 12 (63) 10 (77) 
Yes 15 (58) 7 (47) 14 (64) 9 (38) 7 (37) 3 (23) 
Not reported -- -- -- -- -- -- 
Pierced in past 12 mths (%)       
No 12 (80)  5 (71) 13 (93) 9 (100) 3 (43) 2 (67) 
Yes 1   (7) 1 (14) -- -- 4 (57) 1 (33) 
Not reported 2 (13) 1 (14) 1  (7) -- -- -- 
Who did piercing (%)*      
Chemist/hairdresser/beauty 
salon  
-- -- -- -- -- 1 (100) 
Professional piercer / studio -- 1 (100) -- -- -- -- 
Tattooist / parlour -- -- -- -- -- -- 
Friend -- -- -- -- 1 (25) -- 
Prison inmate -- -- -- -- 1 (25) -- 
Self -- -- -- -- 2 (50) -- 
Family member -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
Needle used by other (%)       
No  -- -- -- -- 4 (100) -- 
Yes -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
Not reported 3 (100) 1 (100) -- -- -- 1 (100) 
Tattoos (%)       
No 2   (8) 9 (60) 6 (27) 11 (46) 1   (5) 7 (54) 
Yes 24 (92) 6 (40) 16 (73) 13 (54) 18 (95) 5 (38) 
Not reported -- -- -- -- -- 1   (8) 
Tattoos in past 12 mths (%)       
No  16 (67) 5 (83) 13 (81) 10 (77) 9 (50) 2 (40) 
Yes 7 (29) 1 (17) 3 (19) 3 (23) 9 (50) 3 (60) 
Not reported 1   (4) -- -- -- -- -- 
Who did tattooing (%)*       
Professional tattooist 3 (43) 1 (100) 1 (33) 2 (67) 6 (67) 3 (100) 
Friend 1 (14) -- 2 (67) 1 (33) 3 (33) -- 
Prison inmate 1 (14) -- 2 (67) -- -- -- 
Self 1 (14) -- -- -- -- -- 
Family member -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
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Table 272 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by 
injector status and survey year 
Sexual behaviour 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 26 N = 15  N = 22 N = 24 N = 19 N = 13 
Sex last month / last 3 months (%)**     
No 9   (35) 8   (53) 6   (27) 3   (13) 4 (13) 2 (15) 
Yes 17   (65) 7   (47) 16   (73) 21   (88) 28 (88) 11 (85) 
Not reported -- -- -- -- -- -- 
Male sex partners in last 3 months**     
    Median n/a n/a n/a n/a 0.5 -- 
    Range n/a n/a n/a n/a 0 – 1 -- 
Female sex partners in last 3 months**     
    Median n/a n/a n/a n/a 1 1 
    Range n/a n/a n/a n/a 0 – 4 0 – 2 
Condom use at last sex (%)        
No 22   (85) 10   (67) 19   (86) 23   (96)   
Yes 4   (15) 5   (33) 3   (14) 1     (4)   
Not reported -- -- -- --   
Condom use with regular sex partner(s) last month (%)*     
No 9   (90) 4   (57) 10   (91) 13   (76) n/a n/a 
Sometimes 1   (10) 1   (14) 1     (9) 4   (24) n/a n/a 
Always -- 2   (29) -- -- n/a n/a 
Condom use with new sex partner(s) last month (%)*     
No 1   (50) -- 2 (100) 1 (100) n/a n/a 
Sometimes 1   (50) -- -- -- n/a n/a 
Always -- -- -- -- n/a n/a 
Condom use with casual sex partner(s) last month (%)*      
No 5   (71) -- 4 (100) 3   (60) n/a n/a 
Sometimes 2   (29) -- -- -- n/a n/a 
Always -- -- -- 2   (40) n/a n/a 
Condom use last sex - regular male partners - last 3 months (%)**   
Never n/a n/a n/a n/a -- -- 
Sometimes n/a n/a n/a n/a 1 (100) -- 
Always n/a n/a n/a n/a -- -- 
Condom use last sex - casual male partners - last 3 months (%)**   
Never n/a n/a n/a n/a -- -- 
Sometimes n/a n/a n/a n/a 1 (100) -- 
Always n/a n/a n/a n/a -- -- 
Condom use last sex - regular female partners - last 3 months (%)**   
Never n/a n/a n/a n/a 7 (70) 7 (70) 
Sometimes n/a n/a n/a n/a 2 (20) 2 (20) 
Always n/a n/a n/a n/a 1 (10) 1 (10) 
Condom use last sex - casual female partners - last 3 months (%)**   
Never n/a n/a n/a n/a 5 (71) -- 
Sometimes n/a n/a n/a n/a 2 (29) -- 
Always n/a n/a n/a n/a -- 1 (100) 
Sex work last month (%)      
No 25   (96) 15 (100) 21   (95) 24 (100) 19 (100) 13 (100) 
Yes 1     (4) -- 1     (5) -- -- -- 
Not reported -- -- -- -- -- -- 
Condom used at last sex work last month (%)    
No -- -- 1 (100) -- -- -- 
Yes 1 (100) -- -- -- -- -- 
Not reported   -- -- -- -- 
Ever had cervical cancer vaccine (women only)*** (%)    
No  n/a n/a n/a n/a 1 (100) -- 
Yes n/a n/a n/a n/a -- -- 
Unsure n/a n/a n/a n/a -- -- 
* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month. 
** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded 
areas indicate previous survey items that were changed in 2010. 
*** Proportion of eligible women i.e. those under 27 years of age in 2007.   
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Table 273 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, 
HBV vaccination and HCV treatment by injector status and survey year 
Testing & treatment 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 26  N = 15  N = 22 N = 24 N = 19 N = 13 
Previous HIV test (%)       
Yes, last year 13 (50) 5 (22) 3 (14) 11 (46) 7 (37) 5 (38) 
>1 year ago 8 (31) 4 (27) 7 (32) 5 (21) 6 (32) 1   (8) 
Never tested 5 (19) 5 (33) 12 (55) 8 (33) 6 (32) 7 (54) 
Not reported -- 1   (7) -- -- -- -- 
HBV infection (%)      
No 19 (73) 14 (93) 20 (91) 23 (96) 17 (89) 12 (92) 
Yes 6 (23) -- -- 1   (4) 2 (11) 1   (8) 
Don’t know 1   (4) 1   (7) 2   (9) -- -- -- 
Not reported   -- -- -- -- 
HBV vaccination (%)*       
No 12 (46) 11 (73) 9 (41) 10 (42) 5 (26) 5 (38) 
Yes 11 (42) 4 (27) 12 (55) 10 (42) 10 (53) 5 (38) 
Don’t know 6 (23) -- 1   (5) 4 (17) 3 (16) 3 (23) 
Not reported   -- -- 1   (5) -- 
Previous HCV test (%)       
Yes, last year 9 (35) 4 (27) 5 (23) 11 (46) 5 (26) 5 (38) 
>1 year ago 11 (42) 3 (20) 7 (32) 7 (29) 7 (37) 1   (8) 
Never tested 6 (23) 8 (53) 10 (45) 6 (25) 6 (32) 7 (54) 
Unsure -- -- -- -- -- -- 
Not reported -- -- -- -- 1 (5) -- 
Any HCV treatment (%)** N = 12 N = 1 N = 7 N = 1 N = 8  N = 0 
Interferon -- -- -- -- -- -- 
Interferon & Ribavirin -- 1 (100) -- -- 1 (13) -- 
Pegasys & Ribavirin -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
No treatment 12 (100) -- 7 (100) 1 (100) 7 (88) -- 
Not reported -- -- -- -- -- -- 
Current HCV treatment        
Interferon -- -- -- -- -- -- 
Interferon & Ribavirin -- -- -- -- 1 (13) -- 
Pegasys & Ribavirin -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
* Number (%) among participants with no history of HBV infection. 
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HIV antibody prevalence 
Table 274 HIV antibody prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
2004       
IDU 15 0 (0) 2 0 (0) 17 0 (0) 
Non-IDU 8 0 (0) -- -- 8 0 (0) 
p value  --  --  -- 
2007       
IDU 16 0 (0) -- -- 16 0 (0) 
Non-IDU 17 0 (0) -- -- 17 0 (0) 
p value  --  --  -- 
2010       
IDU 18 0 (0) 1 0 (0) 19 0 (0) 
Non-IDU 12 0 (0) -- -- 12 0 (0) 
p value  --  --  -- 




HCV antibody prevalence 
Table 275 HCV antibody prevalence by sex, injector status and survey year† 
 Male Female Total 
Injector status No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
IDU 16 10 (63) 2 2 (100) 18 12 (67) 
Non-IDU 9 1 (11) -- -- 9 1 (11) 
p value  0.01  --  <0.01 
2007       
IDU 15 7 (47) -- -- 15 7 (47) 
Non-IDU 17 1   (6) -- -- 17 1   (6) 
p value  0.008  --  0.008 
2010       
IDU 17 8 (47) 1 0     (0) 18 8 (44) 
Non-IDU 12 0   (0) -- -- 12 0   (0) 
p value  <0.01  --  <0.01 
† Excludes equivocal test results and missing values. 
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Table 276 HCV antibody prevalence by sexual identity, sex and survey year† 
  Male Female Total  
Sexual identity No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Heterosexual 25 11 (44) 1 1 (100) 26 12   (46) 
Bisexual -- -- 1 1 (100) 1 1 (100) 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value  --  --  0.3 
2007       
Heterosexual 32 8 (25) -- -- 32 8   (25) 
Bisexual -- -- -- -- -- -- 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value  --  --  -- 
2010       
Heterosexual 28 8 (29) 1 0     (0) 29 8   (28) 
Bisexual 1 0   (0) -- -- 1 0     (0) 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value  0.5  --  0.5 
† Excludes equivocal test results and missing values. 
 
 
Table 277 HCV antibody prevalence by age group, sex and survey year† 
 Male Female Total  
Age group N
o tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
< 20 years 1 0   (0) -- -- 1 0   (0) 
20 – 24 2 1 (50) -- -- 2 1 (50) 
25 – 29 8 2 (25) 3 2 (67) 11 4 (36) 
30 + years 16 9 (56) -- -- 16 9 (56) 
p value  0.4  --  0.6 
2007       
< 20 years 1 0   (0) -- -- 1 0   (0) 
20 – 24 8 1 (13) -- -- 8 1 (13) 
25 – 29 6 1 (17) -- -- 6 1 (17) 
30 + years 17 6 (35) -- -- 17 6 (35) 
p value  0.5  --  0.5 
2010       
< 20 years 3 1 (33) -- -- 3 1 (33) 
20 – 24 7 1 (14) 1 0   (0) 8 1 (13) 
25 – 29 6 2 (33) -- -- 6 2 (33) 
30 + years 13 4 (31) -- -- 13 4 (31) 
p value  0.8  --  0.8 
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Table 278 HCV antibody prevalence by duration of drug injection, sex and survey year† 
 Male Female Total  
Duration of drug injection No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
<3 years -- -- -- -- -- -- 
3 to 5 years -- -- -- -- -- -- 
6 to 10 years 6 2   (33) 1 1 (100) 7 3 (43) 
10 + years 9 8   (89) 1 1 (100) 10 9 (90) 
p value  0.03  --  0.04 
2007       
<3 years 1 0     (0) -- -- 1 0   (0) 
3 to 5 years -- -- -- -- -- -- 
6 to 10 years 4 1   (25) -- -- 4 1 (25) 
10 + years 10 6   (60) -- -- 10 6 (60) 
p value  0.3  --  0.3 
2010       
<3 years 4 0     (0) -- -- 4 0   (0) 
3 to 5 years 3 1   (33) -- -- 3 1 (33) 
6 to 10 years 2 2 (100) 1 0     (0) 3 2 (67) 
10 + years 8 5   (63) -- -- 8 5 (63) 
p value  0.08  --  0.2 
† Excludes equivocal test results and missing values. 
 
 
Table 279 HCV antibody prevalence by last drug injected, duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Last drug injected No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Amphetamine (Speed, Ice) -- -- 9 6   (67) 9 6   (67) 
Heroin -- -- 1 1 (100) 1 1 (100) 
More than one -- -- 7 5   (71) 7 5   (71) 
Other/not reported -- -- -- -- -- -- 
     p value  --  0.7  0.7 
2007       
Amphetamine (Speed, Ice) 1 0 (0) 10 3   (30) 11 3   (27) 
Heroin -- -- 1 1 (100) 1 1 (100) 
More than one -- -- -- -- -- -- 
Other/not reported -- -- 3 3 (100) 3 3 (100) 
     p value  --  0.06  0.04 
2010       
Amphetamine (Speed, Ice) 3 0 (0) 8 3   (38) 11 3   (27) 
Heroin -- -- -- -- -- -- 
More than one -- -- 1 0     (0) 1 0     (0) 
Other/not reported 1 0 (0) 5 5 (100) 6 5   (83) 
     p value  --  0.04  0.06 
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Table 280 HCV antibody prevalence by frequency of injection last month, duration of drug injection 
and survey year† 
 <3 years IDU 3+ years IDU Total  
Frequency of drug injection 
last month 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Less than daily -- -- 5 3   (60) 5 3   (60) 
Daily or more -- -- 4 4 (100) 4 4 (100) 
p value  --  0.3  0.3 
2007       
Less than daily -- -- 5 1   (20) 5 1   (20) 
Daily or more 1 0 (0) 5 3   (60) 6 3   (50) 
p value  --  0.2  0.3 
2010       
Less than daily 2 0 (0) 5 3   (60) 7 3   (43) 
Daily or more -- -- 2 2 (100) 2 2 (100) 
p value  --  0.3  0.2 
† Excludes equivocal test results and missing values. 
 
 
Table 281 HCV antibody prevalence by re-use of someone else’s used needle and syringe last month, 
duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Re-used someone else’s used 










2004       
No -- -- 8 6   (75) 8 6   (75) 
Yes -- -- 2 2 (100) 2 2 (100) 
p value  --  0.4  0.4 
2007       
No 1 0 (0) 10 4   (40) 11 4   (36) 
Yes -- -- -- -- -- -- 
p value  --  --  -- 
2010       
No 2 0 (0) 6 4   (67) 8 4   (50) 
Yes -- -- -- -- -- -- 
p value  --  --  -- 
† Excludes equivocal test results and missing values. 
 
 
Table 282 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey 
year† 
 <3 years IDU 3+ years IDU Total  
Imprisonment last year No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
No -- -- 8 6   (75) 8 6   (75) 
Yes -- -- 2 2 (100) 6 2 (100) 
p value  --  0.7  0.7 
2007       
No -- -- 4 3   (75) 4 3   (75) 
Yes -- -- 10 4   (40) 10 4   (40) 
p value  --  0.2  0.2 
2010       
No 3 0 (0) 7 3   (43) 10 3   (30) 
Yes 1 0 (0) 7 5   (71) 8 5   (63) 
p value  --  0.3  0.2 
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Table 283 HCV antibody by number of previous imprisonments, sex and survey year† 
 Male Female Total  
Number of previous 
imprisonments 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
1 10 4   (40) -- -- 10 4   (40) 
2 to 4 9 4   (44) -- -- 9 4   (44) 
5 to 9 4 3   (75) 1 1 (100) 5 4   (80) 
10 + -- -- 1 1 (100) 1 1 (100) 
p value  0.5  --  0.4 
2007       
1 7 0     (0) -- -- 7 0     (0) 
2 to 4 15 3   (20) -- -- 15 3   (20) 
5 to 9 9 4   (44) -- -- 9 4   (44) 
10 + 1 1 (100) -- -- 1 1 (100) 
p value  0.06  --  0.06 
2010       
1 9 0     (0) -- -- 9 0     (0) 
2 to 4 13 2   (15) 1 0     (0) 14 2   (14) 
5 to 9 4 4 (100) -- -- 4 4 (100) 
10 + 3 2   (67) -- -- 3 2   (67) 
p value  0.001  --  <0.001 
† Excludes equivocal test results and missing values. 
 
 
Table 284 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Non-Indigenous 16 9  (56) 1 1 (100) 17 10 (59) 
Indigenous 3 1  (33) -- -- 3 1 (33) 
p value  0.5  --  0.4 
2007       
Non-Indigenous 28 6  (21) -- -- 28 6 (21) 
Indigenous 4 2  (50) -- -- 4 2 (50) 
p value  0.2  --  0.2 
2010       
Non-Indigenous 24 6 (25) 1 0     (0) 25 6 (24) 
Indigenous 5 2 (40) -- -- 5 2 (40) 
p value  0.5  --  0.5 
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Table 285 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector 
status and survey year† 
 Non-IDU IDU Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Non-Indigenous 5 0 (0) 11 9   (82) 16 9 (56) 
Indigenous 2 0 (0) 1 1 (100) 3 1 (33) 
p value  --  0.6  0.6 
2007       
Non-Indigenous 16 1 (6) 12 5   (42) 28 6 (21) 
Indigenous 1 0 (0) 3 2   (67) 4 2 (50) 
p value  0.8  0.4  0.2 
2010       
Non-Indigenous 9 0 (0) 16 6   (38) 25 6 (24) 
Indigenous 3 0 (0) 2 2 (100) 5 2 (40) 
p value  --  0.1  0.5 
† Excludes equivocal test results and missing values. 
 
 
Table 286 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and 
survey year† 
 Male Female Total  
Residential remoteness No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Highly accessible/accessible 19 8 (42) 2 2 (100)  21 10 (48) 
Moderately accessible 2 1 (50) -- -- 2 1 (50) 
Remote/very remote 1 0   (0) -- -- 1 0   (0) 
p value  0.7  --  0.6 
2007       
Highly accessible/accessible 24  7 (29) -- -- 24 7 (29) 
Moderately accessible 4 1 (25) -- -- 4 1 (25) 
Remote/very remote 4 0   (0) -- -- 4 0   (0) 
p value  0.5  --  0.5 
2010       
Highly accessible/accessible 21 7 (33) 1 0     (0) 22 7 (32) 
Moderately accessible 5 0   (0) -- -- 5 0   (0) 
Remote/very remote 1 0   (0) -- -- 1 0   (0) 
p value  0.3  --  0.3 
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Table 287 HCV antibody prevalence by region/country of birth, sex and survey year† 
 Male Female Total  
Region/Country of birth No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Australia 25 11 (44) 2 2 (100) 27 13 (48) 
Other Oceania -- -- -- -- -- -- 
Asia -- -- -- -- -- -- 
UK & Ireland -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
p value  --  --  -- 
2007       
Australia 31 8  (26) -- -- 31 8 (26) 
Other Oceania -- -- -- -- -- -- 
Asia -- -- -- -- -- -- 
UK & Ireland -- -- -- -- -- -- 
Other 1 0    (0) -- -- 1 0   (0) 
p value  0.6  --  0.6 
2010       
Australia 29 8  (28) 1 0     (0) 30 8 (27) 
Other Oceania -- -- -- -- -- -- 
Asia -- -- -- -- -- -- 
UK & Ireland -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
p value  --  --  -- 
† Excludes equivocal test results and missing values. 
 
 
Table 288 HCV antibody prevalence by main language spoken at home by parents, sex and survey 
year† 
 Male Female Total  
Main language spoken at 
home by parents 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
English  25 11 (44) 2 2 (100) 27 13 (48) 
Non-English  -- -- -- --  -- 
p value  --  --  -- 
2007       
English  31 8 (26) -- -- 31 8 (26) 
Non-English  1 0   (0) -- -- 1 0   (0) 
p value  0.6  --  0.6 
2010       
English  28 8 (29) 1 0     (0) 29 8 (28) 
Non-English  1 0   (0) -- -- 1 0   (0) 
p value  0.5  --  0.5 
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Table 289 Self-reported HCV status versus HCV serology by sex and survey year† 
 Male Female Total  
Self-report HCV No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Positive 8 8 (100) 2 2 (100) 10 10 (100) 
Negative 7 2   (29) -- -- 7 2   (29) 
Not sure 2 1   (50) -- -- 2 1   (50) 
p value  0.01  --  0.006 
2007       
Positive 4 4 (100) -- -- 4 4 (100) 
Negative 11 1     (9) -- -- 11 1     (9) 
Not sure 4 1   (25) -- -- 4 1   (25) 
p value  0.003  --  0.003 
2010       
Positive 7 6   (86) -- -- 7 6   (86) 
Negative 11 1     (9) 1 0     (0) 12 1     (8) 
Not sure -- -- -- --  -- 
p value  0.001  --  0.001 






Table 290 HBV surface-antigen prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
IDU 15 0 (0) 3 1 (33) 18 1 (6) 
Non-IDU 8 0 (0) -- -- 8  0 (0) 
p value  --  --  0.5 
2007       
IDU 14 1 (7) -- -- 14 1 (7) 
Non-IDU 16 0 (0) -- -- 16 0 (0) 
p value  0.3  --  0.3 
2010       
IDU 17 0 (0) 1 0   (0) 18 0 (0) 
Non-IDU 12 0 (0) -- -- 12 0 (0) 
p value  --  --  -- 
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Table 291 HBV core-antibody prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
IDU 16 6 (38) 3 2 (67) 19 8 (42) 
Non-IDU 9 0   (0) -- -- 9 0   (0) 
p value  0.04  --  0.02 
2007       
IDU 15 3 (20) -- -- 15 3 (20) 
Non-IDU 17 0   (0) -- -- 17 0   (0) 
p value  0.05  --  0.05 
2010       
IDU 17 2 (12) 1 0   (0) 18 2 (11) 
Non-IDU 12 3 (25) -- -- 12 3 (25) 
p value  0.4  --  0.3 
† Excludes equivocal test results and missing values. 
 
 
Table 292 HBV core-antibody prevalence by sexual identity, sex and survey year† 
  Male Female Total  
Sexual identity No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Heterosexual 25 6   (24) 2 2 (100) 27 8   (30) 
Bisexual -- -- 1 0     (0) 1 0     (0) 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value  --  0.08  0.5 
2007       
Heterosexual 32 3    (9) -- -- 32 3     (9) 
Bisexual -- -- -- -- -- -- 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value  --  --  -- 
2010       
Heterosexual 28 4   (14) 1 0     (0) 29 4   (14) 
Bisexual 1 1 (100) -- -- 1 1 (100) 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value  0.03  --  0.02 
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Table 293 HBV core-antibody prevalence by age group, sex and survey year† 
 Male Female Total  
Age group No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
< 20 years 1 0   (0) -- -- 1 0   (0) 
20 – 24 2 0   (0) 1 1 (100) 3 1 (33) 
25 – 29 8 3 (38) 3 1   (33) 11 4 (36) 
30 + years 16 3 (19) -- - 16 3 (19) 
p value  0.6  0.3  0.7 
2007       
< 20 years 1 0   (0) -- -- 1 0   (0) 
20 – 24 8 0   (0) -- -- 8 0   (0) 
25 – 29 6 0   (0) -- -- 6 0   (0) 
30 + years 17 3 (18) -- -- 17 3 (18) 
p value  0.4  --  0.4 
2010       
< 20 years 3 0   (0) -- -- 3 0   (0) 
20 – 24 7 0   (0) 1 0     (0) 8 0   (0) 
25 – 29 6 1 (17) -- -- 6 1 (17) 
30 + years 13 4 (31) -- -- 13 4 (31) 
p value  0.3  --  0.3 
† Excludes equivocal test results and missing values. 
 
 
Table 294 HBV core-antibody prevalence by duration of drug injection, sex and survey year† 
 Male Female Total  
Duration of drug injection No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
<3 years -- -- -- -- -- -- 
3 to 5 years -- -- 1 1 (100) 1 1 (100) 
6 to 10 years 6 1 (17) 1 1 (100) 7 2   (29) 
10 + years 9 4 (44) 1  0     (0) 10 4   (40) 
p value  0.3  0.2  0.4 
2007       
<3 years 1 0   (0) -- -- 1 0     (0) 
3 to 5 years -- -- -- -- -- -- 
6 to 10 years 4 0   (0) -- -- 4 0     (0) 
10 + years 10 3 (30) -- -- 10 3   (30) 
p value  0.4  --  0.4 
2010       
<3 years 4 0   (0) -- -- 4 0     (0) 
3 to 5 years 3 0   (0) -- -- 3 0     (0) 
6 to 10 years 2 0   (0) 1 0     (0) 3 0     (0) 
10 + years 8 2 (25) -- -- 8 2   (25) 
p value  0.5  --  0.4 
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Table 295 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey 
year† 
 <3 years IDU 3+ years IDU Total  
Last drug injected No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Amphetamine (Speed, Ice) -- -- 10 5   (50) 10 5   (50) 
Heroin -- -- 1 0     (0) 1 0     (0) 
More than one -- -- 7 2   (29) 7 2   (29) 
Other/not reported -- -- -- -- -- -- 
     p value  --  0.4  0.4 
2007       
Amphetamine (Speed, Ice) 1 0 (0) 10 1   (10) 11 1     (9) 
Heroin -- -- 1 1 (100) 1 1 (100) 
More than one -- -- -- -- -- -- 
Other/not reported -- -- 3 1   (33) 3 1   (33) 
     p value  --  0.1  0.08 
2010       
Amphetamine (Speed, Ice) 3 0 (0) 8 1   (13) 11 1     (9) 
Heroin -- -- -- -- -- -- 
More than one -- -- 1 0     (0) 1 0     (0) 
Other/not reported 1 0 (0) 5 1   (20) 6 1   (17) 
     p value  --  0.9  0.8 
† Excludes equivocal test results and missing values. 
 
 
Table 296 HBV core-antibody prevalence by frequency of injection last month, duration of drug 
injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Frequency of drug injection 
last month 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Less than daily -- -- 6 1 (17) 6 1 (17) 
Daily or more -- -- 4 3 (75) 4 3 (75) 
p value  --  0.07  0.07 
2007       
Less than daily -- -- 5 1 (20) 5 1 (20) 
Daily or more 1 0 (0) 5 1 (20) 6 1 (17) 
p value  --  1.0  0.9 
2010       
Less than daily 2 0 (0) 5 1 (20) 7 1 (14) 
Daily or more -- -- 2 0   (0) 2 0   (0) 
p value  --  0.5  0.6 
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Table 297 HBV core antibody prevalence by re-use of someone else’s used needle and syringe last 
month, duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Re-used someone else’s used 
needle & syringe last month 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
No -- -- 8 3 (38) 8 3 (38) 
Yes -- -- 3 1 (33) 3 1 (33) 
p value  --  0.9  0.9 
2007       
No 1 0 (0) 10 2 (20) 11 2 (18) 
Yes -- -- -- -- -- -- 
p value  --  --  -- 
2010       
No 2 0 (0) 6 1 (17) 8 1 (13) 
Yes -- -- -- -- -- -- 
p value  --  --  -- 
† Excludes equivocal test results and missing values. 
 
 
Table 298 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and 
survey year† 
 <3 years IDU 3+ years IDU Total  
Imprisonment last year No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
No -- -- 8 3 (38) 8 3 (38) 
Yes -- -- 7 2 (29) 7 2 (29) 
p value  --  0.5  0.5 
2007       
No -- -- 4 1 (25) 4 1 (25) 
Yes -- -- 10 2 (20) 10 2 (20) 
p value  --  0.8  0.8 
2010       
No 3 0 (0) 7 0   (0) 10 0   (0) 
Yes 1 0 (0) 7 2 (29) 8 2 (25) 
p value  --  0.1  0.1 
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Table 299 HBV core-antibody by number of previous imprisonments, sex and survey year† 
 Male Female Total  
Number of previous 
imprisonments 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
1 10 3 (30) -- -- 10 3   (30) 
2 to 4 9 1 (11) 1 1 (100) 10 2   (20) 
5 to 9 4 1 (25) 1 0     (0) 5 1   (20) 
10 + -- -- 1 1 (100) 1 1 (100) 
p value  0.6  0.2  0.4 
2007       
1 7 0   (0) -- -- 7 0     (0) 
2 to 4 15 1   (7) -- -- 15 1     (7) 
5 to 9 9 2 (22) -- -- 9 2   (22) 
10 + 1 0   (0) -- -- 1 0     (0) 
p value  0.4  --  0.4 
2010       
1 9 2 (22) -- -- 9 2   (22) 
2 to 4 13 1   (8) 1 0     (0) 14 1     (7) 
5 to 9 4 2 (50) -- -- 4 2   (50) 
10 + 3 0   (0) -- -- 3 0     (0) 
p value  0.2  --  0.2 
† Excludes equivocal test results and missing values. 
 
 
Table 300 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Non-Indigenous 16 4 (25) 2 1  (50) 18 5 (28) 
Indigenous 3 1 (33) -- -- 3 1 (33) 
p value  0.8  --  0.8 
2007       
Non-Indigenous 28 1   (4) -- -- 28 1   (4) 
Indigenous 4 2 (50) -- -- 4 2 (50) 
p value  0.003  --  0.003 
2010       
Non-Indigenous 24 5 (21) 1 0   (0) 25 5 (20) 
Indigenous 5 0   (0) -- -- 5 0   (0) 
p value  0.3  --  0.3 
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Table 301 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector 
status and survey year† 
 Non-IDU IDU Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Non-Indigenous 5 0  (0) 12 5   (42) 17 5 (29) 
Indigenous 2 0  (0) 1 1 (100) 3 1 (33) 
p value  --  0.3  0.9 
2007       
Non-Indigenous 16 0  (0) 12 1     (8) 28 1   (4) 
Indigenous 1 0  (0) 3 2   (67) 4 2 (50) 
p value  --  0.02  0.003 
2010       
Non-Indigenous 9 3 (33) 16 2   (13) 25 5 (20) 
Indigenous 3 0   (0) 2 0     (0) 5 0   (0) 
p value  0.3  0.6  0.3 
† Excludes equivocal test results and missing values. 
 
 
Table 302 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before 
prison and survey year† 
  Male Female Total  
Residential remoteness No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Highly accessible/accessible 19 3 (16) 2 1 (50) 21 4 (19) 
Moderately accessible 2 1 (50) -- -- 2 1 (50) 
Remote/very remote 1 0   (0) -- -- 1 0   (0) 
p value  0.4  --  0.5 
2007       
Highly accessible/accessible 24  2   (8) -- -- 24 2   (8) 
Moderately accessible 4 1 (25) -- -- 4 1 (25) 
Remote/very remote 4 0   (0) -- -- 4 0   (0) 
p value  0.5  --  0.5 
2010       
Highly accessible/accessible 21 3 (14) 1 0   (0) 22 3 (14) 
Moderately accessible 5 2 (40) -- -- 5 2 (40) 
Remote/very remote 1 0   (0) -- -- 1 0   (0) 
p value  0.4  --  0.3 
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Table 303 HBV core-antibody prevalence by region/country of birth, sex and survey year† 
 Male Female Total  
Region/Country of birth No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Australia 25 6 (24) 3 2 (67) 28 8 (29) 
Other Oceania -- -- -- -- -- -- 
Asia -- -- -- -- -- -- 
UK & Ireland -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
p value  --  --  -- 
2007       
Australia 31 3 (10) -- -- 31 3 (10) 
Other Oceania -- -- -- -- -- -- 
Asia -- -- -- -- -- -- 
UK & Ireland -- -- -- -- -- -- 
Other 1 0 (0) -- -- 1 0   (0) 
p value  0.7  --  0.7 
2010       
Australia 29 5 (17) 1 0   (0) 30 5 (17) 
Other Oceania -- -- -- -- -- -- 
Asia -- -- -- -- -- -- 
UK & Ireland -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
p value  --  --  -- 
† Excludes equivocal test results and missing values. 
 
 
Table 304 HBV core-antibody prevalence by main language spoken at home by parents, sex and 
survey year† 
 Male Female Total  
Main language spoken at 
home by parents 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
English  25 6 (24) 3 2 (67) 28 8 (29) 
Non-English  -- -- -- -- -- -- 
p value  --  --  -- 
2007       
English  31 3 (10) -- -- 31 3 (10) 
Non-English  1 0   (0) -- -- 1 0   (0) 
p value  0.7  --  0.7 
2010       
English  28 5 (18) 1 0   (0) 29 5 (17) 
Non-English  1 0   (0) -- -- 1 0   (0) 
p value  0.6  --  0.7 
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Table 305 Hepatitis B virus immune status by injector status and survey year† 
  Hepatitis B Virus Immune Status 
Injector status No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
IDU 20 7 (35) 7 (35) 1 (5) 5   (25) 
Non-IDU 9 8 (89) 0   (0) 0 (0) 1   (11) 
p value     0.05 
2007      
IDU 7 2 (29) 3 (43) 0 (0) 2   (29) 
Non-IDU 7 0   (0) 0   (0) 0 (0) 7 (100) 
p value     0.02 
2010      
IDU 17 10 (59) 2 (12) 0 (0) 5   (29) 
Non-IDU 11 6 (55) 3 (27) 0 (0) 2   (18) 
p value     0.5 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 306 Hepatitis B virus immune status by sexual identity and survey year† 
  Hepatitis B Virus Immune Status 
Sexual identity No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
Heterosexual  28 14   (50) 7   (25) 1 (4) 6 (21) 
Bisexual 1 1 (100) 0     (0) 0 (0) 0   (0) 
Homosexual -- -- -- -- -- 
Unsure -- -- -- -- -- 
p value     0.8 
2007      
Heterosexual  14 2   (14) 3   (21) 0 (0) 9 (64) 
Homosexual -- -- -- -- -- 
Bisexual -- -- -- -- -- 
Unsure -- -- -- -- -- 
p value     -- 
2010      
Heterosexual  27 16   (59) 4   (15) 0 (0) 7 (26) 
Homosexual -- -- -- -- -- 
Bisexual 1 0     (0) 1 (100) 0 (0) 0   (0) 
Unsure -- -- -- -- -- 
p value     0.09 
† Excludes equivocal test results and missing values.   
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Table 307 Hepatitis B virus immune status by age group and survey year† 
  Hepatitis B Virus Immune Status 
Age group No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
< 20 years 1 1 (100) 0   (0) 0   (0) 0     (0) 
20 – 24 3 1   (33) 0   (0) 1 (33) 1   (33) 
25 – 29 12 7   (58) 4 (33) 0   (0) 1     (8) 
30 + years 16 9   (56) 3 (19) 0   (0) 4   (25) 
p value     0.1 
2007      
< 20 years 1 0     (0) 0   (0) 0   (0) 1 (100) 
20 – 24 4 0     (0) 0   (0) 0   (0) 4 (100) 
25 – 29 1 0     (0) 0   (0) 0   (0) 1 (100) 
30 + years 8 2   (25) 3 (38) 0   (0) 3   (38) 
p value     0.4 
2010      
< 20 years 2 1   (50) 0   (0) 0   (0) 1   (50) 
20 – 24 7 4   (57) 0   (0) 0   (0) 3   (43) 
25 – 29 6 5   (83) 1 (17) 0   (0) 0     (0) 
30 + years 13 6   (46) 4 (31) 0   (0) 3   (23) 
p value     0.4 
† Excludes equivocal test results and missing values.  
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 308 Hepatitis B virus immune status by number of previous imprisonments and survey year† 






No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
1 10 5   (50) 
  
3   (30) 0   (0) 2   (20) 
2 to 4 10 8   (80) 1   (10) 1 (10) 0     (0) 
5 to 9 6 1   (17) 1   (17) 0   (0) 4   (67) 
10 + 1 0     (0) 1 (100) 0   (0) 0     (0) 
p value     0.05 
2007      
1 4 0     (0) 0     (0) 0   (0) 4 (100) 
2 to 4 4 1   (25) 1   (25) 0   (0) 2   (50) 
5 to 9 5 0     (0) 2   (40) 0   (0) 3   (60) 
10 + 1 1 (100) 0     (0) 0   (0) 0     (0) 
p value     0.1 
2010      
1 9 4   (44) 2   (22) 0   (0) 3   (33) 
2 to 4 12 9   (75) 1     (8) 0   (0) 2   (17) 
5 to 9 4 2   (50) 2   (50) 0   (0) 0     (0) 
10 + 3 1   (33) 0     (0) 0   (0) 2   (67) 
p value     0.2 
† Excludes equivocal test results and missing values.   
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Table 309 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey 
year† 






No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
Non-Indigenous 18 9   (50) 4   (22) 1 (6) 4 (22) 
Indigenous 3 2   (67) 1   (33) 0 (0) 0   (0) 
p value     0.8 
2007      
Non-Indigenous 12 2   (17) 1     (8) 0 (0) 9 (75) 
Indigenous 2 0     (0) 2 (100) 0 (0) 0   (0) 
p value     0.01 
2010      
Non-Indigenous 24 12   (50) 5   (21) 0 (0) 7 (29) 
Indigenous 4 4 (100) 0     (0) 0 (0) 0   (0) 
p value     0.2 
† Excludes equivocal test results and missing values.  
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 310 Hepatitis B virus immune status by residential remoteness and survey year† 
  Hepatitis B Virus Immune Status 
Residential remoteness No 
tested 
No (%) with no 
evidence of 
HBV immunity 






No (%) vaccine 
conferred 
immunity* 
2004      
Highly accessible/accessible 22 12   (55) 4   (18) 0 (0) 6   (27) 
Moderately accessible 2 1   (50) 1   (50) 0 (0) 0     (0) 
Remote/very remote 1 1 (100) 0     (0) 0 (0) 0     (0) 
p value     0.7 
2007      
Highly accessible/accessible 13 2   (15) 2   (15) 0 (0) 9   (69) 
Moderately accessible 1 0     (0) 1 (100) 0 (0) 0     (0) 
Remote/very remote -- -- -- -- -- 
p value     0.1 
2010      
Highly accessible/accessible 21 12   (57) 3   (14) 0 (0) 6   (29) 
Moderately accessible 5 3   (60) 2   (40) 0 (0) 0     (0) 
Remote/very remote 1 0     (0) 0     (0) 0 (0) 1 (100) 
p value     0.2 
† Excludes equivocal test results and missing values.  
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Table 311 Hepatitis B virus immune status by main language spoken at home by parents and survey 
year† 
  Hepatitis B Virus Immune Status 
Main language 




No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
English 29 15   (52) 7 (24) 1 (3) 6 (21) 
Non-English -- -- -- -- -- 
p value     -- 
2007      
English  14 2   (14) 3 (21) 0 (0) 9 (64) 
Non-English -- -- -- -- -- 
p value     -- 
2010      
English  27 15   (56) 5 (19) 0 (0) 7 (26) 
Non-English 1 1 (100) 0   (0) 0 (0) 0   (0) 
p value     0.7 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 312 Self-reported hepatitis B immunisation versus serological testing and survey year*  
 Male Female Total  
Self-report HBV 
immunisation** 
No tested No immune 
(%) 
No tested No immune 
(%) 
No tested No immune 
(%) 
2004       
No 9 0     (0) -- -- 9 0     (0) 
Yes 10 6   (60) 1 0    (0) 11 6   (55) 
Not sure 1 0     (0) -- -- 1 0     (0) 
p value  0.01  --  0.02 
2007       
No 1 0     (0) -- -- 1 0     (0) 
Yes 9  8   (89) -- -- 9 8   (89) 
Not sure 1 1 (100) -- -- 1 1 (100) 
p value  0.08  --  0.08 
2010       
No 5 0     (0) 1 1 (100) 6 1   (17) 
Yes 14 6   (43) -- -- 14 6   (43) 
Not sure 3 0     (0) -- -- 3 0     (0) 
p value  0.1  --  0.2 
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  












Table 313 Genital chlamydia prevalence by sex and survey year† 
Sex  No tested No with 
chlamydia (%) 
2010   
Male  10 0 (0) 
Female -- -- 
p value  -- 




Table 314 Genital gonorrhoea prevalence by sex and survey year† 
Sex  No tested No with 
gonorrhoea (%) 
2010   
Male  -- -- 
Female -- -- 
p value  -- 




Table 315 Syphilis markers by sex and survey year† 








No with any 
marker for 
syphilis (%) 
2010     
Male  5 0 (0) 0 (0) 0 (0) 
Female  -- -- -- 
p value  -- -- -- 
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Victoria 
2007, 2010 
Table 316 Number (%) of respondents by demographic characteristics, injector status and survey year  
     2004    2007 2010 
Demographic characteristics IDU Non-IDU IDU Non-IDU IDU Non-IDU 
Number of sites surveyed  N = 2 N = 2 
No surveyed -- -- N = 87  N = 75 N = 31  N = 17 
Sex (%)       
Male -- -- 78 (90) 71 (95) 27 (87) 15 (88) 
Female -- -- 9 (10) 4   (5) 4 (13) 2 (12) 
Transgender -- -- -- -- -- -- 
Sexual identity (%)       
Heterosexual -- -- 84 (97) 73 (97) 29 (94) 15 (88) 
Bisexual -- -- 1   (1) 1   (1) 1   (3) -- 
Homosexual -- -- -- 1   (1) 1   (3) 1   (6) 
Unsure -- -- 2   (2) -- -- -- 
Not reported -- -- -- -- -- 1   (6) 
Age and duration of injection (years)      
Median age (years) -- -- 32 32 30 32 
    Age range -- -- 18 – 54 18 – 77 21 – 55 20 – 75 
Age group (%)       
    <25 years -- -- 12 (14) 22 (29) 6 (19) 3 (18) 
    25+ years -- -- 75 (86) 53 (71) 25 (81) 14 (82) 
    Not reported   -- -- -- -- 
Median age 1stIDU (years) -- -- 18 -- 17 -- 
    Age range -- -- 10 – 35 -- 13 – 39 -- 
    Not reported -- -- -- -- -- -- 
Median years IDU -- -- 12 -- 11 -- 
    Range -- -- <1 – 29 -- 2 – 35 -- 
Duration of drug injection (%)      
    <3 years -- -- 4   (5) -- 2   (6) -- 
    3+ years -- -- 83 (95) -- 29 (94) -- 
    Not reported -- -- -- -- -- -- 
Aboriginal and Torres Strait Islander origin (%)     
No -- -- 80 (92) 73 (97) 27 (87) 16 (94) 
Yes -- -- 7   (8) 2   (3) 4 (13) 1   (6) 
Not reported -- -- -- -- -- -- 
Living situation prior to prison (%)*      
Not homeless -- -- n/a n/a -- -- 
Primary homelessness -- -- n/a n/a -- -- 
Secondary homelessness -- -- n/a n/a -- -- 
Tertiary homelessness -- -- n/a n/a -- -- 
Not reported -- -- n/a n/a 31 (100) 17 (100) 
Residential remoteness in 12 months before prison (%)     
 Highly accessible/accessible -- -- 83 (95) 66 (88) 31 (100) 12 (71) 
Moderately accessible -- -- 2   (2) 5   (7) -- -- 
Remote/very remote -- -- 1   (1) -- -- 3 (18) 
Not reported -- -- 1   (1) 4   (5) -- 2 (12) 
Region/Country of birth (%)      
Australia -- -- 67 (77) 62 (83) 28 (90) 12 (71) 
Other Oceania -- -- 3   (3) 2   (3) -- 1   (6) 
Asia -- -- 6   (7) 4   (5) -- 3 (18) 
UK & Ireland -- -- 4   (5) 1   (1) 1   (3) -- 
Other -- -- 7   (8) 5   (7) 1   (3) 1   (6) 
Not reported -- -- -- 1   (1) 1   (3) -- 
Main language spoke at home by parents (%)     
English  -- -- 72 (83) 59 (79) 30 (97) 12 (71) 
Non-English  -- -- 14 (16) 14 (19) 1   (3) 5 (29) 
Not reported -- -- 1   (1) 2   (3) -- -- 
* Not homeless (private rental, home owner/purchaser, public/community housing, drug and alcohol treatment facility, workers’ 
accommodation, prison, nursing home, foster home); Primary homelessness (Sleeping rough, squat, long grass, boat, car); 
Secondary homelessness (Living with parent, siblings, or relatives, crisis accommodation); Tertiary homelessness (Boarding house, 
hostel, caravan park, backpackers, hotel, motel). Living situation question introduced in 2010. 
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Table 316 Number (%) of respondents by demographic characteristics, injector status and survey year 
(cont.) 
     2004    2007 2010 
Demographic characteristics IDU Non-IDU IDU Non-IDU IDU Non-IDU 
First time in prison (%)       
No -- -- 69 (79) 25 (33) 25 (81) 8 (47) 
Yes -- -- 18 (21) 50 (67) 6 (19) 9 (53) 
Not reported -- -- -- -- -- -- 
Lifetime imprisonments (%)       
One -- -- 18 (21) 50 (67) 11 (35) 13 (76) 
Two to four  -- -- 33 (38) 17 (23) 11 (35) 3 (18) 
Five to nine   -- -- 24 (28) 6  (8) 5 (16) 1   (6) 
Ten or more  -- -- 12 (14) 2  (3) 4 (13) -- 
Not reported -- -- -- -- -- -- 
Imprisonment in last year (%)       
No -- -- 22 (32) 6 (24) 16 (52) 13 (76) 
Yes -- -- 47 (68) 19 (76) 13 (42) 2 (12) 
Not reported -- -- -- -- 2   (6) 2 (12) 
Frequency of injection last month (%)      
Not last month -- -- 27 (31) -- 8 (26) -- 
Less than weekly -- -- 7   (8) -- 9 (29) -- 
Weekly not daily -- -- 17 (20) -- 1   (3) -- 
Daily or more -- -- 36 (41) -- 13 (42) -- 
Not reported -- -- -- -- -- -- 
Ever smoked a full cigarette (%)*      
No -- -- 1   (1) 12 (16) -- 2 (12) 
Yes -- -- 86 (99) 63 (84) 31 (100) 14 (82) 
Not reported -- -- -- -- -- 1   (6) 
Median age first smoked (years) -- -- 13 15 13 14 
    Age range -- -- 5 – 25  9 – 30 7 – 35 10 – 21 
Current smoker (%)*       
No -- -- 4   (5) 24 (32) 1   (3) 4 (24) 
Yes -- -- 83 (95) 51 (68) 30 (97) 12 (71) 
Not reported -- -- -- -- -- 1   (6) 
Smoking frequency (%)*       
Occasional – weekly or less -- -- 1   (1) 2   (4) -- -- 
5 to 10 cigarettes a day -- -- 30 (36) 19 (37) 9 (30) 6 (50) 
11 to 20 cigarettes a day -- -- 32 (39) 16 (31) 14 (47) 3 (25) 
Over 20 cigarettes a day -- -- 20 (24) 14 (27) 7 (23) 3 (25) 
Not reported -- -- -- -- -- -- 
Other drugs used last month (%)**      
No drugs in past 4 weeks -- -- n/a n/a 3 (14) 5 (42) 
Cannabis -- -- n/a n/a 14 (74) 6 (86) 
Heroin -- -- n/a n/a 9 (47) 1 (14) 
Cocaine -- -- n/a n/a 1   (5) 1 (14) 
Amphetamine -- -- n/a n/a 11 (58) 3 (43) 
Other's methadone -- -- n/a n/a 3 (16) -- 
Other opiates -- -- n/a n/a 6 (32) 1 (14) 
Other's buprenorphine -- -- n/a n/a 5 (26) -- 
Steroids -- -- n/a n/a 2 (11) -- 
Hallucinogens -- -- n/a n/a 3 (16) -- 
Benzodiazepines -- -- n/a n/a 10 (53) -- 
Ecstasy/MDA -- -- n/a n/a 2 (11) -- 
Inhalants (e.g. petrol) -- -- n/a n/a -- -- 
Other drug -- -- n/a n/a -- -- 
Not reported -- -- n/a n/a 9 (29) 5 (29) 
* Smoking questions not asked in 2004. 
** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected. 
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Table 317 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to 
survey and survey year 
Injecting behaviour 2004 2007 2010 
Last drug injected (%)  N = 87 N = 31 
Amphetamine (Speed, Ice) -- 37 (43) 12 (39) 
Anabolic steroids -- -- -- 
Cocaine -- 1   (1) -- 
Heroin -- 43 (49) 14 (45) 
Heroin + amphetamine -- 4   (5) -- 
Heroin + cocaine -- -- 2   (6) 
Methadone -- -- -- 
Morphine -- 2   (2) 2   (6) 
Other -- -- 1   (3) 
Not reported  -- -- 
No Injected last month -- N = 60  N = 23 
Places injected last month (%)* 
Prison -- 1   (2) 1   (4) 
Own home -- 47 (78) 15 (65) 
Friend’s home -- 32 (53) 8 (35) 
Dealer’s home -- 15 (25) 3 (13) 
Street, park, beach -- 21 (35) 7 (30) 
Car -- 34 (57) 9 (39) 
Public toilet -- 16 (27) 6 (26) 
Commercial injecting room -- -- -- 
Medically Supervised Injecting Centre, Sydney -- -- -- 
Squat -- 3   (5) 2 (9) 
Other place -- 6 (10) -- 
Use of sterile needles & syringes last month (%) 
All injections -- 44 (73) 11 (48) 
Most of the time -- 13 (22) 9 (39) 
Half of the time -- -- 2   (9) 
Some of the time -- 2   (3) 1   (4) 
Not last month -- -- -- 
Not reported  1   (2) -- 
Re-used someone else’s used needle & syringe last month (%) 
None -- 50 (83) 18 (78) 
Once -- 3   (5) 3 (13) 
Twice -- 2   (3) -- 
3-5 times -- 1   (2) -- 
>5 times -- 1   (2) 2   (9) 
Not reported -- 3   (5) -- 
Number of people needle & syringe was re-used after last month (%) 
None -- 50 (83) 18 (78) 
One -- 3   (5) 2   (9) 
Two -- 2   (3) -- 
Three to five -- 1   (2) 1   (4) 
More than five -- 1   (2) -- 
Don’t know how many -- -- 2   (9) 
Not reported  3   (5) -- 
Relationship to people needle & syringe was re-used after last month (%)*  
Regular sex partner -- 6 (10)  4 (17) 
Casual sex partner -- -- -- 
Close friend -- 3   (5) -- 
Acquaintance -- -- 2   (9) 
Other -- 1   (2) 1   (4) 
Equipment used after someone else last month (%)*  
Spoon -- 22 (37) 10 (43) 
Water -- 10 (17) 7 (30) 
Filter -- 11 (18) 6 (26) 
Tourniquet -- 4   (7) 3 (13) 
Drug mix -- 6 (10) 5 (22) 
* More than one option could be selected.  
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Table 318 Number (%) of respondents by treatment for drug use, injector status and survey year 
Treatment for drug use 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed -- -- N = 87 N = 75 N = 31 N = 17 
Any treatment/therapy for drug use (%)   
No -- -- 14 (16) 42 (56) 6 (19) 14 (82) 
Yes -- -- 71 (82) 13 (17) 24 (77) 3 (18) 
Not reported   2   (2) 20 (27) 1   (3) -- 
History of methadone maintenance treatment (%)   
Currently -- -- 37 (43) -- 9 (29) -- 
Previously -- -- 16 (18) -- 4 (13) -- 
Never -- -- 32 (37) -- 17 (55) 17 (100) 
Not reported   2   (2) -- 1   (3) -- 
History of other pharmacotherapy treatment (%)   
Currently -- -- 40 (46) -- 4 (13) -- 
Previously -- -- 12 (14) -- 7 (23) -- 
Never -- -- 35 (40) -- 19 (61) 17 (100) 
Not reported   -- -- 1   (3) -- 
 
 
Table 319 Number (%) of respondents by site of needle and syringe acquisition last month and survey 
year 
Needle & Syringe acquisition*        2004       2007 2010 
No surveyed -- N = 60 N = 31 
From an NSP last month (%)   
Daily or almost daily -- 13 (22) 7 (23) 
A couple of times each week -- 23 (38) 2   (6) 
Less than weekly -- 8 (13) 6 (19) 
Weekly -- n/a 2   (6) 
Once last month -- 7 (12) 1   (3) 
Not in the last month -- 9 (15) 12 (39) 
Not reported -- -- 1   (3) 
From a chemist last month (%)   
Daily or almost daily -- 1   (2) 2   (6) 
A couple of times each week -- 11 (18) 4 (13) 
Less than weekly --  5   (8) 2   (6) 
Weekly -- n/a 5 (16) 
Once last month -- 10 (17) -- 
Not in the last month -- 33 (55) 17 (55) 
Not reported -- --  1   (3) 
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Table 320 Number (%) of respondents by body piercing and tattoos 
Body piercing and tattoos 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed -- -- N = 87 N = 75 N = 31 N = 17 
Body or ear piercings (%)       
No -- -- 35 (40) 53 (71) 14 (45) 12 (71) 
Yes -- -- 52 (60) 22 (29) 17 (55) 5 (59) 
Not reported -- -- -- -- -- -- 
Pierced in past 12 mths (%)       
No -- -- 42 (81) 16 (73) 8 (47) 1 (20) 
Yes -- -- 6 (12) 4 (18) 2 (12) -- 
Not reported -- -- 4   (8) 2   (9) 7 (41) 4 (80) 
Who did piercing (%)*      
Chemist/hairdresser/beauty 
salon  
-- -- 1 (17) 2 (50) -- -- 
Professional piercer / studio -- -- 2 (33) -- -- -- 
Tattooist / parlour -- -- -- 2 (50) 1 (50) -- 
Friend -- -- 1 (17) -- 1 (50) -- 
Prison inmate -- -- -- -- -- -- 
Self -- -- 1 (17) -- 1 (50) -- 
Family member -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
Needle used by other (%)       
No  -- -- 1 (20) -- 2 (100) -- 
Yes -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
Not reported -- -- 4 (80) 4 (100) -- -- 
Tattoos (%)       
No -- -- 26 (30) 45 (60) 8 (26) 10 (59) 
Yes -- -- 61 (70) 30 (40) 23 (74) 7 (41) 
Not reported   -- -- -- -- 
Tattoos in past 12 mths (%)       
No  -- -- 41 (67) 17 (57) 16 (65) 3 (43) 
Yes -- -- 20 (33) 13 (43) 7 (30) 4 (57) 
Not reported -- -- -- -- 1   (4) -- 
Who did tattooing (%)*       
Professional tattooist -- -- 15 (75) 10 (77) 4 (57) 3 (75) 
Friend -- -- 4 (20) 1   (8) 1 (14) 3 (75) 
Prison inmate -- -- 4 (20) 1   (8) -- -- 
Self -- -- 1   (5) 2 (15) -- -- 
Family member -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
* More than one option could be selected.  
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Table 321 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by 
injector status and survey year 
Sexual behaviour 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed -- -- N = 87 N = 75 N = 31 N = 17 
Sex last month / last 3 months (%)**     
No -- -- 19 (22) 20 (27) 1 (11) 8 (12) 
Yes -- -- 68 (78) 55 (73) 8 (89) 57 (86) 
Not reported -- -- -- -- -- 1   (2) 
Male sex partners in last 3 months**    
    Median -- -- n/a n/a 1 0.5 
    Range -- -- n/a n/a 1 – 4 0 – 2 
Female sex partners in last 3 months**    
    Median -- -- n/a n/a 1 1 
    Range -- -- n/a n/a 0 - 20 0 – 5 
Condom use at last sex (%)        
No -- -- 69 (79) 48 (64) n/a  n/a  
Yes -- -- 18 (21) 27 (36) n/a  n/a  
Not reported -- -- -- -- n/a  n/a  
Condom use with regular sex partner(s) last month (%)*     
No -- -- 41 (85) 33 (70) n/a  n/a  
Sometimes -- -- 7 (15) 7 (15) n/a  n/a  
Always -- -- -- 7 (15) n/a  n/a  
Condom use with new sex partner(s) last month (%)*     
No -- -- 10 (56) 1 (13) n/a  n/a  
Sometimes -- -- 3 (17) 3 (38) n/a  n/a  
Always -- -- 5 (28) 4 (50) n/a  n/a  
Condom use with casual sex partner(s) last month (%)*      
No -- -- 15 (58) 3 (33) n/a  n/a  
Sometimes -- -- 4 (15) 3 (33) n/a  n/a  
Always -- -- 7 (27) 3 (33) n/a  n/a  
Condom use last sex - regular male partners - last 3 months (%)**   
Never -- -- n/a n/a 5 (83) -- 
Sometimes -- -- n/a n/a 1 (17) 1 (100) 
Always -- -- n/a n/a -- -- 
Condom use last sex - casual male partners - last 3 months (%)**   
Never -- -- n/a n/a 2 (50) -- 
Sometimes -- -- n/a n/a 1 (25) 1 (100) 
Always -- -- n/a n/a 1 (25) -- 
Condom use last sex - regular female partners - last 3 months (%)**   
Never -- -- n/a n/a 14 (78) 6 (46) 
Sometimes -- -- n/a n/a 4 (22) 4 (31) 
Always -- -- n/a n/a -- 3 (23) 
Condom use last sex - casual female partners - last 3 months (%)**   
Never -- -- n/a n/a 5 (42) 1 (100) 
Sometimes -- -- n/a n/a 4 (33) -- 
Always -- -- n/a n/a 3 (25) -- 
Sex work last month (%)      
No -- -- 85 (98) 74 (99) 27 (87) 15 (88) 
Yes -- -- 2   (2) -- 2   (6) 1   (6) 
Not reported -- -- -- 1   (1) 2   (6) 1   (6) 
Condom used at last sex work last month (%)    
No -- -- -- -- 1 (50) -- 
Yes -- -- 2 (100) -- 1 (50) 1 (100) 
Not reported -- -- -- -- -- -- 
Ever had cervical cancer vaccine (women only)*** (%)    
No  -- -- n/a n/a 2 (100) 1 (50) 
Yes -- -- n/a n/a -- 1 (50) 
Unsure -- -- n/a n/a -- -- 
* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month. 
** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded 
areas indicate previous survey items that were changed in 2010. 
*** Proportion of eligible women i.e. those under 27 years of age in 2007.   
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Table 322 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, 
HBV vaccination and HCV treatment by injector status and survey year 
Testing & treatment 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed --  -- N = 87  N = 75 N = 31  N = 17 
Previous HIV test (%)       
Yes, last year -- -- 43 (49) 13 (17) 13 (42) 5 (29) 
>1 year ago -- -- 28 (32) 19 (25) 13 (42) 5 (29) 
Never tested -- -- 16 (18) 43 (57) 4 (13) 6 (35) 
Not reported   -- -- 1   (3) 1   (6) 
HBV infection (%)      
No -- -- 67 (77) 72 (96) 25 (81) 13 (76) 
Yes -- -- 9 (10) -- 4 (13) 2 (12) 
Don’t know -- -- 11 (13) 2   (3) 2 (6) 2 (12) 
Not reported   -- 1   (1) -- -- 
HBV vaccination (%)*       
No -- -- 25 (29) 43 (57) 5 (16) 6 (35) 
Yes -- -- 51 (59) 20 (27) 15 (48) 6 (35) 
Don’t know -- -- 10 (11) 11 (15) 11 (35) 5 (29) 
Not reported   1   (1) 1   (1) -- -- 
Previous HCV test (%)       
Yes, last year -- -- 11 (13) 53 (71) 18 (58) 5 (29) 
>1 year ago -- -- 41 (47) 10 (13) 12 (39) 6 (35) 
Never tested -- -- 35 (40) 12 (16) 1   (3) 6 (35) 
Unsure -- -- -- -- -- -- 
Not reported -- -- -- -- -- -- 
Any HCV treatment (%)**   N = 46  N = 3 N = 9  N = 1 
Interferon -- -- -- -- -- -- 
Interferon & Ribavirin -- -- -- -- -- -- 
Pegasys & Ribavirin -- -- 1   (2) -- -- -- 
Other -- -- -- -- -- -- 
No treatment -- -- 45 (98) 3 (100) 9 (100) 1 (100) 
Not reported -- -- -- -- -- -- 
Current HCV treatment        
Interferon -- -- -- -- -- -- 
Interferon & Ribavirin -- -- -- -- -- -- 
Pegasys & Ribavirin -- -- 1   (2) -- -- -- 
Other -- -- -- -- -- -- 
* Number (%) among participants with no history of HBV infection. 




HIV antibody prevalence 
Table 323 HIV antibody prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
2004       
IDU -- -- -- -- -- -- 
Non-IDU -- -- -- -- -- -- 
p value  --  --  -- 
2007       
IDU 59 0 (0) 5 0 (0) 64 0 (0) 
Non-IDU 49 0 (0) 4 0 (0) 53 0 (0) 
p value  --  --  -- 
2010       
IDU 17 0 (0) 3 0 (0) 20 0 (0) 
Non-IDU 9 0 (0) 2 0 (0) 11 0 (0) 
p value  --  --  -- 
† Excludes equivocal test results and missing values.   
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HCV antibody prevalence 
Table 324 HCV antibody prevalence by sex, injector status and survey year† 
 Male Female Total 
Injector status No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
IDU -- -- -- -- -- -- 
Non-IDU -- -- -- -- -- -- 
p value  --  --  -- 
2007       
IDU 49 2   (4) 4 1    (25) 53 3   (6) 
Non-IDU 59 40 (68) 7 6    (86) 66 46 (70) 
p value  <0.001  0.04  <0.001 
2010       
IDU 15 6 (40) 3 3  (100) 18 9 (50) 
Non-IDU 10 1 (10) 2 0      (0) 12 1   (8) 
p value  0.1  0.03  0.02 
† Excludes equivocal test results and missing values. 
 
 
Table 325 HCV antibody prevalence by sexual identity, sex and survey year† 
  Male Female Total  
Sexual identity No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Heterosexual -- -- -- -- -- -- 
Bisexual -- -- -- -- -- -- 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value  --  --  -- 
2007       
Heterosexual 106 42   (40) 9 6   (67) 115 48   (42) 
Bisexual -- -- 1 0     (0) 1 0     (0) 
Homosexual 1 0     (0) -- -- 1 0     (0) 
Unsure 1 0     (0) 1 1 (100) 2 1   (50) 
p value  0.5  0.3  0.5 
2010       
Heterosexual 23 6   (26) 4 2   (50) 27 8   (30) 
Bisexual -- -- 1 1 (100) 1 1 (100) 
Homosexual 1 1 (100) -- -- 1 1 (100) 
Unsure -- -- -- -- -- -- 
p value  0.1  0.4  0.1 
† Excludes equivocal test results and missing values. 
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Table 326 HCV antibody prevalence by age group, sex and survey year† 
 Male Female Total  
Age group N
o tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
< 20 years -- -- -- -- -- -- 
20 – 24 -- -- -- -- -- -- 
25 – 29 -- -- -- -- -- -- 
30 + years -- -- -- -- -- -- 
p value  --  --  -- 
2007       
< 20 years 6 0   (0) -- -- 6 0   (0) 
20 – 24 21 4 (19) -- -- 21 4 (19) 
25 – 29 25 17 (68) 3 2   (67) 28 19 (68) 
30 + years 56 21 (38) 8 5    63) 64 26 (41) 
p value  0.001  0.9  0.001 
2010       
< 20 years -- -- -- -- -- -- 
20 – 24 8 3 (38) -- -- 8 3 (38) 
25 – 29 5 1 (20) 3 1   (33) 8 2 (25) 
30 + years 12 3 (25) 2 2 (100) 14 5 (36) 
p value  0.8  0.1  0.8 
† Excludes equivocal test results and missing values. 
 
 
Table 327 HCV antibody prevalence by duration of drug injection, sex and survey year† 
 Male Female Total  
Duration of drug injection No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
<3 years -- -- -- -- -- -- 
3 to 5 years -- -- -- -- -- -- 
6 to 10 years -- -- -- -- -- -- 
10 + years -- -- -- -- -- -- 
p value  --  --  -- 
2007       
<3 years 3 0   (0) -- -- 3 0   (0) 
3 to 5 years 7 4 (57) 1 1 (100) 8 5 (63) 
6 to 10 years 17 9 (53) 2 1   (50) 19 10 (53) 
10 + years 32 27 (84) 4 4 (100) 36 31 (86) 
p value  0.006  0.2  0.003 
2010       
<3 years 2 0   (0) -- -- 2 0   (0) 
3 to 5 years 4 2 (50) -- -- 4 2 (50) 
6 to 10 years 3 1 (33) 1 1 (100) 4 2 (50) 
10 + years 6 3 (50) 2 2 (100) 8 5 (63) 
p value  0.6  --  0.5 
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Table 328 HCV antibody prevalence by last drug injected, duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Last drug injected No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Amphetamine (Speed, Ice) -- -- -- -- -- -- 
Heroin -- -- -- -- -- -- 
More than one -- -- -- -- -- -- 
Other/not reported -- -- -- -- -- -- 
     p value  --  --  -- 
2007       
Amphetamine (Speed, Ice) 3 0 (0) 27 15   (56) 30 15   (50) 
Heroin -- -- 30 26   (87) 30 26   (87) 
More than one -- -- 4 3   (75) 4 3   (75) 
Other/not reported -- -- 2 2 (100) 2 2 (100) 
     p value  --  0.05  0.02 
2010       
Amphetamine (Speed, Ice) 1 0 (0) 5 3   (60) 6 3   (50) 
Heroin 1 0 (0) 7 5   (71) 8 5   (63) 
More than one -- -- 2 0     (0) 2 0     (0) 
Other/not reported -- -- 2 1   (50) 2 1   (50) 
     p value  --  0.4  0.5 
† Excludes equivocal test results and missing values. 
 
 
Table 329 HCV antibody prevalence by frequency of injection last month, duration of drug injection 
and survey year† 
 <3 years IDU 3+ years IDU Total  
Frequency of drug injection 
last month 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Less than daily -- -- -- -- -- -- 
Daily or more -- -- -- -- -- -- 
p value  --  --  -- 
2007       
Less than daily -- -- 20 16 (80) 20 16 (80) 
Daily or more -- -- 26 23 (88) 26 23 (88) 
p value  --  0.4  0.4 
2010       
Less than daily -- -- 5 2 (40) 5 2 (40) 
Daily or more 2 0 (0) 8 6 (75) 10 6 (60) 
p value  --  0.2  0.5 
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Table 330 HCV antibody prevalence by re-use of someone else’s used needle and syringe last month, 
duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Re-used someone else’s used 
needle & syringe last month 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
No -- -- -- -- -- -- 
Yes -- -- -- -- -- -- 
p value  --  --  -- 
2007       
No -- -- 36 30   (83) 36 30   (83) 
Yes -- -- 9 8   (89) 9 8   (89) 
p value  --  0.7  0.7 
2010       
No 2 0 (0) 9 5   (56) 11 5   (45) 
Yes -- -- 2 2 (100) 2 2 (100) 
p value  --  0.2  0.2 
† Excludes equivocal test results and missing values. 
 
 
Table 331 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey 
year† 
 <3 years IDU 3+ years IDU Total  
Imprisonment last year No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
No -- -- -- -- -- -- 
Yes -- -- -- -- -- -- 
p value  --  --  -- 
2007       
No -- -- 13 10 (77) 13 10 (77) 
Yes 1 0  (0) 35 32 (91) 36 32 (89) 
p value  --  0.2  0.3 
2010       
No 1 0  (0) 8 5 (63) 9 5 (56) 
Yes -- -- 8 4 (50) 8 4 (50) 
p value  --  0.6  0.8 
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Table 332 HCV antibody by number of previous imprisonments, sex and survey year† 
 Male Female Total  
Number of previous 
imprisonments 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
1 -- -- -- -- -- -- 
2 to 4 -- -- -- -- -- -- 
5 to 9 -- -- -- -- -- -- 
10 + -- -- -- -- -- -- 
p value  --  --  -- 
2007       
1 48 2   (4) 6 3   (50) 54 5   (9) 
2 to 4 33 17 (52) 3 2   (67) 36 19 (53) 
5 to 9 17 15 (88) 2 2 (100) 19 17 (89) 
10 + 10 8 (80) -- -- 10 8 (80) 
p value  <0.001  0.4  <0.001 
2010       
1 13 4 (31) 2 0     (0) 15 4 (27) 
2 to 4 8 2 (25) 2 2 (100) 10 4 (40) 
5 to 9 3 1 (33) -- -- 3 1 (33) 
10 + 1 0   (0) 1 1 (100) 2 1 (50) 
p value  0.9  0.08  0.9 
† Excludes equivocal test results and missing values. 
 
 
Table 333 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Non-Indigenous -- -- -- -- -- -- 
Indigenous -- -- -- -- -- -- 
p value   --  --  -- 
2007       
Non-Indigenous 100 37 (37) 10 6   (60) 110 43 (39) 
Indigenous 8 5 (63) 1 1 (100) 9 6 (67) 
p value  0.2  0.4  0.1 
2010       
Non-Indigenous 22 6 (27) 5 3   (60) 27 9 (33) 
Indigenous 3 1 (33) -- -- 3 1 (33) 
p value  0.8  --  1.0 
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Table 334 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector 
status and survey year† 
 Non-IDU IDU Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Non-Indigenous -- -- -- -- -- -- 
Indigenous -- -- -- -- -- -- 
p value   --  --  -- 
2007       
Non-Indigenous 51 3 (6) 59 40 (68) 110 43 (39) 
Indigenous 2 0 (0) 7 6 (86) 9 6 (67) 
p value  0.7  0.3  0.1 
2010       
Non-Indigenous 11 1 (9) 16 8 (50) 27 9 (33) 
Indigenous 1 0 (0) 2 1 (50) 3 1 (33) 
p value  0.8  1.0  1.0 
† Excludes equivocal test results and missing values. 
 
 
Table 335 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and 
survey year† 
  Male Female Total  
Residential remoteness No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Highly accessible/accessible -- -- -- -- -- -- 
Moderately accessible -- -- -- -- -- -- 
Remote/very remote -- -- -- -- -- -- 
p value  --  --  -- 
2007       
Highly accessible/accessible 98 42 (43) 11 7 (64) 109 49 (45) 
Moderately accessible 6 0   (0) -- -- 6 0   (0) 
Remote/very remote 1 0   (0) -- -- 1 0   (0) 
p value  0.08  --  0.07 
2010       
Highly accessible/accessible 21 7 (33) 5 3 (60) 26 10 (39) 
Moderately accessible -- -- -- -- -- -- 
Remote/very remote 2 0   (0) -- -- 2 0   (0) 
p value  0.3  --  0.3 
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Table 336 HCV antibody prevalence by region/country of birth, sex and survey year† 
 Male Female Total  
Region/Country of birth No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Australia -- -- -- -- -- -- 
Other Oceania -- -- -- -- -- -- 
Asia -- -- -- -- -- -- 
UK & Ireland -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
p value   --  --  -- 
2007       
Australia 88 31   (35) 8 5   (63) 96 36   (38) 
Other Oceania 3 1   (33) 1 0     (0) 4 1   (25) 
Asia 8 5   (63) 1 1 (100) 9 6   (67) 
UK & Ireland 3 3 (100) 1 1 (100) 4 4 (100) 
Other 6 2   (33) -- -- 6 2   (33) 
p value  0.1  0.4  0.6 
2010       
Australia 22 6   (27) 3 3 (100) 25 9   (36) 
Other Oceania -- -- -- -- -- -- 
Asia 1 0     (0) 2 0     (0) 3 0     (0) 
UK & Ireland -- -- -- -- -- -- 
Other 2 1   (50) -- -- 2 1   (50) 
p value  0.7  0.03  0.4 
† Excludes equivocal test results and missing values. 
 
 
Table 337 HCV antibody prevalence by main language spoken at home by parents, sex and survey 
year† 
 Male Female Total  
Main language spoken at 
home by parents 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
English  -- -- -- -- -- -- 
Non-English  -- -- -- -- -- -- 
p value   --  --  -- 
2007       
English  93 34 (37) 10 6   (60) 103 40 (39) 
Non-English  14 7 (50) 1 1 (100) 15 8 (53) 
p value  0.3  0.4  0.3 
2010       
English  23 7 (30) 4 3   (75) 27 10 (37) 
Non-English  2 0   (0) 1 0     (0) 3 0   (0) 
p value  0.4  0.2  0.2 
† Excludes equivocal test results and missing values. 
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Table 338 Self-reported HCV status versus HCV serology by sex and survey year† 
 Male Female Total  
Self-report HCV No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Positive -- -- -- -- -- -- 
Negative -- -- -- -- -- -- 
Not sure -- -- -- -- -- -- 
p value  --  --  -- 
2007       
Positive 35 35 (100) 7 7 (100) 42 42 (100) 
Negative 24 4   (17) 2 0     (0) 26 4   (15) 
Not sure 2  0     (0) -- -- 2 0     (0) 
p value  <0.001  0.003  <0.001 
2010       
Positive 4 4 (100) 3 3 (100) 7 7 (100) 
Negative 14 1     (7) 1 0     (0) 15 1     (7) 
Not sure 3 1   (33) -- -- 3 1   (33) 
p value  0.001  0.05  <0.001 





Table 339 HBV surface-antigen prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
IDU -- -- -- -- -- -- 
Non-IDU -- -- -- -- -- -- 
p value   --  --  -- 
2007       
IDU 59 4 (7) 6 0   (0) 65 4 (6) 
Non-IDU 49 0 (0) 2 0   (0) 51 0 (0) 
p value  0.06  --  0.07 
2010       
IDU 15 0 (0) 3 0   (0) 18 0 (0) 
Non-IDU 12 0 (0) 2 1 (50) 14 1 (7) 
p value  --  0.2  0.3 
† Excludes equivocal test results and missing values. 
 
 
Table 340 HBV core-antibody prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
IDU -- -- -- -- -- -- 
Non-IDU -- -- -- -- -- -- 
p value   --  --  -- 
2007       
IDU 56 23 (41) 6 2   (33) 62 25 (40) 
Non-IDU 49 2   (4) 4 0     (0) 53 2   (4) 
p value  <0.001  0.2  <0.001 
2010       
IDU 15 2 (13) -- -- 15 2 (13) 
Non-IDU 12 1   (8) 1 1 (100) 13 2 (15) 
p value  0.7  --  0.9 
† Excludes equivocal test results and missing values. 
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Table 341 HBV core-antibody prevalence by sexual identity, sex and survey year† 
  Male Female Total  
Sexual identity No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Heterosexual -- -- -- -- -- -- 
Bisexual -- -- -- -- -- -- 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value   --  --  -- 
2007       
Heterosexual 103 25 (24) 8 1   (13) 111 26 (23) 
Bisexual -- -- 1 0     (0) 1 0   (0) 
Homosexual 1 0   (0) -- -- 1 0   (0) 
Unsure 1 0   (0) 1 1 (100) 2 1 (50) 
p value  0.7  0.1  0.7 
2010       
Heterosexual 25 2   (8) 1 1 (100) 26 3 (12) 
Bisexual -- -- -- -- -- -- 
Homosexual 1 0   (0) -- -- 1 0   (0) 
Unsure -- -- -- -- -- -- 
p value  0.8  --  0.7 
† Excludes equivocal test results and missing values. -- 
 
 
Table 342 HBV core-antibody prevalence by age group, sex and survey year† 
 Male Female Total  
Age group No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
< 20 years -- -- -- -- -- -- 
20 – 24 -- -- -- -- -- -- 
25 – 29 -- -- -- -- -- -- 
30 + years -- -- -- -- -- -- 
p value  --  --  -- 
2007       
< 20 years 5 0   (0) -- -- 5 0   (0) 
20 – 24 21 3 (14) -- -- 21 3 (14) 
25 – 29 25 9 (36) 2 0     (0) 27 9 (33) 
30 + years 54 13 (24) 8 2   (25) 62 15 (24) 
p value  0.2  0.4  0.3 
2010       
< 20 years -- -- -- -- -- -- 
20 – 24 9 0   (0) -- -- 9 0   (0) 
25 – 29 4 0   (0) 1 1 (100) 5 1 (20) 
30 + years 14 3 (21) -- -- 14 3 (21) 
p value  0.2  --  0.3 
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Table 343 HBV core-antibody prevalence by duration of drug injection, sex and survey year† 
 Male Female Total  
Duration of drug injection No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
<3 years -- -- -- -- -- -- 
3 to 5 years -- -- -- -- -- -- 
6 to 10 years -- -- -- -- -- -- 
10 + years -- -- -- -- -- -- 
p value  --  --  -- 
2007       
<3 years 4 0   (0) -- -- 4 0   (0) 
3 to 5 years 7 3 (43) 1 0   (0)   8 3 (38) 
6 to 10 years 16 7 (44) 2 1 (50) 18 8 (44) 
10 + years 29 13 (45) 3 1 (33) 32 14 (44) 
p value  0.4  0.7  0.4 
2010       
<3 years 2 0   (0) -- -- 2 0   (0) 
3 to 5 years 2 0   (0) -- -- 2 0   (0) 
6 to 10 years 3 0   (0) -- -- 3 0   (0) 
10 + years 8 2 (25) -- -- 8 2 (25) 
p value  0.6  --  0.6 
† Excludes equivocal test results and missing values. 
 
 
Table 344 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey 
year† 
 <3 years IDU 3+ years IDU Total  
Last drug injected No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Amphetamine (Speed, Ice) -- -- -- -- -- -- 
Heroin -- -- -- -- -- -- 
More than one -- -- -- -- -- -- 
Other/not reported -- -- -- -- -- -- 
     p value  --  --  -- 
2007       
Amphetamine (Speed, Ice) 4 0 (0) 24 6   (25) 28 6   (21) 
Heroin -- -- 28 15   (54) 28 15   (54) 
More than one -- -- 4 2   (50) 4 2   (50) 
Other/not reported -- -- 2 2 (100) 2 2 (100) 
     p value  --  0.07  0.03 
2010       
Amphetamine (Speed, Ice) 1 0 (0) 4 1   (25) 5 1   (20) 
Heroin 1 0 (0) 5 1   (20) 6 1   (17) 
More than one -- -- 2 0     (0) 2 0     (0) 
Other/not reported -- -- 2 0     (0) 2 0     (0) 
     p value  --  0.8  0.8 




National Prison Entrants’ Bloodborne Virus & Risk Behaviour Survey 2004, 2007, and 2010 
Victoria 
 186 
Table 345 HBV core-antibody prevalence by frequency of injection last month, duration of drug 
injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Frequency of drug injection 
last month 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Less than daily -- -- -- -- -- -- 
Daily or more -- -- -- -- -- -- 
p value  --  --  -- 
2007       
Less than daily -- -- 19 11 (58) 19 11 (58) 
Daily or more 1 0 (0) 23 12 (52) 24 12 (50) 
p value  --  0.7  0.6 
2010       
Less than daily -- -- 4 0   (0) 4 0   (0) 
Daily or more 2 0 (0) 7 1 (14) 9 1 (11) 
p value  --  0.4  0.5 
† Excludes equivocal test results and missing values. 
 
 
Table 346 HBV core antibody prevalence by re-use of someone else’s used needle and syringe last 
month, duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Re-used someone else’s used 
needle & syringe last month 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
No -- -- -- -- -- -- 
Yes -- -- -- -- -- -- 
p value  --  --  -- 
2007       
No 1 0 (0) 35 18 (51) 36 18 (50) 
Yes -- -- 6 4 (67) 6 4 (67) 
p value  --  0.5  0.5 
2010       
No 2 0 (0) 7 1 (14) 9 1 (11) 
Yes -- -- 2 0   (0) 2 0   (0) 
p value  --  0.6  0.6 
† Excludes equivocal test results and missing values. 
 
 
Table 347 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and 
survey year† 
 <3 years IDU 3+ years IDU Total  
Imprisonment last year No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
No -- -- -- -- -- -- 
Yes -- -- -- -- -- -- 
p value  --  --  -- 
2007       
No -- -- 11 4 (36) 11 4 (36) 
Yes 1 0 (0) 33 16 (48) 34 16 (47) 
p value  --  0.5  0.5 
2010       
No 1 0 (0) 5 2 (40) 6 2 (33) 
Yes -- -- 8 0   (0) 8 0   (0) 
p value  --  0.05  0.08 
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Table 348 HBV core-antibody by number of previous imprisonments, sex and survey year† 
 Male Female Total  
Number of previous 
imprisonments 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
1 -- -- -- -- -- -- 
2 to 4 -- -- -- -- -- -- 
5 to 9 -- -- -- -- -- -- 
10 + -- -- -- -- -- -- 
p value  --  --  -- 
2007       
1 48 5 (10) 6 1   (17) 54 6 (11) 
2 to 4 33 9 (27) 3 0     (0) 36 9 (25) 
5 to 9 14 7 (50) 1 1 (100) 15 8 (53) 
10 + 10 4 (40) -- -- 10 4 (40) 
p value  0.008  0.09  0.003 
2010       
1 14 1   (7) 1 0     (0) 15 2 (13) 
2 to 4 7 1 (14) -- -- 7 1 (14) 
5 to 9 3 0   (0) -- -- 3 0   (0) 
10 + 3 1 (33) -- -- 3 1 (33) 
p value  0.5  --  0.7 
† Excludes equivocal test results and missing values. 
 
 
Table 349 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Non-Indigenous -- -- -- -- -- -- 
Indigenous -- -- -- -- -- -- 
p value  --  --  -- 
2007       
Non-Indigenous 97 20 (21) 9 2   (22) 106 22 (21) 
Indigenous 8 5 (63) 1 0     (0) 9 5 (56) 
p value  0.008  0.6  0.02 
2010       
Non-Indigenous 23 2   (9) 1 1 (100) 24 3  (13) 
Indigenous 4 1 (25) -- -- 4 1  (25) 
p value  0.3  --  0.5 




National Prison Entrants’ Bloodborne Virus & Risk Behaviour Survey 2004, 2007, and 2010 
Victoria 
 188 
Table 350 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector 
status and survey year† 
 Non-IDU IDU Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Non-Indigenous -- -- -- -- -- -- 
Indigenous -- -- -- -- -- -- 
p value  --  --  -- 
2007       
Non-Indigenous 51 2   (4) 55 20 (36) 106 22 (21) 
Indigenous 2 0   (0) 7 5 (71) 9 5 (56) 
p value  0.8  0.08  0.02 
2010       
Non-Indigenous 12 2 (17) 12 1   (8) 24 3 (13) 
Indigenous 1 0   (0) 3 1 (33) 4 1 (25) 
p value  0.7  0.3  0.5 
† Excludes equivocal test results and missing values. 
 
 
Table 351 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before 
prison and survey year† 
  Male Female Total  
Residential remoteness No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Highly accessible/accessible -- -- -- -- -- -- 
Moderately accessible -- -- -- -- -- -- 
Remote/very remote -- -- -- -- -- -- 
p value  --  --  -- 
2007       
Highly accessible/accessible 96 25 (26) 10 2   (20) 106 27 (25) 
Moderately accessible 6 0   (0) -- -- 6 0   (0) 
Remote/very remote -- -- -- -- -- -- 
p value  0.2  --  0.2 
2010       
Highly accessible/accessible 23 2   (9) 1 1 (100) 24 3 (13) 
Moderately accessible -- -- -- -- -- -- 
Remote/very remote 2 0   (0) -- -- 2 0   (0) 
p value  0.7  --  0.6 
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Table 352 HBV core-antibody prevalence by region/country of birth, sex and survey year† 
 Male Female Total  
Region/Country of birth No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Australia -- -- -- -- -- -- 
Other Oceania -- -- -- -- -- -- 
Asia -- -- -- -- -- -- 
UK & Ireland -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
p value  --  --  -- 
2007       
Australia 85 17   (20) 7 2   (29) 92 19  (21) 
Other Oceania 3 0     (0) 1 0     (0) 4 0    (0) 
Asia 8 4   (50) 1 0     (0) 9 4  (44) 
UK & Ireland 3 3 (100) 1 0     (0) 4 3  (75) 
Other 6 1   (17) -- -- 6 1  (17) 
p value  0.006  0.8  0.04 
2010       
Australia 24 2     (8) -- -- 24 2    (8) 
Other Oceania -- -- -- -- -- -- 
Asia 1 0     (0) 1 1 (100) 2 1  (50) 
UK & Ireland -- -- -- -- -- -- 
Other 2 1   (50) -- -- 2 1  (50) 
p value  0.2  --  0.09 
† Excludes equivocal test results and missing values. 
 
 
Table 353 HBV core-antibody prevalence by main language spoken at home by parents, sex and 
survey year† 
 Male Female Total  
Main language spoken at 
home by parents 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
English  -- -- -- -- -- -- 
Non-English  -- -- -- -- -- -- 
p value  --  --  -- 
2007       
English  90 19 (21) 9 2   (22) 99 21 (21) 
Non-English  14 5 (36) 1 0     (0) 15 5 (33) 
p value  0.3  0.6  0.3 
2010       
English  24 2   (8) -- -- 24 2   (8) 
Non-English  3 1 (33) 1 1 (100) 4 2 (50) 
p value  0.2  --  0.03 
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Table 354 Hepatitis B virus immune status by injector status and survey year† 
  Hepatitis B Virus Immune Status 
Injector status No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
IDU -- -- -- -- -- 
Non-IDU -- -- -- -- -- 
p value     -- 
 
 
2007     
IDU 67 26 (39) 24 (36) 4   (6) 13   (9)
Non-IDU 53 45 (85) 2   (4) 0   (0) 6 (11) 
p value     <0.001 
2010      
IDU 19 7 (37) 2 (11) 0   (0) 10 (53) 
Non-IDU 14 8 (57) 1   (7) 1   (7) 4 (29) 
p value     0.3 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.   
 
 
Table 355 Hepatitis B virus immune status by sexual identity and survey year† 
  Hepatitis B Virus Immune Status 
Sexual identity No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
Heterosexual  -- -- -- -- -- 
Bisexual -- -- -- -- -- 
Homosexual -- -- -- -- -- 
Unsure -- -- -- -- -- 
p value     -- 
2007      
Heterosexual  116 68   (59) 25 (22) 4 (3) 19   (16) 
Homosexual 1 1 (100)  0   (0) 0 (0) 0     (0) 
Bisexual 1 1 (100) 0   (0) 0 (0) 0     (0) 
Unsure 2 1   (50) 1 (50) 
 
0 (0) 0     (0) 
p value     1.0 
2010      
Heterosexual  30 14   (47) 2   (7) 1 (3) 13   (43) 
Homosexual 1 1 (100) 0   (0) 0 (0) 0     (0) 
Bisexual 1 0     (0) 0  ( 0) 0 (0) 1 (100) 
Unsure -- -- -- -- -- 
p value     0.8 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
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Table 356 Hepatitis B virus immune status by age group and survey year† 
  Hepatitis B Virus Immune Status 
Age group No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
< 20 years -- -- -- -- -- 
20 – 24 -- -- -- -- -- 
25 – 29 -- -- -- -- -- 
30 + years -- -- -- -- -- 
p value     -- 
2007      
< 20 years 6 3 (50) 1 (17) 0  (0) 2 (33) 
20 – 24 21 11 (52) 2 (10) 1  (5) 7 (33) 
25 – 29 29 14 (48) 9 (31) 1  (3) 5 (17) 
30 + years 64 43 (67) 14 (22) 2  (3) 5   (8) 
p value     0.2 
2010      
< 20 years -- -- -- -- -- 
20 – 24 9 4 (44) 0   (0) 0   (0) 5 (56) 
25 – 29 7 3 (43) 0   (0) 1 (14) 3 (43) 
30 + years 17 8 (47) 3 (18) 0   (0) 6 (35) 
p value     0.3 
† Excludes equivocal test results and missing values. 
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 357 Hepatitis B virus immune status by number of previous imprisonments and survey year† 






No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
1 -- -- -- -- -- 
2 to 4 -- -- -- -- -- 
5 to 9 -- -- -- -- -- 
10 + -- -- -- -- -- 
p value     -- 
2007      
1 55 42 (76) 6 (11) 1   (2) 6 (11) 
2 to 4 36 24 (67) 8 (22) 1   (3) 3   (8) 
5 to 9 19 3 (16) 10 (53) 0   (0) 6 (32) 
10 + 10 2 (20) 2 (20) 2 (20) 4 (40) 
p value     <0.001 
2010      
1 17 10 (59) 1   (6) 1   (6) 5 (29) 
2 to 4 8 3 (38) 1 (13) 0   (0) 4 (50) 
5 to 9 4 1 (25) 0   (0) 0   (0) 3 (75) 
10 + 4 1 (25) 1 (25) 0   (0) 2 (50) 
p value     0.7 
† Excludes equivocal test results and missing values.   
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Table 358 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey 
year† 






No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
Non-Indigenous -- -- -- -- -- 
Indigenous -- -- -- -- -- 
p value     -- 
2007      
Non-Indigenous 111 69 (62) 21 (19) 4 (4) 17  (15) 
Indigenous 9 2 (22) 5 (56) 0 (0) 2  (22) 
p value     0.05 
2010      
Non-Indigenous 28 15 (54) 2   (7) 1 (4) 10  (36) 
Indigenous 5 0   (0) 1 (20) 0 (0) 4  (80) 
p value     0.1 
† Excludes equivocal test results and missing values. 
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 359 Hepatitis B virus immune status by residential remoteness and survey year† 
  Hepatitis B Virus Immune Status 
Residential remoteness No 
tested 
No (%) with no 
evidence of 
HBV immunity 






No (%) vaccine 
conferred 
immunity* 
2004      
Highly accessible/accessible -- -- -- -- -- 
Moderately accessible -- -- -- -- -- 
Remote/very remote -- -- -- -- -- 
p value     -- 
2007      
Highly accessible/accessible 110 62   (56) 25   (23) 4 (4) 19 (17) 
Moderately accessible 6 6 (100) 0     (0) 0 (0) 0   (0) 
Remote/very remote 1 0     (0) 1 (100) 0 (0) 0   (0) 
p value     0.2 
2010      
Highly accessible/accessible 29 14   (48) 2     (7) 1 (3) 12 (41) 
Moderately accessible -- -- -- -- -- 
Remote/very remote 2 1   (50) 0     (0) 0 (0) 1 (50) 
p value     0.9 
† Excludes equivocal test results and missing values.  
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Table 360 Hepatitis B virus immune status by main language spoken at home by parents and survey 
year† 
  Hepatitis B Virus Immune Status 
Main language 




No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
English  -- -- -- -- -- 
Non-English -- -- -- -- -- 
p value     -- 
2007      
English  104 62 (60) 22 (21) 2   (2) 18 (17) 
Non-English 15 9 (60) 3 (20) 2 (13) 1   (7) 
p value     0.1 
2010      
English  28 13 (46) 2   (7) 0   (0) 13 (46) 
Non-English 5 2 (40) 1 (20) 1 (20) 1 (20) 
p value     0.07 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 361 Self-reported hepatitis B immunisation versus serological testing and survey year*  
 Male Female Total  
Self-report HBV 
immunisation** 
No tested No immune 
(%) 
No tested No immune 
(%) 
No tested No immune 
(%) 
2004       
No -- -- -- -- -- -- 
Yes -- -- -- -- -- -- 
Not sure -- -- -- -- -- -- 
p value  --  --  -- 
2007       
No 38 3   (8) 4 0     (0) 42 3   (7) 
Yes 26 12 (46) 5 2   (40) 31 14 (45) 
Not sure 16 2 (13) 1 0     (0) 17 2 (12) 
p value  0.001  0.3  <0.001 
2010       
No 5 1 (20) 0 0     (0) 5 1 (20) 
Yes 12 8 (67) 2 2 (100) 14 10 (71) 
Not sure 10 3 (30) -- -- 10 3 (30) 
p value  0.4  --  0.05 
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  











Table 362 Genital chlamydia prevalence by sex and survey year† 
Sex  No tested No with 
chlamydia (%) 
2010   
Male  19 1 (5) 
Female 6 0 (0) 
p value  0.6 




Table 363 Genital gonorrhoea prevalence by sex and survey year† 
Sex  No tested No with 
gonorrhoea (%) 
2010   
Male  19 0 (0) 
Female 6 0 (0) 
p value  -- 




Table 364 Syphilis markers by sex and survey year† 








No with any 
marker for 
syphilis (%) 
2010     
Male  27 1 (4) 0 (0) 1 (4) 
Female 6 0 (0) 0 (0) 0 (0) 
p value  0.6 -- 0.6 
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Western Australia 
2004, 2007, 2010 
Table 365 Number (%) of respondents by demographic characteristics, injector status and survey year  
     2004    2007 2010 
Demographic characteristics IDU Non-IDU IDU Non-IDU IDU Non-IDU 
Number of sites surveyed N = 3 N = 4 N = 2 
No surveyed N = 66 N = 47 N = 55  N = 43 N = 77  N = 45 
Sex (%)       
Male 51 (77) 38 (81) 47 (85) 41   (95) 72 (94) 42 (93) 
Female 15 (23) 9 (19) 8 (15) 2     (5) 5   (6) 3   (7) 
Transgender -- -- -- -- -- -- 
Sexual identity (%)       
Heterosexual 64 (97) 46 (98) 53 (96) 43 (100) 75 (97) 43 (96) 
Bisexual 2   (3) -- -- -- -- 1   (2) 
Homosexual -- 1   (2) 2   (4) -- 1   (1) 1   (2) 
Unsure   -- -- 1   (1) -- 
Not reported   -- -- -- -- 
Age and duration of injection (years)      
Median age (years) 30 30 33 27 29 26 
    Age range 27 – 35 18 – 60 19 – 53 19 – 65 13 – 57 18 – 74 
Age group (%)       
    <25 years 18 (27) 15 (32) 14 (25) 14 (33) 18 (23) 20 (44) 
    25+ years 43 (65) 32 (68) 41 (75) 29 (67) 58 (75) 25 (56) 
    Not reported 5   (8) -- -- -- 1   (1) -- 
Median age 1stIDU (years) 19 -- 19 -- 18 -- 
    Age range 10 – 39 -- 14 – 44 -- 8 – 36 -- 
    Not reported 2 -- 1 -- 2 -- 
Median years IDU 8 -- 12 -- 10 -- 
    Range <1 – 26 -- <1 – 35 -- <1 – 28 -- 
Duration of drug injection (%)      
    <3 years 10 (16) -- 6 (11) -- 11 (14) -- 
    3+ years 52 (84) -- 48 (87) -- 63 (82) -- 
    Not reported  -- 1   (2) -- 3   (4) -- 
Aboriginal and Torres Strait Islander origin (%)     
No 40 (61) 30 (64) 36 (65) 26 (60) 46 (60) 35 (78) 
Yes 26 (39) 17 (36) 17 (31) 17 (40) 31 (40) 10 (22) 
Not reported   2   (4) -- -- -- 
Living situation prior to prison (%)*      
Not homeless n/a n/a n/a n/a 68 (88) 40 (89) 
Primary homelessness n/a n/a n/a n/a 3   (4) -- 
Secondary homelessness n/a n/a n/a n/a 4   (5) 2   (4) 
Tertiary homelessness n/a n/a n/a n/a 2   (3) 3   (7) 
Not reported n/a n/a n/a n/a -- -- 
Residential remoteness in 12 months before prison (%)     
 Highly accessible/accessible 51 (77) 35 (74) 47 (85) 29 (67) 69 (90) 40 (89) 
Moderately accessible 4   (6) 2   (4) 1   (2)  1   (2) 4   (5) 1   (2) 
Remote/very remote 8 (12) 10 (21) 4   (7) 6 (14) 3   (4) 4   (9) 
Not reported 3   (5) -- 3   (5) 7 (16) 1   (1) -- 
Region/Country of birth (%)       
Australia 57 (86) 42 (90) 47 (85) 34 (79) 71 (92) 32 (71) 
Other Oceania 1   (2) 1   (2)  3   (5) 1   (2) 1   (1) 3   (7) 
Asia -- 1   (2) -- 2   (5) 1   (1) 1   (2) 
UK & Ireland 4   (5) 1   (2) 1   (2) 4   (9) 2   (3) 3   (7) 
Other 3   (5) 2   (4) 4   (7) 2   (5) 2   (3) 6 (13) 
Not reported 1   (2) -- -- -- -- -- 
Main language spoke at home by parents (%)     
English  64 (98) 44 (94) 53 (96) 40 (93) 73 (95) 37 (82) 
Non-English  1   (2) 3   (6) 2   (4) 3   (7) 3   (4) 8 (18) 
Not reported -- -- -- -- 1   (1) -- 
* Not homeless (private rental, home owner/purchaser, public/community housing, drug and alcohol treatment facility, workers’ 
accommodation, prison, nursing home, foster home); Primary homelessness (Sleeping rough, squat, long grass, boat, car); 
Secondary homelessness (Living with parent, siblings, or relatives, crisis accommodation); Tertiary homelessness (Boarding house, 
hostel, caravan park, backpackers, hotel, motel). Living situation question introduced in 2010. 
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Table 365 Number (%) of respondents by demographic characteristics, injector status and survey year 
(cont.) 
     2004    2007 2010 
Demographic characteristics IDU Non-IDU IDU Non-IDU IDU Non-IDU 
First time in prison (%)       
No 47 (71) 27 (57) 40 (73) 21 (49) 57 (74) 14 (31) 
Yes 19 (29) 20 (43) 15 (27) 21 (49) 20 (26) 31 (69) 
Not reported -- -- -- 1   (2) -- -- 
Lifetime imprisonments (%)       
One 19 (29) 20 (43) 15 (27) 21 (49) 36 (47) 39 (87) 
Two to four  29 (44) 21 (45) 17 (31) 14 (33) 22 (29) 4   (9) 
Five to nine   12 (18) 3   (6) 9 (16) 2   (5) 11 (14) 2   (4) 
Ten or more  5   (8) -- 2   (4) 1   (2) 8 (10) -- 
Not reported  1   (2) 3   (6) 12 (22) 5 (12) -- -- 
Imprisonment in last year (%)       
No 31 (47) 28 (60) 14 (35) 9 (41) 39 (51) 38 (84) 
Yes 30 (45) 14 (30) 21 (53) 10 (45) 34 (44) 6 (13) 
Not reported 5   (8) 5 (11) 5 (13) 3 (14) 4   (5) 1   (2) 
Frequency of injection last month (%)      
Not last month 26 (39) -- 25 (45) -- 26 (34) -- 
Less than weekly 10 (15) -- 9 (16) -- 22 (29) -- 
Weekly not daily 1   (2) -- 6 (11) -- 6   (8) -- 
Daily or more 29 (44) -- 15 (27) -- 22 (29) -- 
Not reported -- -- -- -- 1   (1) -- 
Ever smoked a full cigarette (%)*      
No n/a n/a 4   (7) 4   (9) 1   (1) 8 (18) 
Yes n/a n/a 51 (93) 39 (91) 76 (99) 37 (82) 
Not reported n/a n/a -- -- -- -- 
Median age first smoked (years) n/a n/a 13 15 13 16 
    Age range n/a n/a 7 – 20 6 – 24 3 – 22 11 – 33 
Current smoker (%)*       
No n/a n/a 7 (13) 11 (26) 3   (4) 13 (29) 
Yes n/a n/a 47 (85) 32 (74) 74 (96) 32 (71) 
Not reported n/a n/a 1   (2) -- -- -- 
Smoking frequency (%)*       
Occasional – weekly or less n/a n/a 3   (6) 5 (16) 7   (9) 1   (3) 
5 to 10 cigarettes a day n/a n/a 15 (31) 10 (31) 28 (38) 17 (53) 
11 to 20 cigarettes a day n/a n/a 16 (33) 13 (41) 26 (35) 9 (28) 
Over 20 cigarettes a day n/a n/a 13 (27) 4 (13) 12 (16) 5 (16) 
Not reported n/a n/a 1   (2) -- 1   (1) -- 
Other drugs used last month (%)**      
No drugs in past 4 weeks n/a n/a n/a n/a 9 (12) 16 (36) 
Cannabis n/a n/a n/a n/a 57 (85) 22 (79) 
Heroin n/a n/a n/a n/a 14 (21) 1   (4) 
Cocaine n/a n/a n/a n/a 1   (1) 1   (4) 
Amphetamine n/a n/a n/a n/a 47 (70) 8 (29) 
Other's methadone n/a n/a n/a n/a 1   (1) -- 
Other opiates n/a n/a n/a n/a 15 (22) -- 
Other's buprenorphine n/a n/a n/a n/a 6   (9) -- 
Steroids n/a n/a n/a n/a -- -- 
Hallucinogens n/a n/a n/a n/a 1   (1) 1   (4) 
Benzodiazepines n/a n/a n/a n/a 10 (15) 1   (4) 
Ecstasy/MDA n/a n/a n/a n/a 8 (12) 4 (14) 
Inhalants (e.g. petrol) n/a n/a n/a n/a -- -- 
Other drug n/a n/a n/a n/a 1   (1) -- 
Not reported n/a n/a n/a n/a 1   (1) 1   (2) 
* Smoking questions not asked in 2004. 
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Table 366  Number (%) of respondents by last drug injected, injecting behaviour in the month prior to 
survey and survey year 
Injecting behaviour 2004 2007 2010 
Last drug injected (%) N = 66  N = 55 N = 77 
Amphetamine (Speed, Ice) 54 (82) 47 (85) 58 (75) 
Anabolic steroids -- -- -- 
Cocaine -- -- -- 
Heroin 7 (11) 7 (13) 10 (13) 
Heroin + amphetamine -- 1   (2) -- 
Heroin + cocaine -- -- -- 
Methadone 3   (5) -- -- 
Morphine 2   (3) -- 4   (5) 
Other -- -- 4   (5) 
Not reported -- -- 1   (1) 
No Injected last month N = 40 N = 30 N = 50 
Places injected last month (%)* 
Prison 1   (3) 1   (3) 1   (2) 
Own home 26 (65) 23 (77) 27 (55) 
Friend’s home 19 (48) 11 (37) 23 (47) 
Dealer’s home 5 (13) 8 (27) 5 (10) 
Street, park, beach 6 (15) 9 (30) 3   (6) 
Car 7 (18) 5 (17) 5 (10) 
Public toilet 2   (5) 4 (13) 3   (6) 
Commercial injecting room -- -- -- 
Medically Supervised Injecting Centre, Sydney -- -- -- 
Squat -- 1   (3) 1   (2) 
Other place -- 3 (10) -- 
Use of sterile needles & syringes last month (%) 
All injections 26 (65) 16 (53) 30 (60) 
Most of the time 9 (23) 11 (37) 15 (30) 
Half of the time 1   (3) -- 2   (4) 
Some of the time 4 (10) 3  (10) 1   (2) 
Not last month -- -- 1   (2) 
Not reported 1   (3) -- 1   (2) 
Re-used someone else’s used needle & syringe last month (%) 
None 29 (73) 21 (70) 41 (82) 
Once -- 6 (20) 3   (6) 
Twice 6 (15) -- 2   (4) 
3-5 times 1   (3) 1   (3) -- 
>5 times 2   (5) 2   (7) 3   (6) 
Not reported 2   (5) -- 1   (2) 
Number of people needle & syringe was re-used after last month (%) 
None 29 (73) 21 (70) 40 (80) 
One 3   (8) 6 (20) 3   (6) 
Two 3   (8) -- 2   (4) 
Three to five 1   (3) 1   (3) -- 
More than five 2   (5) -- 2   (4) 
Don’t know how many -- 1   (3) 2   (4) 
Not reported 2   (5) 1   (3) 1   (2) 
Relationship to people needle & syringe was re-used after last month (%)*  
Regular sex partner 5 (13) 3 (10) 6 (12) 
Casual sex partner -- 1   (3) -- 
Close friend 2   (5) 2   (7) 2   (4) 
Acquaintance -- 2   (7) -- 
Other 4 (10) 2   (7) 1   (2) 
Equipment used after someone else last month (%)*  
Spoon 9 (23) 4 (13) 10 (20) 
Water 8 (20) 8 (27)  8 (16) 
Filter 7 (18) 4 (13)  11 (22) 
Tourniquet 5 (13) 3 (10)  1   (2) 
Drug mix 7 (18) 5 (17)  11 (22) 
* More than one option could be selected. 
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Table 367 Number (%) of respondents by treatment for drug use, injector status and survey year 
Treatment for drug use 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 66 N = 47  N = 55  N = 43 N = 77  N = 45 
Any treatment/therapy for drug use (%)   
No 41 (62) 41 (87) 23 (42) 31 (72) 50 (65) 36   (80) 
Yes 25 (38) 6 (13) 30 (55) 8 (19) 27 (35) 9   (20) 
Not reported   2   (4) 4   (9) -- -- 
History of methadone maintenance treatment (%)   
Currently 3   (5) 1   (2) 2   (4) -- 1   (1) -- 
Previously 3   (5) -- 7 (13) -- 5   (6) -- 
Never 60 (90) 45 (96) 38 (69) -- 71 (92) 45 (100) 
Not reported -- 1   (2) 8 (15) -- -- -- 
History of other pharmacotherapy treatment (%)   
Currently 4   (6) 1   (2) 5   (9) -- -- -- 
Previously 4   (6) -- 7 (13) -- 3   (4) 1     (2) 
Never 58 (88) 45 (96) 43 (78) -- 74 (96) 44   (98) 
Not reported -- 1   (2) -- -- -- -- 
 
 
Table 368 Number (%) of respondents by site of needle and syringe acquisition last month and survey 
year 
Needle & Syringe acquisition*       2004        2007 2010 
No surveyed N = 40 N = 30 N = 76 
From an NSP last month (%)   
Daily or almost daily 3   (8) 1   (3) 2   (3) 
A couple of times each week 5 (13) 2   (7) 2   (3) 
Less than weekly 7 (18) 3 (10) 7   (9) 
Weekly n/a n/a 3   (4) 
Once last month 5 (13) 3 (10) -- 
Not in the last month 18 (45) 17 (57) 55 (72) 
Not reported 2   (5) 4 (13) 7   (9) 
From a chemist last month (%)   
Daily or almost daily 6 (15) 3 (10) 9 (12) 
A couple of times each week 6 (15) 8 (27) 8 (10) 
Less than weekly 8 (20) 5 (17) 18 (23) 
Weekly n/a n/a 11 (14) 
Once last month 6 (15) 5 (17) -- 
Not in the last month 13 (33) 6 (20) 27 (35) 
Not reported 1   (3) 3 (10) 3   (4) 
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Table 369 Number (%) of respondents by body piercing and tattoos 
Body piercing and tattoos 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 66 N = 47  N = 55  N = 43 N = 77  N = 45 
Body or ear piercings (%)       
No 30 (45) 29 (62) 25 (45) 22 (51) 53 (69) 27 (60) 
Yes 36 (55) 18 (38) 29 (53) 21 (49) 24 (31) 18 (40) 
Not reported -- -- 1   (2) -- -- -- 
Pierced in past 12 mths (%)       
No 25 (69) 9 (50) 23 (79) 17 (81) 15 (63) 13 (72) 
Yes 5 (14) 3 (17) 1   (3) 1   (5) 5 (21) 3 (17) 
Not reported 6 (17) 6 (33) 5 (17) 3 (14) 4 (17) 2 (11) 
Who did piercing (%)*      
Chemist/hairdresser/beauty 
salon  
3 (60) -- 1 (100) -- 1 (20) 2 (67) 
Professional piercer / studio 1 (20) 2 (67) 1 (100) -- 4 (80) 1 (33) 
Tattooist / parlour 1 (20) 2 (67) -- -- -- -- 
Friend 1 (20) -- -- -- -- -- 
Prison inmate -- -- -- -- -- -- 
Self 1 (20) -- -- 1 (100) -- -- 
Family member -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
Needle used by other (%)       
No  -- 1 (33) -- 1 (100) -- 1 (33) 
Yes 1 (20) -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
Not reported 4 (80) 2 (67) 1 (100) -- 5 (100) 2 (67) 
Tattoos (%)       
No 23 (25) 31 (66) 21 (38) 27 (63) 22 (29) 26 (58) 
Yes 43 (65) 16 (34) 34 (62) 16 (37) 55 (71) 19 (42) 
Not reported -- -- -- -- -- -- 
Tattoos in past 12 mths (%)       
No  33 (77) 14 (88) 27 (79) 14 (88) 39 (71) 11 (58) 
Yes 10 (23) 2 (13) 7 (21) 2 (13) 16 (29) 8 (42) 
Not reported -- -- -- -- -- -- 
Who did tattooing (%)*       
Professional tattooist 8 (80) 1 (50) 5 (71) 2 (100) 7 (44) 2 (25) 
Friend 3 (30) 1 (50) -- -- 4 (25) 5 (63) 
Prison inmate 2 (20) -- 1 (14) -- 3 (19) -- 
Self 1 (10) -- 1 (14) -- 1   (6) 1 (13) 
Family member -- -- -- -- 2 (13) -- 
Other -- -- -- -- -- -- 
* More than one option could be selected.  
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Table 370 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by 
injector status and survey year 
Sexual behaviour 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 66  N = 47 N = 55  N = 43 N =77  N = 45 
Sex last month / last 3 months (%)**    
No 24   (36) 14   (30) 15   (27) 11   (26) 5   (6) 9 (20) 
Yes 41   (62) 32   (68) 40   (73) 32   (74) 71 (92) 36 (80) 
Not reported 1     (2) 1     (2) -- -- 1   (1) -- 
Male sex partners in last 3 months**    
    Median n/a n/a n/a n/a 1 1 
    Range n/a n/a n/a n/a 1 – 8 0 – 2 
Female sex partners in last 3 months**    
    Median n/a n/a n/a n/a 1 1 
    Range n/a n/a n/a n/a 0 – 12 0 – 6 
Condom use at last sex (%)        
No 46   (70) 36   (77) 42   (76) 26   (60) n/a  n/a  
Yes 20   (30) 11   (23) 13   (24) 17   (40) n/a  n/a  
Not reported   -- -- n/a  n/a  
Condom use with regular sex partner(s) last month (%)*     
No 21   (75) 22   (88) 27   (84) 13   (54) n/a  n/a  
Sometimes 2     (7) 2     (8) 4   (13) 6   (25) n/a  n/a  
Always  5   (18) 1     (4) 1     (3) 5   (21) n/a  n/a  
Condom use with new sex partner(s) last month (%)*     
No 12   (71) 5   (63) 10   (50) 4   (33) n/a  n/a  
Sometimes 1     (6) 2   (25) 5   (25) 5   (42) n/a  n/a  
Always 4   (24) 1   (13) 5   (25) 3   (25) n/a  n/a  
Condom use with casual sex partner(s) last month (%)*      
No 9   (69) 7   (78) 10   (59) 2   (18) n/a  n/a  
Sometimes 1     (8) 2   (22) 5   (29) 5   (45) n/a  n/a  
Always 3   (23) -- 2   (12) 4   (36) n/a  n/a  
Condom use last sex - regular male partners - last 3 months (%)**   
Never n/a n/a n/a n/a 4 (80) 2 (67) 
Sometimes n/a n/a n/a n/a 1 (20) -- 
Always n/a n/a n/a n/a -- 1 (33) 
Condom use last sex - casual male partners - last 3 months (%)**   
Never n/a n/a n/a n/a 1 (50) 1 (100) 
Sometimes n/a n/a n/a n/a -- -- 
Always n/a n/a n/a n/a 1 (50) -- 
Condom use last sex - regular female partners - last 3 months (%)**   
Never n/a n/a n/a n/a 34 (79) 17 (61) 
Sometimes n/a n/a n/a n/a 4   (9) 8 (29) 
Always n/a n/a n/a n/a 5 (12) 3 (11) 
Condom use last sex - casual female partners - last 3 months (%)**   
Never n/a n/a n/a n/a 18 (60) 4 (50) 
Sometimes n/a n/a n/a n/a 6 (20) 1 (13) 
Always n/a n/a n/a n/a 6 (20) 3 (38) 
Sex work last month (%)      
No 65 (100) 46   (98) 52   (95) 43 (100) 76 (99) 44 (98) 
Yes -- 1     (2) 3     (5) -- 1   (1) -- 
Not reported   -- -- -- 1   (2) 
Condom used at last sex work last month (%)    
No -- -- -- -- -- -- 
Yes -- 1 (100) 3 (100) -- 1 (100) -- 
Not reported -- -- -- -- -- -- 
Ever had cervical cancer vaccine (women only)*** (%)     
No  n/a n/a n/a n/a -- 3 (100) 
Yes n/a n/a n/a n/a 1 (100) -- 
Unsure n/a n/a n/a n/a -- -- 
* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month. 
** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded 
areas indicate previous survey items that were changed in 2010. 
*** Proportion of eligible women i.e. those under 27 years of age in 2007.   
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Table 371 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, 
HBV vaccination and HCV treatment by injector status and survey year 
Testing & treatment 2004 2007 2010 
 IDU Non-IDU IDU Non-IDU IDU Non-IDU 
No surveyed N = 66 N = 47  N = 55  N = 43 N = 77  N = 45 
Previous HIV test (%)       
Yes, last year 26 (39) 8   (7) 15 (27) 6 (14) 26 (34) 11 (24) 
>1 year ago 17 (26) 11 (23) 25 (45) 11 (26) 21 (27) 9 (20) 
Never tested 23 (35) 27 (57) 13 (24) 26 (60) 30 (39) 25 (56) 
Not reported -- 1   (2) 2  (40 -- -- -- 
HBV infection (%)      
No 52 (79) 41 (87) 38 (69) 37 (86) 71 (92) 44 (98) 
Yes 5   (8) 1   (2) 10 (18) 1   (2) 4   (5) -- 
Don’t know 9 (14) 5 (11) 7 (13) 5 (12) 1   (1) -- 
Not reported -- -- -- -- 1   (1) 1   (2) 
HBV vaccination (%)*       
No 21 (32) 22 (47) 27 (49) 27 (63) 36 (47) 31 (69) 
Yes 34 (52) 12 (26) 22 (40) 9 (21) 34 (44) 8 (18) 
Don’t know 11 (17) 12 (26) 6 (11) 7 (16) 7   (9) 6 (13) 
Not reported -- 1   (2) -- -- -- -- 
Previous HCV test (%)       
Yes, last year 31 (47) 6 (13) 20 (36) 5 (12) 26 (34) 10 (22) 
>1 year ago 12 (18) 7 (15) 25 (45) 10 (23) 27 (35) 9 (20) 
Never tested 23 (35) 33 (72) 10 (18) 28 (65) 24 (31) 26 (58) 
Unsure -- -- -- -- -- -- 
Not reported -- 1 (<1) -- -- -- -- 
Any HCV treatment (%)** N = 16 N = 2 N = 16  N = 1 N = 22  N = 0 
Interferon -- -- -- -- -- -- 
Interferon & Ribavirin -- -- -- -- -- -- 
Pegasys & Ribavirin -- -- -- -- -- -- 
Other 16 (100) 2 (100) -- -- -- -- 
No treatment -- -- 16 (100) 1 (100) 22 (100) -- 
Not reported -- -- -- -- -- -- 
Current HCV treatment        
Interferon -- -- -- -- -- -- 
Interferon & Ribavirin -- -- -- -- -- -- 
Pegasys & Ribavirin -- -- -- -- -- -- 
Other -- -- -- -- -- -- 
* Number (%) among participants with no history of HBV infection. 
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HIV antibody prevalence 
Table 372 HIV antibody prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
No tested No with 
HIV (%) 
2004       
IDU 44 0 (0) 5 0 (0) 49 0 (0) 
Non-IDU 36 0 (0) 7 0 (0) 43 0 (0) 
p value  --  --  -- 
2007       
IDU 38 0 (0) 5 0 (0) 43 0 (0) 
Non-IDU 36 0 (0) 2 0 (0) 38 0 (0) 
p value  --  --  -- 
2010       
IDU 60 0 (0) 2 0 (0) 62 0 (0) 
Non-IDU 33 0 (0) 2 0 (0) 35 0 (0) 
p value  --  --  -- 




HCV antibody prevalence 
Table 373 HCV antibody prevalence by sex, injector status and survey year† 
 Male Female Total 
Injector status No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
IDU 43 12 (28) 5 4 (80) 48 16 (33) 
Non-IDU 36 2   (6) 7 0   (0) 43 2   (5) 
p value  0.01  0.004  0.001 
2007       
IDU 38 14 (37) 5 2 (40) 43 16 (37) 
Non-IDU 37 1   (3) 2 0   (0) 39 1   (3) 
p value  <0.001  0.3  <0.001 
2010       
IDU 59 22 (37) 2 0   (0) 61 22 (36) 
Non-IDU 33 0   (0) 2 0   (0) 35 0   (0) 
p value  <0.001  --  <0.001 




National Prison Entrants’ Bloodborne Virus & Risk Behaviour Survey 2004, 2007, and 2010 
Western Australia 
203        
Table 374 HCV antibody prevalence by sexual identity, sex and survey year† 
  Male Female Total  
Sexual identity No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Heterosexual 79 14 (18) 12 4 (33) 91 18 (20) 
Bisexual -- -- -- -- -- -- 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value  --  --  -- 
2007       
Heterosexual 73 14 (19) 7 2 (29) 80 16 (20) 
Bisexual -- -- -- -- -- -- 
Homosexual 2 1 (50) -- -- 2 1 (50) 
Unsure -- -- -- -- -- -- 
p value  0.3  --  0.3 
2010       
Heterosexual 90 22 (24) 2 0  (0) 92 22 (24) 
Bisexual -- -- 1 0  (0) 1 0   (0) 
Homosexual 1 0 (0) 1 0  (0) 2 0   (0) 
Unsure -- -- -- -- -- -- 
p value  0.6  --  0.6 
† Excludes equivocal test results and missing values. 
 
 
Table 375 HCV antibody prevalence by age group, sex and survey year† 
 Male Female Total  
Age group N
o tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
< 20 years 11 1   (9) -- -- 11 1   (9) 
20 – 24 18 2 (11) 1 0   (0) 19 2 (11) 
25 – 29 17 1   (6) 2 1 (50) 19 2 (11) 
30 + years 36 10 (28) 7 1 (14) 43 11 (26) 
p value  0.2  0.5  0.3 
2007       
< 20 years 5 0   (0) -- -- 5 0   (0) 
20 – 24 20 1   (5) -- -- 20 1   (5) 
25 – 29 12 1   (8) 2 0   (0) 14 1   (7) 
30 + years 38 13 (34) 5 2 (40) 43 15 (35) 
p value  0.02  0.3  0.01 
2010       
< 20 years 9 0   (0) 1 0   (0) 10 0   (0) 
20 – 24 22 4 (18) 2 0   (0) 24 4 (17) 
25 – 29 27 6 (22) -- -- 27 6 (22) 
30 + years 34 12 (35) 1  0   (0) 35 12 (34) 
p value  0.1  --  0.1 
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Table 376 HCV antibody prevalence by duration of drug injection, sex and survey year† 
 Male Female Total  
Duration of drug injection No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
<3 years 9 0   (0) -- -- 9 0   (0) 
3 to 5 years 5 3 (60) -- -- 5 3 (60) 
6 to 10 years 12 2 (17) 1 1 (100) 13 3 (23) 
10 + years 16 7 (44) 3 2   (67) 19 9 (47) 
p value  0.03  0.6  0.02 
2007       
<3 years 5 -- -- -- 5 0   (0) 
3 to 5 years 7 -- -- -- 7 0   (0) 
6 to 10 years 6 1 (17) 1 0     (0) 7 1 (14) 
10 + years 19 12 (63) 4 2   (50) 23 14 (61) 
p value  0.003  0.4  0.002 
2010       
<3 years 10 1 (10) 1 0     (0) 11 1   (9) 
3 to 5 years 4 2 (50) -- -- 4 2 (50) 
6 to 10 years 16 7 (44) 1 0     (0) 17 7 (41) 
10 + years 27 11 (41) -- -- 27 11 (41) 
p value  0.3  --  0.2 
† Excludes equivocal test results and missing values. 
 
 
Table 377 HCV antibody prevalence by last drug injected, duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Last drug injected No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Amphetamine (Speed, Ice) 8 0  (0) 32 13   (41) 40 13   (33) 
Heroin --  -- -- -- -- -- 
More than one 1 0  (0) 5 3   (60) 6 3   (50) 
Other/not reported -- -- -- -- -- -- 
     p value  --  0.5  0.5 
2007       
Amphetamine (Speed, Ice) 5 0  (0) 34 12   (35) 39 12   (31) 
Heroin -- -- 2 2 (100) 2 2 (100) 
More than one -- -- 1 1 (100) 1 1 (100) 
Other/not reported -- -- -- -- -- -- 
     p value  --  0.09  0.07 
2010       
Amphetamine (Speed, Ice) 9 0   (0) 37 14 (38) 46 14 (30) 
Heroin -- -- 7 6 (86) 7 6 (86) 
More than one -- -- -- -- -- -- 
Other/not reported 2 1 (50) 4 0   (0) 6 1 (17) 
     p value  0.03  0.01  0.01 
† Excludes equivocal test results and missing values. 
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Table 378 HCV antibody prevalence by frequency of injection last month, duration of drug injection 
and survey year† 
 <3 years IDU 3+ years IDU Total  
Frequency of drug injection 
last month 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Less than daily 3 0   (0) 5 3 (60) 8 3 (38) 
Daily or more 4 0   (0) 15 9 (60) 19 9 (47) 
p value  --  0.06  0.6 
2007       
Less than daily -- -- 11 2 (18) 11 2 (18) 
Daily or more 2 0   (0) 11 9 (82) 13 9 (69) 
p value  --  0.003  0.008 
2010       
Less than daily 6 0   (0) 16 7 (44) 22 7 (32) 
Daily or more 4 1 (25) 13 6 (46) 17 7 (41) 
p value  0.2  0.9  0.6 
† Excludes equivocal test results and missing values. 
 
 
Table 379 HCV antibody prevalence by re-use of someone else’s used needle and syringe last month, 
duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Re-used someone else’s used 
needle & syringe last month 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
No 6 0   (0) 14 10 (71) 20 10 (50) 
Yes 1 0   (0) 5 2 (40) 6 2 (33) 
p value  --  0.2  0.5 
2007       
No 2 0   (0) 14 7 (50) 16 7 (44) 
Yes -- -- 7 4 (57) 7 4 (57) 
p value  --  0.8  0.3 
2010       
No 8 1 (13) 23 10 (43) 31 11 (35) 
Yes 1 0   (0) 4 1 (25) 5 1 (20) 
p value  0.7  0.5  0.5 
† Excludes equivocal test results and missing values. 
 
 
Table 380 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey 
year† 
 <3 years IDU 3+ years IDU Total  
Imprisonment last year No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
No 6 0   (0) 18 5 (28) 24 5 (21) 
Yes 3 0   (0) 18 10 (56) 21 10 (48) 
p value  --  0.09  0.06 
2007       
No 2 0   (0) 11 6 (55) 13 6 (46) 
Yes 1 0   (0) 13 3 (23) 14 3 (21) 
p value  --  0.1  0.2 
2010       
No 6 1 (17) 24 11 (46) 30 12 (40) 
Yes 5 0   (0) 22 8 (36) 27 8 (30) 
p value  0.4  0.5  0.4 
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Table 381 HCV antibody by number of previous imprisonments, sex and survey year† 
 Male Female Total  
Number of previous 
imprisonments 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
1 28 0   (0) 5 0   (0) 33 0   (0) 
2 to 4 33 7 (21) 7 4 (57) 40 11 (28) 
5 to 9 12 6 (50) -- -- 12 6 (50) 
10 + 2 1 (50) -- -- 2 1 (50) 
p value  0.001  0.04  0.001 
2007       
1 28 2   (7) 2 1 (50) 30 3 (10) 
2 to 4 22 3 (14) 3 1 (33) 25 4 (16) 
5 to 9 10 3 (30) 1 0   (0) 11 3 (27) 
10 + 3 2 (67) -- -- 3 2 (67) 
p value  0.03  0.7  0.07 
2010       
1 55 7 (13) 2 0   (0) 57 7 (12) 
2 to 4 19 9 (47) 2 0   (0) 21 9 (43) 
5 to 9 13 3 (23) -- -- 13 3 (23) 
10 + 5 3 (60) -- -- 5 3 (60) 
p value  0.004  --  0.007 
† Excludes equivocal test results and missing values. 
 
 
Table 382 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Non-Indigenous 51 6 (12) 6 2 (33) 57 8 (14) 
Indigenous 31 8 (26) 6 2 (33) 37 10 (27) 
p value  0.1  1.0  0.1 
2007       
Non-Indigenous 49 12 (24) 2 1 (50) 51 13 (25) 
Indigenous 25 3 (12) 5 1 (20) 30 4 (13) 
p value  0.2  0.4  0.2 
2010       
Non-Indigenous 60 13 (22) 1 0   (0) 61 13 (21) 
Indigenous 32 9 (28) 3 0   (0) 35 9 (26) 
p value  0.5  --  0.6 
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Table 383 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector 
status and survey year† 
 Non-IDU IDU Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Non-Indigenous 26 1 (4) 29 7 (24) 55 8 (15) 
Indigenous 17 1 (6) 19 9 (47) 36 10 (28) 
p value  0.8  0.1  0.1 
2007       
Non-Indigenous 23 1 (4) 28 12 (43) 51 13 (25) 
Indigenous 16 0 (0) 14 4 (29) 30 4 (13) 
p value  0.4  0.4  0.2 
2010       
Non-Indigenous 26 0 (0) 35 13 (37) 61 13 (21) 
Indigenous 9 0 (0) 26 9 (35) 35 9 (26) 
p value  --  0.8  0.6 
† Excludes equivocal test results and missing values. 
 
 
Table 384 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and 
survey year† 
  Male Female Total  
Residential remoteness No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Highly accessible/accessible 62 13 (21) 8 3 (38) 70 16 (23) 
Moderately accessible 4 0   (0) 1 0   (0) 5 0   (0) 
Remote/very remote 13 1   (8) 2 0   (0) 15 1   (7) 
p value  0.3  0.5  0.2 
2007       
Highly accessible/accessible 57 11 (19) 6 2 (33) 63 13 (21) 
Moderately accessible 2 1 (50) -- -- 2 1 (50) 
Remote/very remote 9 1 (11) 1 0   (0) 10 1 (10) 
p value  0.5  0.5  0.4 
2010       
Highly accessible/accessible 84 19 (23) 3 0   (0) 87 19 (22) 
Moderately accessible 3 2 (67) -- -- 3 2 (67) 
Remote/very remote 5 1 (20) 1 0   (0) 6 1 (17) 
p value  0.2  --  0.2 
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Table 385 HCV antibody prevalence by region/country of birth, sex and survey year† 
 Male Female Total  
Region/Country of birth No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Australia 71 13 (18) 12 4 (33) 83 17 (20) 
Other Oceania 1 0   (0) -- -- 1 0   (0) 
Asia 1 0   (0) -- -- 1 0   (0) 
UK & Ireland 1 0   (0) -- -- 1 0   (0) 
Other 4 1 (25) -- -- 4 1 (25) 
p value  0.9  --  0.9 
2007       
Australia 60 14 (23) 7 2  (29) 67 16 (24) 
Other Oceania 4 0   (0) -- -- 4 0   (0) 
Asia 1 0   (0) -- -- 1 0   (0) 
UK & Ireland 5 0   (0) -- -- 5 0   (0) 
Other 5 1 (20) -- -- 5 1 (20) 
p value  0.6  --  0.6 
2010       
Australia 78 22 (78) 4 0   (0) 82 22 (27) 
Other Oceania 4 0   (0) -- -- 4 0   (0) 
Asia 1 0   (0) -- -- 1 0   (0) 
UK & Ireland 3 0   (0) -- -- 3 0   (0) 
Other 6 0   (0) -- -- 6 0   (0) 
p value  0.3  --  0.3 
† Excludes equivocal test results and missing values. 
 
 
Table 386 HCV antibody prevalence by main language spoken at home by parents, sex and survey 
year† 
 Male Female Total  
Main language spoken at 
home by parents 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
English  76 14 (18) 11 3   (27) 87 17 (20) 
Non-English  2 0   (0) 1 1 (100) 3 1 (33) 
p value  0.5  0.1  0.6 
2007       
English  71 14 (20) 7 2   (29) 78 16 (21) 
Non-English  4 1 (25) -- -- 4 1 (25) 
p value  0.8  --  0.8 
2010       
English  86 22 (26) 4 0     (0) 90 22 (24) 
Non-English  6 0   (0) -- -- 6 0   (0) 
p value  0.2  --  0.2 
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Table 387 Self-reported HCV status versus HCV serology by sex and survey year† 
 Male Female Total  
Self-report HCV No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
No tested No with 
HCV (%) 
2004       
Positive 6 6 (100) 2 2 (100) 8 8 (100) 
Negative 25 6   (24) 3 0     (0) 28  6   (21) 
Not sure 2 1   (50) 1 1 (100) 3 2   (67) 
p value  0.003  0.05  <0.001 
2007       
Positive 8 8 (100) 2 2 (100) 10 10 (100) 
Negative 31 5   (16) 2 0     (0) 33 5   (15) 
Not sure 7 1   (14) -- -- 7 1   (14) 
p value  <0.001  0.05  <0.001 
2010       
Positive 9 9 (100) -- -- 9 9 (100) 
Negative 31 2     (6) 3 0     (0) 34 2     (6) 
Not sure 8 3   (38) -- -- 8 3   (38) 
p value  <0.001  --  <0.001 





Table 388 HBV surface-antigen prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
IDU 44 3 (7) 5 0 (0) 49 3 (6) 
Non-IDU 35  0 (0) 7 0 (0) 42 0 (0) 
p value  0.1  --  0.1 
2007       
IDU 38 2 (5) 5 0 (0) 43  2 (5) 
Non-IDU 37 0 (0) 2 0 (0) 39 0 (0) 
p value  0.2  --  0.2 
2010       
IDU 60 0 (0) 2 0 (0) 62 0 (0) 
Non-IDU 33 0 (0) 2 0 (0) 35 0 (0) 
p value  --  --  -- 
† Excludes equivocal test results and missing values. 
 
 
Table 389 HBV core-antibody prevalence by sex, injector status and survey year† 
 Male Female Total  
Injector status No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
IDU 44 11 (25) 4 2 (50) 48 13 (27) 
Non-IDU 35 3   (9) 5 0   (0) 40 3   (8) 
p value  0.06  0.07  0.02 
2007       
IDU 38 16 (42) 5 2 (40) 43 18 (42) 
Non-IDU 37 4 (11) 2 1 (50) 39 5 (13) 
p value  0.002  0.8  0.003 
2010       
IDU 60 9 (15) 2 0   (0) 62 9 (15) 
Non-IDU 33 7 (21) 2 0   (0) 35 7 (20) 
p value  0.5  --  0.5 
† Excludes equivocal test results and missing values. 
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Table 390 HBV core-antibody prevalence by sexual identity, sex and survey year† 
  Male Female Total  
Sexual identity No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Heterosexual 79 14 (18) 9 2 (22) 88 16 (18) 
Bisexual -- -- -- -- -- -- 
Homosexual -- -- -- -- -- -- 
Unsure -- -- -- -- -- -- 
p value  --  --  -- 
2007       
Heterosexual 73 19 (26) 7 3 (43) 80 22 (28) 
Bisexual -- -- -- -- -- -- 
Homosexual 2 1 (50) -- -- 2 1 (50) 
Unsure -- -- -- -- -- -- 
p value  0.5  --  0.5 
2010       
Heterosexual 91 15 (16) 2 0   (0) 93 15 (16) 
Bisexual -- -- 1 0   (0) 1 0   (0) 
Homosexual 1 1 (100) 1 0   (0) 2 1 (50) 
Unsure -- -- -- -- -- -- 
p value  0.03  --  0.4 
† Excludes equivocal test results and missing values. 
 
 
Table 391 HBV core-antibody prevalence by age group, sex and survey year† 
 Male Female Total  
Age group No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
< 20 years 11 0   (0) -- -- 11 0   (0) 
20 – 24 18 1   (6) 1 0     (0) 19 1   (5) 
25 – 29 17 3 (18) 1 1 (100) 18 4 (22) 
30 + years 36 10 (28) 6 1   (17) 42 11 (26) 
p value  0.08  0.2  0.08 
2007       
< 20 years 5 0   (0) -- -- 5 0   (0) 
20 – 24 20 1   (5) -- -- 20 1   (5) 
25 – 29 12 4 (33) 2 0     (0) 14 4 (29) 
30 + years 38 15 (39) 5 3   (60) 43 18 (42) 
p value  0.02  0.2  0.01 
2010       
< 20 years 9 0   (0) 1 0     (0) 10 0   (0) 
20 – 24 22 2   (9) 2 0     (0) 24 2   (8) 
25 – 29 27 4 (15) -- -- 27 4 (15) 
30 + years 35 10 (29) 1 0     (0) 36 10 (28) 
p value  0.1  --  0.09 




National Prison Entrants’ Bloodborne Virus & Risk Behaviour Survey 2004, 2007, and 2010 
Western Australia 
211        
Table 392 HBV core-antibody prevalence by duration of drug injection, sex and survey year† 
 Male Female Total  
Duration of drug injection No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
<3 years 9 1 (11) -- -- 9 1 (11) 
3 to 5 years 5 0   (0) -- -- 5 0   (0) 
6 to 10 years 13 3 (23) 1 1 (100) 14 4 (29) 
10 + years 16 7 (44) 3 1   (33) 19 8 (42) 
p value  0.1  0.3  0.2 
2007       
<3 years 5 1 (20) -- -- 5 1 (20) 
3 to 5 years 7 1 (14) -- -- 7 1 (14) 
6 to 10 years 6 2 (33) 1 0    (0) 7 2 (29) 
10 + years 19 11 (58) 4 2  (50) 23 13 (57) 
p value  0.2  0.4  0.1 
2010       
<3 years 10 0   (0) 1 0    (0) 11 0   (0) 
3 to 5 years 4 1 (25) -- -- 4 1 (25) 
6 to 10 years 16 2 (13) 1 0    (0) 17 2 (12) 
10 + years 28 5 (18) -- -- 28 5 (18) 
p value  0.5  --  0.4 
† Excludes equivocal test results and missing values. 
 
 
Table 393 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey 
year† 
 <3 years IDU 3+ years IDU Total  
Last drug injected No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Amphetamine (Speed, Ice) 8 1 (13) 32 10   (31) 40 11   (28) 
Heroin -- -- -- -- -- -- 
More than one 1 0   (0) 5 2   (40) 6 2   (33) 
Other/not reported -- -- -- -- -- -- 
     p value  0.7  0.7  0.7 
2007       
Amphetamine (Speed, Ice) 5 1 (20) 34 14   (41) 39 15   (38) 
Heroin -- -- 2 1   (50) 2 1   (50) 
More than one -- -- 1 1 (100) 1 1 (100) 
Other/not reported -- -- -- -- -- -- 
     p value  --  0.5  0.5 
2010       
Amphetamine (Speed, Ice) 9 0   (0) 38 7   (18) 47 7   (15) 
Heroin -- -- 7 1   (14) 7 1   (14) 
More than one -- -- -- -- -- -- 
Other/not reported 2 0   (0) 4 0     (0) 6 0     (0) 
     p value  --  0.6  0.6 
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Table 394 HBV core-antibody prevalence by frequency of injection last month, duration of drug 
injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Frequency of drug injection 
last month 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Less than daily 3 1 (33) 5 4 (80) 8 5 (63) 
Daily or more 4 0   (0) 16 5 (31) 20 5 (25) 
p value  0.2  0.06  0.06 
2007       
Less than daily -- -- 11 4 (36) 11 4 (36) 
Daily or more 2 0   (0) 11 7 (64) 13 7 (54) 
p value  --  0.2  0.4 
2010       
Less than daily 6 0   (0) 16 4 (25) 22 4 (18) 
Daily or more 4 0   (0) 14 0   (0) 18 0   (0) 
p value  --  0.04  0.06 
† Excludes equivocal test results and missing values. 
 
 
Table 395 HBV core antibody prevalence by re-use of someone else’s used needle and syringe last 
month, duration of drug injection and survey year† 
 <3 years IDU 3+ years IDU Total  
Re-used someone else’s used 
needle & syringe last month 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
No 6 1 (17) 15 8 (53) 21 9 (43) 
Yes 1 0   (0) 5 1 (20) 6 1 (17) 
p value  0.7  0.2  0.3 
2007       
No 2 0   (0) 14 6 (43) 16 6 (38) 
Yes -- -- 7 4 (57) 7 4 (57) 
p value  --  0.5  0.4 
2010       
No 8 0   (0) 24 3 (13) 32 3   (9) 
Yes 1 0   (0) 4 0   (0) 5 0   (0) 
p value  --  0.5  0.5 
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Table 396 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and 
survey year† 
 <3 years IDU 3+ years IDU Total  
Imprisonment last year No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
No 6 0   (0) 18 6 (33) 24 6 (25) 
Yes 3 1 (33) 18 6 (33) 21 7 (33) 
p value  0.1  0.6  0.9 
2007       
No 2 1 (50) 11 6 (55) 13 7 (54) 
Yes 1 0   (0) 13 3 (23) 14 3 (21) 
p value  0.4  0.1  0.08 
2010       
No 6 0   (0) 25 3 (12) 31 3 (10) 
Yes 5 0   (0) 22 4 (18) 27 4 (15) 
p value  --  0.6  0.6 
† Excludes equivocal test results and missing values. 
 
 
Table 397 HBV core-antibody by number of previous imprisonments, sex and survey year† 
 Male Female Total  
Number of previous 
imprisonments 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
1 28 2   (7) 3 0   (0) 31 2   (6) 
2 to 4 34 8 (24) 6 2 (23) 40 10 (25) 
5 to 9 12 4 (33) -- -- 12 4 (33) 
10 + 2 0   (0) -- -- 2 0   (0) 
p value  0.2  0.3 
 
 0.1 
2007       
1 28 5 (18) 2 1 (50) 30 6 (20) 
2 to 4 22 3 (14) 3 1 (33) 25 4 (16) 
5 to 9 10 5 (50) 1 0   (0) 11 5 (45) 
10 + 3 2 (67) -- -- 3 2 (67) 
p value  0.04  0.7  0.08 
2010       
1 55 7 (13) 2 0   (0) 57 7 (12) 
2 to 4 19 6 (32) 2 0   (0) 21 6 (29) 
5 to 9 13 3 (23) -- -- 13 3 (23) 
10 + 6 0   (0) -- -- 6 0   (0) 
p value  0.2  --  0.2 
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Table 398 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and 
survey year† 
 Male Female Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Non-Indigenous 52 5 (10) 4 1 (25) 56 6 (11) 
Indigenous 30 9 (30) 5 1 (20) 35 10 (29) 
p value  0.2  0.9  0.03 
2007       
Non-Indigenous 49 10 (20) 2 0   (0) 51 10 (20) 
Indigenous 25 9 (36) 5 3 (60) 30 12 (40) 
p value  0.1  0.2  0.05 
2010       
Non-Indigenous 60 10 (17) 1 0   (0) 61 10 (16) 
Indigenous 33 6 (18) 3 0   (0) 36 6 (17) 
p value  0.9  --  1.0 
† Excludes equivocal test results and missing values. 
 
 
Table 399 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector 
status and survey year† 
 Non-IDU IDU Total  
Aboriginal and Torres Strait 
Islander origin 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Non-Indigenous 25 0   (0) 29 6  (21) 54 6  (11) 
Indigenous 15 3 (20) 19 7  (37) 34 10  (29) 
p value  0.02  0.2  0.03 
2007       
Non-Indigenous 23 1   (4) 28 9  (32) 51 10  (20) 
Indigenous 16 4 (25) 14 8  (57) 30 12  (40) 
p value  0.06  0.1  0.05 
2010       
Non-Indigenous 26 4 (15) 35 6  (17) 61 10  (16) 
Indigenous 9 3 (33) 27 3  (11) 36 6  (17) 
p value  0.3  0.5  1.0 
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Table 400 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before 
prison and survey year† 
  Male Female Total  
Residential remoteness No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Highly accessible/accessible 62 9 (15) 5 1   (20) 67 10 (15) 
Moderately accessible 4 0   (0) 1 0     (0) 5 0   (0) 
Remote/very remote 13 5 (38) 2 0     (0) 15 5 (33) 
p value  0.08  0.7  0.1 
2007       
Highly accessible/accessible 57 13 (23) 6 2   (33) 63 15 (24) 
Moderately accessible 2 0   (0) -- -- 2 0   (0) 
Remote/very remote 9 5 (56) 1 1 (100) 10 6 (60) 
p value  0.08  0.2  0.04 
2010       
Highly accessible/accessible 85 15 (18) 3 0     (0) 88 15 (17) 
Moderately accessible 3 0   (0) -- -- 3 0   (0) 
Remote/very remote 5 1 (20) 1 0     (0) 6 1 (17) 
p value  0.7  --  0.7 
† Excludes equivocal test results and missing values. 
 
 
Table 401 HBV core-antibody prevalence by region/country of birth, sex and survey year† 
 Male Female Total  
Region/Country of birth No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
Australia 71 13   (18) 9 2 (22) 80 15   (19) 
Other Oceania 1 1 (100) -- -- 1 1 (100) 
Asia 1 0     (0) -- -- 1 0     (0) 
UK & Ireland 1 0     (0) -- -- 1 0     (0) 
Other 4 0     (0) -- -- 4 0     (0) 
p value  0.2  --  0.2 
2007       
Australia 60 19   (32) 7 3 (43) 67 22   (33) 
Other Oceania 4 1   (25) -- -- 4 1   (25) 
Asia 1 0     (0) -- -- 1 0     (0) 
UK & Ireland 5 0     (0) -- -- 5 0     (0) 
Other 5 0     (0) -- -- 5 0     (0) 
p value  0.3  --  0.3 
2010       
Australia 79 11   (14) 4 0   (0) 83 11   (13) 
Other Oceania 4 2   (50) -- -- 4 2   (50) 
Asia 1 0     (0) -- -- 1 0     (0) 
UK & Ireland 3 0     (0) -- -- 3 0     (0) 
Other 6 3   (50) -- -- 6 3   (50) 
p value  0.06  --  0.05 
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Table 402 HBV core-antibody prevalence by main language spoken at home by parents, sex and 
survey year† 
 Male Female Total  
Main language spoken at 
home by parents 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
No tested No with 
HBV (%) 
2004       
English  76 14 (18) 8 1   (13) 84 15 (18) 
Non-English  2 0   (0) 1 1 (100) 3 1 (33) 
p value  0.5  0.05  0.5 
2007       
English  71 19 (27) 7 3   (43) 78 22 (28) 
Non-English  4 1 (25) -- -- 4 1 (25) 
p value  0.9  --  0.9 
2010       
English  87 15 (17) 4 0     (0) 91 15 (16) 
Non-English  6 1 (17) -- -- 6 1 (17) 
p value  1.0  --  1.0 
† Excludes equivocal test results and missing values. 
 
 
Table 403 Hepatitis B virus immune status by injector status and survey year† 
  Hepatitis B Virus Immune Status 
Injector status No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
IDU 49 21 (43) 10 (20) 3 (6) 15 (31) 
Non-IDU 42 29 (69) 3   (7) 0 (0) 10 (24) 
p value     0.04 
2007      
IDU 43 16 (27) 16 (37) 2 (5) 9 (21) 
Non-IDU 39 29 (74) 5 (13) 0 (0) 5 (13) 
p value     <0.01 
2010      
IDU 62 28 (45) 9 (15) 0 (0) 25 (40) 
Non-IDU 35 22 (63) 7 (20) 0 (0) 6 (17) 
p value     0.06 
† Excludes equivocal test results and missing values. 
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Table 404 Hepatitis B virus immune status by sexual identity and survey year† 
  Hepatitis B Virus Immune Status 
Sexual identity No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
Heterosexual  90 50   (56) 13 (14) 3 (3) 24   (27) 
Bisexual 1 0     (0) 0   (0) 0 (0) 1 (100) 
Homosexual -- -- -- -- -- 
Unsure -- -- -- -- -- 
p value     0.4 
2007      
Heterosexual  80 44   (55) 20 (25) 2 (3) 14   (18) 
Homosexual -- -- -- -- -- 
Bisexual 2 1   (50) 1 (50) 0 (0) 0     (0) 
Unsure -- -- -- -- -- 
p value     0.8 
2010      
Heterosexual  93 48   (52) 15 (16) 0 (0) 30   (32) 
Bisexual 1 1 (100) 0   (0) 0 (0) 0     (0) 
Homosexual 2 1   (50) 1 (50) 0 (0) 0     (0) 
Unsure -- -- -- -- -- 
p value     0.6 
† Excludes equivocal test results and missing values. 
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 405 Hepatitis B virus immune status by age group and survey year† 
  Hepatitis B Virus Immune Status 
Age group No 
tested 
No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
< 20 years 11 6 (55) 0   (0) 0 (0) 5 (45) 
20 – 24 19 13 (68) 0   (0) 1 (5) 5 (26) 
25 – 29 20 12 (60) 3 (15) 1 (5) 4 (20) 
30 + years 43 21 (49) 10 (23) 1 (2) 11 (26) 
p value     0.3 
2007      
< 20 years 5 3 (60) 0   (0) 0 (0) 2 (40) 
20 – 24 20 16 (80) 1   (5) 0 (0) 3 (15) 
25 – 29 14 8 (57) 3 (21) 1 (7) 2 (14) 
30 + years 43 18 (42) 17 (40) 1 (2) 7 (16) 
p value     0.09 
2010      
< 20 years 10 4 (40) 0   (0) 0 (0) 6 (60) 
20 – 24 24 13 (54) 2   (8) 0 (0) 9 (38) 
25 – 29 27 18 (67) 4 (15) 0 (0) 5 (19) 
30 + years 36 15 (42) 10 (28) 0 (0) 11 (31) 
p value     0.07 
† Excludes equivocal test results and missing values. 




National Prison Entrants’ Bloodborne Virus & Risk Behaviour Survey 2004, 2007, and 2010 
Western Australia 
 218 
Table 406 Hepatitis B virus immune status by number of previous imprisonments and survey year† 






No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
1 33 24 (73) 1   (3) 1 (3) 7   (21) 
2 to 4 41 20 (49) 9 (22) 1 (2) 11   (27) 
5 to 9 12 4 (33) 3 (25) 1 (8) 4   (33) 
10 + 2 0   (0) 0   (0) 0 (0) 2 (100) 
p value     0.08 
2007      
1 30 20 (67) 5 (17) 1 (3) 4   (13) 
2 to 4 25 15 (60) 4 (16) 0 (0) 6   (24) 
5 to 9 11 4 (36) 4 (36) 1 (9) 2   (18) 
10 + 3 1 (33) 2 (67)  0 (0) 0     (0) 
p value     0.4 
2010      
1 57 33 (58) 7 (12) 0 (0) 17   (30) 
2 to 4 21 8 (38) 6 (29) 0 (0) 7   (33) 
5 to 9 13 6 (46) 3 (23) 0 (0) 4   (31) 
10 + 6 3 (50) 0   (0) 0 (0) 3   (50) 
p value     0.5 
† Excludes equivocal test results and missing values.   
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.   
 
 
Table 407 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey 
year† 






No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
Non-Indigenous 58 42 (72) 5   (9) 1 (2) 10 (17) 
Indigenous 36 10 (28) 8 (22) 2 (6) 16 (44) 
p value     <0.001 
2007      
Non-Indigenous 51 32 (63) 9 (18) 1 (2) 9 (18) 
Indigenous 30 13 (43) 11 (37) 1 (2) 5 (17) 
p value     0.2 
2010      
Non-Indigenous 61 40 (66) 10 (16) 0 (0) 11 (18) 
Indigenous 36 10 (28) 6 (17) 0 (0) 20 (56) 
p value     <0.001 
† Excludes equivocal test results and missing values. 
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
  
National Prison Entrants’ Bloodborne Virus & Risk Behaviour Survey 2004, 2007, and 2010 
Western Australia 
219        
Table 408 Hepatitis B virus immune status by residential remoteness and survey year† 
  Hepatitis B Virus Immune Status 
Residential remoteness No 
tested 
No (%) with no 
evidence of 
HBV immunity 






No (%) vaccine 
conferred 
immunity* 
2004      
Highly accessible/accessible 70 42    (60) 7 (10) 3 (4) 18 (26) 
Moderately accessible 5 2    (40) 0   (0) 0 (0) 3 (60) 
Remote/very remote 15 6    (40) 5 (33) 0 (0) 4 (27) 
p value     0.1 
2007      
Highly accessible/accessible 63 38    (60) 13 (21) 2 (3) 10 (16) 
Moderately accessible 2 2  (100) 0   (0) 0 (0) 0   (0) 
Remote/very remote 10 2    (20) 6 (60) 0 (0) 2 (20) 
p value     0.1 
2010      
Highly accessible/accessible 88 47    (53) 15 (17) 0 (0) 26 (30) 
Moderately accessible 3 1    (33) 0   (0) 0 (0) 2 (67) 
Remote/very remote 6 2    (33) 1 (17) 0 (0) 3 (50) 
p value     0.5 
† Excludes equivocal test results and missing values. 
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  
 
 
Table 409 Hepatitis B virus immune status by main language spoken at home by parents and survey 
year† 
  Hepatitis B Virus Immune Status 
Main language 




No (%) with no 
evidence of HBV 
immunity 
No (%) immune 
through past 
exposure 
No (%) HBV 
carrier 
No (%) vaccine 
conferred 
immunity* 
2004      
English  87 47 (54) 12 (14) 3 (3) 25 (29) 
Non-English 3 2 (67) 1 (33) 0 (0) 0   (0) 
p value     0.6  
2007      
English 78 43 (55) 20 (26) 2 (3) 
 
13 (17) 
Non-English  4 2 (50) 1 (25) 0 (0) 1 (25) 
p value     1.0 
2010      
English  91 48 (53) 15 (16) 0 (0) 28 (31) 
Non-English 6 2 (33) 1 (17) 0 (0) 3 (50) 
p value     0.6 
† Excludes equivocal test results and missing values. 
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Table 410 Self-reported hepatitis B immunisation versus serological testing and survey year*  
 Male Female Total  
Self-report HBV 
immunisation** 
No tested No immune 
(%) 
No tested No immune 
(%) 
No tested No immune 
(%) 
2004       
No 31 5 (16) 5 2   (40) 36 7 (19) 
Yes 22 11 (50) 1 1 (100) 23 12 (52) 
Not sure 11 5 (45) 4 1   (25) 15 6 (40) 
p value  0.02  0.4  0.03 
2007       
No 29 3 (10) 4 1   (25) 33 4 (12) 
Yes 18 9 (50) -- -- 18 9 (50) 
Not sure 8 1 (13) -- -- 8 1 (13) 
p value  0.006  --  0.007 
2010       
No 41 13 (32) 2 0     (0) 43 13 (30) 
Yes 27 14 (52) 2  1   (50) 29 15 (52) 
Not sure 9 3 (33) -- -- 9 3 (33) 
p value  0.2  0.3  0.2 
* HBV surface-antibody level of ≥10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.  





Table 411 Genital chlamydia prevalence by sex and survey year† 
Sex  No tested No with 
chlamydia (%) 
2010   
Male  93 5   (5) 
Female 5 1 (20) 
p value  0.2 




Table 412 Genital gonorrhoea prevalence by sex and survey year† 
Sex  No tested No with 
gonorrhoea (%) 
2010   
Male  93 1 (1) 
Female 5 0 (0) 
p value  0.8 




Table 413 Syphilis markers by sex and survey year† 








No with any 
marker for 
syphilis (%) 
2010     
Male  93 2 (2) 2 (2) 2 (2) 
Female 4 0 (0) 0 (0) 0 (0) 
p value  0.8 -- 0.8 
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Methodological Notes 
− Due to the small number of prisoners screened in the ACT, findings for this jurisdiction are 
included in the summary section only.  
 
− Percentages over 1 have been rounded up to the nearest whole number while those less 
than 1 are indicated as ‘<1’.  
 
− The label ‘n/a’ refers to survey items that were added or removed from previous years. 
 
− The Accessibility/Remoteness Index of Australia (ARIA)2 classification was developed in 1997 
and is based on a continuous measure of remoteness developed by the National Key Centre 
for Social Applications of Geographical Information Systems (GISCA). In this classification, an 
ARIA category is allocated on the basis of the average ARIA index score (between 0 and 12) 
within an area (such as an SLA). The ARIA index score is based on the road distance from the 
closest service centres in each of four classes (as defined using 1996 census population data). 
ARIA index scores, and therefore ARIA categories, are capable of being updated over time as 
populations change. ARIA categorises areas into 5 groups as follows:  
 
1. Highly Accessible - relatively unrestricted accessibility to a wide range of goods and 
services and opportunities for social interaction. 
2. Accessible - some restrictions to accessibility of some goods, services and opportunities 
for social interaction. 
3. Moderately Accessible - significantly restricted accessibility of goods, services and 
opportunities for social interaction. 
4. Remote - very restricted accessibility of goods, services and opportunities for social 
interaction. 
5. Very Remote - very little accessibility of goods, services and opportunities for social 
interaction. 
 
For the purpose of this report, 3 ARIA groupings were created: highly accessible + 
accessible, moderately accessible, and remote + very remote. Categories were allocated by 
using the postcode the individual had spent most time in during the 12 months before 
coming into prison. 
 
 
− Living situation prior to prison was recorded for the first time in 2010. The classification 
used is based on that proposed by Mackenzie and Chamberlain18 which includes three 
categories in recognition of the diversity of homelessness:  
 
1. Primary homelessness is experienced by people without conventional accommodation 
(e.g. sleeping rough or in improvised dwellings); 
2. Secondary homelessness  is experienced by people who frequently move from one 
temporary shelter to another (e.g. emergency accommodation, youth refuges, 
"couchsurfing"); 
3. Tertiary homelessness is experienced by people staying in accommodation that falls 
below minimum community standards (e.g. boarding housing and caravan parks). This 
definition was adopted by the Commonwealth Advisory Committee on Homelessness in 
2001 and is widely used in our sector.  
 
− Hepatitis B immune status was determined in accordance with CDC guidelines - 
http://www.cdc.gov/hepatitis/hbv/PDFs/SerologicChartv8.pdf  Participants with surface 
antibody levels above 10mIU/mL were considered to be immune to hepatitis B infection. In 
a limited number of cases hepatitis B surface antibody levels were not reported, vaccination 
conferred immunity to hepatitis B was established through a combination of self-report of 
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having received three doses of the hepatitis B vaccine and hepatitis B surface-antigen and 
hepatitis B core-antibody results. Analysis of self-reported hepatitis B vaccination and 
surface-antibody levels of above 10mIU/mL correlate reasonably will and so justified this 
approach.  
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Appendix 1 – Blood Tests, Test Kits and Testing Laboratories 
Human Immunodeficiency Virus (HIV) Antibody & Antigen 
HIV Ag/Ab Combo Architect. ABBOTT (USA) 
HIV Combi. ROCHE (USA) 
ADVIA Centaur HIV Combo Assay. ROBION AG (Switzerland) 
 
Hepatitis B Surface-Antibody 
Anti-HBs Architect. ABBOTT (USA) 
COBAS 6000. ROCHE (USA) 
 
Hepatitis B Surface-Antigen 
HBsAg Qualitative Architect. ABBOTT (USA) 
COBAS 6000. ROCHE (USA) 
 
Hepatitis B (IgG & IgM) Core-Antibody 
Anti-HBc II Architect. ABBOTT (USA) 
COBAS 6000. ROCHE (USA) 
 
Hepatitis B e-Antibody 
Anti-HBe Architect. ABBOTT (USA) 
COBAS 6000. ROCHE (USA) 
 
Hepatitis B e-Antigen 
HBeAg Architect. ABBOTT (USA) 
COBAS 6000. ROCHE (USA) 
 
Hepatitis C Antibody 
Anti-HCV Architect. ABBOTT (USA) 
COBAS 6000. ROCHE (USA) 
Murex THCV. ABBOTT (USA) 
Chiron Riba HCV 3.0 Immunoblot. NOVARITIS (USA) 
 
Treponema pallidum Antibody 
TPLA test 2.0. SEKISUI (Japan) 
Syphilis TP Architect. ABBOTT (USA) 
Serodia T. pallidum Hemagglutination Assay. FUJIREBIO (Japan) 
Macrovue Rapid Plasma Reagin Assay. BECTON-DICKISON (USA) 
TrepoSpot Immunofluorescent. BIOMÉRIEUX (France) 
 
Chlamydia trachomatis DNA 
COBAS TaqMan CT test 2.0. ROCHE (USA) 
COBAS 4800. ROCHE (USA) 
 
Neisseria gonorrhoea DNA 
COBAS Amplicore NG test. ROCHE (USA) 
COBAS 4800. ROCHE (USA) 
 
Testing Centres: 
ACT ACT Pathology, Canberra 
NSW Institute of Clinical Pathology and Medical Research, New South Wales 
NT NT Government Pathology Service, Northern Territory 
Qld Pathology Queensland, Queensland 
SA Institute of Medical and Veterinary Science, Royal Adelaide Hospital, South Australia 
Tas Royal Hobart Hospital Pathology Services, Tasmania 
Vic Healthscope Pathology, Victoria 
 Melbourne Pathology, Victoria 
WA PathWest Laboratory, Western Australia 
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Appendix 2 – Questionnaire 
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